Researcher Profile and Settings

Master

Affiliation (Master)

• Faculty of Medicine　Specialized Medicine　Reproductive and Developmental Medicine

Affiliation (Master)

• Faculty of Medicine　Specialized Medicine　Reproductive and Developmental Medicine

researchmap

Profile and Settings

Degree

• D.M.Sc（Toho University）

Profile and Settings

• Name (Japanese)

  Manabe

• Name (Kana)

  Atsushi

• Name

  200901065218410408

Alternate Names

http://www.pediatrics-hokudai.jp

Achievement

Research Interests

• 小児   白血病   Children   Leukemia   

Research Areas

• Life sciences / Fetal medicine/Pediatrics
• Life sciences / Hematology and oncology

Research Experience

• 2019/04 - Today Hokkaido University Postgraduate School of Medicine Department of Pediatrics Professor
• 2004/04 - 2019/03 St. Luke's International University St.Luke's International Hospital
• 1997 - 2004 東京大学医科学研究所
• 1993 - 1997 St. Luke's International University St.Luke's International Hospital
• 1990 - 1993 アメリカ セント・ジュード小児研究病院血液腫瘍科
• 1990 - 1993 Dept. of Hematology/Oncology, St. Jude Children's Res. Hosp.
• 1989 - 1990 イタリアローマ・カトリック大学小児がん教室
• 1989 - 1990 Div. of Pediatric Oncology, Catholic Univ. of Rome
• 1985 - 1989 St. Luke's International University St.Luke's International Hospital

Education

•        - 1985  Hokkaido University  School of Medicine

Awards

• 2003 がん研究助成金
  

Published Papers

• Increased response to granulocyte-macrophage colony-stimulating factor in peripheral blood cells and transient manifestations mimicking juvenile myelomonocytic leukemia in a male patient with NEMO deficiency caused by a deep intronic pathogenic variant of IKBKG.

  Masahiro Ueki, Shinsuke Hirabayashi, Yoshitaka Honda, Shunichiro Takezaki, Hiroki Ohata, Shimaa Said Mohamed Ali Abdrabou, Saori Sawai, Yukayo Terashita, Yuko Cho, Hideki Muramatsu, Kazushi Izawa, Takahiro Yasumi, Yoshiyuki Takahashi, Masafumi Yamada, Atsushi Manabe

  Immunological medicine 1 - 8 2024/11/01 

  X-linked NF-κB essential modulator (NEMO) deficiency is a primary immunodeficiency characterized by combined immunodeficiency and ectodermal dysplasia. Monocytes from the patients demonstrate a severely impaired response to tissue necrosis factor or lipopolysaccharide, whereas hyper-inflammation is found in some patients. Juvenile myelomonocytic leukemia (JMML) is a pediatric malignancy caused by hypersensitivity to granulocyte-macrophage colony-stimulating factor (GM-CSF) and aberrant RAS signaling activation. Patients with JMML demonstrate characteristic manifestations such as splenomegaly, monocytosis and the presence of myeloid or erythroid precursors in the peripheral blood. Here, we present the case of a male infant with ectodermal dysplasia, bacterial septicemia, Pneumocystis pneumonia, severe inflammation and transient manifestations mimicking JMML. Genetic analysis revealed a deep intronic germline variant of IKBKG. Full-length IKBKG cDNA and NEMO protein expression were almost inexistent. Peripheral mononuclear cells (PBMCs) from the patient showed increased RAS signaling activation with GM-CSF or Phorbol 12-myristate 13-acetate without the RAS-associated gene variant, although the increased RAS signaling activation in induced-pluripotent stem cell-derived myeloid lineage and bone marrow-derived mesenchymal cells was not evident. The patient with NEMO deficiency demonstrated JMML-like manifestation and severe inflammation. PBMCs of the patient demonstrated increased RAS signaling activation with unknown pathophysiology.
• Biologic and clinical analysis of childhood gamma delta T-ALL identifies LMO2/STAG2 rearrangements as extremely high-risk.

  Shunsuke Kimura, Chun Shik Park, Lindsey E Montefiori, Ilaria Iacobucci, Petri Polonen, Qingsong Gao, Elizabeth D Arnold, Andishe Attarbaschi, Anthony Brown, Barbara Buldini, Kenneth J Caldwell, Yunchao Chang, Chelsey Chen, Cheng Cheng, Zhongshan Cheng, John Choi, Valentino Conter, Kristine R Crews, Hester A de Groot-Kruseman, Takao Deguchi, Mariko Eguchi, Hannah Elisa Muhle, Sarah Elitzur, Gabriele Escherich, Burgess B Freeman, Zhaohui Gu, Katie Han, Keizo Horibe, Toshihiko Imamura, Sima Jeha, Motohiro Kato, Kean Hui Chiew, Tanya Khan, Michal Kicinski, Stefan Kohrer, Steven M Kornblau, Rishi S Kotecha, Chi-Kong Li, Yen-Chun Liu, Franco Locatelli, Selina M Luger, Elisabeth M Paietta, Atsushi Manabe, Hanne Vibeke Marquart, Riccardo Masetti, Mellissa Maybury, Pauline Mazilier, Jules P P Meijerink, Sharnise Mitchell, Takako Miyamura, Andrew S Moore, Koichi Oshima, Katarzyna Pawinska-Wasikowska, Rob Pieters, Mollie S Prater, Shondra M Pruett-Miller, Ching-Hon Pui, Chunxu Qu, Michaela Reiterova, Noemi Reyes, Kathryn G Roberts, Jacob M Rowe, Atsushi Sato, Kjeld Schmiegelow, Martin Schrappe, Shuhong Shen, Szymon Skoczen, Orietta Spinelli, Jan Stary, Michael Svaton, Masatoshi Takagi, Junko Takita, Yanjing Tang, David T Teachey, Paul G Thomas, Daisuke Tomizawa, Jan Trka, Elena Varotto, Tiffaney L Vincent, Jun J Yang, Allen Ej Yeoh, Yinmei Zhou, Martin Zimmermann, Hiroto Inaba, Charles G Mullighan

  Cancer discovery 2024/06/25 

  Acute lymphoblastic leukemia expressing the gamma delta T cell receptor (yo T-ALL) is a poorly understood disease. We studied 200 children with yo T-ALL from 13 clinical study groups to understand the clinical and genetic features of this disease. We found age and genetic drivers were significantly associated with outcome. yo T-ALL diagnosed in children under three years of age was extremely high-risk and enriched for genetic alterations that result in both LMO2 activation and STAG2 inactivation. Mechanistically, using patient samples and isogenic cell lines, we show that inactivation of STAG2 profoundly perturbs chromatin organization by altering enhancer-promoter looping, resulting in deregulation of gene expression associated with T-cell differentiation. High throughput drug screening identified a vulnerability in DNA repair pathways arising from STAG2 inactivation, which can be targeted by Poly(ADP-ribose) polymerase (PARP) inhibition. These data provide a diagnostic framework for classification and risk stratification of pediatric yo T-ALL.
• Identification of Prostaglandin I2 Synthase Rare Variants in Patients With Williams Syndrome and Severe Peripheral Pulmonary Stenosis.

  Ayako Chida-Nagai, Hiroyuki Akagawa, Saori Sawai, Yue-Jiao Ma, Satoshi Yakuwa, Jun Muneuchi, Kazushi Yasuda, Hirokuni Yamazawa, Toshiyuki Yamamoto, Emi Takakuwa, Utano Tomaru, Yoshiyuki Furutani, Tatsuya Kato, Gen Harada, Kei Inai, Toshio Nakanishi, Atsushi Manabe, Atsuhito Takeda, Zhi-Cheng Jing

  Journal of the American Heart Association e032872  2024/04/19 

  BACKGROUND: Peripheral pulmonary stenosis (PPS) is a condition characterized by the narrowing of the pulmonary arteries, which impairs blood flow to the lung. The mechanisms underlying PPS pathogenesis remain unclear. Thus, the aim of this study was to investigate the genetic background of patients with severe PPS to elucidate the pathogenesis of this condition. METHODS AND RESULTS: We performed genetic testing and functional analyses on a pediatric patient with PPS and Williams syndrome (WS), followed by genetic testing on 12 patients with WS and mild-to-severe PPS, 50 patients with WS but not PPS, and 21 patients with severe PPS but not WS. Whole-exome sequencing identified a rare PTGIS nonsense variant (p.E314X) in a patient with WS and severe PPS. Prostaglandin I2 synthase (PTGIS) expression was significantly downregulated and cell proliferation and migration rates were significantly increased in cells transfected with the PTGIS p.E314X variant-encoding construct when compared with that in cells transfected with the wild-type PTGIS-encoding construct. p.E314X reduced the tube formation ability in human pulmonary artery endothelial cells and caspase 3/7 activity in both human pulmonary artery endothelial cells and human pulmonary artery smooth muscle cells. Compared with healthy controls, patients with PPS exhibited downregulated pulmonary artery endothelial prostaglandin I2 synthase levels and urinary prostaglandin I metabolite levels. We identified another PTGIS rare splice-site variant (c.1358+2T>C) in another pediatric patient with WS and severe PPS. CONCLUSIONS: In total, 2 rare nonsense/splice-site PTGIS variants were identified in 2 pediatric patients with WS and severe PPS. PTGIS variants may be involved in PPS pathogenesis, and PTGIS represents an effective therapeutic target.
• TBI, etoposide, and cyclophosphamide conditioning for intermediate-risk relapsed childhood acute lymphoblastic leukemia.

  Hideaki Ueki, Chitose Ogawa, Hiroaki Goto, Masanori Nishi, Junko Yamanaka, Shinji Mochizuki, Takuro Nishikawa, Tadashi Kumamoto, Ritsuo Nishiuchi, Atsushi Kikuta, Shohei Yamamoto, Shunji Igarashi, Atsushi Sato, Toshinori Hori, Akiko M Saito, Tomoyuki Watanabe, Takao Deguchi, Atsushi Manabe, Keizo Horibe, Hidemi Toyoda

  International journal of hematology 2024/01/25 

  BACKGROUND: In children with intermediate-risk relapsed acute lymphoblastic leukemia (ALL), allogeneic hematopoietic stem cell transplantation (allo-HSCT) has markedly improved the outcome of patients with an unsatisfactory minimal residual disease (MRD) response. Total body irradiation (TBI), etoposide (ETP), and cyclophosphamide (CY) have been shown to be equivalent to or better than TBI + ETP for conditioning, so we hypothesized that even greater survival could be achieved due to recent advances in HSCT and supportive care. PROCEDURE: We prospectively analyzed the efficacy and safety of allo-HSCT with a unified conditioning regimen of TBI + ETP + CY in children with intermediate-risk relapsed ALL, based on MRD in the bone marrow after induction, from the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) ALL-R08-II nationwide cohort (UMIN000002025). RESULTS: Twenty patients with post-induction MRD ≥ 10-3 and two not evaluated for MRD underwent allo-HSCT. Engraftment was confirmed in all patients, and no transplantation-related mortality was observed. The 3-year event-free survival and overall survival rates after transplantation were 86.4% ± 7.3% and 95.5% ± 4.4%, respectively. CONCLUSION: Allo-HSCT based on post-induction MRD with TBI + ETP + CY conditioning was feasible in Japanese children with intermediate-risk relapsed ALL.
• Allogeneic Hematopoietic Cell Transplantation for Juvenile Myelomonocytic Leukemia with a Busulfan, Fludarabine, and Melphalan Regimen: JPLSG JMML-11.

  Kazuo Sakashita, Nao Yoshida, Hideki Muramatsu, Yoshitoshi Ohtsuka, Kenichiro Watanabe, Miharu Yabe, Harumi Kakuda, Yuko Honda, Tomoyuki Watanabe, Masami Haba, Shigeru Ohmori, Kazuyuki Matsuda, Yuki Yuza, Akiko Saito, Keizo Horibe, Souichi Adachi, Atsushi Manabe

  Transplantation and cellular therapy 30 (1) 105.e1-105.e10  2024/01 

  Juvenile myelomonocytic leukemia (JMML), which is classified as a myelodysplastic/myeloproliferative neoplasm, is a rare hematologic malignancy of childhood. Most patients with JMML require allogeneic hematopoietic cell transplantation (HCT) as a curative therapy. A Japanese retrospective analysis demonstrated favorable outcomes for a busulfan (BU) + fludarabine (FLU) + melphalan (MEL) regimen, with an overall survival (OS) of 72% and an event-free survival (EFS) of 53%. To further validate the efficacy and safety of this regimen, the Japan Pediatric Leukemia/Lymphoma Study Group (JPLSG) conducted a nationwide prospective study, JMML-11. Between July 2011 and June 2017, 28 patients with newly diagnosed JMML were enrolled in JMML11. Low-dose chemotherapy for tumor control before HCT was recommended, and patients treated with AML-type chemotherapy and azacitidine were excluded. The conditioning regimen comprised i.v. BU, 16 doses administered every 6 h, with dose adjustment based on pharmacokinetic (PK) studies on days -11 to -8; FLU, 30 mg/m2/day or 1 mg/kg/day for patients <10 kg or age <1 year on days -7 to -4; and MEL, 90 mg/m2/day or 3 mg/kg/day for patients <10 kg or <1 year on days -3 to -2. The donor was selected by the physician in charge. A family donor was available for 7 patients (3 HLA-matched siblings, 3 HLA-1-antigen mismatched parents, and 1 haploidentical father). Overall, 21 patients received grafts from unrelated donors, including 8 HLA-matched donors and 13 HLA-mismatched donors. The graft source was related bone marrow (BM) for 7 patients, unrelated BM for 14 patients, and unrelated cord blood for 7 patients. Neutrophil engraftment was achieved in 21 of 28 patients (75%), with a median of 20.5 days (range, 11 to 39 days) after transplantation. The 3-year OS, 3-year EFS, 3-year relapse rate, and 3-year transplantation-related mortality were 63% (95% confidence interval [CI], 42% to 78%), 52% (95% CI, 32% to 69%), 18% (95% CI, 6% to 34%), and 21% (95% CI, 9% to 38%), respectively. WBC count before the conditioning regimen (≥7.0 × 109/L) was significantly associated with inferior EFS and OS. Body surface area ≥.5 m2, spleen size <4 cm before conditioning, and HLA-matched unrelated BM donors were significantly associated with better OS. Adverse effects related to the conditioning regimen included febrile neutropenia (86%), diarrhea (39%), hypoxemia (21%), and mucositis (18%). BU-associated toxicity, including sinusoidal obstruction syndrome (SOS) and thrombotic microangiopathy (TMA), occurred in 7 patients (25%; SOS, n = 6; TMA, n = 2). Retrospective analysis of PK data after the first BU dose in 23 patients, including 6 with SOS and 17 without SOS, did not show significant differences between groups. The JMML-11 study confirms the positive results of previous retrospective analyses. BU+FLU+MEL might become a standard conditioning regimen for patients with JMML.
• Nusinersen induces detectable changes in compound motor action potential response in spinal muscular atrophy type 1 patients with severe impairment of motor function.

  Yuki Ueda, Kiyoshi Egawa, Kentaro Kawamura, Noriki Ochi, Takeru Goto, Shuhei Kimura, Masashi Narugami, Sachiko Nakakubo, Midori Nakajima, Atsushi Manabe, Hideaki Shiraishi

  Brain & development 2023/12/15 

  BACKGROUND: Most long-term affected spinal muscular atrophy (SMA) type 1 patients have severe impairment of motor function and are dependent on mechanical ventilation with tracheostomy. The efficacy and safety of nusinersen in these patients have not been established. METHODS: We retrospectively evaluated the efficacy of intrathecal nusinersen treatment in patients with SMA type 1 who continued treatment for at least 12 months. There were three patients enrolled in our study (3, 4 and 16 years of age) who had severe impairment of gross motor function without head control or the ability to roll over. All three needed mechanical ventilation with tracheostomy and tube feeding. Motor function was assessed using the Children s Hospital of Philadelphia infant test of neuromuscular disorders (CHOP-INTEND) and the caregivers' evaluations. Concurrently, we examined nerve conduction longitudinally and compared compound motor action potential (CMAP) amplitudes. RESULTS: All patients continued nusinersen administration without significant adverse events for more than three years. While CHOP-INTEND scores did not remarkably increase, according to the caregivers, all three patients had improved finger or facial muscle movements that enabled them to make their intentions understood. Some CMAPs before treatment were not identified but became traces after nusinersen administration. CONCLUSIONS: The improvement in motor function that leads to smoother communication could be a basis for continuing nusinersen treatment. Currently available motor function scorings are not efficient for assessing therapeutic interventions in SMA patients with medical care complexity. Longitudinal nerve conduction studies could be an objective indicator.
• Biologic and clinical features of childhood gamma delta T-ALL: identification of STAG2/LMO2 γδ T-ALL as an extremely high risk leukemia in the very young.

  Shunsuke Kimura, Petri Polonen, Lindsey Montefiori, Chun Shik Park, Ilaria Iacobucci, Allen Ej Yeoh, Andishe Attarbaschi, Andrew S Moore, Anthony Brown, Atsushi Manabe, Barbara Buldini, Burgess B Freeman, Chelsey Chen, Cheng Cheng, Chiew Kean Hui, Chi-Kong Li, Ching-Hon Pui, Chunxu Qu, Daisuke Tomizawa, David T Teachey, Elena Varotto, Elisabeth M Paietta, Elizabeth D Arnold, Franco Locatelli, Gabriele Escherich, Hannah Elisa Muhle, Hanne Vibeke Marquart, Hester A de Groot-Kruseman, Jacob M Rowe, Jan Stary, Jan Trka, John Kim Choi, Jules P P Meijerink, Jun J Yang, Junko Takita, Katarzyna Pawinska-Wasikowska, Kathryn G Roberts, Katie Han, Kenneth J Caldwell, Kjeld Schmiegelow, Kristine R Crews, Mariko Eguchi, Martin Schrappe, Martin Zimmerman, Masatoshi Takagi, Mellissa Maybury, Michael Svaton, Michaela Reiterova, Michal Kicinski, Mollie S Prater, Motohiro Kato, Noemi Reyes, Orietta Spinelli, Paul Thomas, Pauline Mazilier, Qingsong Gao, Riccardo Masetti, Rishi S Kotecha, Rob Pieters, Sarah Elitzur, Selina M Luger, Sharnise Mitchell, Shondra M Pruett-Miller, Shuhong Shen, Sima Jeha, Stefan Köhrer, Steven M Kornblau, Szymon Skoczeń, Takako Miyamura, Tiffaney L Vincent, Toshihiko Imamura, Valentino Conter, Yanjing Tang, Yen-Chun Liu, Yunchao Chang, Zhaohui Gu, Zhongshan Cheng, Zhou Yinmei, Hiroto Inaba, Charles G Mullighan

  medRxiv : the preprint server for health sciences 2023/11/08 

  PURPOSE: Gamma delta T-cell receptor-positive acute lymphoblastic leukemia (γδ T-ALL) is a high-risk but poorly characterized disease. METHODS: We studied clinical features of 200 pediatric γδ T-ALL, and compared the prognosis of 93 cases to 1,067 protocol-matched non-γδ T-ALL. Genomic features were defined by transcriptome and genome sequencing. Experimental modeling was used to examine the mechanistic impacts of genomic alterations. Therapeutic vulnerabilities were identified by high throughput drug screening of cell lines and xenografts. RESULTS: γδ T-ALL in children under three was extremely high-risk with 5-year event-free survival (33% v. 70% [age 3-<10] and 73% [age ≥10], P =9.5 x 10 -5 ) and 5-year overall survival (49% v. 78% [age 3-<10] and 81% [age ≥10], P =0.002), differences not observed in non-γδ T-ALL. γδ T-ALL in this age group was enriched for genomic alterations activating LMO2 activation and inactivating STAG2 inactivation ( STAG2/LMO2 ). Mechanistically, we show that inactivation of STAG2 profoundly perturbs chromatin organization by altering enhancer-promoter looping resulting in deregulation of gene expression associated with T-cell differentiation. Drug screening showed resistance to prednisolone, consistent with clinical slow treatment response, but identified a vulnerability in DNA repair pathways arising from STAG2 inactivation, which was efficaciously targeted by Poly(ADP-ribose) polymerase (PARP) inhibition, with synergism with HDAC inhibitors. Ex-vivo drug screening on PDX cells validated the efficacy of PARP inhibitors as well as other potential targets including nelarabine. CONCLUSION: γδ T-ALL in children under the age of three is extremely high-risk and enriched for STAG2/LMO2 ALL. STAG2 loss perturbs chromatin conformation and differentiation, and STAG2/LMO2 ALL is sensitive to PARP inhibition. These data provide a diagnostic and therapeutic framework for pediatric γδ T-ALL. SUPPORT: The authors are supported by the American and Lebanese Syrian Associated Charities of St Jude Children's Research Hospital, NCI grants R35 CA197695, P50 CA021765 (C.G.M.), the Henry Schueler 41&9 Foundation (C.G.M.), and a St. Baldrick's Foundation Robert J. Arceci Innovation Award (C.G.M.), Gabriella Miller Kids First X01HD100702 (D.T.T and C.G.M.) and R03CA256550 (D.T.T. and C.G.M.), F32 5F32CA254140 (L.M.), and a Garwood Postdoctoral Fellowship of the Hematological Malignancies Program of the St Jude Children's Research Hospital Comprehensive Cancer Center (S.K.). This project was supported by the National Cancer Institute of the National Institutes of Health under the following award numbers: U10CA180820, UG1CA189859, U24CA114766, U10CA180899, U10CA180866 and U24CA196173. DISCLAIMER: The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The funding agencies were not directly involved in the design of the study, gathering, analysis and interpretation of the data, writing of the manuscript, or decision to submit the manuscript for publication.
• Use of lacosamide for focal epilepsy in a child with kidney failure undergoing peritoneal dialysis.

  Yuki Ueda, Ayako Furugen, Masaki Kobayashi, Yasuyuki Sato, Yasuhiro Ueda, Asako Hayashi, Takeru Goto, Shuhei Kimura, Masashi Narugami, Sachiko Nakakubo, Midori Nakajima, Kiyoshi Egawa, Takayuki Okamoto, Atsushi Manabe, Hideaki Shiraishi

  Brain & development 2023/10/30 

  BACKGROUND: Lacosamide (LCM) has become commonly used for focal onset seizures due to its high tolerability and low drug interactions. Unlike patients on hemodialysis (HD), pharmacokinetic data and dosing recommendations for patients undergoing peritoneal dialysis (PD) are scant. CASE REPORT: A 2-year-old girl with end-stage kidney disease undergoing PD suffered prolonged focal onset seizures. The patient had congenital anomalies of the kidney and urinary tract associated with branchio-oto-renal syndrome due to an EYA1 gene mutation. She also had neurological sequelae from post-resuscitation encephalopathy at the age of one month. Antiseizure medication with few drug interactions, less impact on the neurodevelopmental state and possibility of intravenous administration was preferred. LCM met those criteria and was carefully administered. Although the patient had recurrent prolonged seizures during the titration periods, LCM could be continued without any apparent side effects. The blood levels of LCM increased linearly to the optimal level. We confirmed excretion of LCM in the PD fluid. Kidney transplantation was done three months after and her seizures were well controlled. CONCLUSIONS: LCM might be a promising option for patients undergoing PD. Due to the lower removal efficacy in PD compared with in HD, close attention should be paid to possible drug excess.
• Genome-wide assessment of genetic risk loci for childhood acute lymphoblastic leukemia in Japanese patients.

  Mayumi Hangai, Takahisa Kawaguchi, Masatoshi Takagi, Keitaro Matsuo, Soyoung Jeon, Charleston W K Chiang, Andrew T Dewan, Adam J De Smith, Toshihiko Imamura, Yasuhiro Okamoto, Akiko M Saito, Takao Deguchi, Michiaki Kubo, Yoichi Tanaka, Yoko Ayukawa, Toshinari Hori, Kentaro Ohki, Nobutaka Kiyokawa, Takeshi Inukai, Yuki Arakawa, Makiko Mori, Daisuke Hasegawa, Daisuke Tomizawa, Hiroko Fukushima, Yuki Yuza, Yasushi Noguchi, Yuichi Taneyama, Setsuo Ota, Hiroaki Goto, Masakatsu Yanagimachi, Dai Keino, Kazutoshi Koike, Daisuke Toyama, Yozo Nakazawa, Kozue Nakamura, Koichi Moriwaki, Yujin Sekinaka, Daisuke Morita, Shinsuke Hirabayashi, Yosuke Hosoya, Yuri Yoshimoto, Hiroki Yoshihara, Miwa Ozawa, Shinobu Kobayashi, Naho Morisaki, Tshewang Gyeltshen, Osamu Takahashi, Yukinori Okada, Makiko Matsuda, Toshihiro Tanaka, Johji Inazawa, Junko Takita, Yasushi Ishida, Akira Ohara, Catherine Metayer, Joseph L Wiemels, Xiaomei Ma, Shuki Mizutani, Katsuyoshi Koh, Yukihide Momozawa, Keizo Horibe, Fumihiko Matsuda, Motohiro Kato, Atsushi Manabe, Kevin Y Urayama

  Haematologica 2023/10/26 

  Not available.
• Prenatal metal concentrations and physical abnormalities in the Japan Environment and Children's Study.

  Yuichi Nakamura, Sumitaka Kobayashi, Kazutoshi Cho, Sachiko Itoh, Chihiro Miyashita, Takeshi Yamaguchi, Hiroyoshi Iwata, Naomi Tamura, Yasuaki Saijo, Yoshiya Ito, Yoshitaka Seto, Ryota Honjo, Akiko Ando, Yuta Furuse, Atsushi Manabe, Reiko Kishi

  Pediatric research 2023/10/19 

  BACKGROUND: The association between prenatal metal exposure and congenital anomalies is unclear. We aimed to examine the association between exposure to cadmium, lead, mercury, selenium, and manganese and physical abnormalities. METHODS: Data from 89,887 pregnant women with singleton pregnancies who participated in the Japan Environment and Children's Study (JECS) were used. The correlation between maternal blood metal concentrations and physical abnormalities during the second or third trimester was investigated using logistic regression models. Physical anomalies included those observed at birth or at 1 month, primarily from ICD-10 Chapter 17, particularly congenital anomalies associated with environmental factors (e.g., hypospadias, cryptorchidism, cleft lip and palate, digestive tract atresia, congenital heart disease, and chromosomal abnormalities) and minor abnormalities. RESULTS: After adjusting for covariates, the OR (95% CIs) of physical abnormalities for a one-unit rise in Mn concentrations in all individuals were 1.26 (1.08, 1.48). The OR (95% CIs) of physical abnormalities in the 4th quartile (≥18.7 ng/g) were 1.06 (1.01, 1.13) (p-value for the trend = 0.034) compared with those in the 1st quartile (≤12.5 ng/g). CONCLUSION: In Japan, maternal blood Mn concentrations above threshold during pregnancy may slightly increase the incidence of physical abnormalities. IMPACT: Physical abnormalities (including minor anomalies and congenital anomalies) are associated with prenatal manganese concentrations. They are not associated with cadmium, lead, mercury, and selenium concentrations.
• Slow-growing WNT medulloblastoma with atypical magnetic resonance imaging findings: illustrative case.

  Makoto Mizushima, Michinari Okamoto, Shigeru Yamaguchi, Sogo Oki, Hiroaki Motegi, Minako Sugiyama, Atsushi Manabe, Ai Shimizu, Kentaro Nishioka, Takayuki Hashimoto, Junko Hirato, Yonehiro Kanemura, Miki Fujimura

  Journal of neurosurgery. Case lessons 6 (7) 2023/08/14 

  BACKGROUND: Medulloblastomas, with four molecular subgroups, are generally rapid-growing tumors with significant contrast enhancement and well-defined margins. However, each subgroup's clinical features, including disease time course and imaging characteristics, are not well defined. OBSERVATIONS: The authors describe the case of a 15-year-old female who presented with a 7-month history of impaired left-hand movement and was found to have a lesion on the dorsal side of the fourth ventricle. T2-weighted magnetic resonance imaging (MRI) at the patient's first presentation showed diffuse hyperintense signal without apparent mass, and gadolinium-enhanced T1-weighted imaging showed very slight contrast enhancement. In 1 month, her symptoms progressed, and follow-up MRI revealed an increase in the size of the lesion, showing greater diffusion restriction and contrast enhancement. She underwent gross-total resection, and pathology was consistent with classic medulloblastoma. Genetic analysis of the tumor confirmed the wingless (WNT) molecular subgroup. Adjuvant chemotherapy and proton beam therapy were performed. At the 18-month follow-up, MRI showed no recurrence of disease. LESSONS: Slow-growing medulloblastoma is very rare and not known to be associated with a specific molecular subgroup. Here, the authors report a case of slow-growing WNT medulloblastoma, indicating that slow growth may be a feature of this subgroup.
• Challenges to Widespread Use of Fertility Preservation Facilities for Pediatric Cancer Patients in Japan.

  Tadashi Maezawa, Nao Suzuki, Hiroki Takeuchi, Mikiko Nishioka, Moe Hidaka, Atsushi Manabe, Yuhki Koga, Hiroshi Kawaguchi, Yoji Sasahara, Masahito Tachibana, Shotaro Iwamoto, Akihito Horie, Hidefumi Hiramatsu, Motohiro Kato, Miyuki Harada, Yuki Yuza, Masahiro Hirayama, Junko Takita, Tomoaki Ikeda, Kimikazu Matsumoto

  Journal of adolescent and young adult oncology 2023/08/03 

  Purpose: Although fertility preservation for pediatric cancer patients is becoming more widespread in Japan, some facilities do not provide sufficient information regarding fertility. This study aimed to elucidate the problems pertaining to the lack of information about fertility among patients. Methods: Based on a 2020 survey, seminars addressing fertility preservation were held from the Designated Pediatric Cancer Care Hospitals in each of the seven blocks in Japan to their partner hospital (pediatric cancer hospitals). The seminar consisted of lectures and group discussions, and a questionnaire was also administered after each seminar. Results: In the group discussions, a lack of explanations to patients and explanatory materials for children were cited as issues by many facilities. The survey results revealed a lack of material explaining fertility preservation and a lack of knowledge among health care providers. There were also many requests to use the patient explanation videos presented at the seminar. Conclusion: The results indicate that further education for health care providers by seminar and other sources and enhancement of explanatory materials are important for fertility preservation in pediatric cancer hospitals in Japan.
• Therapeutic Drug Monitoring of Oral Voriconazole in an Infant Less than Six Months of Age and Pharmacokinetics Changes Induced by Development of CYP2C19 in the Growth Process: A Novel Case Report

  Atsushi Yamaguchi, Yuki Tazawa, Masashiro Ueki, Masafumi Yamada, Atsushi Manabe, Mitsuru Sugawara, Yoh Takekuma

  YAKUGAKU ZASSHI 143 (6) 545 - 549 0031-6903 2023/06/01 [Refereed]
  
• Efficacy of sirolimus for epileptic seizures in childhood associated with focal cortical dysplasia type II

  Hideaki Shiraishi, Tsuyoshi Teramoto, Saki Yokoshiki, Jun Tohyama, Yuki Ueda, Kiyoshi Egawa, Norihiro Sato, Atsushi Manabe, Mitsuhiro Kato

  BRAIN & DEVELOPMENT 45 (6) 343 - 347 0387-7604 2023/06 

  Objective: The efficacy of the mechanistic target of rapamycin inhibitor, sirolimus, was recently reported for patients more than 6 years of age by Kato et al. We evaluated the efficacy and safety of sirolimus in a 2-year-old patient with recurrent focal seizures with impaired consciousness after focal cortical dysplasia (FCD) type IIa resection. Methods: The patient was a 2-year-old girl who had recurrent seizures after undergoing FCD resection at 4 months of age. The initial dose of sirolimus was 0.5 mg/day and was gradually increased using the trough blood concentration before oral administration as an index, and evaluation was performed at 92 weeks. Results: The trough blood level of sirolimus was increased to 6.1 ng/mL and maintenance therapy was started at 40 weeks. Focal seizures with impairment of consciousness with tonic extension of the limbs decreased. No critically serious adverse events occurred. Conclusion: Sirolimus was effective against epileptic seizures from FCD type II even for a child under 5 years of age. There were no critically serious adverse events and administration could be continued. (c) 2023 Published by Elsevier B.V. on behalf of The Japanese Society of Child Neurology. This is an open access article under the CC BY-NCND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
• ブスルファンの著しい薬物動態変動が認められた小児の1例

  山口 敦史, 武隈 洋, 仁木 加寿子, 平林 真介, 寺下 友佳代, 長谷河 昌孝, 長 祐子, 真部 淳, 菅原 満

  TDM研究 (一社)日本TDM学会 40 (2) 212 - 212 0911-1026 2023/06
• Rare TCF3 variants associated with pediatric B cell acute lymphoblastic leukemia.

  Satoshi Miyamoto, Kevin Y Urayama, Yuki Arakawa, Katsuyoshi Koh, Yuki Yuza, Daisuke Hasegawa, Yuichi Taneyama, Yasushi Noguchi, Masakatsu Yanagimachi, Takeshi Inukai, Setsuo Ota, Hiroyuki Takahashi, Dai Keino, Daisuke Toyama, Junko Takita, Daisuke Tomizawa, Tomohiro Morio, Kazutoshi Koike, Koichi Moriwaki, Yuya Sato, Junya Fujimura, Daisuke Morita, Yujin Sekinaka, Kozue Nakamura, Kazuo Sakashita, Hiroaki Goto, Atsushi Manabe, Masatoshi Takagi

  Pediatric hematology and oncology 1 - 7 2023/05/02 

  Germline genetic variants influence development of pediatric B cell acute lymphoblastic leukemia (B-ALL). Genome-wide association studies (GWAS) have identified several pediatric B-ALL susceptibility loci. IKZF1 and PAX5, transcription factors involved in B cell development, have been reported as susceptibility genes for B-ALL development. Therefore, we hypothesized that rare variants of genes involved in B cell development would be candidate susceptibility loci for pediatric B-ALL. Thus, we sequenced TCF3, a key transcription factor gene involving in B cell development. Saliva DNA from 527 pediatric patients with pediatric B-ALL in remission who were registered with the Tokyo Children's Cancer Study Group (TCCSG) were examined. As a TCF3 gene-based evaluation, the numbers of rare deleterious germline TCF3 sequence variants in patients with pediatric B-ALL were compared with those in cancer-free individuals using data in public databases. As a TCF3 single-variant evaluation, the frequencies of rare deleterious germline TCF3 sequence variants in patients with pediatric B-ALL were also compared with those in control data. TCF3 gene-based analysis revealed significant associations between rare deleterious variants and pediatric B-ALL development. In addition, TCF3 variant-based analysis showed particularly strong association between variant rs372168347 (three in 521 TCCSG and three in the 15780 gnomAD whole genome analysis cohort, p = 0.0006) and pediatric B-ALL development. TCF3 variants are known to influence B cell maturation and may increase the risk of preleukemic clone emergence.
• Gタンパク共役型受容体101(GPR101)遺伝子変異を同定した複合型下垂体機能低下症の兄弟例

  森川 俊太郎, 金子 直哉, 中山 加奈子, 菱村 希, 山口 健史, 佐々木 大輔, 上田 泰弘, 渡邊 さやか, 青柳 勇人, 中村 明枝, 真部 淳

  日本内分泌学会雑誌 (一社)日本内分泌学会 99 (1) 311 - 311 0029-0661 2023/05
• 北海道の小児医療体制を支える広域搬送システムの有用性

  武田 充人, 真部 淳

  小児保健研究 (公社)日本小児保健協会 82 (講演集) 133 - 133 0037-4113 2023/05
• Changes in bone turnover markers after discontinuing long-term glucocorticoid administration in children with idiopathic nephrotic syndrome: a multicenter retrospective observational study.

  Yasuhiro Ueda, Takayuki Okamoto, Yasuyuki Sato, Asako Hayashi, Toshiyuki Takahashi, Ryota Suzuki, Aoyagi H, MICHIHIKO UENO, Kobayashi N, Uetake K, Nakanishi M, Ariga T, Atsushi Manabe

  Pediatric nephrology (Berlin, Germany) 2023/04/13 [Refereed]
   

  Background

  Glucocorticoids affect bone turnover. Little is known about how bone turnover changes when glucocorticoids are discontinued following long-term administration.

  Methods

  This retrospective observational study was conducted on the relationship between discontinuation of long-term administration of glucocorticoid and bone turnover markers (BTMs) in patients with childhood-onset idiopathic nephrotic syndrome. Serum bone alkaline phosphatase (BAP), intact procollagen type 1 N-terminal propeptide (P1NP), and tartrate-resistant acid phosphatase-5b (TRACP-5b) were evaluated as BTMs.

  Results

  Thirty-eight pairs of BTMs at glucocorticoid administration and after discontinuation were analyzed in 29 patients. The median age at baseline was 12.4 (interquartile range, 9.0-14.5) years, and the median time from the onset of nephrotic syndrome was 5.9 (3.3-9.7) years. The mean period from prednisolone discontinuation to the measurement of BTMs after glucocorticoid discontinuation was 3.5 ± 1.0 months. Changes in BTMs after glucocorticoid discontinuation were modest when the daily prednisolone dose was < 0.25 mg/kg/day (ln BAP standard deviation [SD] score, p = 0.19; log intact P1NP SD score, p = 0.70; TRACP-5b, p = 0.95). When the daily prednisolone dose was ≥ 0.25 mg/kg/day, all BTMs increased significantly after glucocorticoid discontinuation (ln BAP SD score, p < 0.01; log intact P1NP SD score, p < 0.01; TRACP-5b, p < 0.01).

  Conclusions

  Decreased BTMs can rise within a few months of discontinuing long-term glucocorticoid administration. When the administered glucocorticoid dose is low, changes in BTMs may be small. A higher resolution version of the Graphical abstract is available as Supplementary information.
• Outcomes following induction failure in Japanese children with acute lymphoblastic leukemia.

  Chihaya Imai, Atsushi Sato, Mitsuteru Hiwatari, Yasuto Shimomura, Toshinori Hori, Souichi Suenobu, Toshihiko Imamura, Junichi Hara, Daisuke Hasegawa, Hiroyuki Takahashi, Kunihiko Moriya, Saori Katayama, Daisuke Tomizawa, Hiroshi Moritake, Takashi Taga, Keizo Horibe, Katsuyoshi Koh, Atsushi Manabe, Yasuhiro Okamoto

  International journal of hematology 118 (1) 99 - 106 2023/04/10 

  The characteristics and prognosis of Japanese children with acute lymphoblastic leukemia (ALL) who fail to achieve complete remission after remission induction chemotherapy (i.e., experience induction failure) are poorly understood. Therefore, we retrospectively analyzed data of patients enrolled in Japanese clinical trials for newly diagnosed ALL between 1996 and 2009. Among 4956 participants, 89 (1.8%) experienced induction failure. With a 6.0-year median follow-up, the 5-year overall survival rate of the entire cohort was 43.0% ± 5.5%. Survival rates did not differ between patients with B-cell precursor ALL (BCP-ALL) and T-cell ALL (T-ALL). In multivariate analysis, day 15 M3 marrow (bone marrow blast count ≥ 25%) was significantly correlated with poorer survival in the whole or BCP-ALL cohorts. In T-ALL, age < 6 years was significantly associated with poor survival. However, due to the small sample size, this correlation must be further investigated. Most T-ALL and BCR-ABL-positive BCP-ALL patients underwent allogeneic stem cell transplantation (allo-SCT). Survival rates did not differ between BCR-ABL-negative BCP-ALL patients who did and did not undergo allo-SCT, possibly due to the inclusion of lower-risk patients in the latter group. In conclusion, the induction failure rate and survival after diagnosis of induction failure in our study were comparable to previously reported figures.
• 前思春期のビスフェノール類曝露と性・ステロイドホルモン値との関連 北海道スタディ

  池田 敦子, 山口 健史, アイツバマイ ゆふ, 池中 良徳, ケテマ・ラヘルメスフィ, 曾 怡, 中村 明枝, 橘田 岳也, 今 雅史, 篠原 信雄, 真部 淳, 宮下 ちひろ, コバチ・アドリアン, 岸 玲子

  日本衛生学雑誌 (一社)日本衛生学会 78 (Suppl.) S181 - S181 0021-5082 2023/03
• 高用量ステロイド吸入により医原性グルココルチコイド過剰および二次性副腎皮質機能不全をきたした女児例

  小野 夏実, 金子 直哉, 中山 加奈子, 菱村 希, 山口 健史, 森川 俊太郎, 真部 淳, 中村 明枝

  臨床小児医学 (財)小児愛育協会 70 (1-6) 57 - 63 0035-550X 2023/03 

  副腎皮質ステロイドは多くの疾患の治療に欠かせない薬剤である一方,その副作用は多岐にわたる。今回われわれは,気管支喘息治療に用いた吸入ステロイドが原因で,グルココルチコイド過剰症状と二次性副腎皮質機能不全を呈した11歳女児例を経験した。吸入ステロイドを開始した3年後に成長率低下,易疲労感を主訴に近医受診し,随時採血で血漿ACTH,血清コルチゾールは測定感度未満であった。当院で入院精査を行い,吸入ステロイドが原因となった二次性副腎皮質機能低下症と診断した。吸入ステロイドの漸減中止とともに成長率は改善し,副腎皮質機能も回復した。全身性のステロイド投与による二次性副腎皮質機能低下症は比較的よく知られる病態であるが,本症例のように吸入ステロイドを高用量で長期間に渡って使用する場合でも,副腎機能に留意する必要がある。(著者抄録)
• Sunburst appearanceを呈する頭蓋骨腫瘤を契機に発見された神経芽腫の1例

  北川 悠, 竹中 淳規, 渡邊 史郎, 平田 健司, 内山 裕子, 木村 理奈, 中川 純一, 池辺 洋平, 長谷河 昌孝, 澤井 彩織, 寺下 友佳代, 杉山 未奈子, 平林 真介, 長 祐子, 山口 秀, 真部 淳, 工藤 與亮

  北海道放射線医学雑誌 (NPO)メディカルイメージラボ 3 33 - 36 2023/03 

  症例は9歳女児。左頭部腫瘤を主訴に近医を受診し、頭部CTで左前頭骨にsunburst appearanceを呈する腫瘤性病変を指摘され、その他にも右頭頂骨と左下顎頭に骨病変を認めた。体幹部造影CTを施行したところ、後縦隔の胸椎椎体前方から左側にかけて巨大な軟部腫瘤を認めた。血清神経特異エノラーゼ(NSE)や尿中バニリルマンデル酸(VMA)/ホモバニリン酸(HVA)が高値であり、神経芽腫が第一に疑われた。123I-MIBGシンチグラフィを施行したところ、後縦隔腫瘤のほか頭蓋骨を含めた全身骨にも集積が見られ、神経芽腫とその骨転移が疑われた。頭蓋骨腫瘤の生検術により神経芽腫の診断が確定した。神経芽腫は小児期に発生する頭蓋外の固形悪性腫瘍の中で最も頻度が高い。転移性頭蓋骨腫瘍がsunburst appearanceを呈することは比較的稀であるが、小児では神経芽腫の転移でしばしば経験される。神経芽腫の骨転移の部位として、頭蓋骨は頻度が高く、小児においてsunburst appearanceを呈し多発する頭蓋骨腫瘤を見た場合には神経芽腫の骨転移を考慮する必要がある。(著者抄録)
• 小児がん経験者(CCS)フォロー中に甲状腺がんを発症した4例

  金子 直哉, 菱村 希, 寺下 友佳代, 中山 加奈子, 山口 健史, 森川 俊太郎, 長谷河 昌孝, 澤井 彩織, 杉山 未奈子, 平林 真介, 長 祐子, 真部 淳, 中村 明枝

  日本内分泌学会雑誌 (一社)日本内分泌学会 98 (4) 719 - 719 0029-0661 2023/02
• A nationwide survey of late effects in survivors of juvenile myelomonocytic leukemia in Japan.

  Shuichi Ozono, Kazuo Sakashita, Nao Yoshida, Harumi Kakuda, Kenichiro Watanabe, Miho Maeda, Yasushi Ishida, Atsushi Manabe, Takashi Taga, Hideki Muramatsu

  Pediatric blood & cancer 70 (2) e30126  2023/02 

  We conducted a cross-sectional study using a questionnaire to explore the late effects in survivors of allogenic hematopoietic stem cell transplantation (HSCT) for juvenile myelomonocytic leukemia (JMML). The attending pediatric hematologists/oncologists completed the questionnaires. Of the 30 survivors, approximately 83% showed more than one late effect. The identified late effects included endocrine, dental, skin, ophthalmologic, musculoskeletal, pulmonary, neurocognitive, and cardiovascular dysfunction. The prevalence of short stature, pulmonary, cardiovascular, and nephrological complications was significantly elevated among survivors who were 12 years or more lapsed after HSCT. Therefore, a multidisciplinary follow-up system for survivors of JMML is crucial.
• Therapeutic effects of KRM-II-81, positive allosteric modulator for α2/3 subunit containing GABAA receptors, in a mouse model of Dravet syndrome.

  Sachiko Nakakubo, Yasuyoshi Hiramatsu, Takeru Goto, Syuhei Kimura, Masashi Narugami, Midori Nakajima, Yuki Ueda, Hideaki Shiraishi, Atsushi Manabe, Dishary Sharmin, James M Cook, Kiyoshi Egawa

  Frontiers in pharmacology 14 1273633 - 1273633 2023 

  Introduction: Dravet syndrome (DS) is an intractable epilepsy syndrome concomitant with neurodevelopmental disorder that begins in infancy. DS is dominantly caused by mutations in the SCN1A gene, which encodes the α subunit of a voltage-gated Na channel. Pre-synaptic inhibitory dysfunction is regarded as the pathophysiological mechanism, but an effective strategy for ameliorating seizures and behavioral problems is still under development. Here, we evaluated the effects of KRM-II-81, a newly developed positive allosteric modulator for α 2/3 subunit containing GABAA receptors (α2/3-GABAAR) in a mice model of DS both in vivo and at the neuronal level. Methods: We used knock-in mice carrying a heterozygous, clinically relevant SCN1A mutation (background strain: C57BL/6 J) as a model of the DS (Scn1a WT/A1783V mice), knock-in mouse strain carrying a heterozygous, clinically relevant SCN1A mutation (A1783V). Seizure threshold and locomotor activity was evaluated by using the hyperthermia-induced seizure paradigm and open filed test, respectively. Anxiety-like behavior was assessed by avoidance of the center region in locomotor activity. We estimated a sedative effect by the total distance traveled in locomotor activity and grip strength. Inhibitory post synaptic currents (IPSCs) were recorded from a hippocampal CA1 pyramidal neuron in an acutely prepared brain slice. Results: KRM-II-81 significantly increased the seizure threshold of Scn1a WT/A1783V mice in a dose-dependent manner. A low dose of KRM-II-81 specifically improved anxiety-like behavior of Scn1a WT/A1783V mice. A sedative effect was induced by relatively high dose of KRM-II-81 in Scn1a WT/A1783V mice, the dose of which was not sedative for WT mice. KRM-II-81 potentiated IPSCs by increasing its decay time kinetics. This effect was more prominent in Scn1a WT/A1783V mice. Discussion: Higher activation of α2/3-GABAAR by KRM-II-81 suggests a compensatory modification of post synaptic inhibitory function against presynaptic inhibitory dysfunction in Scn1a WT/A1783V. The increased sensitivity for KRM-II-81 may be relevant to the distinct dose-dependent effect in each paradigm of Scn1a WT/A1783V mice. Conclusion: Selective activation for α2/3-GABAAR by KRM-II-81 could be potential therapeutic strategy for treating seizures and behavioral problems in DS.
• The heterozygous NUDT15 variant is not associated with the severity of 6-mercaptopurine-related side effects in early intensification therapy for childhood acute lymphoblastic leukemia

  Jimei Zhao, Masahiro Ueki, Saori Sawai, Minako Sugiyama, Yukayo Terashita, Shinsuke Hirabayashi, Yuko Cho, Ryoji Kobayashi, Yoichi Tanaka, Atsushi Manabe

  EJC Paediatric Oncology 1 100006 - 100006 2772-610X 2023
• Preterm toddlers have low nighttime sleep quality and high daytime activity.

  Yoko Asaka, Yusuke Mitani, Hidenobu Ohta, Takayo Nakazawa, Rika Fukutomi, Kyoko Kobayashi, Mayuko Kumagai, Hitomi Shinohara, Michiko Yoshida, Akiko Ando, Yuko Yoshimura, Machiko Nakagawa, Yoshihisa Oishi, Masato Mizushima, Hiroyuki Adachi, Yosuke Kaneshi, Keita Morioka, Yoshitaka Seto, Rinshu Shimabukuro, Michio Hirata, Takashi Ikeda, Miwa Ozawa, Masahiro Takeshima, Atsushi Manabe, Tsutomu Takahashi, Kazuo Mishima, Mitsuru Kikuchi, Hitoshi Yoda, Isao Kusakawa, Kazutoshi Cho

  Scientific reports 12 (1) 20032 - 20032 2022/11/21 

  A number of studies have been made on the sleep characteristics of children born preterm in an attempt to develop methods to address the sleep problems commonly observed among such children. However, the reported sleep characteristics from these studies vary depending on the observation methods used, i.e., actigraphy, polysomnography and questionnaire. In the current study, to obtain reliable data on the sleep characteristics of preterm-born children, we investigated the difference in sleep properties between 97 preterm and 97 term toddlers of approximately 1.5 years of age using actigraphy. Actigraphy units were attached to the toddlers' waists with an adjustable elastic belt for 7 consecutive days, and a child sleep diary was completed by their parents. In the study, we found that preterm toddlers had more nocturnal awakenings and more daytime activity, suggesting that preterm-born children may have a different process of sleep development in their early development.
• Clinical characteristics and outcomes of B-cell precursor ALL with MEF2D rearrangements: a retrospective study by the Ponte di Legno Childhood ALL Working Group.

  Kentaro Ohki, Ellie R Butler, Nobutaka Kiyokawa, Shinsuke Hirabayashi, Anke K Bergmann, Anja Möricke, Judith M Boer, Hélène Cavé, Giovanni Cazzaniga, Allen Eng Juh Yeoh, Masashi Sanada, Toshihiko Imamura, Hiroto Inaba, Charles G Mullighan, Mignon L Loh, Ulrika Norén-Nyström, Lee-Yung Shih, Marketa Zaliova, Ching-Hon Pui, Oskar A Haas, Christine J Harrison, Anthony V Moorman, Atsushi Manabe

  Leukemia 2022/10/29
• Long-term consequences of residual lesions after chemoradiotherapy in patients with germinoma at onset.

  Shigeru Yamaguchi, Michinari Okamoto, Yukitomo Ishi, Ryosuke Sawaya, Hiroaki Motegi, Minako Sugiyama, Taisuke Harada, Noriyuki Fujima, Takashi Mori, Takayuki Hashimoto, Emi Takakuwa, Atsushi Manabe, Kohsuke Kudo, Hidefumi Aoyama, Miki Fujimura

  Journal of neurosurgery. Pediatrics 1 - 8 2022/09/09 

  OBJECTIVE: In patients with intracranial germ cell tumors, residual lesions are sometimes observed after completion of primary chemoradiotherapy. Although salvage resection of these end-of-treatment residual lesions is recommended for patients with nongerminomatous germ cell tumors, the necessity of early salvage resection for those with germinoma is not clear. The aim of this study was to investigate the frequency of residual germinoma lesions after primary chemoradiotherapy, as well as their management, long-term consequences, and prognosis. METHODS: The authors retrospectively reviewed patients who were primarily treated for germinoma between 2002 and 2021. Residual lesions were evaluated with MRI with and without contrast enhancement within 2 weeks after chemoradiotherapy. The decision to perform salvage resection of residual lesions was at the discretion of the treating physicians. The change in appearance of residual lesions was assessed with serial MRI. Overall survival (OS), progression-free survival (PFS), and recurrence pattern were also investigated. RESULTS: Sixty-nine patients were treated with chemoradiotherapy for germinoma, with a mean follow-up period of 108 months. Residual lesions were radiologically observed in 30 patients (43.5%). Among these, 5 patients (3 with pineal lesions and 2 with basal ganglia lesions) underwent salvage resection. Pathological examination revealed teratomatous components in 3 patients, whereas no tumoral components were identified in 2 patients. One patient with a basal ganglia lesion showed worsening of hemiparesis postoperatively. The remaining 25 patients received watchful observation without surgical intervention. Chronological periodic radiological change in residual lesions was evaluated in 21 patients. One year after primary treatment, the size of the residual lesions was stable and had decreased in 10 and 11 patients, respectively. None of the lesions increased in size. The 10-year PFS and OS rates were 96.7% and 97.3% in patients without residual lesions (n = 39), and 87.1% and 100% in patients with residual lesions (n = 30), respectively. Presence of residual lesions had no significant effect on PFS or OS. All recurrences occurred at distant sites or via dissemination without progression of the primary tumor site, regardless of the presence of residual lesion. CONCLUSIONS: End-of-treatment residual lesions are not rare in patients with germinoma, and these residual lesions seldom show progression. Because of the potential risk of surgical complications, the indication for early salvage surgery for residual lesions should be carefully determined. Watchful observation is recommended for the majority of these cases.
• Prominence of NUDT15 genetic variation associated with 6‐mercaptopurine tolerance in a genome‐wide association study of Japanese children with acute lymphoblastic leukaemia

  Yoichi Tanaka, Kevin Y. Urayama, Makiko Mori, Yuki Arakawa, Daisuke Hasegawa, Yasushi Noguchi, Masakatsu Yanagimachi, Dai Keino, Setsuo Ota, Koshi Akahane, Takeshi Inukai, Mayumi Hangai, Takahisa Kawaguchi, Masatoshi Takagi, Katsuyoshi Koh, Fumihiko Matsuda, Atsushi Manabe

  British Journal of Haematology 199 (2) 260 - 269 0007-1048 2022/08/12
• 腹膜透析中に発症した焦点性てんかんに対してラコサミドを導入した小児例の経験

  植田 佑樹, 佐藤 泰征, 林 麻子, 上田 泰弘, 木村 修平, 後藤 健, 中久保 佐千子, 中島 翠, 江川 潔, 岡本 孝之, 白石 秀明, 古堅 彩子, 小林 正紀, 真部 淳

  てんかん研究 (一社)日本てんかん学会 40 (2) 467 - 467 0912-0890 2022/08
• 北海道における成人先天性心疾患の移行医療からみえてくるもの

  武田 充人, 山澤 弘州, 泉 岳, 佐々木 大輔, 永井 礼子, 辻岡 孝郎, 真部 淳

  小児保健研究 (公社)日本小児保健協会 81 (講演集) 134 - 134 0037-4113 2022/05
• A retrospective analysis of azacitidine treatment for juvenile myelomonocytic leukemia.

  Yuko Honda, Hideki Muramatsu, Yuka Nanjo, Shinsuke Hirabayashi, Toru Meguro, Nao Yoshida, Harumi Kakuda, Shuichi Ozono, Manabu Wakamatsu, Hiroshi Moritake, Masahiro Yasui, Hideki Sano, Atsushi Manabe, Kazuo Sakashita

  International journal of hematology 115 (2) 263 - 268 2022/02 

  Juvenile myelomonocytic leukemia (JMML) is a pediatric hematological malignancy with a poor prognosis. Although several case series have been published describing hematological and molecular responses to azacitidine (AZA) treatment in patients with JMML, the efficacy and safety profile of AZA is not well investigated, especially in Asian children and children undergoing hematopoietic stem cell transplantation (HSCT). We retrospectively analyzed 5 patients who received a total of 12 cycles (median 2 cycles) of AZA treatment in Japan. All five patients were boys and their ages at the time of treatment were 21, 23, 24, 26, and 46 months, respectively. All five patients tolerated AZA treatment, including four patients who received AZA after HSCT. Therapeutic toxicity with AZA was mostly limited to hematological toxicity. The only serious non-hematological adverse event was hyperbilirubinemia (grades III-IV) observed in a patient who received AZA after a second HSCT. Two out of five patients treated with AZA achieved a partial response (PR), while three patients treated for post-transplant relapse did not have an objective response. Future prospective studies should be conducted to develop combination therapies with AZA and other molecular targeted drugs for high-risk patients.
• Prospective validation of the provisional entity of refractory cytopenia of childhood, proposed by the World Health Organization.

  Asahito Hama, Daisuke Hasegawa, Atsushi Manabe, Kazue Nozawa, Atsushi Narita, Hideki Muramatsu, Yoshiyuki Kosaka, Masao Kobayashi, Katsuyoshi Koh, Yoshiyuki Takahashi, Kenichiro Watanabe, Akira Ohara, Masafumi Ito, Seiji Kojima

  British journal of haematology 196 (4) 1031 - 1039 2022/02 

  In 2008, the World Health Organization proposed a new entity of childhood myelodysplastic syndrome (MDS), which was referred to as refractory cytopenia of childhood (RCC). However, whether this morphological classification reflects clinical outcomes remains unclear. We performed a prospective evaluation of bone marrow morphology in 252 children with acquired bone marrow failure between 2009 and 2013. Of 252 patients, 63 were diagnosed with aplastic anaemia (AA), 131 with RCC without multilineage dysplasia (RCC-w/o-MLD) and 58 with RCC with MLD (RCC-MLD). One patient with AA, three with RCC-w/o-MLD and nine with RCC-MLD presented with chromosomal abnormalities at diagnosis (P = 0·001). The response rates to immunosuppressive therapy (IST) at 6 months and the cumulative incidence of clonal evolution at 5 years did not significantly differ among the three groups. A multivariate analysis revealed that the morphological classification of RCC-MLD was a significant risk factor for secondary graft failure after haematopoietic cell transplantation (HCT) (P = 0·003). In view of these findings, RCC could be divided into two categories, RCC-w/o-MLD and RCC-MLD, because children with this condition exhibited a distinct morphology, frequent chromosomal abnormalities at diagnosis and a high frequency of secondary graft failure after HCT.
• Factors related to employment in childhood cancer survivors in Japan: A preliminary study.

  Kyoko Kobayashi, Yasushi Ishida, Michiyo Gunji, Kyoko Nagase, Yuri Yoshimoto-Suzuki, Yosuke Hosoya, Daisuke Hasegawa, Atsushi Manabe, Sachiko Ohde, Miwa Ozawa

  Frontiers in pediatrics 10 961935 - 961935 2022 

  PURPOSE: Previous research has revealed vocational and academic difficulties in childhood cancer survivors, and explored impact of survivors' medical history and physical function on vocational and academic status. However, we often encounter survivors with similar diagnoses and late effects but different academic or employment statuses. This raises the question of what affects academic attainment and employment other than treatment or late effects. This study aimed to explore factors associated with childhood cancer survivors' employment status and academic achievement. METHODS: Comprehensive health check-up and questionnaire survey were conducted for 69 survivors who were over the age of 18 and participated in St. Luke's Lifetime cohort study. We obtained survivors' biological function using comprehensive health check-up, neurocognitive states, quality of life, transition readiness, and family function. We conducted univariate analysis (Mann-Whitney U tests or chi-square tests) to compare the differences between the regular workers/students and non-regular workers/unemployed groups. The variables with p-values <0.1 were used as independent variables multivariate logistic regression to explore predictors of employment status and academic attainment. RESULTS: Result of the univariate analysis, intelligence quotient, SF-8 PCS, transition readiness, family function were used for multivariate logistic regression as independent variables. The stepwise likelihood method was conducted; intelligence quotient (odds ratio [OR] = 1.100; 95% confidence interval [CI] 1.015-1.193; p = 0.021), transition readiness (OR = 0.612; 95% CI 0.396-0.974; p = 0.038), and family function (OR = 2.337; 95% CI 1.175-4.645; p = 0.015) were found to be associated with survivors' regular workers/students in the final regression model. CONCLUSION: Long-term follow-up of pediatric cancer survivors requires the provision of total care, which supports physical, psychological, and social functions to improve health, readiness for transition to self-management, and family functioning.
• Significance of active screening for detection of health problems in childhood cancer survivors.

  Yuri Yoshimoto-Suzuki, Daisuke Hasegawa, Yosuke Hosoya, Go Saito, Kyoko Nagase, Michiyo Gunji, Kyoko Kobayashi, Yasushi Ishida, Atsushi Manabe, Miwa Ozawa

  Frontiers in pediatrics 10 947646 - 947646 2022 

  Background: Childhood cancer survivors (CCSs) have a lifelong increased risk of chronic health problems, most of which are associated with the curative therapies. Recent studies have suggested that prospective active screening using comprehensive assessments for CCSs is superior in identifying undiagnosed chronic health problems. Methods: To assess the significance of active screening using comprehensive medical examinations for detecting chronic health problems in multiple organ systems in CCSs, we retrospectively compared the frequency and severity of health problems between two different cohorts of CCSs in a single institution: 110 CCSs who visited the outpatient clinic for regular follow-ups between December 2010 and December 2015 (regular follow-up group) vs. 58 CCSs who underwent comprehensive medical examinations between February 2016 and September 2019 (active screening group). CCSs were defined as patients aged ≥ 18 years who had been diagnosed as having childhood cancer ≥ 10 years before and had survived without cancer for ≥ 5 years. Results: Patient characteristics were similar between the two groups except for primary diagnosis (more brain tumors and embryonal tumors in the active screening group) and treatment history (more alkylating agents used and surgical interventions performed in the active screening group). The prevalence and the median number of health problems were significantly higher in the active screening group than in the regular follow-up group: 93% vs. 67% and 1.0 [0.0-8.0] vs. 2.0 [0.0-7.0] respectively. In term of organ-specific health problems, pulmonary dysfunction, neurocognitive impairment, ocular abnormalities, and dental abnormalities were identified more in the active screening group, partly because these problems had not been assessed in the regular follow-up group. Nevertheless, the prevalence of grade 3-5 health problems was similar between the two groups, except for pulmonary dysfunction. Conclusion: Active screening using comprehensive medical examinations was effective for identifying health problems in CCSs. Although the prevalence of severe problems identified by both approaches was similar, comprehensive medical examinations could detect overlooked problems such as severe pulmonary dysfunction, dental maldevelopment, and borderline intellectual functioning, which might have an impact on quality of life in CCSs.
• Intrathecal therapy in acute lymphoblastic leukemia case with spinal deformity.

  Yurika Kuroko, Hiroki Yoshihara, Yosuke Hosoya, Atsushi Manabe, Daisuke Hasegawa

  Pediatrics international : official journal of the Japan Pediatric Society 64 (1) e14845  2022/01
• Hepatoblastoma with bone/bone marrow metastasis in Li-Fraumeni syndrome patient.

  Masataka Hasegawa, Minako Sugiyama, Yukayo Terashita, Yuko Cho, Atsushi Manabe

  Pediatrics international : official journal of the Japan Pediatric Society 64 (1) e15135  2022/01
• NUDT15 variants confer high incidence of second malignancies in children with acute lymphoblastic leukemia.

  Masanori Yoshida, Kazuhiko Nakabayashi, Wentao Yang, Aiko Sato-Otsubo, Shin-Ichi Tsujimoto, Hiroko Ogata-Kawata, Tomoko Kawai, Keisuke Ishiwata, Mika Sakamoto, Kohji Okamura, Kaoru Yoshida, Ryota Shirai, Tomoo Osumi, Takaya Moriyama, Rina Nishii, Hiroyuki Takahashi, Chikako Kiyotani, Yoko Shioda, Keita Terashima, Sae Ishimaru, Yuki Yuza, Masatoshi Takagi, Yuki Arakawa, Akitoshi Kinoshita, Moeko Hino, Toshihiko Imamura, Daisuke Hasegawa, Yozo Nakazawa, Mayuko Okuya, Harumi Kakuda, Nao Takasugi, Akiko Inoue, Kentaro Ohki, Takako Yoshioka, Shuichi Ito, Daisuke Tomizawa, Katsuyoshi Koh, Kimikazu Matsumoto, Masashi Sanada, Nobutaka Kiyokawa, Akira Ohara, Seishi Ogawa, Atsushi Manabe, Akira Niwa, Kenichiro Hata, Jun J Yang, Motohiro Kato

  Blood advances 5 (23) 5420 - 5428 2021/12/14 

  The effect of genetic variation on second malignant neoplasms (SMNs) remains unclear. First, we identified the pathogenic germline variants in cancer-predisposing genes among 15 children with SMNs after childhood leukemia/lymphoma using whole-exome sequencing. Because the prevalence was low, we focused on the association between SMNs and NUDT15 in primary acute lymphoblastic leukemia (ALL) cases. NUDT15 is one of the 6-mercaptopurine (6-MP) metabolic genes, and its variants are common in East Asian individuals. The prevalence of NUDT15 hypomorphic variants was higher in patients with SMNs (n = 14; 42.9%) than in the general population in the gnomAD database (19.7%; P = .042). In the validation study with a cohort of 438 unselected patients with ALL, the cumulative incidence of SMNs was significantly higher among those with (3.0%; 95% confidence interval [CI], 0.6% to 9.4%) than among those without NUDT15 variants (0.3%; 95% CI, 0.0% to 1.5%; P = .045). The 6-MP dose administered to patients with ALL with a NUDT15 variant was higher than that given to those without SMNs (P = .045). The 6-MP-related mutational signature was observed in SMN specimens after 6-MP exposure. In cells exposed to 6-MP, a higher level of 6-MP induced DNA damage in NUDT15-knockdown induced pluripotent stem cells. Our study indicates that NUDT15 variants may confer a risk of SMNs after treatment with 6-MP in patients with ALL.
• Notable therapeutic response in a patient with systemic juvenile xanthogranuloma with KIF5B-ALK fusion.

  Minako Sugiyama, Shinsuke Hirabayashi, Yukitomo Ishi, Junko Kikuchi, Ayako Ishikura, Hiroaki Motegi, Yuki Ueda, Saori Sawai, Kazuya Hara, Yukayo Terashita, Yuko Cho, Emi Takakuwa, Shohei Honda, Shigeru Yamaguchi, Ichiro Kinoshita, Atsushi Manabe

  Pediatric blood & cancer 68 (11) e29227  2021/11
• Hematopoietic stem cell transplantation for infants with high-risk KMT2A gene-rearranged acute lymphoblastic leukemia.

  Takayuki Takachi, Tomoyuki Watanabe, Takako Miyamura, Akiko Moriya Saito, Takao Deguchi, Toshinori Hori, Tomomi Yamada, Shigeru Ohmori, Masami Haba, Yuki Aoki, Sae Ishimaru, Shinya Sasaki, Junjiro Ohshima, Akihiro Iguchi, Yoshiyuki Takahashi, Nobuyuki Hyakuna, Atsushi Manabe, Keizo Horibe, Eiichi Ishii, Katsuyoshi Koh, Daisuke Tomizawa

  Blood advances 5 (19) 3891 - 3899 2021/10/12 

  The role of allogeneic hematopoietic stem cell transplantation (HSCT) for infants with acute lymphoblastic leukemia (ALL) and KMT2A gene rearrangement (KMT2A-r) is controversial in terms of both its efficacy and potential for acute and late toxicities. In Japanese Pediatric Leukemia/Lymphoma Study Group trial MLL-10, by introducing intensive chemotherapy, indication of HSCT was restricted to patients with high-risk (HR) features only (KMT2A-r and either age <180 days or presence of central nervous system leukemia). Of the 56 HR patients, 49 achieved complete remission. Forty-three patients received HSCT in first remission including 38 patients receiving protocol-specified HSCT with conditioning consisting of individualized targeted doses of busulfan, etoposide, and cyclophosphamide. Three-year event-free survival (EFS) of 56.8% (95% confidence interval [CI], 42.4% to 68.8%) and overall survival of 80.2% (95% CI, 67.1% to 88.5%) were accomplished. Univariable analysis showed that Interfant-HR criteria and flow cytometric minimal residual disease (MRD; ≥0.01%), both at the end of induction and at the end of consolidation (EOC), were significantly associated with poorer EFS. In the multivariable analysis, positive MRD at EOC was solely associated with poor EFS (P < .001). Rapid pretransplant MRD clearance and tailored HSCT strategy in the MLL-10 trial resulted in a favorable outcome for infants with HR KMT2A-r ALL. However, considering the high rate of potentially life-threatening toxicities and the risk of late effects, its indication should be further restricted or even eliminated in the future by introducing more effective therapeutic modalities with minimal toxicities. This trial was registered at the University Hospital Medical Information Network Clinical Trials Registry (UMIN-CTR) as #UMIN000004801.
• 芽球性形質細胞様樹状細胞腫瘍の小児に対する造血細胞移植を回避した治療(Treatment in pediatric blastic plasmacytoid dendritic cell neoplasm(BPDCN) without transplantation)

  足洗 美穂, 西村 聡, 水城 和義, 出口 隆生, 真部 淳, 長谷川 大輔

  日本血液学会学術集会 83回 PS - 5 2021/09
• Prospective validation of the provisional entity of RCC proposed by the WHO(和訳中)

  濱 麻人, 真部 淳, 長谷川 大輔, 野沢 和江, 成田 敦, 村松 秀城, 高橋 義行, 渡邉 健一郎, 小原 明, 伊藤 雅文, 小島 勢二

  日本血液学会学術集会 83回 OS1 - 2 2021/09
• Treatment in pediatric blastic plasmacytoid dendritic cell neoplasm(BPDCN) without transplantation(和訳中)

  足洗 美穂, 西村 聡, 水城 和義, 出口 隆生, 真部 淳, 長谷川 大輔

  日本血液学会学術集会 83回 PS - 5 2021/09
• Risk factors for hospitalisation due to respiratory syncytial virus infection in children receiving prophylactic palivizumab.

  Ayako Chida-Nagai, Hiroki Sato, Itsumi Sato, Masahiro Shiraishi, Daisuke Sasaki, Gaku Izumi, Hirokuni Yamazawa, Kazutoshi Cho, Atsushi Manabe, Atsuhito Takeda

  European journal of pediatrics 181 (2) 539 - 547 2021/08/21 

  Respiratory syncytial virus (RSV) is a common pathogen that causes extremely severe respiratory symptoms in the first few weeks and months of life. In infants with cardiopulmonary diseases, RSV infections have a significant clinical impact. Palivizumab, a humanised monoclonal antibody for RSV, has been shown to significantly reduce the rate of hospitalisation of high-risk infants diagnosed with RSV. However, we have experienced a significant number of RSV infections in our institution that required hospitalisation or intensive care, despite the administration of palivizumab. This study aimed to analyse the risk factors associated with severe RSV despite the use of palivizumab. We retrospectively reviewed the medical records of 688 patients who visited or were admitted to our hospital and received palivizumab. Thirty-seven (5.4%) patients required hospitalisation for RSV, despite receiving palivizumab. In addition, 31 of these patients (83.8%) required hospitalisation out of season for palivizumab injection. Preterm birth (≤ 28-week gestation), bronchopulmonary dysplasia (BPD), and trisomy 21 were risk factors for RSV-related hospitalisation in infected patients, despite receiving palivizumab. Furthermore, subgroup analysis of 69 patients with RSV revealed that hemodynamically significant congenital heart disease (CHD) was also a risk factor for RSV-related hospitalisation.Conclusion: Preterm birth (≤ 28 weeks of gestation), BPD, trisomy 21, hemodynamically significant CHD, and CHD requiring surgery or cardiac catheterisation/intervention during infancy could be considered when determining whether year-round administration of palivizumab is appropriate. What is Known: • Respiratory syncytial virus causes severe respiratory symptoms in infants, particularly those with cardiopulmonary diseases. • The use of palivizumab has reduced the rate of hospitalisation of infants diagnosed with RSV. Despite this, the rate of hospitalisation is still high. What is New: • We identified that preterm birth (≤ 28-week gestation), bronchopulmonary dysplasia, trisomy 21, and hemodynamically significant congenital heart disease were risk factors for RSV-related hospitalisation, even after receiving palivizumab treatment. • High-risk infants should be closely monitored and the prolonged use of palivizumab should be considered.
• Clonal evidence for the development of neuroblastoma with extensive copy-neutral loss of heterozygosity arising in a mature teratoma.

  Rintaro Ono, Hiroo Ueno, Kenichi Yoshida, Satoko Takahashi, Hiroki Yoshihara, Taiki Nozaki, Koyu Suzuki, Atsuko Nakazawa, Ryunosuke Saiki, Masafumi Seki, Junko Takita, Seishi Ogawa, Atsushi Manabe, Daisuke Hasegawa

  Cancer science 112 (7) 2921 - 2927 2021/07 

  Mature teratomas are usually benign tumors that rarely undergo malignant transformation. We report an advanced neuroblastoma arising in a mature teratoma of the ovary. Whole-exome sequencing identified extensive copy-neutral loss of heterozygosity (LOH) in both neuroblastoma and teratoma elements, suggesting that the neuroblastoma evolved from the teratoma. In addition, several truncating germline heterozygous variants in tumor suppressor genes, including RBL2 and FBXW12, became homozygous as a result of LOH. Collectively, we speculate that extensive LOH in teratoma cells may force heterozygous germline variants to become homozygous, which, in turn, may contribute to the development of neuroblastoma with the acquisition of additional chromosomal changes.
• Extremely low 18F-fluorodeoxyglucose uptake in the brain of a patient with metastatic neuroblastoma and its recovery after chemotherapy: A case report.

  Yutaka Hoshino, Minako Sugiyama, Kenji Hirata, Shohei Honda, Hitoshi Saito, Atsushi Manabe, Kohsuke Kudo

  Acta radiologica open 10 (7) 20584601211026810 - 20584601211026810 2021/07 

  Commonly, physiological 18F-fluorodeoxyglucose (FDG) uptake in the brain can be observed in 18F-FDG positron emission tomography. Abnormal uptake of 18F-FDG in the brain suggests disorders of central nervous system. Here, we present a case of extremely low 18F-FDG uptake in the brain of a 4-year-old girl with whole-body metastatic neuroblastoma. Almost missing of physiological 18F-FDG uptake in the brain was ascribed at least partly to the metastatic neuroblastoma. The brain could regain physiological 18F-FDG uptake after chemotherapy.
• Absent XIAP expression in T cell blasts and causal XIAP mutations including non-coding deletion.

  Shimaa Said Mohamed Ali Abdrabou, Nariaki Toita, Shin Ichihara, Yusuke Tozawa, Michiko Takahashi, Shin-Ichi Fujiwara, Toshifumi Ashida, Osamu Ohara, Tadashi Ariga, Atsushi Manabe, Mutsuko Konno, Masafumi Yamada

  Pediatrics international : official journal of the Japan Pediatric Society 64 (1) e14892  2021/06/18 

  BACKGROUND: X-linked inhibitor of apoptosis protein (XIAP) deficiency is one of inborn errors of immunity characterized by recurrent hemophagocytic lymphohistiocytosis (HLH) and refractory inflammatory bowel disease (IBD) mimicking Crohn's disease (CD). The aim of this study is to make accurate diagnosis of XIAP deficiency based on genetic and XIAP expression studies and to investigate endoscopic findings shared by patients with this disease. METHODS: Four male patients with recurrent HLH and long-term refractory IBD were studied for the diagnosis of XIAP deficiency. Parallelly, endoscopic findings of the four patients were also studied. RESULTS: These four patients were diagnosed with XIAP deficiency based on the absent XIAP expression in cultured T-cell blasts. Sequence analysis of the responsible gene, XIAP, demonstrated two novel nonsense mutations of p.Gln114X and p.Glu25X, and a previously reported nonsense mutation of p.Arg381X. Although no mutations in the coding region were detected in the fourth patient, further studies demonstrated a novel 2199 bp deletion encompassing non-coding exon 1, presumably affecting transcription and stability of XIAP mRNA. All of the patients eventually underwent hematopoietic stem cell transplantation, leading to a complete or partial remission of IBD. These four patients shared an endoscopic finding of multiple wide and longitudinal ulcers with straight and non-raised edge in the colon. CONCLUSIONS: XIAP expression in T-cell blasts could facilitate the diagnosis of this disease especially with causal mutations in non-coding regions.
• Clinical significance of comprehensive genomic profiling tests covered by public insurance in patients with advanced solid cancers in Hokkaido, Japan

  Junko Kikuchi, Yoshihito Ohhara, Kohichi Takada, Hiroki Tanabe, Kazuteru Hatanaka, Toraji Amano, Kanako C Hatanaka, Yutaka Hatanaka, Takashi Mitamura, Momoko Kato, Yuka Shibata, Ichiro Yabe, Akira Endoh, Yoshito Komatsu, Yoshihiro Matsuno, Minako Sugiyama, Atsushi Manabe, Akihiro Sakurai, Masato Takahashi, Hirohito Naruse, Yoshihiro Torimoto, Hirotoshi Dosaka-Akita, Ichiro Kinoshita

  Japanese Journal of Clinical Oncology 51 (5) 753 - 761 2021/04/30 

  Comprehensive cancer genomic profiling has been used recently for patients with advanced solid cancers. Two cancer genomic profiling tests for patients with no standard treatment are covered by Japanese public health insurance since June 2019. We prospectively analyzed data of 189 patients with solid cancers who underwent either of the two-cancer genomic profiling tests at Hokkaido University Hospital and its liaison hospitals and whose results were discussed in molecular tumor board at Hokkaido University Hospital between August 2019 and July 2020. All 189 patients had appropriate results. Actionable gene alterations were identified in 93 patients (49%). Frequent mutations included PIK3CA (12%) mutation, BRCA1/2 alteration (7%), ERBB2 amplification (6%) and tumor mutation burden-High (4%). The median turnaround time from sample shipping to acquisition by the expert panel was 26 days. Although 115 patients (61%) were provided with information for genotype-matched therapies, only 21 (11%) received them. Notably, four of eight patients below the age of 20 years were provided information for genotype-matched therapies, and three received them. Their response rates and disease control rates were 29% and 67%, respectively. Most patients who did not undergo the genotype-matched therapies were provided information for only investigational drugs in phases I and II at distant clinical trial sites in central Japan. Twenty-six patients were informed of suspected germline findings, while 11 patients (42%) received genetic counseling. The publicly reimbursed cancer genomic profilings may lead to the modest but favorable therapeutic efficacy of genotype-matched therapy for solid cancer patients with no standard therapy. However, poor access to genotype-matched therapy needs to be resolved.
• Flurothyl-induced seizure paradigm revealed higher seizure susceptibility in middle-aged Angelman syndrome mouse model.

  Kiyoshi Egawa, Sachiko Nakakubo, Shuhei Kimura, Takeru Goto, Atsushi Manabe, Hideaki Shiraishi

  Brain & development 43 (4) 515 - 520 2021/04 

  INTRODUCTION: Epilepsy is one of the main clinical problems in Angelman syndrome (AS). Seizures typically start in early childhood then decrease or are often alleviated by young adulthood. Several studies using AS model mice showed comparable seizure susceptibility during young adulthood. In contrast, the course of epilepsy post young adulthood differs from persistently relieved to rerising among reports. To elucidate this, we evaluated the seizure susceptibility of AS model mice of two different ages. METHODS: Mice lacking maternal Ube3a gene (Ube3am-/p+) of C57BL/6 background or their littermate wild type (WT) were divided into two groups by age, 2 to 3 months (2-3 M) and 6 to 12 months (6-12 M), corresponding to adolescent to young adult aged and middle aged humans, respectively. Seizure susceptibility was evaluated by flurothyl inhalation or intraperitoneal injection of pentylenetetrazole (PTZ IP)-induced acute seizure protocol. RESULTS: In the flurothyl-induced seizure paradigm, the latency to seizure occurrence had a significant interaction with genotype and age. Post-hoc analysis revealed that the latency was significantly shorter at 6-12 M than at 2-3 M in Ube3am-/p+ mice, and in Ube3am-/p+ mice than in WT mice at 6-12 M. No significant interaction or difference was observed by PTZ IP. CONCLUSION: The flurothyl-induced seizure paradigm revealed that seizure susceptibility of Ube3am-/p+ mice increased with age, similar to clinical studies reporting the reappearance of epilepsy in older age. The flurothyl-induced seizure paradigm applied to middle-aged Ube3am-/p+ mice could be a suitable protocol for screening drugs against seizures in AS.
• Incidence of alveolar capillary dysplasia with misalignment of pulmonary veins in infants with unexplained severe pulmonary hypertension: The roles of clinical, pathological, and genetic testing.

  Tetsuo Onda, Takuma Akimoto, Itaru Hayasaka, Masahiko Ikeda, Yuta Furuse, Akiko Ando, Yuichi Nakamura, Ryota Honjo, Atsushi Manabe, Itsuko Furuta, Kazutoshi Cho

  Early human development 155 105323 - 105323 2021/04 

  BACKGROUND: Alveolar capillary dysplasia with misalignment of pulmonary veins (ACDMPV) is a rare and fatal disorder that occurs in the developing fetal lungs; at birth, infants exhibit an oxygenation disorder accompanied by severe pulmonary hypertension (PH) and have a very short life span. ACDMPV is definitively diagnosed by pathological findings, and infants born with unexplained severe PH may not be properly diagnosed without a biopsy or autopsy. METHODS: Japanese infants with unexplained severe PH were enrolled in this study. Genetic analyses were performed on DNA extracted from peripheral blood leukocytes. Sanger sequencing or next-generation sequencing was performed by coding exons and introns for FOXF1 in all samples. For individuals without pathogenic exonic variants, multiplex ligation-dependent probe amplification was performed to identify copy number variations (CNVs) in exons, introns, and in the upstream region of FOXF1. RESULTS: This study included 30 infants who were diagnosed over the course of nine years. Four individuals had the pathogenic variations on the exon 1 of FOXF1, including two frameshift and two missense variations. Pathogenic CNVs were found in another five individuals. CONCLUSION: In the pathologically proven ACDMPV patients, the ratios of cases with exonic variations, CNVs, and no genetic findings were reported as 45%, 45% and 10%, respectively. We estimate that about 30% (10 (9 + 1) out of 30) of individuals with unexplained severe PH had ACDMPV.
• High-grade neuroepithelial tumor with BCL6 corepressor-alteration presenting pathological and radiological calcification: A case report.

  Yukitomo Ishi, Ai Shimizu, Emi Takakuwa, Minako Sugiyama, Michinari Okamoto, Hiroaki Motegi, Shinsuke Hirabayashi, Yuko Cho, Akihiro Iguchi, Atsushi Manabe, Sumihito Nobusawa, Shinya Tanaka, Shigeru Yamaguchi

  Pathology international 71 (5) 348 - 354 2021/03/13 

  A 5-year-old girl presented with headache and vomiting. Head computed tomography and magnetic resonance imaging showed a right frontal lobe tumor with marked calcification. The patient underwent resection surgery with suspicion of anaplastic ependymoma, and the tumor was gross totally removed. Pathological examination revealed areas of dense tumor cells with a high nucleocytoplasmic ratio and myxoid areas consisting of tumor cells with a round-shaped nucleus and eosinophilic cytoplasm. Perivascular pseudorosette, necrosis, circumscribed growth, and microcalcification were also observed. Immunohistochemistry demonstrated negative staining for glial fibrillary protein and epithelial membrane antigen. Diagnosis of a high-grade neuroepithelial tumor (HGNET) with BCL6 corepressor (BCOR) alteration was made based on pathological findings and internal tandem duplication in the exon 15 of BCOR. Although calcification on radiological and pathological examination is not typical, it would be essential to recognize that calcification could appear in HGNET-BCOR.
• Clinical characteristics and outcomes of B-ALL with ZNF384 rearrangements: a retrospective analysis by the Ponte di Legno Childhood ALL Working Group.

  Shinsuke Hirabayashi, Ellie R Butler, Kentaro Ohki, Nobutaka Kiyokawa, Anke K Bergmann, Anja Möricke, Judith M Boer, Hélène Cavé, Giovanni Cazzaniga, Allen Eng Juh Yeoh, Masashi Sanada, Toshihiko Imamura, Hiroto Inaba, Charles Mullighan, Mignon L Loh, Ulrika Norén-Nyström, Agata Pastorczak, Lee-Yung Shih, Marketa Zaliova, Ching-Hon Pui, Oskar A Haas, Christine J Harrison, Anthony V Moorman, Atsushi Manabe

  Leukemia 35 (11) 3272 - 3277 2021/03/10
• In-Hospital Management Might Reduce Induction Deaths in Pediatric Patients With Acute Lymphoblastic Leukemia: Results From a Japanese Cohort.

  Shunsuke Nakagawa, Motohiro Kato, Toshihiko Imamura, Chihaya Imai, Katsuyoshi Koh, Yoshifumi Kawano, Yasuto Shimomura, Arata Watanabe, Atsushi Kikuta, Akiko Saito, Keizo Horibe, Atsushi Manabe, Akira Ohara, Yasuhiro Okamoto

  Journal of pediatric hematology/oncology 43 (2) 39 - 46 2021/03/01 

  Induction deaths (ID) remain a critical issue in the treatment of pediatric patients with acute lymphoblastic leukemia (ALL). The reported rate of ID in this population is 1% or higher. We speculate that this proportion might be lower in Japan because of mandatory hospitalization during induction therapy to manage complications. We retrospectively analyzed the incidence of ID among children with ALL enrolled in 4 Japanese study groups between 1994 and 2013. Among 5620 children, 41 (0.73%) cases of ID were noted. The median age was 6.5 years; 24 children were female, and 7 had T-cell ALL. Infection was the most common cause of ID (n=22), but the incidence (0.39%) was lower than that reported in western countries. Mortality within 48 hours from the onset of infection was low, comprising 25% of infection-related deaths. The incidence of infections caused by Bacillus species was low. Only 1 patient died because of Aspergillus infection. Fatal infections mostly occurred during the third week of induction therapy. Our findings suggest that close monitoring, stringent infection control, and immediate administration of appropriate antibiotics through hospitalization might be important strategies in reducing the rate of infection-related ID in pediatric patients with ALL.
• 生後早期に血管内塞栓術を施行したガレン大静脈瘤の早産児例

  本庄 遼太, 中村 雄一, 安藤 明子, 恩田 哲雄, 古瀬 優太, 長 和俊, 武田 充人, 真部 淳

  日本小児科学会雑誌 (公社)日本小児科学会 125 (2) 348 - 348 0001-6543 2021/02
• 先天性心疾患術後から乳び胸管理に難渋しリンパ管造影を実施したヌーナン症候群の乳児例

  佐藤 逸美, 白石 真大, 佐々木 大輔, 永井 礼子, 泉 岳, 山澤 弘州, 武田 充人, 真部 淳

  日本小児科学会雑誌 (公社)日本小児科学会 125 (2) 318 - 318 0001-6543 2021/02
• Ruxolitinib for hematopoietic cell transplantation-associated hemophagocytic lymphohistiocytosis.

  Rintaro Ono, Miho Ashiarai, Shinsuke Hirabayashi, Kazuyoshi Mizuki, Yosuke Hosoya, Hiroki Yoshihara, Junya Ohtake, Shinichiro Mori, Atsushi Manabe, Daisuke Hasegawa

  International journal of hematology 113 (2) 297 - 301 2021/02 

  Hemophagocytic lymphohistiocytosis (HLH) is a severe complication after allogeneic hematopoietic cell transplantation (HCT) and can cause graft failure or multi-organ failure. Here, we report two children with refractory HCT-associated HLH treated with ruxolitinib. In the first patient, ruxolitinib resolved fever, cytopenia and hyperferritinemia. In another patient, although severe hepatic failure, which developed and worsened before the administration of ruxolitinib, was irreversible, rapid improvement in fever, leukopenia and hyperferritinemia was observed. Of note, multiplex cytokine profiling showed amelioration of cytokine storm in both patients. Ruxolitinib may be an encouraging option for HCT-associated HLH.
• Acquisition of monosomy 7 and a RUNX1 mutation in Pearson syndrome.

  Akira Nishimura, Shinsuke Hirabayashi, Daisuke Hasegawa, Kenichi Yoshida, Yuichi Shiraishi, Miho Ashiarai, Yosuke Hosoya, Tohru Fujiwara, Hideo Harigae, Satoru Miyano, Seishi Ogawa, Atsushi Manabe

  Pediatric blood & cancer 68 (2) e28799  2021/02 

  Pearson syndrome (PS) is a very rare and often fatal multisystem disease caused by deletions in mitochondrial DNA that result in sideroblastic anemia, vacuolization of marrow precursors, and pancreatic dysfunction. Spontaneous recovery from anemia is often observed within several years of diagnosis. We present the case of a 4-month-old male diagnosed with PS who experienced prolonged severe pancytopenia preceding the emergence of monosomy 7. Whole-exome sequencing identified two somatic mutations, including RUNX1 p.S100F that was previously reported as associated with myeloid malignancies. The molecular defects associated with PS may have the potential to progress to advanced myelodysplastic syndrome .
• Correction to: FLEND (nelarabine, fludarabine, and etoposide) for relapsed T-cell acute lymphoblastic leukemia in children: a report from Japan Children's Cancer Group.

  Tadashi Kumamoto, Hiroaki Goto, Chitose Ogawa, Toshinori Hori, Takao Deguchi, Takuya Araki, Akiko M Saito, Atsushi Manabe, Keizo Horibe, Hidemi Toyoda

  International journal of hematology 113 (2) 308 - 309 2021/02
• An international retrospective study for tolerability of 6-mercaptopurine on NUDT15 bi-allelic variants in children with acute lymphoblastic leukemia.

  Yoichi Tanaka, Allen Eng Juh Yeoh, Takaya Moriyama, Chi-Kong Li, Ko Kudo, Yuki Arakawa, Jassada Buaboonnam, Hui Zhang, Hsi-Che Liu, Hany Ariffin, Zhiwei Chen, Shirley K Y Kham, Rina Nishii, Daisuke Hasegawa, Junya Fujimura, Dai Keino, Kensuke Kondoh, Atsushi Sato, Takahiro Ueda, Masaki Yamamoto, Yuichi Taneyama, Moeko Hino, Masatoshi Takagi, Akira Ohara, Etsuro Ito, Katsuyoshi Koh, Hiroki Hori, Atsushi Manabe, Jun J Yang, Motohiro Kato

  Haematologica 106 (7) 2026 - 2029 2021/01/28 

  Not available.
• Vaginal Transmission of Cancer from Mothers with Cervical Cancer to Infants.

  Ayumu Arakawa, Hitoshi Ichikawa, Takashi Kubo, Noriko Motoi, Tadashi Kumamoto, Miho Nakajima, Kan Yonemori, Emi Noguchi, Kuniko Sunami, Kouya Shiraishi, Hiroki Kakishima, Hiroshi Yoshida, Tomoro Hishiki, Naonori Kawakubo, Takafumi Kuroda, Takako Kiyokawa, Kyosuke Yamada, Nozomu Yanaihara, Kazuaki Takahashi, Aikou Okamoto, Shinsuke Hirabayashi, Daisuke Hasegawa, Atsushi Manabe, Kentaro Ono, Masaki Matsuoka, Yasuhito Arai, Yosuke Togashi, Tatsuhiro Shibata, Hiroyoshi Nishikawa, Kazunori Aoki, Noboru Yamamoto, Takashi Kohno, Chitose Ogawa

  The New England journal of medicine 384 (1) 42 - 50 2021/01/07 

  Two cases of pediatric lung cancer (in 23-month-old and 6-year-old boys) resulting from mother-to-infant transmission of uterine cervical tumors were incidentally detected during routine next-generation sequencing of paired samples of tumor and normal tissue. Spontaneous regression of some lesions in the first child and slow growth of the tumor mass in the second child suggested the existence of alloimmune responses against the transmitted tumors. Immune checkpoint inhibitor therapy with nivolumab led to a strong regression of all remaining tumors in the first child. (Funded by the Japan Agency for Medical Research and Development and others; TOP-GEAR UMIN Clinical Trials Registry number, UMIN000011141.).
• Diagnostic Capability of Cerebrospinal Fluid-Placental Alkaline Phosphatase Value in Intracranial Germ Cell Tumor.

  Michinari Okamoto, Shigeru Yamaguchi, Yukitomo Ishi, Hiroaki Motegi, Takashi Mori, Takayuki Hashimoto, Yukayo Terashita, Shinsuke Hirabayashi, Minako Sugiyama, Akihiro Iguchi, Yuko Cho, Atsushi Manabe, Kiyohiro Houkin

  Oncology 99 (1) 23 - 31 2021 

  OBJECTIVE: Most types of intracranial germ cell tumors (IGCTs) are sensitive to chemoradiation. However, biopsy specimens are usually small and thus cannot be used for obtaining an accurate pathological diagnosis. Recently, the cerebrospinal fluid (CSF) placental alkaline phosphatase (PLAP) value has been considered a new biomarker of IGCTs. The present study aimed to evaluate the discriminatory characteristics of the CSF-PLAP value upon diagnosis and at the time of recurrence in patients with IGCTs. METHODS: Between 2015 and 2019, this study included 37 patients with tumors located in the intraventricular and/or periventricular region. The CSF-PLAP level was assessed before the patients received any treatment. The PLAP level was evaluated during and after first-line chemoradiotherapy in 7 patients with IGCTs. The CSF-PLAP values were compared according to histological diagnosis, and the correlation between these values and radiographical features was assessed. The CSF-PLAP values of 6 patients with IGCTs with suspected recurrence were evaluated based on neuroimaging findings. RESULTS: The CSF-PLAP values were significantly higher in patients with IGCTs than in those with other types of brain tumor (n = 19 vs. 18; median: 359.0 vs. <8.0 pg/mL). The specificity and sensitivity were 88 and 95%, respectively, with a cutoff value of 8.0 pg/mL. In patients with IGCT, the CSF-PLAP value was higher in patients with germinoma than in those with nongerminomatous germ cell tumors (n = 12 vs. 7; median: 415.0 vs. 359.0 pg/mL). Regarding the time course, the CSF-PLAP value decreased to below the detection limit after the reception of first-line chemoradiotherapy in all 7 patients. A significant correlation was observed between the initial CSF-PLAP value and the tumor reduction volume after receiving first-line chemoradiotherapy (p < 0.0003, R2 = 0.6165, logY = 1.202logX - 1.727). Among the patients with suspected IGCT recurrence (n = 6), the CSF-PLAP value was high in patients with recurrence (n = 3; median: 259.0 pg/mL), and that in patients (n = 3) without recurrence was below the lower detection limit. CONCLUSIONS: The CSF-PLAP level is a useful biomarker during the initial diagnosis of IGCTs and at the time of recurrence. It may be associated with the volume of germinomatous components of tumors.
• CAN HIGH LEVEL SERUM HCG-B BE CONSIDERED EQUIVALENT TO A DIAGNOSIS OF CHORIOCARCINOMA IN PRIMARY CENTRAL NERVOUS SYSTEM GERM-CELL TUMOR?

  Hiroaki Motegi, Shigeru Yamaguchi, Yukitomo Ishi, Michinari Okamoto, Akihiro Iguchi, Yuko Cho, Minako Sugiyama, Atsushi Manabe, Kiyohiro Houkin

  NEURO-ONCOLOGY 22 329 - 330 1522-8517 2020/12 [Refereed]
  
• 当院の先天性門脈体循環シャント症例の臨床検討

  辻岡 孝郎, 泉 岳, 武田 充人, 小杉山 清隆, 山澤 弘州, 谷口 宏太, 永井 礼子, 本多 昌平, 阿保 大介, 川村 典生, 真部 淳

  日本小児循環器学会雑誌 (NPO)日本小児循環器学会 36 (Suppl.2) s2 - 356 0911-1794 2020/11
• 当院の先天性門脈体循環シャント症例の臨床検討

  辻岡 孝郎, 泉 岳, 武田 充人, 小杉山 清隆, 山澤 弘州, 谷口 宏太, 永井 礼子, 本多 昌平, 阿保 大介, 川村 典生, 真部 淳

  日本小児循環器学会雑誌 (NPO)日本小児循環器学会 36 (Suppl.2) s2 - 356 0911-1794 2020/11
• FLEND (nelarabine, fludarabine, and etoposide) for relapsed T-cell acute lymphoblastic leukemia in children: a report from Japan Children's Cancer Group.

  Tadashi Kumamoto, Hiroaki Goto, Chitose Ogawa, Toshinori Hori, Takao Deguchi, Takuya Araki, Akiko M Saito, Atsushi Manabe, Keizo Horibe, Hidemi Toyoda

  International journal of hematology 112 (5) 720 - 724 2020/11 

  Nelarabine is a key drug for T-cell acute lymphoblastic leukemia (T-ALL). Fludarabine and etoposide might have synergistic effect with nelarabine by inhibiting ribonucleotide reductase and by preparing cell cycle for G1/S phase, respectively. We had started phase 1/2 multicenter clinical trial of combination chemotherapy consisted of nelarabine, fludarabine, and etoposide (FLEND therapy) for children with relapsed/refractory T-ALL which has been conducted since October 2011. Although we could not complete this trial because of recruitment difficulties, we treated five children with first-relapsed T-ALL which were enrolled in the phase 1 dose escalation study of fludarabine and etoposide with nelarabine. No dose-limiting toxicity occurred, and frequent grade 3-4 toxicity was hematological toxicity and febrile neutropenia, as expected. There was no neurotoxicity. All 2 patients who received the target dose of FLEND, in which nelarabine (650 mg/m2), fludarabine (30 mg/m2), and etoposide (100 mg/m2) were administered for 5 consecutive days, were induced to complete remission. We concluded that FLEND might be safe and one of the promising combination chemotherapies to relapsed/refractory T-ALL.
• Landscape of driver mutations and their clinical impacts in pediatric B-cell precursor acute lymphoblastic leukemia.

  Hiroo Ueno, Kenichi Yoshida, Yusuke Shiozawa, Yasuhito Nannya, Yuka Iijima-Yamashita, Nobutaka Kiyokawa, Yuichi Shiraishi, Kenichi Chiba, Hiroko Tanaka, Tomoya Isobe, Masafumi Seki, Shunsuke Kimura, Hideki Makishima, Masahiro M Nakagawa, Nobuyuki Kakiuchi, Keisuke Kataoka, Tetsuichi Yoshizato, Dai Nishijima, Takao Deguchi, Kentaro Ohki, Atsushi Sato, Hiroyuki Takahashi, Yoshiko Hashii, Sadao Tokimasa, Junichi Hara, Yoshiyuki Kosaka, Koji Kato, Takeshi Inukai, Junko Takita, Toshihiko Imamura, Satoru Miyano, Atsushi Manabe, Keizo Horibe, Seishi Ogawa, Masashi Sanada

  Blood advances 4 (20) 5165 - 5173 2020/10/27 

  Recent genetic studies using high-throughput sequencing have disclosed genetic alterations in B-cell precursor acute lymphoblastic leukemia (B-ALL). However, their effects on clinical outcomes have not been fully investigated. To address this, we comprehensively examined genetic alterations and their prognostic impact in a large series of pediatric B-ALL cases. We performed targeted capture sequencing in a total of 1003 pediatric patients with B-ALL from 2 Japanese cohorts. Transcriptome sequencing (n = 116) and/or array-based gene expression analysis (n = 120) were also performed in 203 (84%) of 243 patients who were not categorized into any disease subgroup by panel sequencing or routine reverse transcription polymerase chain reaction analysis for major fusions in B-ALL. Our panel sequencing identified novel recurrent mutations in 2 genes (CCND3 and CIC), and both had positive correlations with ETV6-RUNX1 and hypodiploid ALL, respectively. In addition, positive correlations were also newly reported between TCF3-PBX1 ALL with PHF6 mutations. In multivariate Cox proportional hazards regression models for overall survival, TP53 mutation/deletion, hypodiploid, and MEF2D fusions were selected in both cohorts. For TP53 mutations, the negative effect on overall survival was confirmed in an independent external cohort (n = 466). TP53 mutation was frequently found in IGH-DUX4 (5 of 57 [9%]) ALL, with 4 cases having 17p LOH and negatively affecting overall survival therein, whereas TP53 mutation was not associated with poor outcomes among NCI (National Cancer Institute) standard risk (SR) patients. A conventional treatment approach might be enough, and further treatment intensification might not be necessary, for patients with TP53 mutations if they are categorized into NCI SR.
• A risk-stratified therapy for infants with acute lymphoblastic leukemia: a report from the JPLSG MLL-10 trial.

  Daisuke Tomizawa, Takako Miyamura, Toshihiko Imamura, Tomoyuki Watanabe, Akiko Moriya Saito, Atsushi Ogawa, Yoshihiro Takahashi, Masahiro Hirayama, Tomohiko Taki, Takao Deguchi, Toshinori Hori, Masashi Sanada, Shigeru Ohmori, Masami Haba, Akihiro Iguchi, Yuki Arakawa, Yuhki Koga, Atsushi Manabe, Keizo Horibe, Eiichi Ishii, Katsuyoshi Koh

  Blood 136 (16) 1813 - 1823 2020/10/15 

  The prognosis for infants with acute lymphoblastic leukemia (ALL), particularly those with KMT2A gene rearrangement (KMT2A-r), is dismal. Continuous efforts have been made in Japan to investigate the role of hematopoietic stem cell transplantation (HSCT) for infants with KMT2A-r ALL, but improvement in outcome was modest. In the Japanese Pediatric Leukemia/Lymphoma Study Group MLL-10 trial, infants with ALL were stratified into 3 risk groups (low risk [LR], intermediate risk [IR], and high risk [HR]) according to KMT2A status, age, and presence of central nervous system leukemia. Children's Oncology Group AALL0631 modified chemotherapy with the addition of high-dose cytarabine in early intensification was introduced to KMT2A-r patients, and the option of HSCT was restricted to HR patients only. The role of minimal residual disease (MRD) was also evaluated. Ninety eligible infants were stratified into LR (n = 15), IR (n = 19), or HR (n = 56) risk groups. The 3-year event-free survival (EFS) rate for patients with KMT2A-r ALL (IR + HR) was 66.2% (standard error [SE], 5.6%), and for those with germline KMT2A (KMT2A-g) ALL (LR), the 3-year EFS rate was 93.3% (SE, 6.4%). The 3-year EFS rate was 94.4% (SE, 5.4%) for IR patients and 56.6% (SE, 6.8%) for HR patients. In multivariable analysis, female sex and MRD ≥0.01% at the end of early consolidation were significant factors for poor prognosis. Risk stratification and introduction of intensive chemotherapy in this study were effective and were able to eliminate HSCT for a subset of infants with KMT2A-r ALL. Early clearance of MRD seems to have translated into favorable outcomes and should be incorporated into risk stratifications in future trials. This trial was registered at the University Hospital Medical Information Network Clinical Trials Registry (UMIN-CTR) as #UMIN000004801.
• 下垂体単独ランゲルハンス細胞組織球症の一例

  渡邊 敏史, 平林 真介, 原 和也, 杉山 未奈子, 長 祐子, 高桑 恵美, 茂木 洋晃, 山口 秀, 井口 晶裕, 真部 淳

  日本小児血液・がん学会雑誌 (一社)日本小児血液・がん学会 57 (4) 306 - 306 2187-011X 2020/10
• カテコラミン過剰分泌による症状を呈した神経芽腫の2例

  中山 加奈子, 中村 明枝, 橋本 佳帆子, 鎌田 瑛理, 菱村 希, 山口 健史, 井口 晶裕, 本多 昌平, 木田 毅, 真部 淳

  日本内分泌学会雑誌 (一社)日本内分泌学会 96 (2) 552 - 552 0029-0661 2020/10
• AYA世代小児がん経験者における口腔内状態と晩期合併症の検討

  細谷 要介, 宇治川 清登, 長谷川 大輔, 鈴木 優里, 小林 京子, 真部 淳, 石田 也寸志, 小澤 靖弘, 小澤 美和

  日本小児血液・がん学会雑誌 (一社)日本小児血液・がん学会 57 (4) 276 - 276 2187-011X 2020/10
• 小児がん経験者の就労状況への関連要因の探索

  小林 京子, 石田 也寸志, 小澤 美和, 郡司 美千代, 細谷 要介, 長谷川 大輔, 真部 淳

  日本小児血液・がん学会雑誌 (一社)日本小児血液・がん学会 57 (4) 380 - 380 2187-011X 2020/10
• Onset mechanism of a female patient with Dent disease 2.

  Takayuki Okamoto, Nana Sakakibara, Kandai Nozu, Toshiyuki Takahashi, Asako Hayashi, Yasuyuki Sato, China Nagano, Masafumi Matsuo, Kazumoto Iijima, Atsushi Manabe

  Clinical and experimental nephrology 24 (10) 946 - 954 2020/10 

  BACKGROUND: Approximately 15% of patients with Dent disease have pathogenic variants in the OCRL gene on Xq25-26, a condition that is referred to as Dent disease 2 (Dent-2). Dent-2 patients sometimes show mild extrarenal features of Lowe syndrome, such as mild mental retardation, suggesting that Dent-2 represents a mild form of Lowe syndrome. To date, eight female patients with Lowe syndrome have been reported, but no female Dent-2 patients have been reported. METHODS: In this study, we performed genetic testing of the first female Dent-2 patient to detect the presence of an OCRL variant. Aberrant splicing was demonstrated by in vivo, in vitro, and in silico assays, and skewed X-chromosome inactivation (XCI) in our patient and asymptomatic mothers of three Lowe patients with the heterozygous OCRL variant was evaluated by HUMARA assays using genomic DNA and RNA expression analysis. RESULTS: Our patient had an OCRL heterozygous intronic variant of c.1603-3G > C in intron 15 that led to a 169-bp insertion in exon 16, yielding the truncating mutation r.1602_1603ins (169) (p.Val535Glyfs*6) in exon 16. HUMARA assays of leukocytes obtained from this patient demonstrated incompletely skewed XCI (not extremely skewed). On the other hand, the asymptomatic mothers of 3 Lowe patients demonstrated random XCI. These results may lead to our patient's Dent-2 phenotype. CONCLUSIONS: This is the first report of a female patient clinically and genetically diagnosed with Dent-2 caused by an OCRL heterozygous splicing site variant and skewed XCI. Skewed XCI may be one of the factors associated with phenotypic diversity in female patients with Lowe syndrome and Dent-2.
• Impact of immunophenotypic characteristics on genetic subgrouping in childhood acute lymphoblastic leukemia: Tokyo Children's Cancer Study Group (TCCSG) study L04-16.

  Kentaro Ohki, Hiroyuki Takahashi, Takashi Fukushima, Toru Nanmoku, Shinpei Kusano, Makiko Mori, Yozo Nakazawa, Yuki Yuza, Masahiro Migita, Haruna Okuno, Akira Morimoto, Hiroshi Yoshino, Motohiro Kato, Yasuhide Hayashi, Atsushi Manabe, Akira Ohara, Daisuke Hasegawa, Takeshi Inukai, Daisuke Tomizawa, Katsuyoshi Koh, Nobutaka Kiyokawa

  Genes, chromosomes & cancer 59 (10) 551 - 561 2020/10 

  Immunophenotyping was performed in 1044 consecutive childhood acute lymphoblastic leukemia (ALL) patients enrolled in the Tokyo Children's Cancer Study Group L04-16 trial, revealing novel findings associated with genetic abnormalities. In addition to TCF3-PBX1 and MEF2D fusions, the CD10(+) subtype of KMT2A-MLLT3-positive ALL frequently exhibited the cytoplasmic-μ(+) pre-B ALL immunophenotype. Although ETV6-RUNX1 was significantly correlated with myeloid antigen expression, more than half of patients expressed neither CD33 nor CD13, while the CD27(+) /CD44(-) immunophenotype was maintained. Expression of CD117 and CD56 in B-cell precursor-ALL was limited to certain subtypes including ETV6-RUNX1 and KMT2A-MLLT3. Besides BCR-ABL1, CRLF2, hyperdiploidy, and hypodiploidy, CD66c was also expressed in Ph-like kinase fusion-, PAX5 fusion-, and DUX4 fusion-positive ALL, but not in MEF2D fusion-positive ALL, indicating constant selectivity of CD66c expression. In T-ALL, SIL-TAL1-positive patients were likely to exhibit a more mature immunophenotype. Expression of CD21 and CD10 was not rare in T-ALL, while lack of CD28 was an additional feature of early T-cell precursor-ALL. Considering the immunophenotype as a prognostic maker, MEF2D fusion-positive ALL with CD5 expression may be associated with a poorer prognosis in comparison with those lacking CD5 expression. In cases with characteristic marker expression, the presence of certain fusion transcripts could be predicted accurately.
• Clinical utility of target capture-based panel sequencing in hematological malignancies: A multicenter feasibility study.

  Takahiko Yasuda, Masashi Sanada, Dai Nishijima, Takashi Kanamori, Yuka Iijima, Hiroyoshi Hattori, Akiko Saito, Hiroaki Miyoshi, Yuichi Ishikawa, Norio Asou, Kensuke Usuki, Shinsuke Hirabayashi, Motohiro Kato, Masaki Ri, Hiroshi Handa, Tadao Ishida, Hirohiko Shibayama, Masahiro Abe, Chisako Iriyama, Kennosuke Karube, Momoko Nishikori, Koichi Ohshima, Keisuke Kataoka, Kenichi Yoshida, Yuichi Shiraishi, Hiroaki Goto, Souichi Adachi, Ryoji Kobayashi, Hitoshi Kiyoi, Yasushi Miyazaki, Seishi Ogawa, Hiroki Kurahashi, Hisayuki Yokoyama, Atsushi Manabe, Shinsuke Iida, Akihiro Tomita, Keizo Horibe

  Cancer science 111 (9) 3367 - 3378 2020/09 

  Although next-generation sequencing-based panel testing is well practiced in the field of cancer medicine for the identification of target molecules in solid tumors, the clinical utility and clinical issues surrounding panel testing in hematological malignancies have yet to be fully evaluated. We conducted a multicenter prospective clinical sequencing study to verify the feasibility of a panel test for hematological tumors, including acute myeloid leukemia, acute lymphoblastic leukemia, multiple myeloma, and diffuse large B-cell lymphoma. Out of 96 eligible patients, 79 patients (82%) showed potentially actionable findings, based on the clinical sequencing assays. We identified that genetic alterations with a strong clinical significance were found at a higher frequency in terms of diagnosis (n = 60; 63%) and prognosis (n = 61; 64%) than in terms of therapy (n = 8; 8%). Three patients who harbored a germline mutation in either DDX41 (n = 2) or BRCA2 (n = 1) were provided with genetic counseling. At 6 mo after sequencing, clinical actions based on the diagnostic (n = 5) or prognostic (n = 3) findings were reported, but no patients were enrolled in a clinical trial or received targeted therapies based on the sequencing results. These results suggest that panel testing for hematological malignancies would be feasible given the availability of useful diagnostic and prognostic information. This study is registered with the UMIN Clinical Trial Registry (UMIN000029879, multiple myeloma; UMIN000031343, adult acute myeloid leukemia; UMIN000033144, diffuse large B-cell lymphoma; and UMIN000034243, childhood leukemia).
• Statement on the prevention and treatment of COVID-19 in patients with pediatric cancer in Japan.

  Tomoko Iehara, Atsushi Manabe, Hajime Hosoi

  Pediatric blood & cancer 67 (9) e28440  2020/09
• Pulmonary vasodilators can lead to various complications in pulmonary "arterial" hypertension associated with congenital heart disease.

  Ayako Chida-Nagai, Koichi Sagawa, Takao Tsujioka, Takanori Fujimoto, Kota Taniguchi, Osamu Sasaki, Gaku Izumi, Hirokuni Yamazawa, Naoki Masaki, Atsushi Manabe, Atsuhito Takeda

  Heart and vessels 35 (9) 1307 - 1315 2020/09 [Refereed][Not invited]
   

  Congenital heart disease-associated pulmonary arterial hypertension (CHD-PAH) is one of the major complications in patients with CHD. A timely closure of the left-to-right shunt will generally result in the normalization of the pulmonary hemodynamics, but a few patients have severe prognosis in their early childhood. We hypothesized that wide-ranging pathological mechanism in PAH could elucidate the clinical state of severe CHD-PAH. Using electronic medical records, we retrospectively analyzed six infants with severe CHD-PAH who had treatment-resistant PH. All patients were born with congenital malformation syndrome. After starting on a pulmonary vasodilator, five of the six patients developed complications including pulmonary edema and interstitial lung disease (ILD), and four patients had alveolar hemorrhage. After steroid therapy, the clinical condition improved in four patients, but two patients died. The autopsy findings in one of the deceased patients indicated the presence of recurrent alveolar hemorrhage, pulmonary venous hypertension, ILD, and PAH. Based on the clinical course of these CHD-PAH in patients and the literature, CHD-PAH can occur with pulmonary vascular obstructive disease (PVOD)/pulmonary capillary hemangiomatosis (PCH), ILD, and/or alveolar hemorrhage. The severity of CHD-PAH may depend on a genetic disorder, respiratory infection, and upper airway stenosis. Additionally, pulmonary vasodilators may be involved in the development of PVOD/PCH and ILD. When patients with CHD-PAH show unexpected deterioration, clinicians should consider complications associated with PVOD/PCH and/or pulmonary disease. In addition, the choice of upfront combination therapy for pediatric patients with CHD-PAH should be selected carefully.
• Comparison of child and family reports of health-related quality of life in pediatric acute lymphoblastic leukemia patients after induction therapy.

  Shohei Nakajima, Iori Sato, Takafumi Soejima, Katsuyoshi Koh, Motohiro Kato, Yasuhiro Okamoto, Toshihiko Imamura, Miho Maeda, Yasushi Ishida, Atsushi Manabe, Kiyoko Kamibeppu

  BMC pediatrics 20 (1) 390 - 390 2020/08/19 

  BACKGROUND: This study aims at determining the health-related quality of life (HRQOL) of children with acute lymphoblastic leukemia (ALL) after the induction therapy, assessing the agreement between child self-reports and family proxy-reports HRQOL, and determining the factors related to this agreement, especially child age, family attendance, and children's social relationships beyond the family. METHODS: We analyzed questionnaire data (2012-2017) from the Japanese Pediatric Leukemia/Lymphoma Study Group's clinical study (ALL-B12). Participants were children with B-cell precursor ALL aged 5-18 and their family members, who mostly took care of the child during hospitalization. Participants answered the Pediatric Quality of Life Inventory™ (PedsQL™) Generic Core Scales (PedsQL-G), and Cancer Module (PedsQL-C) to measure pediatric HRQOL. We calculated the differences between child self-reported and family proxy-reported subscale scores along with intraclass correlation coefficients (ICC). We conducted multiple regression analyses according to all participant pairs and age groups (young children, school age, and adolescents), with ICCs for all PedsQL-G subscales (ICC-G) and all PedsQL-C subscales (ICC-C) as the outcome variables. RESULTS: Five hundred twenty-two pairs of children and their families were analyzed. We observed a moderate level of agreement on most PedsQL subscales between child self-reports and family proxy-reports; however, worry had the weakest agreement for all PedsQL subscales (ICC = .32, 95% confidence interval = .24-.40). The agreement of ICC-C was positively related to family attendance in the hospitalization, only for the young children group (B = .185, p = .003). CONCLUSIONS: We observed some differences between child self-reports and family proxy-reports of HRQOL of children with ALL. Both child self-reports and family proxy-reports captured HRQOL in the induction therapy. We suggest that attending to young children's hospitalization affects the level of agreement between reports on their HRQOL.
• Clinical features of children with polycythemia vera, essential thrombocythemia, and primary myelofibrosis in Japan: A retrospective nationwide survey

  Hisashi Ishida, Yuji Miyajima, Nobuyuki Hyakuna, Satoru Hamada, Takeo Sarashina, Risa Matsumura, Katsutsugu Umeda, Tetsuo Mitsui, Naoto Fujita, Daisuke Tomizawa, Kevin Y. Urayama, Yasushi Ishida, Takashi Taga, Masatoshi Takagi, Souichi Adachi, Atsushi Manabe, Toshihiko Imamura, Katsuyoshi Koh, Akira Shimada

  eJHaem 1 (1) 86 - 93 2688-6146 2020/07
• カテコラミン過剰に伴う症状を契機に診断に至った神経芽腫の1例

  橋本 佳帆子, 中山 加奈子, 山口 健史, 原 和也, 寺下 友佳代, 杉山 未奈子, 長 祐子, 井口 晶裕, 本多 昌平, 中村 明枝, 真部 淳

  日本小児科学会雑誌 (公社)日本小児科学会 124 (7) 1156 - 1156 0001-6543 2020/07
• Nationwide study of pediatric B-cell precursor acute lymphoblastic leukemia with chromosome 8q24/MYC rearrangement in Japan.

  Kimiyoshi Sakaguchi, Toshihiko Imamura, Sae Ishimaru, Chihaya Imai, Hidemi Shimonodan, Naoto Fujita, Keiko Okada, Takeshi Taketani, Rie Kanai, Hisamichi Tauchi, Motohiro Kato, Yasuko Kojima, Arata Watanabe, Takao Deguchi, Yoshiko Hashii, Nobutaka Kiyokawa, Tomohiko Taki, Akiko M Saito, Keizo Horibe, Atsushi Manabe, Atsushi Sato, Katsuyoshi Koh

  Pediatric blood & cancer 67 (7) e28341  2020/07 [Refereed][Not invited]
   

  BACKGROUND: Rearrangements of chromosome 8q24/MYC (8q24/MYC-r), resulting from t(8;14)(q24;q32), t(2;8)(p11;q24), or t(8;22)(q24;q11), are mainly associated with Burkitt lymphoma/leukemia (BL) and rarely observed in patients with B-cell precursor acute lymphoblastic leukemia (BCP-ALL). The characteristics of BCP-ALL with 8q24/MYC-r are poorly understood. PROCEDURE: A retrospective nationwide study of data from patients with pediatric BCP-ALL with 8q24/MYC-r in Japan was conducted to clarify the clinical and biological characteristics associated with 8q24/MYC-r BCP-ALL. RESULTS: Ten patients with BCP-ALL with 8q24/MYC-r, including three with double-hit leukemia (DHL) (two with t(8;14)(q24;q32) and t(14;18)(q32;q21) and one with t(8;14) and t(3;22)(q27;q11)), were identified. Patients with BCP-ALL with 8q24/MYC-r had higher median age and uric acid and lactate dehydrogenase levels, than those without 8q24/MYC-r. All patients were initially treated with ALL-type chemotherapy; however, four, including one with DHL, were switched to BL-type chemotherapy, based on cytogenetic findings. One patient relapsed after standard-risk ALL-type chemotherapy, and two patients with DHL did not attain complete remission with chemotherapy; all three died within 11 months. The other seven patients treated with BL-type or high-risk ALL-type chemotherapy are alive without disease. CONCLUSIONS: The clinical and laboratory features of BL with IG-MYC rearrangement, displaying a BCP immunophenotype (Wagener et al. and Herbrueggen et al. termed it as pre-BLL), are similar to those of BCP-ALL with 8q24/MYC-r. Low-risk ALL-type chemotherapy may not be appropriate for them, and further studies are required to establish an adequate therapeutic strategy. Further studies of DHL to identify new treatment strategies are also needed.
• Refractory malignant hepatocellular tumor consisting of hepatocellular carcinoma and hepatoblastoma in a 10-year-old male

  Minako Sugiyama, Shinsuke Hirabayashi, Yukayo Terashita, Yuko Cho, Akihiro Iguchi, Yoshihito Ohhara, Daisuke Abo, Shohei Honda, Emi Takakuwa, Atsushi Manabe

  2020/06/22
• Flash survey on severe acute respiratory syndrome coronavirus-2 infections in paediatric patients on anticancer treatment.

  Ondrej Hrusak, Tomas Kalina, Joshua Wolf, Adriana Balduzzi, Massimo Provenzi, Carmelo Rizzari, Susana Rives, María Del Pozo Carlavilla, Maria E V Alonso, Nerea Domínguez-Pinilla, Jean-Pierre Bourquin, Kjeld Schmiegelow, Andishe Attarbaschi, Pernilla Grillner, Karin Mellgren, Jutte van der Werff Ten Bosch, Rob Pieters, Triantafyllia Brozou, Arndt Borkhardt, Gabriele Escherich, Melchior Lauten, Martin Stanulla, Owen Smith, Allen E J Yeoh, Sarah Elitzur, Ajay Vora, Chi-Kong Li, Hany Ariffin, Alexandra Kolenova, Luciano Dallapozza, Roula Farah, Jelena Lazic, Atsushi Manabe, Jan Styczynski, Gabor Kovacs, Gabor Ottoffy, Maria S Felice, Barbara Buldini, Valentino Conter, Jan Stary, Martin Schrappe

  European journal of cancer (Oxford, England : 1990) 132 11 - 16 2020/06 

  INTRODUCTION: Since the beginning of COVID-19 pandemic, it is known that the severe course of the disease occurs mostly among the elderly, whereas it is rare among children and young adults. Comorbidities, in particular, diabetes and hypertension, clearly associated with age, besides obesity and smoke, are strongly associated with the need for intensive treatment and a dismal outcome. A weaker immunity of the elderly has been proposed as a possible explanation of this uneven age distribution. Thus, there is concern that children treated for cancer may allso be at risk for an unfavourable course of infection. Along the same line, anecdotal information from Wuhan, China, mentioned a severe course of COVID-19 in a child treated for leukaemia. AIM AND METHODS: We made a flash survey on COVID-19 incidence and severity among children on anticancer treatment. Respondents were asked by email to fill in a short Web-based survey. RESULTS: We received reports from 25 countries, where approximately 10,000 patients at risk are followed up. At the time of the survey, more than 200 of these children were tested, nine of whom were positive for COVID-19. Eight of the nine cases had asymptomatic to mild disease, and one was just diagnosed with COVID-19. We also discuss preventive measures that are in place or should be taken and treatment options in immunocompromised children with COVID-19. CONCLUSION: Thus, even children receiving anticancer chemotherapy may have a mild or asymptomatic course of COVID-19. While we should not underestimate the risk of developing a more severe course of COVID-19 than that observed here, the intensity of preventive measures should not cause delays or obstructions in oncological treatment.
• 131 I-MIBG therapy with WT-1 peptide for refractory neuroblastoma.

  Minako Sugiyama, Kinuya Seigo, Yosuke Hosoya, Akihiro Iguchi, Atsushi Manabe

  Pediatrics international : official journal of the Japan Pediatric Society 62 (6) 746 - 747 2020/06/01 [Refereed][Not invited]
  
• Successful treatment of dumbbell-shaped Hodgkin lymphoma with massive sacral bone destruction.

  Minako Sugiyama, Yukayo Terashita, Yuko Cho, Akihiro Iguchi, Ryuta Arai, Emi Takakuwa, Shohei Honda, Atsushi Manabe

  Pediatric blood & cancer 67 (5) e28210  2020/05 [Refereed][Not invited]
  
• Nationwide epidemiological survey of familial myelodysplastic syndromes/acute myeloid leukemia in Japan: a multicenter retrospective study.

  Kensuke Takaoka, Junji Koya, Akihide Yoshimi, Takashi Toya, Takashi Kobayashi, Yasuhito Nannya, Kumi Nakazaki, Shunya Arai, Hironori Ueno, Kensuke Usuki, Takeshi Yamashita, Daisuke Imanishi, Shinya Sato, Kenshi Suzuki, Hironori Harada, Atsushi Manabe, Yasuhide Hayashi, Yasushi Miyazaki, Mineo Kurokawa

  Leukemia & lymphoma 61 (7) 1 - 7 2020/03/11 [Refereed][Not invited]
   

  Although several pedigrees of familial myelodysplastic syndromes/acute myeloid leukemia (fMDS/AML) have been reported, the epidemiology and clinical features has been poorly understood. To explore the epidemiology of this entity, we performed a retrospective nationwide epidemiological survey in Japan using questionnaire sheets. The questionnaire was sent to 561 institutions or hospitals certified by Japanese Society of Hematology, unearthing the existence of 41 pedigrees of fMDS/AML. Among them, we obtained the clinical information of 31 patients in 20 pedigrees. The median age of the initial diagnosis was 51 years (range 9-88 years) and the WHO classification 2008 ranged from refractory anemia (RA) to AML. Focusing on the familial MDS patients, refractory anemia with excess blasts (RAEB)-2 was the largest group (27.3%). The median overall survival (OS) of fMDS and fAML in this study were 71.6 and 12.4 months, and the five-year OS were 61.3 and 50%, respectively.
• 病棟でアデノウイルスによる感染性胃腸炎が発生した際の伝播防止対策に関する検討

  石黒 信久, 長 祐子, 井口 晶裕, 杉山 未奈子, 寺下 友佳代, 武田 充人, 真部 淳

  日本小児科学会雑誌 (公社)日本小児科学会 124 (2) 486 - 486 0001-6543 2020/02
• 当科における尿細管間質性腎炎ぶどう膜炎症候群症例の臨床的特徴

  林 麻子, 佐藤 泰征, 高橋 俊行, 上田 泰弘, 真部 淳, 岡本 孝之

  日本小児科学会雑誌 (公社)日本小児科学会 124 (2) 272 - 272 0001-6543 2020/02
• 当院で管理中の先天性門脈体循環シャント6例の検討

  辻岡 孝郎, 泉 岳, 武田 充人, 小杉山 清隆, 山澤 弘州, 阿部 二郎, 谷口 宏太, 佐々木 大輔, 永井 礼子, 本多 昌平, 荒 桃子, 阿保 大介, 曽山 武士, 川村 典生, 渡辺 正明, 後藤 了一, 嶋村 剛, 神山 俊哉, 武冨 紹信, 真部 淳

  日本小児科学会雑誌 (公社)日本小児科学会 124 (2) 250 - 250 0001-6543 2020/02
• 当院で管理中の先天性門脈体循環シャント6例の検討

  辻岡 孝郎, 泉 岳, 武田 充人, 小杉山 清隆, 山澤 弘州, 阿部 二郎, 谷口 宏太, 佐々木 大輔, 永井 礼子, 本多 昌平, 荒 桃子, 阿保 大介, 曽山 武士, 川村 典生, 渡辺 正明, 後藤 了一, 嶋村 剛, 神山 俊哉, 武冨 紹信, 真部 淳

  日本小児科学会雑誌 (公社)日本小児科学会 124 (2) 250 - 250 0001-6543 2020/02
• 小児科スタッフが中高生以上のがん患者と関わる上で抱えている課題に関する質問紙調査

  半谷 まゆみ, 関 正史, 三谷 友一, 樋渡 光輝, 岩崎 美和, 木村 敬子, 副島 尭史, 佐藤 伊織, 松本 公一, 康 勝好, 真部 淳, 高木 正稔, 藤村 純也, 滝田 順子

  日本小児血液・がん学会雑誌 (一社)日本小児血液・がん学会 56 (5) 447 - 453 2187-011X 2020/02 [Refereed][Not invited]
   

  【背景】白血病を中心に、思春期・若年成人(Adolescents and Young Adults;AYA)世代のがん治療における小児科の優位性が示されてきたことに伴い、小児期と成人期の間にあたる彼らが小児科で治療される機会は増えてきている。しかし、この年代の患者と関わる上で小児科スタッフが抱える問題について、まとまった報告はない。【目的】中高生以上のがん患者と関わる小児科スタッフたちの現状を把握し、課題を整理する。【方法】総合病院小児科あるいは小児専門病院、計6施設で、中高生以上のがん患者と日常的に関わる機会のある多職種スタッフ(医師、看護師、薬剤師、院内学級教師など)を対象として、中高生以上のがん患者との関わり等について質問紙調査を実施した。【結果】計93名のスタッフから回答を得た。医師よりも他職種のほうが患者との関わり方に難しさを実感しており、特に心の問題やライフイベントに関する問題が難しいと回答した者が多かった。また、妊孕性に関する説明は施設間で勧奨度に相違があった。【結語】中高生以上のがん患者を小児科で診療する上で、病院スタッフが様々な問題を抱えていることが分かった。今後小児科で思春期・若年成人世代のがん患者の診療機会が増加することが見込まれる中、多職種・多施設間での更なる情報共有により、患者が安心して闘病生活を送れるよう心理社会的課題などに対するサポート体制の充実が望まれる。(著者抄録)
• Immune thrombocytopenia in a case of trisomy 18

  Minako Sugiyama, Yukayo Terashita, Atsuhito Takeda, Akihiro Iguchi, Atsushi Manabe

  PEDIATRICS INTERNATIONAL 62 (2) 240 - 242 1328-8067 2020/02 [Refereed][Not invited]
  
• Relationship between Sedative Antihistamines and the Duration of Febrile Seizures.

  Atsuro Daida, Gaku Yamanaka, Shin-Ichi Tsujimoto, Mina Yokoyama, Kuniyoshi Hayashi, Kevin Y Urayama, Yasushi Ishida, Atsushi Manabe, Isao Kusakawa, Masaaki Ogihara, Hisashi Kawashima

  Neuropediatrics 51 (2) 154 - 159 2020/01/14 [Refereed][Not invited]
   

  Some studies have shown that sedative antihistamines prolong febrile seizure duration. Although the collective evidence is still mixed, the Japanese Society of Child Neurology released guidelines in 2015 that contraindicated the use of sedative antihistamines in patients with febrile seizure. Focused on addressing limitations of previous studies, we conducted a cross-sectional study to evaluate the relationship between febrile seizure duration and the use of sedative antihistamines. Data were collected from patients who visited St. Luke's International Hospital due to febrile seizure between August 2013 and February 2016. Patients were divided into groups based on their prescribed medications: sedative antihistamine, nonsedative antihistamine, and no antihistamine. Seizure duration was the primary outcome and was examined using multivariate analyses. Of the 426 patients included, sedative antihistamines were administered to 24 patients. The median seizure duration was approximately 3 minutes in all three groups. There was no statistical difference in the bivariate (p = 0.422) or multivariate analyses (p = 0.544). Our results do not support the relationship between sedative antihistamine use and prolonged duration of febrile seizure. These results suggest that the use of antihistamines may be considered for patients with past history of febrile seizure, when appropriate.
• 褐色細胞腫との鑑別を要した神経芽腫の2歳女児例

  山口 健史, 中村 明枝, 中山 加奈子, 菱村 希, 橋本 佳帆子, 長 祐子, 本多 昌平, 真部 淳

  日本内分泌学会雑誌 (一社)日本内分泌学会 95 (3) 873 - 873 0029-0661 2020/01
• Corticosteroid-induced glaucoma in pediatric patients with hematological malignancies.

  Minako Sugiyama, Yukayo Terashita, Kazuya Hara, Yuko Cho, Akihiro Iguchi, Shinki Chin, Atsushi Manabe

  Pediatric blood & cancer 66 (12) e27977  2019/12 [Refereed][Not invited]
   

  BACKGROUND: Corticosteroids, especially dexamethasone, play a critical role in chemotherapy for pediatric hematological malignancies. We previously observed that patients with complaints of headache or photophobia during corticosteroid administration had high intraocular pressure (IOP). PROCEDURE: We measured IOP during corticosteroid administration in 15 patients with acute leukemia or lymphoma undergoing treatment at our institution from January 2016 to December 2018. IOP was measured by an ophthalmologist within seven days of the initiation of standard dose of corticosteroid, which was defined as 60 mg/m2 /day for prednisolone and 10 mg/m2 /day for dexamethasone. RESULTS: Fifteen patients received 52 courses of chemotherapy containing corticosteroids. IOP exceeded 21 mmHg among 13 patients in 28 courses. Twelve of the 13 patients were administered topical treatment, and six of the 12 patients needed additional diuretic agents. IOP during the chemotherapy courses containing dexamethasone was significantly higher compared with IOP during the chemotherapy courses containing prednisolone. Only two patients complained of symptoms, such as headache and photophobia, and one of the two patients underwent trabeculotomy. Funduscopic findings were normal in all patients. There was a dose-associated decrease in IOP with reduction of dexamethasone dose. CONCLUSIONS: IOP should be measured during administration of substantial corticosteroid doses even in patients with no symptoms. Further investigations regarding the level of IOP for intervention need to be conducted.
• DNA methylation-based classification reveals difference between pediatric T-cell acute lymphoblastic leukemia and normal thymocytes.

  Shunsuke Kimura, Masafumi Seki, Tomoko Kawai, Hiroaki Goto, Kenichi Yoshida, Tomoya Isobe, Masahiro Sekiguchi, Kentaro Watanabe, Yasuo Kubota, Yasuhito Nannya, Hiroo Ueno, Yusuke Shiozawa, Hiromichi Suzuki, Yuichi Shiraishi, Kentaro Ohki, Motohiro Kato, Katsuyoshi Koh, Ryoji Kobayashi, Takao Deguchi, Yoshiko Hashii, Toshihiko Imamura, Atsushi Sato, Nobutaka Kiyokawa, Atsushi Manabe, Masashi Sanada, Marc R Mansour, Akira Ohara, Keizo Horibe, Masao Kobayashi, Akira Oka, Yasuhide Hayashi, Satoru Miyano, Kenichiro Hata, Seishi Ogawa, Junko Takita

  Leukemia 34 (4) 1163 - 1168 2019/11/15 [Refereed][Not invited]
  
• Bortezomib-containing therapy in Japanese children with relapsed acute lymphoblastic leukemia.

  Daisuke Hasegawa, Yuri Yoshimoto, Shunsuke Kimura, Tadashi Kumamoto, Naoko Maeda, Junichi Hara, Atsushi Kikuta, Akiko Kada, Toshimi Kimura, Yuka Iijima-Yamashita, Akiko M Saito, Keizo Horibe, Atsushi Manabe, Chitose Ogawa

  International journal of hematology 110 (5) 627 - 634 2019/11 

  Outcomes of children treated for relapsed acute lymphoblastic leukemia (ALL) remain poor. Bortezomib (BZM), a proteasome inhibitor, has shown promising activity against lymphoid malignancies. We conducted a phase I study to evaluate the safety and tolerability of multidrug chemotherapy including BZM in Japanese children with relapsed ALL. Three of five children with relapsed ALL enrolled in the study between November 2014 and April 2016 were evaluated. BZM (1.3 mg/m2) was administered on days 8, 11, 15, and 18 of multidrug induction chemotherapy. Pharmacokinetic studies were performed. Age at study entry was 5, 7, and 7 years old, respectively. Two patients had hyperdiploid B-precursor ALL, and one had T cell ALL. Although all patients experienced grade 3-4 hematologic toxicity and grade 3 elevation of aminotransferases, no dose-limiting toxicities were observed. The maximum tolerated dose was defined as 1.3 mg/m2. Peripheral neuropathy and respiratory complications were not observed. Complete remission was achieved in all three patients. The mean maximum plasma concentration and area under the concentration-time curve was 74.0 ng/mL and 73.9 ng h/mL, respectively. Thus, adding BZM to 5-drug induction chemotherapy appears safe and well-tolerated in Japanese children with relapsed ALL.
• Very late relapse cases of TCF3-ZNF384-positive acute lymphoblastic leukemia.

  Akira Nishimura, Daisuke Hasegawa, Shinsuke Hirabayashi, Shoichiro Kanabuchi, Kaoru Yamamoto, Saori Aiga, Misa Nishitani, Yosuke Hosoya, Yasushi Noguchi, Kentaro Ohki, Nobutaka Kiyokawa, Shinichiro Mori, Atsushi Manabe

  Pediatric blood & cancer 66 (11) e27891  1545-5009 2019/11 [Refereed][Not invited]
  
• Nationwide survey of pediatric hypodiploid acute lymphoblastic leukemia in Japan.

  Sae Ishimaru, Yasuhiro Okamoto, Chihaya Imai, Hirotoshi Sakaguchi, Tomohiko Taki, Daisuke Hasegawa, Yuko Cho, Harumi Kakuda, Hideki Sano, Atsushi Manabe, Toshihiko Imamura, Motohiro Kato, Yuki Arakawa, Hidemi Shimonodan, Atsushi Sato, Souichi Suenobu, Takeshi Inukai, Arata Watanabe, Yoshifumi Kawano, Atsushi Kikuta, Keizo Horibe, Akira Ohara, Katsuyoshi Koh

  Pediatrics international : official journal of the Japan Pediatric Society 61 (11) 1103 - 1108 1328-8067 2019/11 [Refereed][Not invited]
   

  BACKGROUND: Ploidy is a highly significant prognostic factor for pediatric acute lymphoblastic leukemia (ALL). Children with hypodiploid ALL have poor outcomes despite current intensive chemotherapy. Little has been investigated with regard to hypodiploid ALL in Japanese children. METHODS: We retrospectively collected clinical data on hypodiploid ALL cases from the registries of prospective multicenter trials conducted by the four independent clinical study groups in Japan between 1997 and 2012. RESULTS: A total of 117 ALL patients with hypodiploidy were analyzed in this study. There were 101, eight, and eight patients with 45, 44, and fewer than 44 chromosomes, respectively. The 5 year overall survival rates differed significantly: 86.0%, 87.5%, and 62.5% for patients with 45, 44, and fewer than 44 chromosomes, respectively (P = 0.037). Of the eight patients with 44 chromosomes, seven were alive, including five patients who maintained complete remission without undergoing hematopoietic stem cell transplantation (HSCT). Of the eight patients with fewer than 44 chromosomes, six were good responders to prednisolone and none had induction failure, but the relapse rate was high (5/8). No patients had central nervous system relapse. Four patients underwent HSCT after relapse, but only one survived. CONCLUSIONS: Outcomes of Japanese ALL patients with fewer than 44 chromosomes were poor, as previously reported in other countries. Although the sample size was small, patients with 44 chromosomes had better prognoses than those previously reported. Further studies including international collaboration are needed to improve outcomes for pediatric ALL patients with fewer than 44 chromosomes.
• 【2019年の白血病診療-新たな武器を上手に活用するために】フィラデルフィア染色体様(Ph-like)急性リンパ性白血病の診断と治療

  小野 林太郎, 真部 淳

  内科 (株)南江堂 124 (4) 2167 - 2169 0022-1961 2019/10 

  ＜文献概要＞▼遺伝子解析技術の進歩により,Ph+ALLと類似した遺伝子発現パターンを呈するB前駆細胞型ALLの一群が同定された.▼Ph-like ALLではIKZF1の遺伝子異常に加え,ABL1関連遺伝子やJAK関連遺伝子異常など,キナーゼ遺伝子の変異を高率に伴うことが示されている.▼Ph-like ALLは男児に多く,初診時白血球数が多く,また寛解導入療法後のMRD陽性例を多く認める.▼当初は予後不良と考えられていたが,MRDによる治療層別化により,その他のB前駆細胞型ALLと同等の成績が得られている.▼チロシンキナーゼ阻害薬やJAK阻害薬による治療効果が期待され,今後前向き臨床試験での検証が望まれる.
• Germline GATA2変異を伴う骨髄異形成症候群(MDS)の1例

  水城 和義, 平林 真介, 長谷川 大輔, 山本 俊亮, 山本 薫, 足洗 美穂, 小野 林太郎, 細谷 要介, 鈴木 美慧, 松本 公宏, 川口 裕之, 真部 淳

  臨床血液 (一社)日本血液学会-東京事務局 60 (10) 1502 - 1502 0485-1439 2019/10
• 長期にわたる免疫抑制治療後にステロイド離脱が可能となった移植後自己免疫性溶血性貧血(AIHA)

  小野 林太郎, 細谷 要介, 山本 俊亮, 山本 薫, 西村 聡, 足洗 美穂, 平林 真介, 長谷川 大輔, 真部 淳

  日本小児血液・がん学会雑誌 (一社)日本小児血液・がん学会 56 (4) 324 - 324 2187-011X 2019/10
• ウィリアムズ症候群を背景に発症したバーキットリンパ腫

  長谷河 昌孝, 長 祐子, 原 和也, 寺下 友佳代, 杉山 未奈子, 大久保 淳, 井口 晶裕, 真部 淳, 荒 桃子, 本多 昌平, 武冨 紹信, 高桑 恵美, 松野 吉宏

  日本小児血液・がん学会雑誌 (一社)日本小児血液・がん学会 56 (4) 299 - 299 2187-011X 2019/10 [Refereed][Not invited]
  
• Pediatric patients with cancer predisposition in Japan: Results of a questionnaire survey.

  Yoshiko Nakano, Yukiko Tsunematsu, Fumito Yamazaki, Atsushi Manabe, Akira Nakagawara, Eiso Hiyama, Tadashi Kumamoto

  Pediatric blood & cancer 66 (10) e27937  2019/10 [Refereed][Not invited]
  
• 過去10年間に当院外来を受診した異物誤飲の小児患者に関する検討

  山本 俊亮, 島袋 林秀, 梅原 直, 右田 美里, 平田 倫生, 小澤 美和, 真部 淳, 松藤 凡, 草川 功

  日本小児救急医学会雑誌 (一社)日本小児救急医学会 18 (3) 343 - 347 1346-8162 2019/10 [Refereed][Not invited]
   

  2007年〜2016年の10年間で、当院を受診した異物誤飲に関連した小児患者(誤飲関連受診患者)534名を後方視的に調査した。発生状況や画像検査により異物誤飲が確認された患者(誤飲診断患者)は324名で、そのうち4歳以下の乳幼児が80%以上を占めていた。受診時間帯は16〜24時が多く、誤飲関連受診患者数および誤飲診断患者数ともに増加傾向にあった。誤飲診断患者の割合は約60%で10年間ほぼ一定の割合であった。また、画像検査の施行件数も増加する一方、画像検査で診断できた症例(画像診断患者)は30-40%で経年的変化はなかった。誤飲したかもしれないという受診者の不安・心配を許容しつつも、緊急性の高い対象物を具体的に把握して不要な画像検索を避けること、緊急性が高い対象物については重点的に予防の必要性について啓発活動を行うことが今後の課題であった。(著者抄録)
• Break Apart FISH Probeで転座判定に苦慮したKMT2A-MLLT10 mRNA陽性AMLの一症例

  小栗 聡, 佐藤 かおり, 市川 絢子, 藤澤 真一, 原 和也, 杉山 未奈子, 寺下 友佳代, 長 祐子, 井口 晶裕, 杉田 純一, 西田 睦, 豊嶋 崇徳, 真部 淳

  日本染色体遺伝子検査学会雑誌 日本染色体遺伝子検査学会 37 (2) 47 - 47 1884-3026 2019/09
• Efficacy of the NCCV Cocktail‐1 vaccine for refractory pediatric solid tumors: a phase I clinical trial

  Akazawa Y, Hosono A, Yoshikawa T, Kaneda H, Nitani C, Hara J, Kinoshita Y, Kohashi K, Manabe A, Fukutani M, Wakabayashi M, Sato A, Shoda K, Shimomura M, Mizuno S, Nakamoto Y, Nakatsura T

  Cancer Science 110 (12) 3650 - 3662 1347-9032 2019/09 [Refereed][Not invited]
  
• A germline HLTF mutation in familial MDS induces DNA damage accumulation through impaired PCNA polyubiquitination.

  Kensuke Takaoka, Masahito Kawazu, Junji Koya, Akihide Yoshimi, Yosuke Masamoto, Hiroaki Maki, Takashi Toya, Takashi Kobayashi, Yasuhito Nannya, Shunya Arai, Toshihide Ueno, Hironori Ueno, Kenshi Suzuki, Hironori Harada, Atsushi Manabe, Yasuhide Hayashi, Hiroyuki Mano, Mineo Kurokawa

  Leukemia 33 (7) 1773 - 1782 0887-6924 2019/07 [Refereed][Not invited]
   

  Although several causal genes of familial myelodysplastic syndromes (MDS) have been identified, the genetic landscape and the molecular pathogenesis are not totally understood. To explore novel driver genes and their pathogenetic significance, we performed whole-exome sequence analysis of four individuals from a familial MDS pedigree and 10 candidate single-nucleotide variants (C9orf43, CYP7B1, EFHB, ENTPD7, FAM160B2, HELZ2, HLTF, INPP5J, ITPKB, and RYK) were identified. Knockdown screening revealed that Hltf downregulation enhanced colony-forming capacity of primary murine bone marrow (BM) stem/progenitor cells. γH2AX immunofluorescent staining assay revealed increased DNA damage in a human acute myeloid leukemia (AML) cell line ectopically expressing HLTF E259K, which was not observed in cells expressing wild-type HLTF. Silencing of HLTF in human AML cells also led to DNA damage, indicating that HLTF E259K is a loss-of-function mutation. Molecularly, we found that an E259K mutation reduced the binding capacity of HLTF with ubiquitin-conjugating enzymes, methanesulfonate sensitive 2 and ubiquitin-conjugating enzyme E2N, resulting in impaired polyubiquitination of proliferating cell nuclear antigen (PCNA) in HLTF E259K-transduced cells. In summary, our results indicate that a familial MDS-associated HLTF E259K germline mutation induces accumulation of DNA double-strand breaks, possibly through impaired PCNA polyubiquitination.
• Kawasaki disease shock syndrome: Case report and cytokine profiling.

  Ono R, Shimizu M, Yamamoto K, Umehara N, Manabe A

  Pediatrics international : official journal of the Japan Pediatric Society 61 (6) 620 - 622 1328-8067 2019/06 [Refereed][Not invited]
  
• Dasatinib and low-intensity chemotherapy for Philadelphia chromosome-positive acute lymphoblastic leukemia in a child with Down syndrome.

  Shinsuke Hirabayashi, Daisuke Hasegawa, Kaoru Yamamoto, Akira Nishimura, Yosuke Hosoya, Takuya Shuo, Nobutaka Kiyokawa, Masatomo Miura, Naoto Takahashi, Atsushi Manabe

  Pediatric blood & cancer 66 (5) e27612  1545-5009 2019/05 [Refereed][Not invited]
  
• Clinical and biological features of paediatric acute myeloid leukaemia (AML) with primary induction failure in the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 study.

  Miyamura T, Moritake H, Nakayama H, Tanaka S, Tomizawa D, Shiba N, Saito AM, Tawa A, Shimada A, Iwamoto S, Hayashi Y, Koike T, Horibe K, Manabe A, Mizutani S, Taga T, Adachi S

  British journal of haematology 185 (2) 284 - 288 0007-1048 2019/04 [Refereed][Not invited]
   

  The prognosis of paediatric acute myeloid leukaemia (AML) with primary induction failure (PIF) is extremely poor, and effective treatment strategies have not been established. We investigated the clinical and biological features of paediatric AML patients with PIF registered to the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 study. The 3-year overall survival rate of the 41 PIF patients was 19.0%. High leucocyte count, M7 morphology, and unfavourable genetic aberrations, such as FLT3-internal tandem duplication, NUP98-NSD1 and high MECOM or PRDM16 expression, were risk factors for PIF. More effective treatment strategies based on leukaemia biology need to be urgently explored.
• 画像診断 今月の症例 心膜外脂肪壊死(epipericardial fat necrosis:EFN)

  佐藤 崇翔, 野崎 太希, 松迫 正樹, 真部 淳, 宮嵜 治

  小児科臨床 (株)日本小児医事出版社 72 (3) 233 - 236 0021-518X 2019/03
• 小児急性リンパ性白血病における高用量メトトレキサート投与時の薬物動態解析

  田中 庸一, 浦山 ケビン, 森 麻希子, 長谷川 大輔, 赤羽 弘資, 太田 節雄, 真部 淳

  日本薬学会年会要旨集 (公社)日本薬学会 139年会 (4) 65 - 65 0918-9823 2019/03 [Refereed][Not invited]
  
• 川崎病急性期に急性腎不全,顕性黄疸,低酸素血症,低血圧を合併した10歳女児の1例

  小野林太郎, 山本俊亮, 山本薫, 梅原直, 清水正樹, 谷内江昭宏, 真部淳

  心臓 (公財)日本心臓財団 51 (3) 365 - 366 0586-4488 2019/03 [Not refereed][Not invited]
  
• Duplication of ALK F1245 missense mutation due to acquired uniparental disomy associated with aggressive progression in a patient with relapsed neuroblastoma.

  Shunsuke Kimura, Daisuke Hasegawa, Yuri Yoshimoto, Masafumi Seki, Atsuro Daida, Masahiro Sekiguchi, Shinsuke Hirabayashi, Yosuke Hosoya, Masao Kobayashi, Satoru Miyano, Seishi Ogawa, Junko Takita, Atsushi Manabe

  Oncology letters 17 (3) 3323 - 3329 1792-1074 2019/03 [Refereed][Not invited]
   

  Recent genome-wide analysis of neuroblastoma (NBL) revealed amplification and heterozygous mutation of anaplastic lymphoma kinase (ALK) are responsible for oncogenicity, frequently observed during relapses. A 3-year-old girl with relapsed high-risk NBL had a heterozygous ALK F1245L mutation at diagnosis, which became homozygous due to uniparental disomy (UPD) of the entire chromosome 2, confirmed by single nucleotide polymorphism array and variant allele frequency of this mutation. The ALK inhibitor, crizotinib, failed to control the tumor and the patient died of the disease. Further genomic analysis using targeted capture sequencing for 381 genes related to pediatric cancers identified more alterations acquired at relapse, such as TSC complex subunit 2 and protein tyrosine phosphatase receptor type D. In addition to these several acquired mutations, this extremely rare duplication of ALK mutation might explain the aggressive clinical course after relapse, because acquired UPD, resulting in the duplication of an oncogenic mutation, has been reported for various neoplasms. Although a clinical benefit of ALK inhibitors in patients with NBL has not been confirmed yet, a treatment based on the ALK mutation status will be promising in future using more potent next-generation ALK inhibitors.
• 腸管気腫を来した血液腫瘍性疾患・原発性免疫不全症の5例

  西村 聡, 足洗 美穂, 神谷 尚宏, 山本 俊亮, 山本 薫, 友田 昂宏, 井上 真依子, 井上 健斗, 宮本 智史, 小野 林太郎, 平林 真介, 磯田 健志, 柳町 昌克, 細谷 要介, 長谷川 大輔, 今井 耕輔, 高木 正稔, 金兼 弘和, 真部 淳, 森尾 友宏

  日本小児科学会雑誌 (公社)日本小児科学会 123 (2) 273 - 273 0001-6543 2019/02
• 寛解導入療法中に肺胞出血をきたしNO吸入療法が有効であったAMLの1例

  足洗 美穂, 梅原 直, 黒子 由梨香, 山本 薫, 山本 俊亮, 小野 林太郎, 平林 真介, 細谷 要介, 長谷川 大輔, 真部 淳

  日本小児科学会雑誌 (公社)日本小児科学会 123 (2) 320 - 320 0001-6543 2019/02
• Pediatric oncologic emergencies: Clinical and imaging review for pediatricians.

  Atsuhiko Handa, Taiki Nozaki, Akari Makidono, Tetsuhiko Okabe, Yuka Morita, Kazutoshi Fujita, Masaki Matsusako, Tatsuo Kono, Yasuyuki Kurihara, Daisuke Hasegawa, Tadashi Kumamoto, Chitose Ogawa, Yuki Yuza, Atsushi Manabe

  Pediatrics international : official journal of the Japan Pediatric Society 61 (2) 122 - 139 2019/02 

  Children with cancer are at increased risk of life-threatening emergencies, either from the cancer itself or related to the cancer treatment. These conditions need to be assessed and treated as early as possible to minimize morbidity and mortality. Cardiothoracic emergencies encompass a variety of pathologies, including pericardial effusion and cardiac tamponade, massive hemoptysis, superior vena cava syndrome, pulmonary embolism, and pneumonia. Abdominal emergencies include bowel obstruction, intussusception, perforation, tumor rupture, intestinal graft-versus-host disease, acute pancreatitis, neutropenic colitis, and obstructive uropathy. Radiology plays a vital role in the diagnosis of these emergencies. We here review the clinical features and imaging in pediatric patients with oncologic emergencies, including a review of recently published studies. Key radiological images are presented to highlight the radiological approach to diagnosis. Pediatricians, pediatric surgeons, and pediatric radiologists need to work together to arrive at the correct diagnosis and to ensure prompt and appropriate treatment strategies.
• NOTCH1 pathway activating mutations and clonal evolution in pediatric T-cell acute lymphoblastic leukemia.

  Kimura S, Seki M, Yoshida K, Shiraishi Y, Akiyama M, Koh K, Imamura T, Manabe A, Hayashi Y, Kobayashi M, Oka A, Miyano S, Ogawa S, Takita J

  Cancer science 110 (2) 784 - 794 1347-9032 2019/02 [Refereed][Not invited]
   

  Molecular mechanisms involved in the relapse of T-cell acute lymphoblastic leukemia (T-ALL) are not fully understood, although activating NOTCH1 signaling due to NOTCH1/FBXW7 alterations is a major oncogenic driver. To unravel the relevance of NOTCH1/FBXW7 mutations associated with relapse, we performed whole-exome sequencing in 30 pediatric T-ALL cases, among which 11 diagnosis-relapse paired cases were further investigated to track the clonal evolution of relapse using amplicon-based deep sequencing. NOTCH1/FBXW7 alterations were detected in 73.3% (diagnosis) and 72.7% (relapse) of cases. Single nucleotide variations in the heterodimerization domain were the most frequent (40.0%) at diagnosis, whereas proline, glutamic acid, serine, threonine-rich (PEST) domain alterations were the most frequent at relapse (54.5%). Comparison between non-relapsed and relapsed cases at diagnosis showed a predominance of PEST alterations in relapsed cases (P = .045), although we failed to validate this in the TARGET cohort. Based on the clonal analysis of diagnosis-relapse samples, we identified NOTCH1 "switching" characterized by different NOTCH1 mutations in a major clone between diagnosis and relapse samples in 2 out of 11 diagnosis-relapse paired cases analyzed. We found another NOTCH1 "switching" case in a previously reported Berlin-Frankfurt-Münster cohort (n = 13), indicating NOTCH1 importance in both the development and progression of T-ALL. Despite the limitations of having a small sample size and a non-minimal residual disease-based protocol, our results suggest that the presence of NOTCH1 mutations might contribute to the disease relapse of T-ALL.
• Clinical and molecular characteristics of MEF2D fusion-positive B-cell precursor acute lymphoblastic leukemia in childhood, including a novel translocation resulting in MEF2D-HNRNPH1 gene fusion.

  Kentaro Ohki, Nobutaka Kiyokawa, Yuya Saito, Shinsuke Hirabayashi, Kazuhiko Nakabayashi, Hitoshi Ichikawa, Yukihide Momozawa, Kohji Okamura, Ai Yoshimi, Hiroko Ogata-Kawata, Hiromi Sakamoto, Motohiro Kato, Keitaro Fukushima, Daisuke Hasegawa, Hiroko Fukushima, Masako Imai, Ryosuke Kajiwara, Takashi Koike, Isao Komori, Atsushi Matsui, Makiko Mori, Koichi Moriwaki, Yasushi Noguchi, Myoung-Ja Park, Takahiro Ueda, Shohei Yamamoto, Koichi Matsuda, Teruhiko Yoshida, Kenji Matsumoto, Kenichiro Hata, Michiaki Kubo, Yoichi Matsubara, Hiroyuki Takahashi, Takashi Fukushima, Yasuhide Hayashi, Katsuyoshi Koh, Atsushi Manabe, Akira Ohara

  Haematologica 104 (1) 128 - 137 0390-6078 2019/01 [Refereed][Not invited]
   

  Fusion genes involving MEF2D have recently been identified in precursor B-cell acute lymphoblastic leukemia, mutually exclusive of the common risk stratifying genetic abnormalities, although their true incidence and associated clinical characteristics remain unknown. We identified 16 cases of acute lymphoblastic leukemia and 1 of lymphoma harboring MEF2D fusions, including MEF2D-BCL9 (n=10), MEF2D-HNRNPUL1 (n=6), and one novel MEF2D-HNRNPH1 fusion. The incidence of MEF2D fusions overall was 2.4% among consecutive precursor B-cell acute lymphoblastic leukemia patients enrolled onto a single clinical trial. They frequently showed a cytoplasmic μ chain-positive pre-B immunophenotype, and often expressed an aberrant CD5 antigen. Besides up- and down-regulation of HDAC9 and MEF2C, elevated GATA3 expression was also a characteristic feature of MEF2D fusion-positive patients. Mutations of PHF6, recurrent in T-cell acute lymphoblastic leukemia, also showed an unexpectedly high frequency (50%) in these patients. MEF2D fusion-positive patients were older (median age 9 years) with elevated WBC counts (median: 27,300/ml) at presentation and, as a result, were mostly classified as NCI high risk. Although they responded well to steroid treatment, MEF2D fusion-positive patients showed a significantly worse outcome, with 53.3% relapse and subsequent death. Stem cell transplantation was ineffective as salvage therapy. Interestingly, relapse was frequently associated with the presence of CDKN2A/CDKN2B gene deletions. Our observations indicate that MEF2D fusions comprise a distinct subgroup of precursor B-cell acute lymphoblastic leukemia with a characteristic immunophenotype and gene expression signature, associated with distinct clinical features.
• Diplotype analysis of NUDT15 variants and 6-mercaptopurine sensitivity in pediatric lymphoid neoplasms.

  Shinichi Tsujimoto, Tomoo Osumi, Meri Uchiyama, Ryota Shirai, Takaya Moriyama, Rina Nishii, Yuji Yamada, Ko Kudo, Masahiro Sekiguchi, Yuki Arakawa, Masanori Yoshida, Toru Uchiyama, Kiminori Terui, Shuichi Ito, Katsuyoshi Koh, Junko Takita, Etsuro Ito, Daisuke Tomizawa, Atsushi Manabe, Nobutaka Kiyokawa, Jun J Yang, Motohiro Kato

  Leukemia 32 (12) 2710 - 2714 0887-6924 2018/12 [Refereed][Not invited]
  
• Sequential use of second-generation tyrosine kinase inhibitors following imatinib therapy in pediatric chronic myeloid leukemia: A report from the Japanese Pediatric Leukemia/Lymphoma Study Group.

  Hidemitsu Kurosawa, Akihiko Tanizawa, Hideki Muramatsu, Chikako Tono, Akihiro Watanabe, Haruko Shima, Masaki Ito, Yuki Yuza, Kazuko Hamamoto, Noriko Hotta, Masahiko Okada, Akiko Moriya Saito, Atsushi Manabe, Shuki Mizutani, Souichi Adachi, Keizo Horibe, Eiichi Ishii, Hiroyuki Shimada

  Pediatric blood & cancer 65 (12) e27368  1545-5009 2018/12 [Refereed][Not invited]
   

  BACKGROUND: The details of the sequential use of imatinib for first-line treatment followed by second-generation tyrosine kinase inhibitors (2G-TKIs) for pediatric chronic myeloid leukemia (CML) are still unknown. This study analyzed clinical responses and adverse effects of the use of 2G-TKIs following imatinib in pediatric chronic phase (CP)-CML. PROCEDURES: The Japanese Pediatric Leukemia/Lymphoma Study Group conducted a retrospective study of patients with newly diagnosed CML from 1996 to 2011. A total of 152 cases that received imatinib as first-line therapy were analyzed. RESULTS: Excluding 46 cases treated with hematopoietic stem cell transplantation before nilotinib and dasatinib became available, 31 of 106 patients changed to 2G-TKIs. The primary reason for changing from imatinib was poor response, followed by intolerance, with the main reason for the latter being musculoskeletal events. Switches from imatinib to 2G-TKIs with intolerance occurred significantly earlier than switches with poor response. Sixteen and 15 patients were treated with nilotinib and dasatinib, respectively, following imatinib therapy. After switching to 2G-TKIs, the response status improved in 63% of evaluable patients. The adverse effect profiles of nilotinib and dasatinib tended to be different, with hyperbilirubinemia observed in 33% of nilotinib-treated patients, but in none of the cases with dasatinib. CONCLUSION: This retrospective study represents the first series of children and adolescents in whom sequential use of imatinib followed by 2G-TKIs was reported. These data provide useful insights into the selection of 2G-TKIs as first-line treatment for children and adolescents with CP-CML.
• Regional evaluation of childhood acute lymphoblastic leukemia genetic susceptibility loci among Japanese

  Kevin Y. Urayama, Masatoshi Takagi, Takahisa Kawaguchi, Keitaro Matsuo, Yoichi Tanaka, Yoko Ayukawa, Yuki Arakawa, Daisuke Hasegawa, Yuki Yuza, Takashi Kaneko, Yasushi Noguchi, Yuichi Taneyama, Setsuo Ota, Takeshi Inukai, Masakatsu Yanagimachi, Dai Keino, Kazutoshi Koike, Daisuke Toyama, Yozo Nakazawa, Hidemitsu Kurosawa, Kozue Nakamura, Koichi Moriwaki, Hiroaki Goto, Yujin Sekinaka, Daisuke Morita, Motohiro Kato, Junko Takita, Toshihiro Tanaka, Johji Inazawa, Katsuyoshi Koh, Yasushi Ishida, Akira Ohara, Shuki Mizutani, Fumihiko Matsuda, Atsushi Manabe

  Scientific Reports 8 (1) 789  2045-2322 2018/12/01 [Refereed][Not invited]
   

  Genome-wide association studies (GWAS) performed mostly in populations of European and Hispanic ancestry have confirmed an inherited genetic basis for childhood acute lymphoblastic leukemia (ALL), but these associations are less clear in other races/ethnicities. DNA samples from ALL patients (aged 0-19 years) previously enrolled onto a Tokyo Children's Cancer Study Group trial were collected during 2013-2015, and underwent single nucleotide polymorphism (SNP) microarray genotyping resulting in 527 B-cell ALL for analysis. Cases and control data for 3,882 samples from the Nagahama Study Group and Aichi Cancer Center Study were combined, and association analyses across 10 previous GWAS-identified regions were performed after targeted SNP imputation. Linkage disequilibrium (LD) patterns in Japanese and other populations were evaluated using the varLD score based on 1000 Genomes data. Risk associations for ARID5B (rs10821936, OR = 1.84, P = 6 × 10-17) and PIP4K2A (rs7088318, OR = 0.76, P = 2 × 10-4) directly transferred to Japanese, and the IKZF1 association was detected by an alternate SNP (rs1451367, OR = 1.52, P = 2 × 10-6). Marked regional LD differences between Japanese and Europeans was observed for most of the remaining loci for which associations did not transfer, including CEBPE, CDKN2A, CDKN2B, and ELK3. This study represents a first step towards characterizing the role of genetic susceptibility in childhood ALL risk in Japanese.
• Clinical and Genetic Characteristics of Patients with Shwachman-Diamond Syndrome in Japan

  Watanabe Kenichiro, Kanegane Hirokazu, Hamabata Takayuki, Kozuki Kagehiro, Umeda Katsutsugu, Ueno Hiroo, Yoshida Kenichi, Hama Asahito, Okuno Yusuke, Muramatsu Hideki, Takahashi Yoshiyuki, Hasegawa Daisuke, Manabe Atsushi, Ohara Akira, Ito Masafumi, Ogawa Seishi, Kojima Seiji, Ito Etsuro

  BLOOD 132 0006-4971 2018/11/29 [Not refereed][Not invited]
  
• Diagnosis of Inherited Bone Marrow Failure Syndromes Using Sequencing Approaches

  Narita Atsushi, Muramatsu Hideki, Okuno Yusuke, Yoshida Kenichi, Shiraishi Yuichi, Sakaguchi Hirotoshi, Kawashima Nozomu, Wang Xinan, Xu Yinyan, Chiba Kenichi, Tanaka Hiroko, Hama Asahito, Sanada Masashi, Hitoshi Kanno, Yamaguchi Hiroki, Ohga Shouichi, Manabe Atsushi, Harigae Hideo, Kunishima Shinji, Ishii Eiichi, Kobayashi Masao, Koike Kenichi, Watanabe Kenichiro, Ito Etsuro, Takata Minoru, Yabe Miharu, Ogawa Seishi, Miyano Satoru, Kojima Seiji, Takahashi Yoshiyuki

  PEDIATRIC BLOOD & CANCER 65 S7-S7  1545-5009 2018/11 [Not refereed][Not invited]
  
• Treatment Outcome of Children with Acute Lymphoblastic Leukemia Harbouring Newly Identified Genetic Abnormalities: Results from TCCSG Study L04-16

  Ohki Kentaro, Kiyokawa Nobutaka, Takahashi Hiroyuki, Kajiwara Ryosuke, Kato Motohiro, Hasegawa Daisuke, Tomizawa Daisuke, Noguchi Yasushi, Koike Kazutoshi, Toyama Daisuke, Yabe Hiromasa, Michiko Kajiwara, Fujimura Junya, Sotomatsu Manabu, Ota Setsuo, Maeda Miho, Goto Hiroaki, Kato Yoko, Mori Tetsuya, Inukai Takeshi, Shimada Hiroyuki, Fukushima Keitaro, Ogawa Chitose, Fukushima Takashi, Koh Katsuyoshi, Manabe Atsushi, Ohara Akira

  PEDIATRIC BLOOD & CANCER 65 S7 - S8 1545-5009 2018/11 [Refereed][Not invited]
  
• Morphological Features of Bone Marrow in Patients with Inherited Bone Marrow Failure

  Hama Asahito, Hasegawa Daisuke, Manabe Atsushi, Nozawa Kazue, Narita Atsushi, Okuno Yusuke, Muramatsu Hideki, Takahashi Yoshiyuki, Watanabe Kenichiro, Ohara Akira, Ito Masafumi, Kojima Seiji

  PEDIATRIC BLOOD & CANCER 65 S66-S66  1545-5009 2018/11 [Not refereed][Not invited]
  
• Clinical characteristics of pediatric patients with myeloid sarcoma without bone marrow involvement in Japan.

  Taga T, Imamura T, Nakashima K, Maeda N, Watanabe A, Miyajima Y, Sakaguchi S, Sano H, Hasegawa D, Kawasaki H, Adachi S, Takagi M, Koh K, Manabe A, Taki T, Ishida Y

  International journal of hematology 108 (4) 438 - 442 0925-5710 2018/10 [Refereed][Not invited]
   

  Myeloid sarcoma (MS) is a rare neoplastic condition that is often described in association with acute myeloid leukemia (AML). MS in childhood has received little attention, particularly in Japan. We carried out a nationwide retrospective analysis of Japanese children diagnosed with MS without bone marrow involvement. Inclusion criteria were diagnosis of MS at younger than 20 years of age between January 1, 2000 and December 31, 2013. There was a predominance of males (8:2), and the median age at MS diagnosis was 4 years. Sites of involvement varied and included skin (n = 3), head and/or neck (n = 2), and multiple sites (n = 2). Karyotypes were evaluated in seven patients, with one individual carrying t(8;21) and t(9;11). Four patients developed bone marrow involvement 2–55 months after diagnosis of MS. All patients received chemotherapy for de novo AML and two individuals received HSCT in first remission. Seven of ten patients survived for 50–152 months (median, 93 months) without disease after initial chemotherapy. This retrospective study confirmed that pediatric MS without bone marrow involvement in Japan is a very rare disease. MS patients responded favorably to therapies for de novo AML, and HSCT in first remission was not indicated for all patients.
• シーケンスによる先天性骨髄不全症の診断(Diagnosis of Inherited Bone Marrow Failure Syndromes Using Sequencing Approaches)

  Narita Atsushi, Muramatsu Hideki, Okuno Yusuke, Yoshida Kenichi, Shiraishi Yuichi, Sakaguchi Hirotoshi, Kawashima Nozomu, Wang Xinan, Xu Yinyan, Chiba Kenichi, Tanaka Hiroko, Hama Asahito, Sanada Masashi, Kanno Hitoshi, Yamaguchi Hiroki, Ohga Shouichi, Manabe Atsushi, Harigae Hideo, Kunishima Shinji, Ishii Eiichi, Kobayashi Masao, Koike Kenichi, Watanabe Kenichiro, Ito Etsuro, Takata Minoru, Yabe Miharu, Ogawa Seishi, Miyano Satoru, Kojima Seiji, Takahashi Yoshiyuki

  日本小児血液・がん学会雑誌 55 (4) 153 - 153 2187-011X 2018/10
• 腸管気腫を来した血液腫瘍性疾患の2例

  山本 俊亮, 西村 聡, 小野 林太郎, 山本 薫, 足洗 美穂, 平林 真介, 細谷 要介, 長谷川 大輔, 真部 淳

  日本小児血液・がん学会雑誌 (一社)日本小児血液・がん学会 55 (4) 335 - 335 2187-011X 2018/10
• AYA世代の小児がん経験者とそのきょうだいの心的外傷後ストレス症状(PTSS)と外傷体験後成長(PTG)

  山本 薫, 永瀬 恭子, 郡司 美千代, 小林 京子, 平林 真介, 細谷 要介, 長谷川 大輔, 細谷 亮太, 石田 也寸志, 真部 淳, 小澤 美和

  日本小児血液・がん学会雑誌 (一社)日本小児血液・がん学会 55 (4) 343 - 343 2187-011X 2018/10
• 小児がん経験者の知識とセルフマネジメントスキルの現状

  小林 京子, 石田 也寸志, 郡司 美千代, 永瀬 恭子, 前田 邦枝, 小澤 美和, 細谷 要介, 長谷川 大輔, 細谷 亮太, 真部 淳

  日本小児血液・がん学会雑誌 (一社)日本小児血液・がん学会 55 (4) 382 - 382 2187-011X 2018/10
• 集中治療室入院中の患児のきょうだいへの支援の一例

  大久保 香織, 三浦 絵莉子, 野口 楓, 植松 温子, 長谷川 大輔, 小澤 美和, 真部 淳

  日本小児血液・がん学会雑誌 (一社)日本小児血液・がん学会 55 (4) 391 - 391 2187-011X 2018/10
• Whole-exome analysis to detect congenital hemolytic anemia mimicking congenital dyserythropoietic anemia.

  Motoharu Hamada, Sayoko Doisaki, Yusuke Okuno, Hideki Muramatsu, Asahito Hama, Nozomu Kawashima, Atsushi Narita, Nobuhiro Nishio, Kenichi Yoshida, Hitoshi Kanno, Atsushi Manabe, Takashi Taga, Yoshiyuki Takahashi, Satoru Miyano, Seishi Ogawa, Seiji Kojima

  International journal of hematology 108 (3) 306 - 311 0925-5710 2018/09 [Refereed][Not invited]
   

  Congenital dyserythropoietic anemia (CDA) is a heterogeneous group of rare congenital disorders characterized by ineffective erythropoiesis and dysplastic changes in erythroblasts. Diagnosis of CDA is based primarily on the morphology of bone marrow erythroblasts; however, genetic tests have recently become more important. Here, we performed genetic analysis of 10 Japanese patients who had been diagnosed with CDA based on laboratory findings and morphological characteristics. We examined 10 CDA patients via central review of bone marrow morphology and genetic analysis for congenital bone marrow failure syndromes. Sanger sequencing for CDAN1, SEC23B, and KLF1 was performed for all patients. We performed whole-exome sequencing in patients without mutation in these genes. Three patients carried pathogenic CDAN1 mutations, whereas no SEC23B mutations were identified in our cohort. WES unexpectedly identified gene mutations known to cause congenital hemolytic anemia in two patients: canonical G6PD p.Val394Leu mutation and SPTA1 p.Arg28His mutation. Comprehensive genetic analysis is warranted for more effective diagnosis of patients with suspected CDA.
• Secondary bone/soft tissue sarcoma in childhood cancer survivors: a nationwide hospital-based case-series study in Japan.

  Ishida Y, Maeda M, Adachi S, Rikiishi T, Sato M, Kawaguchi H, Manabe A, Tokuyama M, Hori H, Okamura J, Ogawa A, Goto H, Kobayashi R, Yoshinaga S, Fujimoto J, Kuroda T

  Japanese journal of clinical oncology 48 (9) 806 - 814 0368-2811 2018/09 [Refereed][Not invited]
   

  Background: Secondary cancer is the most life-threatening late effect of childhood cancer. We investigated the clinical features of secondary bone/soft tissue sarcoma among childhood cancer survivors (CCSs). Methods: We conducted a retrospective case-series study of 10 069 CCSs newly diagnosed with cancer between 1980 and 2009 across 15 Japanese hospitals. Twenty-one cases of pathologically diagnosed secondary bone/soft tissue sarcoma were selected, and the respective clinical courses were determined using additional questionnaires. Results: The primary cancers included retinoblastoma (n = 7), acute lymphoblastic leukemia (n = 5), lymphoma (n = 5), osteosarcoma (n = 1), rhabdomyosarcoma (n = 1), brain tumor (n = 1) and Langerhans cell histiocytosis (n = 1). The median age at the primary cancer diagnosis was 2.9 years, and the male-to-female ratio was 16:5. The histological classifications of the secondary sarcoma included osteosarcoma (n = 10), malignant peripheral nerve sheath tumor (n = 4), rhabdomyosarcoma (n = 3), Ewing's sarcoma (n = 3) and primitive neuroectodermal tumor (n = 1). The median latency period to the secondary sarcoma was 10.2 years. Significant risk factors for secondary sarcoma in the multivariate Cox regression model included a history of retinoblastoma as the primary cancer (hazard ratio [HR], 20.9; 95% confidence interval [CI], 5.70-76.5) and autologous stem cell transplantation (SCT) (HR, 2.56; 95% CI, 1.08-6.03). Seventeen CCSs with secondary sarcoma underwent radiation, and nine, hematopoietic SCT. Twelve CCSs with secondary sarcoma achieved disease-free survival, while CCSs with hematological cancer or relapsed primary cancer who developed secondary sarcoma had the worst prognoses. Conclusion: The prognoses of CCSs with secondary sarcoma may depend on the primary cancer or prior relapse of primary cancer.
• 本邦におけるShwachman-Diamond症候群の全国的コホートの構築(Establishment of a nationwide cohort for Shwachman-Diamond syndrome in Japan)

  渡邉 健一郎, 金兼 弘和, 濱端 隆行, 上月 景弘, 梅田 雄嗣, 濱 麻人, 奥野 友介, 村松 秀城, 高橋 義行, 長谷川 大輔, 真部 淳, 小原 明, 伊藤 雅文, 小島 勢二, 伊藤 悦朗

  臨床血液 59 (9) 1497 - 1497 0485-1439 2018/09 [Refereed][Not invited]
  
• Treatment outcome of children with acute lymphoblastic leukemia: the Tokyo Children’s Cancer Study Group (TCCSG) Study L04-16

  Hiroyuki Takahashi, Ryosuke Kajiwara, Motohiro Kato, Daisuke Hasegawa, Daisuke Tomizawa, Yasushi Noguchi, Kazutoshi Koike, Daisuke Toyama, Hiromasa Yabe, Michiko Kajiwara, Junya Fujimura, Manabu Sotomatsu, Setsuo Ota, Miho Maeda, Hiroaki Goto, Yoko Kato, Tetsuya Mori, Takeshi Inukai, Hiroyuki Shimada, Keitaro Fukushima, Chitose Ogawa, Atsushi Makimoto, Takashi Fukushima, Kentaro Ohki, Katsuyoshi Koh, Nobutaka Kiyokawa, Atsushi Manabe, Akira Ohara

  International Journal of Hematology 108 (1) 98 - 108 1865-3774 2018/07/01 [Refereed][Not invited]
   

  The survival rate of children with acute lymphoblastic leukemia (ALL) has increased to approximately 90% after substantial progress in risk-oriented treatment strategies. Between 2005 and 2013, the Tokyo Children’s Cancer Study Group (TCCSG) conducted a risk-oriented, non-randomized study, L04-16. The principal aim of this study was to assemble background characteristics and treatment outcomes, and gather genetic information on leukemic cells under central diagnosis. This report outlines the background characteristics and treatment outcomes of 1033 children with ALL treated according to a TCCSG platform. The 5-year event-free and overall survival (OS) rates for all children were 78.1 ± 1.3 and 89.6 ± 1.0%, respectively. The OS rate was significantly higher in children with B-cell precursor (BCP)-ALL (91.9 ± 1.0%, n = 916) than in those with T-ALL (71.9 ± 4.3%, n = 117, p & lt 0.001). In univariate analysis for BCP-ALL, children aged 1–6 years (5y-OS: 94.2 ± 1.0%), with an initial white blood cell count of & lt 20,000/μL (94.0 ± 1.0%), high hyperdiploidy (95.4 ± 1.6%), ETV6-RUNX1 (97.4 ± 1.2%) or TCF3-PBX1 (96.9 ± 2.1%), and “Day8NoBlasts” (96.4 ± 1.1%) had the best outcomes. Genetic investigation revealed two novel fusion genes within this cohort: ETV6-ZNF385A and ZNF362-TCF4. Our study highlighted the clinical aspects of genomic features of ALL in Japanese children. We provide fundamental information for the further molecular investigation of this disease.
• Phase II/III study in children and adolescents with newly diagnosed B-cell precursor acute lymphoblastic leukemia: protocol for a nationwide multicenter trial in Japan.

  Koh K, Kato M, Saito AM, Kada A, Kawasaki H, Okamoto Y, Imamura T, Horibe K, Manabe A

  Japanese journal of clinical oncology 48 (7) 684 - 691 0368-2811 2018/07 [Refereed][Not invited]
   

  B-cell precursor acute lymphoblastic leukemia is the most common pediatric malignancy, but its treatment needs to be modified to cause low acute toxicity and few late complications with a high cure rate. In this trial, we will stratify patients with B-cell precursor acute lymphoblastic leukemia into standard, intermediate and high risk groups according to prognostic factors. In addition, we will establish an evaluation system for minimal residual disease that will enable us to stratify patients based on minimal residual disease in subsequent clinical trials. We will clarify the impact of dexamethasone/vincristine pulse therapy during maintenance therapy in the standard risk group, and intensive l-asparaginase therapy in the intermediate risk group. In the high risk group, usefulness of vincristine intensification will be assessed. This trial has been registered in the UMIN Clinical Trials Registry as UMIN000009339 [http://www.umin.ac.jp/ctr/].
• Nationwide survey of therapy-related leukemia in childhood in Japan

  Toshihiko Imamura, Takashi Taga, Masatoshi Takagi, Hirohide Kawasaki, Katsuyoshi Koh, Tomohiko Taki, Souichi Adachi, Atsushi Manabe, Yasushi Ishida, On behalf of the Leukemia/Lymphoma Committee

  International Journal of Hematology 108 (1) 91 - 97 1865-3774 2018/07/01 [Refereed][Not invited]
   

  Therapy-related leukemia (t-leukemia) is associated with dismal prognosis. Published pediatric t-leukemia data are somewhat outdated and may not reflect recent advances in treatment. We report a retrospective nationwide survey of patients diagnosed between 2000 and 2013 in Japan. We identified 43 patients with pediatric t-leukemia 33 had t-acute myeloid leukemia (t-AML), eight had t-acute lymphoblastic leukemia (t-ALL) and two had t-acute undifferentiated leukemia. Median age at onset and latency were 12 years and 3.8 years, respectively, consistent with previous reports. Of t-AML patients, 63.6% harbored topoisomerase II inhibitor (topo II)-related genetic abnormalities, while only 12.5% of t-ALL patients had such alterations, suggesting that topo II is not key to t-ALL leukemogenesis. The 7-year overall survival (OS) for all 43 patients was 39.2 ± 11.6%. The 5-year OS was 50 ± 20.4% in t-ALL, and 55.2 ± 11.0% in t-AML. Allogeneic hematopoietic cell transplantation (allo-HCT) was associated with superior 5-year OS (HCT(+) vs. HCT(−), 78.8 vs. 12.1% p & lt 0.001), and 26 of 32 patients received allo-HCT in complete remission (CR). Only allo-HCT was associated with superior OS on multivariate analysis (HR 0.003, 95% CI 0.0001–0.098 p & lt 0.001). These findings suggest that allo-HCT in CR improves pediatric t-leukemia outcomes.
• Secondary cancer after a childhood cancer diagnosis: viewpoints considering primary cancer

  Yasushi Ishida, Miho Maeda, Souichi Adachi, Hiroko Inada, Hiroshi Kawaguchi, Hiroki Hori, Atsushi Ogawa, Kazuko Kudo, Chikako Kiyotani, Hiroyuki Shichino, Takeshi Rikiishi, Ryoji Kobayashi, Maho Sato, Jun Okamura, Hiroaki Goto, Atsushi Manabe, Shinji Yoshinaga, Dongmei Qiu, Junichiro Fujimoto, Tatsuo Kuroda

  International Journal of Clinical Oncology 1 - 11 1437-7772 2018/06/05 [Refereed][Not invited]
   

  Backgrounds: Multidisciplinary therapy has increased the risk of subsequent late effects, but detailed analyses on secondary cancers in childhood cancer survivors (CCSs) are limited in Asian countries. Methods: This was a retrospective cohort study comprising 10,069 CCSs who were diagnosed between 1980 and 2009 across 15 Japanese hospitals. We conducted secondary analyses to estimate the incidence of secondary cancer according to each primary malignancy and to elucidate the association between primary and secondary cancers. We also explored the risk factors for the development of secondary cancer in each independent primary malignancy. Results: The cumulative incidence of secondary cancer at 20 years varied among primary cancers: hematological malignancy, 3.1% (95% CI 2.2–4.3) retinoblastoma, 6.6% (95% CI 1.5–16.8) pediatric solid tumor, 2.5% (95% CI 1.3–4.2) brain tumors, 5.2% (95% CI 1.7–11.8) bone/soft tissue sarcoma, 5.2% (95% CI 2.3–10.1) and others, 3.3% (95% CI 1.6–6.0) (p = 0.015). The cumulative incidence of secondary cancers is highest in those with osteosarcoma (13.1%) followed by those with hepatoblastoma (8.4%) and retinoblastoma (6.6%). Close association between the primary and secondary cancer diagnoses was found. The risk factors for secondary cancer development depended on the primary cancer, but autologous/allogeneic stem cell transplantation was a relatively common risk factor. Conclusion: The cumulative incidence of secondary cancer varied among primary cancers. The primary cancer was closely associated with the secondary cancer but stem cell transplantation was a common risk factor for secondary cancers among CCSs.
• Preclinical evaluation of NUDT15-guided thiopurine therapy and its effects on toxicity and antileukemic efficacy.

  Rina Nishii, Takaya Moriyama, Laura J Janke, Wenjian Yang, Chase C Suiter, Ting-Nien Lin, Lie Li, Kentaro Kihira, Hidemi Toyoda, Ute Hofmann, Matthias Schwab, Masatoshi Takagi, Tomohiro Morio, Atsushi Manabe, Shirley Kham, Nan Jiang, Karen R Rabin, Motohiro Kato, Katsuyoshi Koh, Allen Eng-Juh Yeoh, Hiroki Hori, Jun J Yang

  Blood 131 (22) 2466 - 2474 1528-0020 2018/05/31 [Refereed][Not invited]
   

  Thiopurines (eg, 6-mercaptopurine [MP]) are highly efficacious antileukemic agents, but they are also associated with dose-limiting toxicities. Recent studies by us and others have identified inherited NUDT15 deficiency as a novel genetic cause of thiopurine toxicity, and there is a strong rationale for NUDT15-guided dose individualization to preemptively mitigate adverse effects of these drugs. Using CRISPR-Cas9 genome editing, we established a Nudt15-/- mouse model to evaluate the effectiveness of this strategy in vivo. Across MP dosages, Nudt15-/- mice experienced severe leukopenia, rapid weight loss, earlier death resulting from toxicity, and more bone marrow hypocellularity compared with wild-type mice. Nudt15-/- mice also showed excessive accumulation of a thiopurine active metabolite (ie, DNA-incorporated thioguanine nucleotides [DNA-TG]) in an MP dose-dependent fashion, as a plausible cause of increased toxicity. MP dose reduction effectively normalized systemic exposure to DNA-TG in Nudt15-/- mice and largely eliminated Nudt15 deficiency-mediated toxicity. In 95 children with acute lymphoblastic leukemia, MP dose adjustment also directly led to alteration in DNA-TG levels, the effects of which were proportional to the degree of NUDT15 deficiency. Using leukemia-bearing mice with concordant Nudt15 genotype in leukemia and host, we also confirmed that therapeutic efficacy was preserved in Nudt15-/- mice receiving a reduced MP dose compared with Nudt15+/+ counterparts exposed to a standard dose. In conclusion, we demonstrated that NUDT15 genotype-guided MP dose individualization can preemptively mitigate toxicity without compromising therapeutic efficacy.
• Risk factors for psychological and psychosomatic symptoms among children with malignancies

  Kenichi Maeda, Daisuke Hasegawa, Kevin Y Urayama, Shinichi Tsujimoto, Yuriko Azami, Miwa Ozawa, Atsushi Manabe

  Journal of Paediatrics and Child Health 54 (4) 411 - 415 1440-1754 2018/04/01 [Refereed][Not invited]
   

  Aim: With increasing survival rates in paediatric malignancies, the quality-of-life of children during hospitalisation should be given more attention. We aimed to identify factors associated with psychological and psychosomatic symptoms (PPS) that required medication among children hospitalised for treatment of malignancies. Methods: We retrospectively analysed data of 190 patients aged 2–18 years old. They were diagnosed with malignant diseases and admitted for treatment at St. Luke's International Hospital between 2003 and 2013. Patients were considered as having PPS if they were prescribed psychotropic agents during hospitalisation. Results: Of the 190 patients, 56 (30%) were prescribed psychotropic agents for PPS. Types of PPS included insomnia in 21 (38%), anxiety in 11 (20%), and others conditions (psychogenetic nausea, agitation, delirium, depression). The most prescribed psychotropic agents were etizolam for 34 cases (61%), followed by diazepam and risperidone. The multivariable analyses confirmed statistically significant independent associations for haematopoietic stem cell transplantation (HSCT) (odds ratio (OR), 5.21 95% confidence interval (CI), 1.77–15.35), older age (12–18 years vs. 2–5 years, OR, 3.74 95% CI, 1.04–10.00), and opioid use (OR, 7.15 95% CI, 2.36–21.69). Conclusions: Older age at admission, undergoing HSCT, and those given opioids were found to be risk factors for PPS among children with malignancies. Appropriate preventive measures against PPS may be warranted for patients with these risk factors.
• NUDT15ハプロタイプの6-メルカプトプリン感受性への影響

  田中 庸一, 近藤 健介, 康 勝好, 尾鳥 勝也, 真部 淳

  日本薬学会年会要旨集 (公社)日本薬学会 138年会 (4) 61 - 61 0918-9823 2018/03
• Prognostic value of genetic mutations in adolescent and young adults with acute myeloid leukemia.

  Yachiyo Kuwatsuka, Daisuke Tomizawa, Rika Kihara, Yasunobu Nagata, Norio Shiba, Yuka Iijima-Yamashita, Akira Shimada, Takao Deguchi, Hayato Miyachi, Akio Tawa, Takashi Taga, Akitoshi Kinoshita, Hideki Nakayama, Nobutaka Kiyokawa, Akiko Moriya Saito, Katsuyoshi Koh, Hiroaki Goto, Yoshiyuki Kosaka, Norio Asou, Shigeki Ohtake, Shuichi Miyawaki, Yasushi Miyazaki, Toru Sakura, Yukiyasu Ozawa, Noriko Usui, Heiwa Kanamori, Yoshikazu Ito, Kiyotoshi Imai, Youko Suehiro, Shinichi Kobayashi, Kunio Kitamura, Emiko Sakaida, Seishi Ogawa, Tomoki Naoe, Yasuhide Hayashi, Keizo Horibe, Atsushi Manabe, Shuki Mizutani, Souichi Adachi, Hitoshi Kiyoi

  International journal of hematology 107 (2) 201 - 210 0925-5710 2018/02 [Refereed][Not invited]
   

  Clinical outcomes and the genetic background of acute myeloid leukemia (AML) in adolescent and young adults (AYAs) are known to differ in younger children and older adults. To clarify the impact of genetic mutations on clinical outcomes of AYAs with AML, we analyzed data from the JPLSG AML-05 and JALSG AML201 studies. AYAs aged 15-39 years (n = 103) were included. FLT3-ITD, KIT, CEBPA, NRAS, KRAS, WT1, MLL-PTD, and NPM1 mutations were analyzed. Overall survival (OS) of the AYAs was 61% and event-free survival was 38% at 3 years. FLT3-ITD (HR 2.10; 95% CI 1.07-4.12; p = 0.031) and NPM1 (HR 0.24; 95% CI 0.06-1.00; p = 0.050) mutations were associated with risk of overall mortality in multivariate analysis. OS was significantly different according to FLT3-ITD and NPM1 mutation status (p = 0.03). Survival was 100% with NPM1 mutations in the absence of FLT3-ITD and 35% (95% CI 14-57%) with FLT3-ITD in the absence of NPM1 mutations. The OS of AYAs, children (n = 413) and older adults (n = 124) of the AML-05 and AML201 participants were significantly different (p < 0.0001). This is the first report to combine clinical and genetic data of AYA AML from the major Japanese pediatric and adult study groups.
• 幼弱T細胞性急性リンパ性白血病の予後因子の検討(Prognostic analysis of immature T-cell acute lymphoblastic leukemia)

  木村 俊介, 関 正史, 吉田 健一, 上野 浩生, 大木 健太郎, 小林 良二, 出口 隆生, 橋井 佳子, 今村 俊彦, 佐藤 篤, 清河 信敬, 小林 正夫, 岡 明, 林 泰秀, 真部 淳, 小原 明, 堀部 敬三, 宮野 悟, 小川 誠司, 滝田 順子

  日本小児科学会雑誌 122 (2) 234 - 234 0001-6543 2018/02 [Refereed]
  
• 小児がん経験者の成人男性の性機能及び性行動に関する検討

  相賀 咲央莉, 小澤 美和, 石田 也寸志, 長沖 優子, 伊藤 純子, 吉本 優里, 平林 真介, 細谷 要介, 長谷川 大輔, 真部 淳, 細谷 亮太

  日本小児科学会雑誌 (公社)日本小児科学会 122 (2) 358 - 358 0001-6543 2018/02
• [Transplantation-associated thrombotic microangiopathy confirmed by renal biopsy].

  Miyamoto S, Kimura S, Hosoya Y, Hasegawa D, Ishida H, Daida A, Matsui T, Yoshimoto Y, Hirabayashi S, Fujimaru T, Kumamoto T, Mori SI, Suzuki K, Manabe A

  [Rinsho ketsueki] The Japanese journal of clinical hematology 59 (4) 389 - 394 0485-1439 2018 [Refereed][Not invited]
  
• Treatment and biology of pediatric acute lymphoblastic leukemia

  Motohiro Kato, Atsushi Manabe

  Pediatrics International 60 (1) 4 - 12 1442-200X 2018/01/01 [Refereed][Not invited]
   

  Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy. In the past ALL was intractable but now the survival probability is as high as 80–90%. Improved supportive care, treatment stratification based on relapse risk, biological features of leukemic cells, and optimization of treatment regimens by nationwide and international collaboration have contributed to this dramatic improvement. While including traditional risk factors (e.g. age and leukocyte count at diagnosis), the treatment has been modified based on biological characteristics (aneuploidy and translocation) and treatment response (assessed by minimal residual disease). Treatment for pediatric ALL typically consists of induction therapy with steroids, vincristine, and asparaginase with or without anthracycline, followed by multi-agent consolidation including high-dose methotrexate and re-induction therapy. After consolidation, less intensive maintenance therapy is required for 1–2 years to maintain event-free survival. Recently, using advanced genomic analysis technology, novel sentinel genomic alterations that may provide more precise stratification or therapeutic targets, were identified. Moreover, in the last decade germline variations have been recognized as similarly important contributors to understanding the etiology and sensitivity of ALL to treatment. A more individualized approach based on genomic features (somatic and germline) and treatment response, the introduction of newly developed agents such as molecular targeted drugs or immunotherapy, and social support including long-term follow up are required for further improvement.
• Survey of families regarding life of their children with cancer in wards

  Irie Wataru, Hasegawa Daisuke, Kamiya Takahiro, Nagase Kyoko, Yoshikawa Kumiko, Sekitomi Akiko, Amano Kokoro, Ishii Rina, Serizawa Hiroko, Sakamoto Yokie, Ohno Naoko, Kanke Miwa, Tamura Taeko, Manabe Atsushi, Ishida Yasushi, Hirata Mika, Hosoya Ryota

  The Japanese Journal of Pediatric Hematology / Oncology 日本小児血液・がん学会 55 (1) 7 - 14 2187-011X 2018 

  Children with cancer require long-term hospitalization. Thus far, few studies have addressed issues related to the quality of life of childhood cancer patients during hospitalization from the children’s family perspective. In this study, we aimed to clarify the characteristics of childhood cancer patients’ lives in the hospital. Forty-three families of children with cancer who were hospitalized between April 2004 and October 2009 in our hospital participated in this cross-sectional questionnaire survey. Twenty-two families (51%) felt that the hospital regulations overly restrict TV viewing. This answer was not affected by children’s age and TV viewing time before hospitalization. The families who felt restricted by TV regulation answered that their children were under stress due to the deprivation of distraction. Hospitalized children were more likely to have a mobile phone than their age group peers who were not hospitalized. Over 50% of the families provided mobile phones to their children during hospitalization. Regarding hospital diet, 78% of families who experienced difficulty because they were prohibited from bringing their own meals from home and/or the store to their children felt that children did not eat hospital diet at all during hospitalization. Sixty-three percent of the families perceived a change in their children’s sense of taste. In particular, children tended to prefer salty and strong flavors during hospitalization. The results of our survey suggest that the utilization of electronic devices and bringing meals might lead to greater satisfaction during hospitalization rather than strictly adhering to hospital regulations. More flexibility in hospital regulations may improve the quality of life of hospitalized children with cancer.
• Nationwide Survey of Pediatric Hypodiploid Acute Lymphoblastic Leukemia in Japan

  Ishimaru Sae, Okamoto Yasuhiro, Imai Chihaya, Sakaguchi Hirotoshi, Taki Tomohiko, Hasegawa Daisuke, Cho Yuko, Kakuda Harumi, Sano Hideki, Manabe Atushi, Imamura Toshihiko, Kato Motohiro, Arakawa Yuki, Shimonodan Hidemi, Sato Atsushi, Suenobu So-ichi, Inukai Takeshi, Watanabe Arata, Kawano Yoshifumi, Kikuta Atsushi, Horibe Keizo, Ohara Akira, Koh Katsuyoshi

  BLOOD 130 0006-4971 2017/12/07 [Refereed][Not invited]
  
• A nationwide survey of hypoplastic myelodysplastic syndrome (a multicenter retrospective study)

  Takashi Kobayashi, Yasuhito Nannya, Motoshi Ichikawa, Kenji Oritani, Yuzuru Kanakura, Akihiro Tomita, Hitoshi Kiyoi, Masayoshi Kobune, Junji Kato, Hiroshi Kawabata, Motohiro Shindo, Yoshihiro Torimoto, Yuji Yonemura, Nobuyoshi Hanaoka, Hideki Nakakuma, Daisuke Hasegawa, Atsushi Manabe, Naohito Fujishima, Nobuharu Fujii, Mitsune Tanimoto, Yasuyoshi Morita, Akira Matsuda, Atsushi Fujieda, Naoyuki Katayama, Haruhiko Ohashi, Hirokazu Nagai, Yoshiki Terada, Masayuki Hino, Ken Sato, Naoshi Obara, Shigeru Chiba, Kensuke Usuki, Masatsugu Ohta, Osamu Imataki, Makiko Uemura, Tomoiku Takaku, Norio Komatsu, Akira Kitanaka, Kazuya Shimoda, Kenichiro Watanabe, Kaoru Tohyama, Akifumi Takaori-Kondo, Hideo Harigae, Shunya Arai, Yasushi Miyazaki, Keiya Ozawa, Mineo Kurokawa

  AMERICAN JOURNAL OF HEMATOLOGY 92 (12) 1324 - 1332 0361-8609 2017/12 [Refereed][Not invited]
   

  Hypoplastic myelodysplastic syndrome (hMDS) is a distinct entity with bone marrow (BM) hypocellularity and the risk of death from BM failure (BMF). To elucidate the characteristics of hMDS, the data of 129 patients diagnosed between April 2003 and March 2012 were collected from 20 institutions and the central review team of the National Research Group on Idiopathic Bone Marrow Failure Syndromes, and compared with 115 non-hMDS patients. More RA and fewer CMMoL and RAEB-t in French-American-British (FAB) and more RCUD and MDS-U and fewer RCMD in World Health Organization (WHO) classifications were found in hMDS than non-hMDS with significant differences. The overall survival (OS) and AML progression-free survival (AML-PFS) of hMDS were higher than those of non-hMDS, especially in patients at age 50 and of lower risk in Revised International Prognostic Scoring System (IPSS-R). In competing risks analysis, hMDS exhibited decreased risk of AML-progression in lower IPSS or IPSS-R risk patients, and higher risk of death from BMF in patients at age 50. Poor performance status (PS 2) and high karyotype risks in IPSS-R (high and very high) were significant risk factors of death and AML-progression in Cox proportional hazards analysis.
• Constitutional abnormalities of IDH1 combined with secondary mutations predispose a patient with Maffucci syndrome to acute lymphoblastic leukemia

  Shinsuke Hirabayashi, Masafumi Seki, Daisuke Hasegawa, Motohiro Kato, Nobuyuki Hyakuna, Takuya Shuo, Shunsuke Kimura, Kenichi Yoshida, Keisuke Kataoka, Yoichi Fujii, Yuichi Shiraishi, Kenichi Chiba, Hiroko Tanaka, Nobutaka Kiyokawa, Satoru Miyano, Seishi Ogawa, Junko Takita, Atsushi Manabe

  PEDIATRIC BLOOD & CANCER 64 (12) 1545-5009 2017/12 [Refereed][Not invited]
   

  Maffucci syndrome is a nonhereditary disorder caused by somatic mosaic isocitrate dehydrogenase 1 or 2 (IDH1 or IDH2) mutations and is characterized by multiple enchondromas along with hemangiomas. Malignant transformation of enchondromas to chondrosarcomas and secondary neoplasms, such as brain tumors or acute myeloid leukemia, are serious complications. A 15-year-old female with Maffucci syndrome developed B-cell precursor acute lymphoblastic leukemia (BCP-ALL). A somatic mutation in IDH1 was detected in hemangioma and leukemic cells. KRAS mutation and deletion of IKZF1 were detected in leukemic cells. Patients with Maffucci syndrome may, therefore, be at risk of BCP-ALL associated with secondary genetic events that affect lymphocyte differentiation.
• AYA世代小児がん経験者の為の包括的ドックからの報告 食行動と生活習慣病への看護介入の必要性

  前田 邦枝, 永瀬 恭子, 郡司 美千代, 小林 京子, 細谷 要介, 小澤 美和, 長谷川 大輔, 真部 淳, 石田 也寸志

  日本小児血液・がん学会雑誌 (一社)日本小児血液・がん学会 54 (4) 429 - 429 2187-011X 2017/10
• AYA世代小児がん経験者の長期フォローアップにおける自立支援ケア計画の視点と目標 実践報告

  郡司 美千代, 永瀬 恭子, 小林 京子, 前田 邦枝, 小澤 美和, 細谷 要介, 長谷川 大輔, 真部 淳, 細谷 亮太, 石田 也寸志

  日本小児血液・がん学会雑誌 (一社)日本小児血液・がん学会 54 (4) 430 - 430 2187-011X 2017/10
• Plasma asparaginase activity, asparagine concentration, and toxicity after administration of Erwinia asparaginase in children and young adults with acute lymphoblastic leukemia: Phase I/II clinical trial in Japan

  Chitose Ogawa, Fumi Taguchi, Hiroaki Goto, Katsuyoshi Koh, Daisuke Tomizawa, Akira Ohara, Atsushi Manabe

  PEDIATRIC BLOOD & CANCER 64 (9) 1545-5009 2017/09 [Refereed][Not invited]
   

  BackgroundA phase I/II study of Erwinia asparaginase in Japanese children and young adults with acute lymphoblastic leukemia (ALL) was performed to investigate its activity and toxicity. ProcedureEligible patients were in remission and had developed allergy to Escherichia coli asparaginase. Erwina asparaginase was intramuscularly administrated on days 2, 5, 7, 9, 11, and 13. To measure the plasma l-asparagine concentration (PAC), amino acids were derivatized with N-(5-fluoro-2,4-dinitrophenyl)-l-leucinamide. ResultsSix consecutive patients completed the phase I study with 25,000 IU/m(2) per dose without dose-limiting toxicity and 18 patients completed the phase II study with 25,000 IU/m(2) per dose. Median age of 24 patients was 7.5 (range 2-16) years. The half-life of plasma asparaginase activity (PAA) was 16.9 7.5 hr and the maximum PAA was 3.10 +/- 1.47 IU/ml (n = 23, noncompartment model). PAA of 0.1 IU/ml or more was achieved in all 23 patients (100%) 48 hr and in 18 of 23 patients (78.3%) 72 hr after the first administration. During the 2-week study, 94.2% (65 of 69) of the 48-hr samples and 80.4% (37 of 46) of the 72-hr samples had PAA of 0.1 IU/ml or more. PAC less than 1.0 M was achieved in 95.7% patients 48 and 72 hr after administration. PAC values in all the samples were greater than the limit of quantitation (0.0625 M). Karnofsky performance status of all patients was good during the 2-week study. ConclusionsErwinia asparaginase 25,000 IU/m(2) per dose x six intramuscular administrations in 2 weeks was well tolerated, pharmacologically efficacious, and safe in Japanese patients with ALL/lymphoblastic lymphoma.
• Recurrent SPI1 (PU.1) fusions in high-risk pediatric T cell acute lymphoblastic leukemia

  Masafumi Seki, Shunsuke Kimura, Tomoya Isobe, Kenichi Yoshida, Hiroo Ueno, Yaeko Nakajima-Takagi, Changshan Wang, Lin Lin, Ayana Kon, Hiromichi Suzuki, Yusuke Shiozawa, Keisuke Kataoka, Yoichi Fujii, Yuichi Shiraishi, Kenichi Chiba, Hiroko Tanaka, Teppei Shimamura, Kyoko Masuda, Hiroshi Kawamoto, Kentaro Ohki, Motohiro Kato, Yuki Arakawa, Katsuyoshi Koh, Ryoji Hanada, Hiroshi Moritake, Masaharu Akiyama, Ryoji Kobayashi, Takao Deguchi, Yoshiko Hashii, Toshihiko Imamura, Atsushi Sato, Nobutaka Kiyokawa, Akira Oka, Yasuhide Hayashi, Masatoshi Takagi, Atsushi Manabe, Akira Ohara, Keizo Horibe, Masashi Sanada, Atsushi Iwama, Hiroyuki Mano, Satoru Miyano, Seishi Ogawa, Junko Takita

  NATURE GENETICS 49 (8) 1274 - + 1061-4036 2017/08 [Refereed][Not invited]
   

  The outcome of treatment-refractory and/or relapsed pediatric T cell acute lymphoblastic leukemia (T-ALL) is extremely poor(1), and the genetic basis for this is not well understood. Here we report comprehensive profiling of 121 cases of pediatric TALL using transcriptome and/or targeted capture sequencing, through which we identified new recurrent gene fusions involving SPI1 (STMN1-SPI1 and TCF7-SPI1). Cases positive for fusions involving SPI1 (encoding PU.1), accounting for 3.9% (7/181) of the examined pediatric T-ALL cases, showed a double-negative (DN; CD4(-)CD8(-)) or CD8(+) single-positive (SP) phenotype and had uniformly poor overall survival. These cases represent a subset of pediatric T-ALL distinguishable from the known T-ALL subsets(2) in terms of expression of genes involved in T cell precommitment, establishment of T cell identity, and post-beta-selection maturation and with respect to mutational profile. PU.1 fusion proteins retained transcriptional activity and, when constitutively expressed in mouse stem/progenitor cells, induced cell proliferation and resulted in a maturation block. Our findings highlight a unique role of SPI1 fusions in high-risk pediatric T-ALL.
• Bortezomib combined with standard induction chemotherapy in Japanese children with refractory acute lymphoblastic leukemia

  Akihiro Iguchi, Yuko Cho, Minako Sugiyama, Yukayo Terashita, Tadashi Ariga, Yosuke Hosoya, Shinsuke Hirabayashi, Atsushi Manabe, Keisuke Hara, Tetsuya Aiba, Tsugumi Shiokawa, Hiroko Tada, Norihiro Sato

  INTERNATIONAL JOURNAL OF HEMATOLOGY 106 (2) 291 - 298 0925-5710 2017/08 [Refereed][Not invited]
   

  Bortezomib has been shown to be effective and well-tolerated in patients with refractory acute lymphoblastic leukemia (ALL) in the Therapeutic Advances in Childhood Leukemia trial. However, the safety and efficacy of bortezomib have not been evaluated in Japanese pediatric patients. Here, we report the results of a clinical trial designed to evaluate the safety of bortezomib combined with induction chemotherapy in Japanese children with refractory ALL. A total of six patients with B-precursor ALL were enrolled in this study. Four-dose bortezomib (1.3 mg/m(2)/dose) combined with two standard induction chemotherapies was used. Prolonged pancytopenia (grade 4) was observed in all patients. Four of the six patients developed severe infectious complications. Peripheral neuropathy (grade 2) occurred in five patients. The individual plasma bortezomib concentration-time profiles were not related to toxicity and efficacy. Five patients were evaluable for response, and four patients achieved complete response (CR) or CR without platelet recovery (80%). In conclusion, four-dose bortezomib (1.3 mg/m(2)/dose) combined with standard re-induction chemotherapy was associated with a high risk of infectious complications induced by prolonged neutropenia, although high efficacy has been achieved for Japanese pediatric patients with refractory ALL. Attention must be given to severe infectious complications when performing re-induction chemotherapy including bortezomib.
• EP300-ZNF384 fusion gene product up-regulates GATA3 gene expression and induces hematopoietic stem cell gene expression signature in B-cell precursor acute lymphoblastic leukemia cells

  Akinori Yaguchi, Takeshi Ishibashi, Kazuki Terada, Hitomi Ueno-Yokohata, Yuya Saito, Junya Fujimura, Toshiaki Shimizu, Kentaro Ohki, Atsushi Manabe, Nobutaka Kiyokawa

  INTERNATIONAL JOURNAL OF HEMATOLOGY 106 (2) 269 - 281 0925-5710 2017/08 [Refereed][Not invited]
   

  ZNF384-related fusion genes are associated with a distinct subgroup of B-cell precursor acute lymphoblastic leukemias in childhood, with a frequency of approximately 3-4%. We previously identified a novel EP300-ZNF384 fusion gene. Patients with the ZNF384-related fusion gene exhibit a hematopoietic stem cell (HSC) gene expression signature and characteristic immunophenotype with negative or low expression of CD10 and aberrant expression of myeloid antigens, such as CD33 and CD13. However, the molecular basis of this pathogenesis remains completely unknown. In the present study, we examined the biological effects of EP300-ZNF384 expression induced by retrovirus- mediated gene transduction in an REH B-cell precursor acute lymphoblastic leukemia cell line, and observed the acquisition of the HSC gene expression signature and an up-regulation of GATA3 gene expression, as assessed by microarray analysis. In contrast, the gene expression profile induced by wild-type ZNF384 in REH cells was significantly different from that by EP300-ZNF384 expression. Together with the results of reporter assays, which revealed the enhancement of GATA3-promoter activity by EP300-ZNF384 expression, these findings suggest that EP300-ZNF384 mediates GATA3 gene expression and may be involved in the acquisition of the HSC gene expression signature and characteristic immunophenotype in B-cell precursor acute lymphoblastic leukemia cells.
• Salvage therapy for children with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia

  Yuichi Kodama, Atsushi Manabe, Hirohide Kawasaki, Itaru Kato, Keisuke Kato, Atsushi Sato, Kimikazu Matsumoto, Motohiro Kato, Hidefumi Hiramatsu, Hideki Sano, Takashi Kaneko, Megumi Oda, Akiko M. Saito, Souichi Adachi, Keizo Horibe, Shuki Mizutani, Eiichi Ishii, Hiroyuki Shimada

  PEDIATRIC BLOOD & CANCER 64 (8) 1545-5009 2017/08 [Refereed][Not invited]
   

  BackgroundIn the tyrosine kinase inhibitor (TKI) era, outcomes after salvage therapy for relapsed or refractory Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) remain unclear. ProcedureThe clinical courses of 19 patients with relapse (n = 13) or induction failure (n = 6) in the Japanese Pediatric Leukemia/Lymphoma Study Group Ph+ ALL04 study were retrospectively reviewed. ResultsFifteen male and four female patients had a median age of 8 (range 4-15) years at relapse or induction failure. Patients received imatinib in combination with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD) and methotrexate and cytarabine (MTX/Ara-C) (n = 9), imatinib in combination with other chemotherapy (n = 5), chemotherapy without imatinib (n = 2), imatinib alone (n = 2), or no additional chemotherapy (n = 1). Two patients underwent hematopoietic stem cell transplantation (HSCT) without achieving complete remission (CR) and died of leukemia. The remaining 17 patients achieved CR with salvage therapies and underwent HSCT whilst in CR: 10 patients remain alive in CR, five died of transplantation-related complications, and two died of relapse. In six of seven patients with available data on minimal residual disease (MRD), imatinib in combination with the first course of hyper-CVAD was more effective in achieving a favorable MRD response compared with the Ph+ ALL04 induction regimen. ConclusionThis study suggested that cross-resistance to imatinib failed to develop after conventional chemotherapy. Imatinib in combination with chemotherapy including hyper-CVAD+MTX/Ara-C was effective and safe for relapsed or refractory Ph+ ALL patients who received frontline therapy without imatinib.
• Recurrent SPI1 (PU.1) fusions in high-risk pediatric T cell acute lymphoblastic leukemia

  Masafumi Seki, Shunsuke Kimura, Tomoya Isobe, Kenichi Yoshida, Hiroo Ueno, Yaeko Nakajima-Takagi, Changshan Wang, Lin Lin, Ayana Kon, Hiromichi Suzuki, Yusuke Shiozawa, Keisuke Kataoka, Yoichi Fujii, Yuichi Shiraishi, Kenichi Chiba, Hiroko Tanaka, Teppei Shimamura, Kyoko Masuda, Hiroshi Kawamoto, Kentaro Ohki, Motohiro Kato, Yuki Arakawa, Katsuyoshi Koh, Ryoji Hanada, Hiroshi Moritake, Masaharu Akiyama, Ryoji Kobayashi, Takao Deguchi, Yoshiko Hashii, Toshihiko Imamura, Atsushi Sato, Nobutaka Kiyokawa, Akira Oka, Yasuhide Hayashi, Masatoshi Takagi, Atsushi Manabe, Akira Ohara, Keizo Horibe, Masashi Sanada, Atsushi Iwama, Hiroyuki Mano, Satoru Miyano, Seishi Ogawa, Junko Takita

  Nature Genetics 49 (8) 1274 - 1281 1546-1718 2017/08/01 [Refereed][Not invited]
   

  The outcome of treatment-refractory and/or relapsed pediatric T cell acute lymphoblastic leukemia (T-ALL) is extremely poor, and the genetic basis for this is not well understood. Here we report comprehensive profiling of 121 cases of pediatric T-ALL using transcriptome and/or targeted capture sequencing, through which we identified new recurrent gene fusions involving SPI1 (STMN1-SPI1 and TCF7-SPI1). Cases positive for fusions involving SPI1 (encoding PU.1), accounting for 3.9% (7/181) of the examined pediatric T-ALL cases, showed a double-negative (DN CD4 - CD8 -) or CD8 + single-positive (SP) phenotype and had uniformly poor overall survival. These cases represent a subset of pediatric T-ALL distinguishable from the known T-ALL subsets in terms of expression of genes involved in T cell precommitment, establishment of T cell identity, and post-β-selection maturation and with respect to mutational profile. PU.1 fusion proteins retained transcriptional activity and, when constitutively expressed in mouse stem/progenitor cells, induced cell proliferation and resulted in a maturation block. Our findings highlight a unique role of SPI1 fusions in high-risk pediatric T-ALL.
• Clinical utility of next-generation sequencing for inherited bone marrow failure syndromes

  Hideki Muramatsu, Yusuke Okuno, Kenichi Yoshida, Yuichi Shiraishi, Sayoko Doisaki, Atsushi Narita, Hirotoshi Sakaguchi, Nozomu Kawashima, Xinan Wang, Yinyan Xu, Kenichi Chiba, Hiroko Tanaka, Asahito Hama, Masashi Sanada, Yoshiyuki Takahashi, Hitoshi Kanno, Hiroki Yamaguchi, Shouichi Ohga, Atsushi Manabe, Hideo Harigae, Shinji Kunishima, Eiichi Ishii, Masao Kobayashi, Kenichi Koike, Kenichiro Watanabe, Etsuro Ito, Minoru Takata, Miharu Yabe, Seishi Ogawa, Satoru Miyano, Seiji Kojima

  GENETICS IN MEDICINE 19 (7) 796 - 802 1098-3600 2017/07 [Refereed][Not invited]
   

  Purpose: Precise genetic diagnosis of inherited bone marrow failure syndromes (IBMFS), a heterogeneous group of genetic disorders, is challenging but essential for precise clinical decision making. Methods: We analyzed 121 IBMFS patients using a targeted sequencing covering 184 associated genes and 250 IBMFS patients using whole-exome sequencing (WES). Results: We achieved successful genetic diagnoses for 53 of 121 patients (44%) using targeted sequencing and for 68 of 250 patients (27%) using WES. In the majority of cases (targeted sequencing: 45/53, 85%; WES: 63/68, 93%), the detected variants were concordant with, and therefore supported, the clinical diagnoses. However, in the remaining 13 cases (8 patients by target sequencing and 5 patients by WES), the clinical diagnoses were incompatible with the detected variants. Conclusion: Our approach utilizing targeted sequencing and WES achieved satisfactory diagnostic rates and supported the efficacy of massive parallel sequencing as a diagnostic tool for IBMFS.
• Myelodysplastic syndrome (MDS) and juvenile myelomonocytic leukemia (JMML)

  Daisuke Hasegawa, Atsushi Manabe

  Hematological Disorders in Children: Pathogenesis and Treatment 87 - 108 2017/06/14 [Refereed][Not invited]
   

  Myelodysplastic syndrome (MDS) is a group of clonal hematopoietic stem cell disorders and is uncommon in children comparing to adults. According to the proportion of blasts in the bone marrow (BM) and peripheral blood, it is divided into low-grade MDS and advanced MDS. Low-grade MDS often shows hypocellular BM, which makes differentiation from aplastic anemia and inherited bone marrow failure syndrome challenging. Treatment strategy for low-grade MDS should be determined based on the severity of cytopenias, karyotypes, and donor availability. In advanced MDS, two-thirds have chromosomal aberrations such as monosomy 7, and acute myeloid leukemia (AML) is the major differential diagnosis. Allogeneic hematopoietic cell transplantation (HCT) is the mainstay of treatment for children with advanced MDS however, relapse and transplant-related mortality are obstacle to cure. Juvenile myelomonocytic leukemia (JMML) is an aggressive myeloid neoplasm of early childhood characterized by excessive proliferation of monocytic and granulocytic cells. The hypersensitivity of myeloid progenitor cells to GM-CSF is regarded as a hallmark of JMML and is caused by mutations in genes regulating the RAS signaling pathway (i.e., NRAS, KRAS, NF1, PTPN11, and CBL). Although allogeneic HCT is the treatment of choice for most patients with JMML, a subset of patients harboring mutations in CBL or RAS can be managed without HCT.
• The effects of inherited NUDT15 polymorphisms on thiopurine active metabolites in Japanese children with acute lymphoblastic leukemia

  Takaya Moriyama, Rina Nishii, Ting-Nien Lin, Kentaro Kihira, Hidemi Toyoda, Nersting Jacob, Motohiro Kato, Katsuyoshi Koh, Hiroto Inaba, Atsushi Manabe, Kjeld Schmiegelow, Jun J. Yang, Hiroki Hori

  PHARMACOGENETICS AND GENOMICS 27 (6) 236 - 239 1744-6872 2017/06 [Refereed][Not invited]
   

  Thiopurines [e.g. mercaptopurine (MP)] are widely used as chemotherapeutic agents in the treatment of pediatric acute lymphoblastic leukemia with dose-limiting hematopoietic toxicity. Recently, germline variants in NUDT15 have been identified as a major genetic cause for MP-related bone marrow suppression, and there is increasing interest in the clinical implementation of NUDT15 genotype-guided MP dose individualization. Therefore, we sought to evaluate the effects of NUDT15 on thiopurine metabolism and identify pharmacologic markers to inform NUDT15 genotype-guided MP dosing. In 55 Japanese children with acute lymphoblastic leukemia, we simultaneously measured both thioguanine nucleotides (TGN) in red blood cells and DNA-incorporated thioguanine (DNA-TG) in white blood cells. TGN levels were significantly lower in patients with NUDT15 deficiency, likely because of toxicity-related MP dose reduction. In contrast, when exposed to the same dose of MP, DNA-TG accumulated more efficiently in vivo with increasing number of risk alleles in NUDT15 (P=4.0x10(-9)). Cytosolic TGN and nuclear DNA-TG were correlated positively with each other across genotype groups (P=6.5x10(-4)), but the ratio of DNA-TG to TGN was significantly higher in NUDT15-deficient patients (P=3.6x10(-9)), consistent with excessive MP activation. In conclusion, our results suggest that DNA-TG is a more relevant MP metabolite than TGN to inform NUDT15 genotype-guided dose adjustments.
• ZNF384関連融合遺伝子はALLの細胞マーカーに特徴を有する亜群を規定する

  清河 信敬, 大木 健太郎, 平林 真介, 福島 敬, 康 勝好, 真部 淳, 小原 明

  Cytometry Research (一社)日本サイトメトリー学会 27 (Suppl.) 64 - 64 0916-6920 2017/06
• Risk Factors for Hospital-acquired Clostridium difficile Infection Among Pediatric Patients With Cancer

  Atsuro Daida, Hiroki Yoshihara, Ikuko Inai, Daisuke Hasegawa, Yasushi Ishida, Kevin Y. Urayama, Atsushi Manabe

  JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY 39 (3) E167 - E172 1077-4114 2017/04 [Refereed][Not invited]
   

  Hospital-acquired Clostridium difficile infection (CDI) may cause life-threatening colitis for children with cancer, making identification of risk factors important. We described characteristics of pediatric cancer patients with primary and recurring CDI, and evaluated potential risk factors. Among 189 cancer patients, 51 cases (27%) of CDI and 94 matched controls of cancer patients without CDI were analyzed. Multivariable logistic regression was used to evaluate the association between CDI and several potential risk factors. Median age of CDI cases was lower (3.3 y; 0.60 to 16.2) than controls (7.7 y; 0.4 to 20.5). Median duration of neutropenia before CDI was longer for CDI cases (10.0 d; 0.0 to 30.0) compared with duration calculated from reference date in controls (6.0 d; 0.0 to 29.0). Multivariable analysis showed that older age was associated with reduced risk (>= 7 vs. 0 to 3 y, odds ratio=0.11; 95% confidence interval, 0.02-0.54), and prolonged neutropenia was associated with increased risk (odds ratio=1.11; 95% confidence interval, 1.01-1.22). CDI recurred in 26% of cases. Younger age and prolonged neutropenia were risk factors for CDI in children with cancer. Increasing awareness to these risk factors will help to identify opportunities for CDI prevention in cancer patients.
• Interaction between NUDT15 and ABCC4 variants enhances intolerability of 6-mercaptopurine in Japanese patients with childhood acute lymphoblastic leukemia.

  Tanaka Y, Nakadate H, Kondoh K, Nakamura K, Koh K, Manabe A

  The pharmacogenomics journal 1470-269X 2017/04 [Refereed][Not invited]
  
• Infantile fibrosarcoma treated with postoperative vincristine and dactinomycin

  Hiroki Yoshihara, Yuri Yoshimoto, Yosuke Hosoya, Daisuke Hasegawa, Takafumi Kawano, Akiko Sakoda, Hajime Okita, Atsushi Manabe

  PEDIATRICS INTERNATIONAL 59 (3) 371 - 374 1328-8067 2017/03 [Refereed][Not invited]
   

  Infantile fibrosarcoma is a non-rhabdomyosarcoma soft-tissue sarcoma that occurs in infancy and which has a relatively good prognosis. A vincristine and dactinomycin (VA) regimen has been shown to be effective, although the duration of chemotherapy has not been well defined. We describe the case of a 4-month-old boy with a mass at the left dorsum of the foot who was diagnosed with infantile fibrosarcoma after resection of the tumor, the margin of which was macroscopically positive. VA treatment was carried out with careful monitoring of response and adverse effects. Pancytopenia was seen during the second cycle, and therapy was reduced thereafter. The treatment was continued for 38 weeks (12 cycles). There was no functional impairment, and no evidence of recurrence at 18 months after therapy.
• Pediatric intestinal Beh double dagger et disease complicated by myeloid malignancies

  Kiichiro Kanamitsu, Akira Shimada, Ritsuo Nishiuchi, Tomonari Shigemura, Yozo Nakazawa, Kenichi Koike, Yuichi Kodama, Yuichi Shinkoda, Yoshifumi Kawano, Kozo Yasui, Koji Sasaki, Ryosuke Kajiwara, Hirokazu Tsukahara, Atsushi Manabe

  INTERNATIONAL JOURNAL OF HEMATOLOGY 105 (3) 377 - 382 0925-5710 2017/03 [Refereed][Not invited]
   

  Beh double dagger et disease (BD) is rarely seen in children. Its clinical manifestations are believed to differ between pediatric and adult patients. The characteristics of BD complicated by myelodysplastic syndrome (MDS) are well established for adult patients; however, because only a few cases of pediatric-onset BD complicated by MDS have been reported, its clinical characteristics remain unknown. We here retrospectively review pediatric-onset BD complicated by myeloid malignancies in Japan, having identified five such patients. All patients were female and had gastrointestinal involvements, but lacked both major features of BD, i.e., uveitis and association with HLA-B51. All patients had advanced MDS or acute myeloid leukemia and received chemotherapy followed by hematopoietic stem cell transplantation. These five cases suggest that intestinal BD and myeloid malignancies have one or more pathophysiological mechanisms in common.
• 小児急性リンパ性白血病患児における高用量メトトレキサート投与後の血中濃度に影響を与える因子の検討

  田中 庸一, 浦山 ケビン, 森 麻希子, 長谷川 大輔, 太田 節雄, 柳町 昌克, 康 勝好, 尾鳥 勝也, 真部 淳

  日本薬学会年会要旨集 (公社)日本薬学会 137年会 (4) 176 - 176 0918-9823 2017/03 [Refereed][Not invited]
  
• Long-term outcome of 6-month maintenance chemotherapy for acute lymphoblastic leukemia in children.

  M Kato, S Ishimaru, M Seki, K Yoshida, Y Shiraishi, K Chiba, N Kakiuchi, Y Sato, H Ueno, H Tanaka, T Inukai, D Tomizawa, D Hasegawa, T Osumi, Y Arakawa, T Aoki, M Okuya, K Kaizu, K Kato, Y Taneyama, H Goto, T Taki, M Takagi, M Sanada, K Koh, J Takita, S Miyano, S Ogawa, A Ohara, M Tsuchida, A Manabe

  Leukemia 31 (3) 580 - 584 1476-5551 2017/03 [Refereed][Not invited]
   

  In the treatment of childhood acute lymphoblastic leukemia (ALL), excess shortening of maintenance therapy resulted in high relapse rate, as shown by our previous trial, TCCSG L92-13, in which maintenance therapy was terminated at 1 year from initiation of treatment. In this study, we aimed to confirm the long-term outcome of L92-13, and to identify who can or cannot be cured by shorter duration of maintenance therapy. To obtain sentinel cytogenetics information that had been missed before, we performed genetic analysis with genomic microarray and target intron-capture sequencing from diagnostic bone marrow smear. Disease-free survival (DFS) at 10 years from the end of therapy was 66.0±2.8%. Females (n=138) had better DFS (74.6±3.7%) than males (n=142, 57.5±4.2%, P=0.002). Patients with TCF3-PBX1 (n=11) and ETV6-RUNX1 (n=16) had excellent DFS (90.9±8.7% and 93.8±6.1%, respectively), whereas high hyperdiploidy (n=23) was the most unfavorable subgroup, with 56.6±10.3% of DFS. Short duration of therapy can cure more than half of pediatric ALL, especially females, TCF3-PBX1 and ETV6-RUNX1. Our retrospective observations suggest a gender/karyotype inhomogeneity on the impact of brief therapy.
• Long-term outcome of 6-month maintenance chemotherapy for acute lymphoblastic leukemia in children

  M. Kato, S. Ishimaru, M. Seki, K. Yoshida, Y. Shiraishi, K. Chiba, N. Kakiuchi, Y. Sato, H. Ueno, H. Tanaka, T. Inukai, D. Tomizawa, D. Hasegawa, T. Osumi, Y. Arakawa, T. Aoki, M. Okuya, K. Kaizu, K. Kato, Y. Taneyama, H. Goto, T. Taki, M. Takagi, M. Sanada, K. Koh, J. Takita, S. Miyano, S. Ogawa, A. Ohara, M. Tsuchida, A. Manabe

  LEUKEMIA 31 (3) 580 - 584 0887-6924 2017/03 [Refereed][Not invited]
   

  In the treatment of childhood acute lymphoblastic leukemia (ALL), excess shortening of maintenance therapy resulted in high relapse rate, as shown by our previous trial, TCCSG L92-13, in which maintenance therapy was terminated at 1 year from initiation of treatment. In this study, we aimed to confirm the long-term outcome of L92-13, and to identify who can or cannot be cured by shorter duration of maintenance therapy. To obtain sentinel cytogenetics information that had been missed before, we performed genetic analysis with genomic microarray and target intron-capture sequencing from diagnostic bone marrow smear. Disease-free survival (DFS) at 10 years from the end of therapy was 66.0 +/- 2.8%. Females (n= 138) had better DFS (74.6 +/- 3.7%) than males (n= 142, 57.5 +/- 4.2%, P= 0.002). Patients with TCF3-PBX1 (n= 11) and ETV6-RUNX1 (n= 16) had excellent DFS (90.9 +/- 8.7% and 93.8 +/- 6.1%, respectively), whereas high hyperdiploidy (n= 23) was the most unfavorable subgroup, with 56.6 +/- 10.3% of DFS. Short duration of therapy can cure more than half of pediatric ALL, especially females, TCF3-PBX1 and ETV6-RUNX1. Our retrospective observations suggest a gender/karyotype inhomogeneity on the impact of brief therapy.
• Haploidentical hematopoietic cell transplantation for disseminated Ewing sarcoma

  Hiroki Yoshihara, Tadashi Kumamoto, Rintaro Ono, Keiko Akahane, Taiki Nozaki, Shogo Kobayashi, Atsushi Kikuta, Seiichi Matsumoto, Daisuke Hasegawa, Chitose Ogawa, Atsushi Manabe

  PEDIATRICS INTERNATIONAL 59 (2) 223 - 226 1328-8067 2017/02 [Refereed][Not invited]
   

  We describe the case of a 13-year-old girl with multifocal disseminated Ewing sarcoma family of tumor (ESFT) who received a 5/8 human leukocyte antigen-matched haploidentical hematopoietic cell transplantation to generate a graft-versus-tumor effect. The patient had grade 2 acute graft-versus-host disease (GVHD) of the skin and chronic GVHD nausea and abdominal pain that required prednisolone for 17 months, but has been free from ESFT for 3 years 10 months after therapy. The present case suggests a beneficial effect of haploidentical hematopoietic cell transplantation in disseminated ESFT.
• 小児白血病における血液凝固障害に対する支持療法 JPLSGアンケート調査

  大曽根 眞也, 福島 啓太郎, 矢野 道広, 嘉数 真理子, 佐野 弘純, 加藤 陽子, 新小田 雄一, 篠田 邦大, 真部 淳, 足立 壮一

  日本小児科学会雑誌 (公社)日本小児科学会 121 (2) 251 - 251 0001-6543 2017/02
• 小児白血病診療時の中心静脈カテーテルの使用・管理法 JPLSGアンケート調査

  佐野 弘純, 福島 啓太郎, 矢野 道広, 大曽根 眞也, 嘉数 真理子, 加藤 陽子, 新小田 雄一, 篠田 邦大, 真部 淳, 足立 壮一, 日本小児白血病リンパ腫研究グループ

  日本小児科学会雑誌 (公社)日本小児科学会 121 (2) 467 - 467 0001-6543 2017/02
• 小児白血病における抗腫瘍薬の急性毒性に対する対策の現状 JPLSGアンケート調査

  矢野 道広, 福島 啓太郎, 佐野 弘純, 大曽根 眞也, 嘉数 真理子, 加藤 陽子, 新小田 雄一, 篠田 邦大, 真部 淳, 足立 壮一, 日本小児白血病リンパ腫研究グループ

  日本小児科学会雑誌 (公社)日本小児科学会 121 (2) 467 - 467 0001-6543 2017/02
• Familial hematological malignancies.

  Shinsuke Hirabayashi, Atsushi Manabe

  [Rinsho ketsueki] The Japanese journal of clinical hematology 58 (10) 1878 - 1883 0485-1439 2017 [Refereed][Not invited]
   

  The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues was last updated in 2008. The study of cancer genomes has identified inherited genetic drivers that predispose cancer cells to clonal evolution. The revisions in the categories of myeloid neoplasms and acute leukemia were published as a monograph in 2016. We described familial hematological malignancies using the 2016 edition of the WHO classification.
• Phase I study of glypican-3-derived peptide vaccine therapy for patients with refractory pediatric solid tumors.

  Tsuchiya N, Hosono A, Yoshikawa T, Shoda K, Nosaka K, Shimomura M, Hara J, Nitani C, Manabe A, Yoshihara H, Hosoya Y, Kaneda H, Kinoshita Y, Kohashi K, Yoshimura K, Fujinami N, Saito K, Mizuno S, Nakatsura T

  Oncoimmunology 7 (1) e1377872  2162-4011 2017 [Refereed][Not invited]
   

  The carcinoembryonic antigen glypican-3 (GPC3) is a good target of anticancer immunotherapy against pediatric solid tumors expressing GPC3. In this non-randomized, open-label, phase I clinical trial, we analyzed the safety and efficacy of GPC3-peptide vaccination in patients with pediatric solid tumors. Eighteen patients with pediatric solid tumors expressing GPC3 underwent GPC3-peptide vaccination (intradermal injections every 2 weeks), with the primary endpoint being the safety of GPC3-peptide vaccination and the secondary endpoints being immune response, as measured by interferon (IFN)-γ enzyme-linked immunospot assay and Dextramer staining, and the clinical outcomes of tumor response, progression free survival (PFS), and overall survival (OS). Our findings indicated that GPC3 vaccination was well tolerated. We observed disease-control rates [complete response (CR)+partial response+stable disease] of 66.7% after 2 months, and although patients in the progression group unable to induce GPC3-peptide-specific cytotoxic T lymphocytes (CTLs) received poor prognoses, patients in the partial-remission and remission groups or those with hepatoblastoma received good prognoses. The GPC3-peptide vaccine induced a GPC3-specific CTL response in seven patients, with PFS and OS significantly longer in patients with high GPC3-specific CTL frequencies than in those with low frequencies. Furthermore, we established GPC3-peptide-specific CTL clones from a resected-recurrent tumor from one patient, with these cells exhibiting GPC3-peptide-specific cytokine secretion. The results of this trial demonstrated that the GPC3-peptide-specific CTLs induced by the GPC3-peptide vaccine infiltrated tumor tissue, and use of the GPC3-peptide vaccine might prevent the recurrence of pediatric solid tumors, especially hepatoblastomas, after a second CR.
• ZNF384-related fusion genes define a subgroup of childhood B-cell precursor acute lymphoblastic leukemia with a characteristic immunotype

  Shinsuke Hirabayashi, Kentaro Ohki, Kazuhiko Nakabayashi, Hitoshi Ichikawa, Yukihide Momozawa, Kohji Okamura, Akinori Yaguchi, Kazuki Terada, Yuya Saito, Ai Yoshimi, Hiroko Ogata-Kawata, Hiromi Sakamoto, Motohiro Kato, Junya Fujimura, Moeko Hino, Akitoshi Kinoshita, Harumi Kakuda, Hidemitsu Kurosawa, Keisuke Kato, Ryosuke Kajiwara, Koichi Moriwaki, Tsuyoshi Morimoto, Kozue Nakamura, Yasushi Noguchi, Tomoo Osumi, Kazuo Sakashita, Junko Takita, Yuki Yuza, Koich Matsuda, Teruhiko Yoshida, Kenji Matsumoto, Kenichiro Hata, Michiaki Kubo, Yoichi Matsubara, Takashi Fukushima, Katsuyoshi Koh, Atsushi Manabe, Akira Ohara, Nobutaka Kiyokawa

  HAEMATOLOGICA 102 (1) 118 - 129 0390-6078 2017/01 [Refereed][Not invited]
   

  Fusion genes involving ZNF384 have recently been identified in B-cell precursor acute lymphoblastic leukemia, and 7 fusion partners have been reported. We further characterized this type of fusion gene by whole transcriptome sequencing and/or polymerase chain reaction. In addition to previously reported genes, we identified BMP2K as a novel fusion partner for ZNF384. Including the EP300-ZNF384 that we reported recently, the total frequency of ZNF384-related fusion genes was 4.1% in 291 B-cell precursor acute lymphoblastic leukemia patients enrolled in a single clinical trial, and TCF3-ZNF384 was the most recurrent, with a frequency of 2.4%. The characteristic immunophenotype of weak CD10 and aberrant CD13 and/or CD33 expression was revealed to be a common feature of the leukemic cells harboring ZNF384-related fusion genes. The signature gene expression profile in TCF3-ZNF384-positive patients was enriched in hematopoietic stem cell features and related to that of EP300-ZNF384-positive patients, but was significantly distinct from that of TCF3-PBX1-positive and ZNF384-fusion-negative patients. However, clinical features of TCF3-ZNF384-positive patients are markedly different from those of EP300-ZNF384-positive patients, exhibiting higher cell counts and a younger age at presentation. TCF3-ZNF384-positive patients revealed a significantly poorer steroid response and a higher frequency of relapse, and the additional activating mutations in RAS signaling pathway genes were detected by whole exome analysis in some of the cases. Our observations indicate that ZNF384-related fusion genes consist of a distinct subgroup of B-cell precursor acute lymphoblastic leukemia with a characteristic immunophenotype, while the clinical features depend on the functional properties of individual fusion partners.
• ZNF384-related fusion genes define a subgroup of childhood B-cell precursor acute lymphoblastic leukemia with a characteristic immunotype.

  Shinsuke Hirabayashi, Kentaro Ohki, Kazuhiko Nakabayashi, Hitoshi Ichikawa, Yukihide Momozawa, Kohji Okamura, Akinori Yaguchi, Kazuki Terada, Yuya Saito, Ai Yoshimi, Hiroko Ogata-Kawata, Hiromi Sakamoto, Motohiro Kato, Junya Fujimura, Moeko Hino, Akitoshi Kinoshita, Harumi Kakuda, Hidemitsu Kurosawa, Keisuke Kato, Ryosuke Kajiwara, Koichi Moriwaki, Tsuyoshi Morimoto, Kozue Nakamura, Yasushi Noguchi, Tomoo Osumi, Kazuo Sakashita, Junko Takita, Yuki Yuza, Koich Matsuda, Teruhiko Yoshida, Kenji Matsumoto, Kenichiro Hata, Michiaki Kubo, Yoichi Matsubara, Takashi Fukushima, Katsuyoshi Koh, Atsushi Manabe, Akira Ohara, Nobutaka Kiyokawa

  Haematologica 102 (1) 118 - 129 0390-6078 2017/01 [Refereed][Not invited]
   

  Fusion genes involving ZNF384 have recently been identified in B-cell precursor acute lymphoblastic leukemia, and 7 fusion partners have been reported. We further characterized this type of fusion gene by whole transcriptome sequencing and/or polymerase chain reaction. In addition to previously reported genes, we identified BMP2K as a novel fusion partner for ZNF384 Including the EP300-ZNF384 that we reported recently, the total frequency of ZNF384-related fusion genes was 4.1% in 291 B-cell precursor acute lymphoblastic leukemia patients enrolled in a single clinical trial, and TCF3-ZNF384 was the most recurrent, with a frequency of 2.4%. The characteristic immunophenotype of weak CD10 and aberrant CD13 and/or CD33 expression was revealed to be a common feature of the leukemic cells harboring ZNF384-related fusion genes. The signature gene expression profile in TCF3-ZNF384-positive patients was enriched in hematopoietic stem cell features and related to that of EP300-ZNF384-positive patients, but was significantly distinct from that of TCF3-PBX1-positive and ZNF384-fusion-negative patients. However, clinical features of TCF3-ZNF384-positive patients are markedly different from those of EP300-ZNF384-positive patients, exhibiting higher cell counts and a younger age at presentation. TCF3-ZNF384-positive patients revealed a significantly poorer steroid response and a higher frequency of relapse, and the additional activating mutations in RAS signaling pathway genes were detected by whole exome analysis in some of the cases. Our observations indicate that ZNF384-related fusion genes consist of a distinct subgroup of B-cell precursor acute lymphoblastic leukemia with a characteristic immunophenotype, while the clinical features depend on the functional properties of individual fusion partners.
• Pediatric thromboembolism: a national survey in Japan

  Akira Ishiguro, Chibueze Chioma Ezinne, Nobuaki Michihata, Hisaya Nakadate, Atsushi Manabe, Masashi Taki, Midori Shima

  INTERNATIONAL JOURNAL OF HEMATOLOGY 105 (1) 52 - 58 0925-5710 2017/01 [Refereed][Not invited]
   

  Thromboembolism is being detected at increasing rates in pediatric tertiary care hospitals. The incidence of pediatric thrombophilia differs across countries, and is unknown in Japan. We sent a survey to 520 pediatric department heads and 629 specialists, requesting details on patients who developed symptomatic thromboembolism between 2006 and 2010. Of 280 eligible cases, congenital thrombophilia and other conditions were reported. Congenital thrombophilia (n = 54, 19.3 %) comprised defects in protein C (27), protein S (9), and antithrombin (7). None had mutations in factor V Leiden or prothrombin G20210A, both of which are frequent in Caucasians. Non-congenital causes of thrombophilia included congenital heart disease, the use of central venous catheters, nephrotic syndrome, antiphospholipid syndrome, and malignancy with or without use of L-asparaginase. Patients with congenital thrombophilia developed thromboembolism at a significantly younger age (median 1.0 vs. 5.0 years, p = 0.014), had a higher frequency of consanguinity (35.2 vs. 1.8 %, p < 0.001) and post-thrombotic syndromes (29.6 vs. 13.3 %, p = 0.007) than those who did not. Thromboembolism in children with congenital thrombophilia recurred more frequently (50.0 vs. 13.7 %, p < 0.001) and was associated with more sequelae (61.1 vs. 37.2 %, p = 0.009) than in children without congenital thrombophilia. This nationwide survey provides the first comprehensive study of Japanese children with symptomatic thromboembolism. Significant recurrence and sequelae require optimized standards.
• Chemotherapy for a child with relapsed acute myeloid leukemia complicated with persistent hepatitis C virus infection.

  Shunsuke Kimura, Shinsuke Hirabayashi, Daisuke Hasegawa, Wakako Sumiya, Megumi Seya, Toshihiro Matsui, Yuri Yoshimoto, Yosuke Hosoya, Nobuyoshi Mori, Akira Matsui, Atsushi Manabe

  [Rinsho ketsueki] The Japanese journal of clinical hematology 58 (6) 619 - 623 0485-1439 2017 [Refereed][Not invited]
   

  An 8-year-old Mongolian female was diagnosed with acute myeloid leukemia (AML) and treated at a hospital in Mongolia according to the BFM-AML2004 SR protocol. Although complete remission (CR) was achieved, chemotherapy was interrupted because of shortage of drugs. The patient moved to Japan 7 months after diagnosis. Screening for viral infection revealed the presence of hepatitis C virus (HCV) antibody and RNA. At 11 months after initial diagnosis, the patient experienced bone marrow relapse and a RUNX1-RUNX1T1 fusion transcript was detected. Considering the inadequate intensity of initial treatment and the persistent HCV infection, chemotherapy was preferred and initiated over hematopoietic cell transplantation. After the first course of induction therapy, a second CR was confirmed and the chimeric transcript disappeared. The viral load mildly increased during myelosuppression and transient elevation of liver enzymes was observed along with hematological recovery. HCV infection remained stable, without progression to reactivation of hepatitis C. Given the high risk of second relapse and liver fibrosis and sclerosis following chronic HCV infection, treatment against HCV may be indicated during second remission.
• Pediatric thromboembolism: a national survey in Japan

  Akira Ishiguro, Chibueze Chioma Ezinne, Nobuaki Michihata, Hisaya Nakadate, Atsushi Manabe, Masashi Taki, Midori Shima

  International Journal of Hematology 105 (1) 52 - 58 1865-3774 2017/01/01 [Refereed][Not invited]
   

  Thromboembolism is being detected at increasing rates in pediatric tertiary care hospitals. The incidence of pediatric thrombophilia differs across countries, and is unknown in Japan. We sent a survey to 520 pediatric department heads and 629 specialists, requesting details on patients who developed symptomatic thromboembolism between 2006 and 2010. Of 280 eligible cases, congenital thrombophilia and other conditions were reported. Congenital thrombophilia (n = 54, 19.3 %) comprised defects in protein C (27), protein S (9), and antithrombin (7). None had mutations in factor V Leiden or prothrombin G20210A, both of which are frequent in Caucasians. Non-congenital causes of thrombophilia included congenital heart disease, the use of central venous catheters, nephrotic syndrome, antiphospholipid syndrome, and malignancy with or without use of L-asparaginase. Patients with congenital thrombophilia developed thromboembolism at a significantly younger age (median 1.0 vs. 5.0 years, p = 0.014), had a higher frequency of consanguinity (35.2 vs. 1.8 %, p <  0.001) and post-thrombotic syndromes (29.6 vs. 13.3 %, p = 0.007) than those who did not. Thromboembolism in children with congenital thrombophilia recurred more frequently (50.0 vs. 13.7 %, p <  0.001) and was associated with more sequelae (61.1 vs. 37.2 %, p = 0.009) than in children without congenital thrombophilia. This nationwide survey provides the first comprehensive study of Japanese children with symptomatic thromboembolism. Significant recurrence and sequelae require optimized standards.
• The Association Between L-Asparaginase Hypersensitivity and Genetic Variants in Japanese Childhood ALL Patients

  Yoichi Tanaka, Kevin Y. Urayama, Takahisa Kawaguchi, Makiko Mori, Daisuke Hasegawa, Sae Ishimaru, Yuichi Taneyama, Kazuki Terada, Masakatsu Yanagimachi, Setsuo Ota, Hiroyuki Takahashi, Takeshi Inukai, Daisuke Toyama, Dai Keino, Koichi Moriwaki, Masatoshi Takagi, Junya Fujimura, Yujin Sekinaka, Kozue Nakamura, Yuya Sato, Keitaro Matsuo, Akira Ohara, Katsuyoshi Koh, Fumihiko Matsuda, Atsushi Manabe

  BLOOD 128 (22) 0006-4971 2016/12 [Refereed][Not invited]
   

  0
• 再発神経芽腫において獲得された片親性ダイソミーによるALK遺伝子のホモ変異(Homozygous missense mutation in ALK gene due to acquired uniparental disomy in a child with relapsed neuroblastoma)

  木村 俊介, 長谷川 大輔, 代田 惇朗, 関 正史, 吉本 優里, 平林 真介, 細谷 要介, 滝田 順子, 真部 淳

  日本小児血液・がん学会雑誌 53 (4) 238 - 238 2187-011X 2016/11
• MEF2DおよびZNF384関連融合遺伝子陽性症例は小児B前駆細胞性ALLの中のサブグループを形成する(Incidence and clinical relevance of MEF2D- and ZNF384-related fusion genes in childhood B-cell precursor acute lymphoblastic leukemia: TCCSG L0416/0616 study)

  大木 健太郎, 平林 真介, 加藤 元博, 中林 一彦, 秦 健一郎, 梶原 良介, 高橋 浩之, 福島 敬, 康 勝好, 真部 淳, 小原 明, 清河 信敬

  日本小児血液・がん学会雑誌 53 (4) 259 - 259 2187-011X 2016/11
• 小児再発急性リンパ性白血病患者に対するボルテゾミブ併用多剤化学療法の安全性を検討する第I相試験(Phase I Study of Bortezomib-Containing Multiagent Chemotherapy in Children with Relapsed Acute Lymphoblastic Leukemia)

  長谷川 大輔, 熊本 忠史, 齋藤 明子, 嘉田 晃子, 山下 友加, 前田 尚子, 菊田 敦, 原 純一, 真部 淳, 小川 千登世

  日本小児血液・がん学会雑誌 53 (4) 253 - 253 2187-011X 2016/11
• 本邦における小児がん患児に対する疼痛管理の現状と課題 JPLSG施設調査より

  加藤 陽子, 福島 啓太郎, 新小田 雄一, 森 尚子, 大曽根 眞也, 嘉数 真理子, 佐野 弘純, 篠田 邦大, 矢野 道広, 真部 淳, 足立 壯一, 日本小児白血病リンパ腫研究グループ(JPLSG)

  日本小児血液・がん学会雑誌 (一社)日本小児血液・がん学会 53 (4) 271 - 271 2187-011X 2016/11
• 本邦における小児緩和ケア提供体制の現状と課題 JPLSG施設調査より

  森 尚子, 福島 啓太郎, 加藤 陽子, 新小田 雄一, 大曽根 眞也, 嘉数 真理子, 佐野 弘純, 篠田 邦大, 矢野 道広, 真部 淳, 足立 壯一, 日本小児白血病リンパ腫研究グループ(JPLSG)

  日本小児血液・がん学会雑誌 (一社)日本小児血液・がん学会 53 (4) 271 - 271 2187-011X 2016/11
• 本邦における小児がん患者に対する検査・処置時の鎮静および疼痛管理の現状と課題 JPLSG施設調査より

  新小田 雄一, 福島 啓太郎, 加藤 陽子, 森 尚子, 大曽根 眞也, 嘉数 真理子, 佐野 弘純, 篠田 邦大, 矢野 道広, 真部 淳, 足立 壮一, 日本小児白血病リンパ腫研究グループ(JPLSG)

  日本小児血液・がん学会雑誌 (一社)日本小児血液・がん学会 53 (4) 355 - 355 2187-011X 2016/11
• 小児白血病における腫瘍崩壊症候群およびhyperleukocytosisに対する対応 JPLSG施設アンケート調査の結果

  嘉数 真理子, 福島 啓太郎, 矢野 道広, 大曽根 眞也, 佐野 弘純, 加藤 陽子, 新小田 雄一, 篠田 邦大, 真部 淳, 足立 壯一, 日本小児白血病リンパ腫研究グループ(JPLSG)

  日本小児血液・がん学会雑誌 (一社)日本小児血液・がん学会 53 (4) 369 - 369 2187-011X 2016/11
• 下肢痛にて発症した壊血病の1例

  瀬谷 恵, 半田 淳比古, 松井 俊大, 吉本 優里, 長谷川 大輔, 小澤 美和, 真部 淳, 草川 功

  日本小児科学会雑誌 (公社)日本小児科学会 120 (11) 1695 - 1695 0001-6543 2016/11
• 当院における小児がんの晩期合併症に関する検討(Late effects in the children of cancer survivors: from the single institute experience)

  齋藤 合, 吉本 優里, 細谷 要介, 平林 真介, 長谷川 大輔, 石田 也寸志, 浦山 ケビン, 小澤 美和, 細谷 亮太, 真部 淳

  日本小児血液・がん学会雑誌 53 (4) 275 - 275 2187-011X 2016/11
• 軽症血友病Aに合併した慢性特発性血小板減少症性紫斑病に対して脾臓摘出術を行った1例

  瀬谷 恵, 長谷川 大輔, 平林 真介, 細谷 要介, 小澤 美和, 迫田 晃子, 松藤 凡, 真部 淳

  日本小児血液・がん学会雑誌 (一社)日本小児血液・がん学会 53 (4) 321 - 321 2187-011X 2016/11
• 高リスク神経芽腫発症から23年後に膀胱癌を発症した一例

  細谷 要介, 長谷川 大輔, 永瀬 恭子, 郡司 美千代, 小林 京子, 小澤 美和, 石田 也寸志, 鈴木 高祐, 服部 一紀, 真部 淳

  日本小児血液・がん学会雑誌 (一社)日本小児血液・がん学会 53 (4) 397 - 397 2187-011X 2016/11
• 母子共に末期がんの家族に対するチームアプローチにおける多職種カンファレンスの意義

  小口 祐子, 大川 智子, 小川 恵理子, 阿佐美 百合子, 宮本 智史, 木村 俊介, 長谷川 大輔, 小澤 美和, 真部 淳, 山本 光映

  日本小児血液・がん学会雑誌 (一社)日本小児血液・がん学会 53 (4) 444 - 444 2187-011X 2016/11
• 小児造血器腫瘍に対する共通免疫学的診断パネルによって診断されたBilineal Leukemiaの特徴(The characteristics of Bilineal Leukemia diagnosed by nationwide immunophenotyping for pediatric hematological malignancy in Japan)

  出口 隆生, 清河 信敬, 大木 健太郎, 橋井 佳子, 真部 淳, 足立 壯一, 齋藤 明子, 堀部 敬三, 駒田 美弘

  日本小児血液・がん学会雑誌 53 (4) 280 - 280 2187-011X 2016/11
• 本邦において2002年から2011年までに発生した2例の小児BCL2およびMYC dual-hit白血病(Two cases of pediatric BCL2 and MYC dual-hit leukemia between 2002 and 2011 in Japan)

  坂口 公祥, 今村 俊彦, 石丸 紗恵, 今井 千速, 下之段 秀美, 岡田 恵子, 出口 隆生, 橋井 佳子, 清河 信敬, 齋藤 明子, 真部 淳, 佐藤 篤, 康 勝好

  日本小児血液・がん学会雑誌 53 (4) 370 - 370 2187-011X 2016/11
• 小児再生不良性貧血および骨髄異形成症候群の形態中央診断 1500例のまとめ(Central morphology review of aplastic anemia and myelodysplastic syndrome in children: the summary of 1,500 cases)

  濱 麻人, 真部 淳, 長谷川 大輔, 野沢 和江, 成田 敦, 村松 秀城, 高橋 義行, 渡邉 健一郎, 小原 明, 伊藤 雅文, 小島 勢二

  日本小児血液・がん学会雑誌 53 (4) 233 - 233 2187-011X 2016/11 [Refereed][Not invited]
  
• 本邦における治療関連性急性白血病および悪性リンパ腫の全国調査結果について(Nation-wide survey of therapy related leukemia and lymphoma in Japan)

  今村 俊彦, 多賀 崇, 高木 正稔, 河崎 裕英, 康 勝好, 滝 智彦, 足立 壮一, 真部 淳, 石田 也寸志, 日本小児血液・がん学会白血病リンパ腫委員会

  日本小児血液・がん学会雑誌 53 (4) 275 - 275 2187-011X 2016/11 [Refereed][Not invited]
  
• Cervical ultrasound and computed tomography of Kawasaki disease: Comparison with lymphadenitis

  Taiki Nozaki, Yuka Morita, Daisuke Hasegawa, Akari Makidono, Yuri Yoshimoto, Jay Starkey, Isao Kusakawa, Atsushi Manabe, Yukihisa Saida

  PEDIATRICS INTERNATIONAL 58 (11) 1146 - 1152 1328-8067 2016/11 [Refereed][Not invited]
   

  BackgroundDifferentiating Kawasaki disease (KD) from cervical lymphadenitis (CL) is clinically difficult but essential given that treatment and outcome differ significantly. Research on differentiation between KD and CL using ultrasound (US) and computed tomography (CT) is limited. The purpose of this study was to identify cervical US and CT findings that may differentiate KD from CL. MethodsWe retrospectively reviewed cervical US of 25 KD patients and 25 CL patients, and CT of 14 KD patients, and 14 CL patients. Two radiologists analyzed specific imaging features on US (lymph node size, shape, echogenicity, margins, laterality, necrosis, and presence of normal hilum) and on CT (size and location of enlarged nodes, laterality, perinodal infiltration, and retropharyngeal edema). ResultsOn US, patients with KD more frequently had lymph nodes with a cluster of grapes appearance (KD vs CL: 64% vs 32%, P < 0.05) and less frequently had poorly circumscribed margins (0% vs 36%, P < 0.01), necrosis (0% vs 32%, P < 0.01), or non-visualization of the hilum (4% vs 36%, P < 0.01). On CT, KD patients more frequently had retropharyngeal edema (100% vs 29%, P < 0.001) and less frequently had level 4 lymphadenopathy (14% vs 79%, P < 0.01) than CL patients. ConclusionsUltrasound is mainly useful for excluding purulent lymphadenopathy while CT is a useful diagnostic tool for differentiating KD from CL, especially in patients with incomplete KD, who present with prominent cervical lymphadenopathy and other equivocal principal findings.
• Cervical ultrasound and computed tomography of Kawasaki disease: Comparison with lymphadenitis

  Taiki Nozaki, Yuka Morita, Daisuke Hasegawa, Akari Makidono, Yuri Yoshimoto, Jay Starkey, Isao Kusakawa, Atsushi Manabe, Yukihisa Saida

  Pediatrics International 58 (11) 1146 - 1152 1442-200X 2016/11/01 [Refereed][Not invited]
   

  Background: Differentiating Kawasaki disease (KD) from cervical lymphadenitis (CL) is clinically difficult but essential given that treatment and outcome differ significantly. Research on differentiation between KD and CL using ultrasound (US) and computed tomography (CT) is limited. The purpose of this study was to identify cervical US and CT findings that may differentiate KD from CL. Methods: We retrospectively reviewed cervical US of 25 KD patients and 25 CL patients, and CT of 14 KD patients, and 14 CL patients. Two radiologists analyzed specific imaging features on US (lymph node size, shape, echogenicity, margins, laterality, necrosis, and presence of normal hilum) and on CT (size and location of enlarged nodes, laterality, perinodal infiltration, and retropharyngeal edema). Results: On US, patients with KD more frequently had lymph nodes with a “cluster of grapes” appearance (KD vs CL: 64% vs 32%, P < 0.05) and less frequently had poorly circumscribed margins (0% vs 36%, P < 0.01), necrosis (0% vs 32%, P < 0.01), or non-visualization of the hilum (4% vs 36%, P < 0.01). On CT, KD patients more frequently had retropharyngeal edema (100% vs 29%, P < 0.001) and less frequently had level 4 lymphadenopathy (14% vs 79%, P < 0.01) than CL patients. Conclusions: Ultrasound is mainly useful for excluding purulent lymphadenopathy while CT is a useful diagnostic tool for differentiating KD from CL, especially in patients with incomplete KD, who present with prominent cervical lymphadenopathy and other equivocal principal findings.
• 本邦におけるt(8;14)(q24;q32)再構成を伴う小児の前駆B細胞性急性リンパ芽球性白血病(Pediatric B cell precursor acute lymphoblastic leukemia with t(8;14)(q24;q32) rearrangement in Japan)

  Sakaguchi Kimiyoshi, Imamura Toshihiko, Ishimaru Sae, Imai Chihaya, Shimonodan Hidemi, Hamamoto Kazuko, Okada Keiko, Taketani Takeshi, Kanai Rie, Kato Motohiro, Kojima Yasuko, Watanabe Arata, Deguchi Takao, Hashii Yoshiko, Kiyokawa Nobutaka, Saito-Moriya Akiko, Manabe Atsushi, Sato Atsushi, Koh Katsuyoshi

  臨床血液 57 (9) 1503 - 1503 0485-1439 2016/09
• 脳動静脈奇形(AVM)の出血に対し血管内塞栓術とAVM摘出術を施行した2ヵ月女児例

  後藤 耕策, 吉本 優里, 角谷 和歌子, 松井 俊大, 秋山 類, 藤井 本晴, 小澤 美和, 真部 淳, 新見 康成, 草川 功

  日本小児科学会雑誌 (公社)日本小児科学会 120 (9) 1393 - 1393 0001-6543 2016/09
• Ewing sarcoma/primitive neuroectodermal tumor of the kidney treated with chemotherapy including ifosfamide

  Hiroki Yoshihara, Takahiro Kamiya, Yosuke Hosoya, Daisuke Hasegawa, Chitose Ogawa, Hiroshi Asanuma, Ryuichi Mizuno, Ryota Hosoya, Atsushi Manabe

  PEDIATRICS INTERNATIONAL 58 (8) 766 - 769 1328-8067 2016/08 [Refereed][Not invited]
   

  Ewing sarcoma/primitive neuroectodermal tumor (ES/PNET) of the kidney is extremely rare, and is usually diagnosed after nephrectomy without neoadjuvant chemotherapy. Although ifosfamide and etoposide improve survival to a great extent in ES/PNET, the use of nephrotoxic agent, particularly ifosfamide, is a concern after nephrectomy. We describe the case of a 14-year-old female patient with abdominal mass who was diagnosed with ES/PNET of the right kidney after nephrectomy. Adjuvant chemotherapy including ifosfamide and etoposide were given. The estimated glomerular filtration rate decreased to 75% after the end of therapy. There was no evidence of recurrence 70 months after initial diagnosis.
• Ewing sarcoma/primitive neuroectodermal tumor of the kidney treated with chemotherapy including ifosfamide

  Hiroki Yoshihara, Takahiro Kamiya, Yosuke Hosoya, Daisuke Hasegawa, Chitose Ogawa, Hiroshi Asanuma, Ryuichi Mizuno, Ryota Hosoya, Atsushi Manabe

  Pediatrics International 58 (8) 766 - 769 1442-200X 2016/08/01 [Refereed][Not invited]
   

  Ewing sarcoma/primitive neuroectodermal tumor (ES/PNET) of the kidney is extremely rare, and is usually diagnosed after nephrectomy without neoadjuvant chemotherapy. Although ifosfamide and etoposide improve survival to a great extent in ES/PNET, the use of nephrotoxic agent, particularly ifosfamide, is a concern after nephrectomy. We describe the case of a 14-year-old female patient with abdominal mass who was diagnosed with ES/PNET of the right kidney after nephrectomy. Adjuvant chemotherapy including ifosfamide and etoposide were given. The estimated glomerular filtration rate decreased to 75% after the end of therapy. There was no evidence of recurrence 70 months after initial diagnosis.
• Overview.

  Manabe A

  [Rinsho ketsueki] The Japanese journal of clinical hematology 57 (7) 881  0485-1439 2016/07 [Refereed][Not invited]
  
• 治療方針に難渋したIgA血管炎に伴う腸重積の1例

  栗山 絢子, 真部 淳, 瀬谷 恵, 松井 俊大, 右田 美里, 迫田 晃子, 草川 功, 松藤 凡

  日本小児救急医学会雑誌 (一社)日本小児救急医学会 15 (2) 260 - 260 1346-8162 2016/06
• Secondary cancers after a childhood cancer diagnosis: a nationwide hospital-based retrospective cohort study in Japan

  Yasushi Ishida, Dongmei Qiu, Miho Maeda, Junichiro Fujimoto, Hisato Kigasawa, Ryoji Kobayashi, Maho Sato, Jun Okamura, Shinji Yoshinaga, Takeshi Rikiishi, Hiroyuki Shichino, Chikako Kiyotani, Kazuko Kudo, Keiko Asami, Hiroki Hori, Hiroshi Kawaguchi, Hiroko Inada, Souichi Adachi, Atsushi Manabe, Tatsuo Kuroda

  INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY 21 (3) 506 - 516 1341-9625 2016/06 [Refereed][Not invited]
   

  The epidemiology of secondary cancers in childhood cancer survivors has been unknown in Asian countries. Our aim is to assess the incidence and risk factors for secondary cancers through a nationwide survey in Japan. A retrospective cohort study comprising 10,069 children who were diagnosed with cancer between 1980 and 2009 was conducted in 15 Japanese hospitals. The cumulative incidence rate was calculated using death as the competing risk and compared by the Gray method. The standardized incidence ratio (SIR) was defined as the ratio of the number of observed cancers divided by the number of expected cancers. The risk factors were analyzed using Cox regression analysis. One hundred and twenty-eight patients (1.3 %) developed secondary cancers within a median follow-up of 8.4 years. The cumulative incidence rate was 1.1 % (95 % confidence interval [CI] 0.9-1.4) at 10 years and 2.6 % (95 % CI 2.1-3.3) at 20 years after primary cancer diagnosis. Sensitivity analysis, limited to 5-year survivors (n = 5,387), confirmed these low incidence rates. The SIR of secondary cancers was 12.1 (95 % CI 10.1-14.4). In the Cox analysis, the hazard ratios for secondary cancers were 3.81 (95 % CI 1.53-9.47) for retinoblastoma, 2.78 (95 % CI 1.44-5.38) for bone/soft tissue sarcomas, and 1.81 (95 % CI 1.16-2.83) for allogeneic stem cell transplantation. The cumulative incidence of secondary cancers in children in Japan was not high; however, the SIR was relatively high. Retinoblastoma or sarcoma in addition to allogeneic stem cell transplantation were significant risk factors for secondary cancers.
• Severe 6-mercaptopurine-induced hematotoxicity in childhood an ALL patient with homozygous NUDT15 missence variants.

  Shunsuke Kimura, Daisuke Hasegawa, Yuri Yoshimoto, Shinsuke Hirabayashi, Yosuke Hosoya, Hiroki Yoshihara, Tadashi Kumamoto, Yoichi Tanaka, Atsushi Manabe

  [Rinsho ketsueki] The Japanese journal of clinical hematology 57 (6) 748 - 53 0485-1439 2016/06 [Refereed][Not invited]
   

  Thiopurine S-methyltransferase (TPMT) and nucleoside diphosphate-linked moiety X-type motif 15 (NUDT15) variants are considered to be genes responsible for severe myelotoxicity induced by 6-mercaptopurine (6MP). We report a 4-year-old girl with acute lymphoblastic leukemia, who developed the complication of severe 6MP-induced myelotoxicity due to homozygous NUDT15 variant alleles. In early consolidation therapy containing 6MP, her course was complicated by severe neutropenia (Grade 4) and chemotherapy had to be discontinued for 33 days. The 6MP dose was subsequently adjusted based on the white blood cell count. The ratios of the prescribed 6MP dose over the protocol dose in early consolidation, central nervous system (CNS) prophylaxis, re-induction, interim maintenance and maintenance therapy were 63%, 27%, 4%, 26% and 7%, respectively. Suspension of therapy was required during early consolidation, CNS prophylaxis and interim maintenance therapy. We investigated candidate genes for 6MP-associated myelotoxicity and found homozygous NUDT15 variant alleles and a heterozygous inosine triphosphate pyrophosphatase (ITPA) variant allele. In patients with homozygous NUDT15 variants, drastic reduction (less than 10%) of the 6MP dose from the protocol dose might be required not only during maintenance therapy, but also during other treatment courses containing 6MP. Screening of candidate genes at diagnosis is recommended in order to avoid serious adverse events.
• Secondary cancers after a childhood cancer diagnosis: a nationwide hospital-based retrospective cohort study in Japan

  Yasushi Ishida, Dongmei Qiu, Miho Maeda, Junichiro Fujimoto, Hisato Kigasawa, Ryoji Kobayashi, Maho Sato, Jun Okamura, Shinji Yoshinaga, Takeshi Rikiishi, Hiroyuki Shichino, Chikako Kiyotani, Kazuko Kudo, Keiko Asami, Hiroki Hori, Hiroshi Kawaguchi, Hiroko Inada, Souichi Adachi, Atsushi Manabe, Tatsuo Kuroda

  International Journal of Clinical Oncology 21 (3) 506 - 516 1437-7772 2016/06/01 [Refereed][Not invited]
   

  Background: The epidemiology of secondary cancers in childhood cancer survivors has been unknown in Asian countries. Our aim is to assess the incidence and risk factors for secondary cancers through a nationwide survey in Japan. Methods: A retrospective cohort study comprising 10,069 children who were diagnosed with cancer between 1980 and 2009 was conducted in 15 Japanese hospitals. The cumulative incidence rate was calculated using death as the competing risk and compared by the Gray method. The standardized incidence ratio (SIR) was defined as the ratio of the number of observed cancers divided by the number of expected cancers. The risk factors were analyzed using Cox regression analysis. Results: One hundred and twenty-eight patients (1.3 %) developed secondary cancers within a median follow-up of 8.4 years. The cumulative incidence rate was 1.1 % (95 % confidence interval [CI] 0.9–1.4) at 10 years and 2.6 % (95 % CI 2.1–3.3) at 20 years after primary cancer diagnosis. Sensitivity analysis, limited to 5-year survivors (n = 5,387), confirmed these low incidence rates. The SIR of secondary cancers was 12.1 (95 % CI 10.1–14.4). In the Cox analysis, the hazard ratios for secondary cancers were 3.81 (95 % CI 1.53–9.47) for retinoblastoma, 2.78 (95 % CI 1.44–5.38) for bone/soft tissue sarcomas, and 1.81 (95 % CI 1.16–2.83) for allogeneic stem cell transplantation. Conclusions: The cumulative incidence of secondary cancers in children in Japan was not high however, the SIR was relatively high. Retinoblastoma or sarcoma in addition to allogeneic stem cell transplantation were significant risk factors for secondary cancers.
• 先天性QT延長症候群と局在関連てんかんを合併したKCNQ1変異を認める女児例

  代田 惇朗, 小野 林太郎, 荻原 正明, 平林 真介, 横山 美奈, 白井 丈晶, 小澤 美和, 草川 功, 真部 淳

  脳と発達 (一社)日本小児神経学会 48 (Suppl.) S369  0029-0831 2016/05 [Not refereed][Not invited]
  
• Characterization of pediatric Philadelphia-negative B-cell precursor acute lymphoblastic leukemia with kinase fusions in Japan

  T. Imamura, N. Kiyokawa, M. Kato, C. Imai, Y. Okamoto, M. Yano, K. Ohki, Y. Yamashita, Y. Kodama, A. Saito, M. Mori, S. Ishimaru, T. Deguchi, Y. Hashii, Y. Shimomura, T. Hori, K. Kato, H. Goto, C. Ogawa, K. Koh, T. Taki, A. Manabe, A. Sato, A. Kikuta, S. Adachi, K. Horibe, A. Ohara, A. Watanabe, Y. Kawano, E. Ishii, H. Shimada

  BLOOD CANCER JOURNAL 6 2044-5385 2016/05 [Not refereed][Not invited]
   

  Recent studies revealed that a substantial proportion of patients with high-risk B-cell precursor acute lymphoblastic leukemia (BCP-ALL) harbor fusions involving tyrosine kinase and cytokine receptors, such as ABL1, PDGFRB, JAK2 and CRLF2, which are targeted by tyrosine kinase inhibitors (TKIs). In the present study, transcriptome analysis or multiplex reverse transcriptase-PCR analysis of 373 BCP-ALL patients without recurrent genetic abnormalities identified 29 patients with kinase fusions. Clinically, male predominance (male/female: 22/7), older age at onset (mean age at onset: 8.8 years) and a high white blood cell count at diagnosis (mean: 94 200/mu l) reflected the predominance of National Cancer Institute high-risk (NCI-HR) patients (NCI-standard risk/HR: 8/21). Genetic analysis identified three patients with ABL1 rearrangements, eight with PDGFRB rearrangements, two with JAK2 rearrangements, three with IgH-EPOR and one with NCOR1-LYN. Of the 14 patients with CRLF2 rearrangements, two harbored IgH-EPOR and PDGFRB rearrangements. IKZF1 deletion was present in 16 of the 22 patients. The 5-year event-free and overall survival rates were 48.6 +/- 9.7% and 73.5 +/- 8.6%, respectively. The outcome was not satisfactory without sophisticated minimal residual disease-based stratification. Furthermore, the efficacy of TKIs combined with conventional chemotherapy without allogeneic hematopoietic stem cell transplantation in this cohort should be determined.
• A Cytokine-Based Diagnostic Program in Pediatric Aplastic Anemia and Hypocellular Refractory Cytopenia of Childhood

  Shaimaa Elmahdi, Asahito Hama, Atsushi Manabe, Daisuke Hasegawa, Hideki Muramatsu, Atsushi Narita, Nobuhiru Nishio, Olfat Ismael, Nozomu Kawashima, Yusuke Okuno, Yinyan Xu, Xinan Wang, Yoshiyuki Takahashi, Masafumi Ito, Seiji Kojima

  PEDIATRIC BLOOD & CANCER 63 (4) 652 - 658 1545-5009 2016/04 [Refereed][Not invited]
   

  BackgroundDistinguishing hypocellular refractory cytopenia of childhood (RCC) from aplastic anemia (AA) is challenging. Thus far, no studies have compared the cytokine profiles in patients with AA to those with hypocellular RCC. In the present study, we addressed whether thrombopoietin (TPO) and interleukin 17 (IL-17) plasma levels are useful for differentiating between the two diseases. MethodsWe measured the endogenous plasma concentrations of TPO and IL-17 in 29 patients with AA, 34 patients with hypocellular RCC, and 31 healthy controls using sensitive enzyme-linked immunosorbent assays. ResultsThe TPO and IL-17 plasma levels were significantly lower in patients with hypocellular RCC than in patients with AA (P < 0.001 and P = 0.007, respectively). The multivariate logistic regression analysis identified moderate disease severity, TPO levels of <1,369.8 pg/ml (TPO-low group, n = 32; odds ratio (OR), 13.40; 95% confidence intervals (CI), 3.001-51.254; P < 0.001), and IL-17 levels of <22.2 pg/ml (IL-17-low group, n = 33; OR, 4.11; 95% CI, 1.03319.404; P = 0.031) as independent factors discriminating hypocellular RCC from AA. Importantly, 25 (78.1%) of 32 patients in the TPO-low group and 25 (75.8%) of 33 patients in the IL-17-low group were diagnosed as having hypocellular RCC. Moreover, 22 (71%) of 31 patients in the TPO-high group and 21 (70%) of 30 patients in the IL-17-high group were diagnosed as having AA. ConclusionsTPO and IL-17 levels are useful for differentiating hypocellular RCC from AA. Prospective studies are required to confirm our findings.
• Residual disease detected by multidimensional flow cytometry shows prognostic significance in childhood acute myeloid leukemia with intermediate cytogenetics and negative FLT3-ITD: a report from the Tokyo Children's Cancer Study Group

  Dai Keino, Akitoshi Kinoshita, Daisuke Tomizawa, Hiroyuki Takahashi, Kohmei Ida, Hidemitsu Kurosawa, Kazutoshi Koike, Setsuo Ota, Noriyuki Iwasaki, Junya Fujimura, Yuki Yuza, Chikako Kiyotani, Shohei Yamamoto, Tomoo Osumi, Takahiro Ueda, Shinji Mochizuki, Keiichi Isoyama, Ryoji Hanada, Akio Tawa, Atsushi Manabe, Yoichi Toguchi, Akira Ohara

  INTERNATIONAL JOURNAL OF HEMATOLOGY 103 (4) 416 - 422 0925-5710 2016/04 [Refereed][Not invited]
   

  Residual disease (RD) after induction chemotherapy may predict clinical outcome in acute myeloid leukemia (AML). In the present study, we investigated the prognostic significance of RD detected by multidimensional flow cytometry (MDF) among 34 children treated for AML in a clinical trial (JPLSG AML-05) in Japan. Bone marrow samples were analyzed at the points of the end of the first induction course (BMA-1) and second induction course (BMA-2) by MDF. RD was evaluated by detecting the immature cells showing abnormal antigen expression pattern; CD34(+), CD15(+), CD7(+). Thirteen (39.4 %) of 34 patients at BMA-1 and 8 (27.6 %) of 34 at BMA-2 had RD levels >= 0.1 %. There was no significant difference in 3y-EFS and 3y-OS between patients with RD levels >= 0.1 % and those with RD levels <0.1 % (53.8 versus 70.0 %, P = 0.30 and 50.0 versus 66.7 %, P = 0.27, respectively). However, IR cytogenetics and negative FLT3-ITD patients with RD levels >= 0.1 % exhibited significantly lower 3y-EFS and 3y-OS than those with RD levels <0.1 % (33.3 versus 83.3 %, P = 0.02 and 20.0 versus 76.9 %, P = 0.005, respectively). Our study suggests that RD shows prognostic relevance in pediatric patients with IR cytogenetics and negative FLT3-ITD AML.
• NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity

  Takaya Moriyama, Rina Nishii, Virginia Perez-Andreu, Wenjian Yang, Federico Antillon Klussmann, Xujie Zhao, Ting-Nien Lin, Keito Hoshitsuki, Jacob Nersting, Kentaro Kihira, Ute Hofmann, Yoshihiro Komada, Motohiro Kato, Robert McCorkle, Lie Li, Katsuyoshi Koh, Cesar Rolando Najera, Shirley Kow-Yin Kham, Tomoya Isobe, Zhiwei Chen, Edwynn Kean-Hui Chiew, Deepa Bhojwani, Cynthia Jeffries, Yan Lu, Matthias Schwab, Hiroto Inaba, Ching-Hon Pui, Mary V. Relling, Atsushi Manabe, Hiroki Hori, Kjeld Schmiegelow, Allen E. J. Yeoh, William E. Evans, Jun J. Yang

  NATURE GENETICS 48 (4) 367 - + 1061-4036 2016/04 [Refereed][Not invited]
   

  Widely used as anticancer and immunosuppressive agents, thiopurines have narrow therapeutic indices owing to frequent toxicities, partly explained by TPMT genetic polymorphisms. Recent studies identified germline NUDT15 variation as another critical determinant of thiopurine intolerance, but the underlying molecular mechanisms and the clinical implications of this pharmacogenetic association remain unknown. In 270 children enrolled in clinical trials for acute lymphoblastic leukemia in Guatemala, Singapore and Japan, we identified four NUDT15 coding variants (p.Arg139Cys, p.Arg139His, p.Val18Ile and p.Val18_Val19insGlyVal) that resulted in 74.4-100% loss of nucleotide diphosphatase activity. Loss-of-function NUDT15 diplotypes were consistently associated with thiopurine intolerance across the three cohorts (P = 0.021, 2.1 x 10(-5) and 0.0054, respectively; meta-analysis P = 4.45 x 10(-8), allelic effect size = -11.5). Mechanistically, NUDT15 inactivated thiopurine metabolites and decreased thiopurine cytotoxicity in vitro, and patients with defective NUDT15 alleles showed excessive levels of thiopurine active metabolites and toxicity. Taken together, these results indicate that a comprehensive pharmacogenetic model integrating NUDT15 variants may inform personalized thiopurine therapy.
• Guest Editorial: Inherited bone marrow failure and myelodysplasia in children: how much do we know about pediatric diseases?

  Atsushi Manabe

  International Journal of Hematology 103 (4) 359  1865-3774 2016/04/01 [Refereed][Not invited]
  
• Residual disease detected by multidimensional flow cytometry shows prognostic significance in childhood acute myeloid leukemia with intermediate cytogenetics and negative FLT3-ITD: a report from the Tokyo Children's Cancer Study Group.

  Dai Keino, Akitoshi Kinoshita, Daisuke Tomizawa, Hiroyuki Takahashi, Kohmei Ida, Hidemitsu Kurosawa, Kazutoshi Koike, Setsuo Ota, Noriyuki Iwasaki, Junya Fujimura, Yuki Yuza, Chikako Kiyotani, Shohei Yamamoto, Tomoo Osumi, Takahiro Ueda, Shinji Mochizuki, Keiichi Isoyama, Ryoji Hanada, Akio Tawa, Atsushi Manabe, Yoichi Toguchi, Akira Ohara

  International journal of hematology 103 (4) 416 - 22 1865-3774 2016/04 [Refereed][Not invited]
   

  Residual disease (RD) after induction chemotherapy may predict clinical outcome in acute myeloid leukemia (AML). In the present study, we investigated the prognostic significance of RD detected by multidimensional flow cytometry (MDF) among 34 children treated for AML in a clinical trial (JPLSG AML-05) in Japan. Bone marrow samples were analyzed at the points of the end of the first induction course (BMA-1) and second induction course (BMA-2) by MDF. RD was evaluated by detecting the immature cells showing abnormal antigen expression pattern; CD34(+), CD15(+), CD7(+). Thirteen (39.4 %) of 34 patients at BMA-1 and 8 (27.6 %) of 34 at BMA-2 had RD levels ≥0.1 %. There was no significant difference in 3y-EFS and 3y-OS between patients with RD levels ≥0.1 % and those with RD levels <0.1 % (53.8 versus 70.0 %, P = 0.30 and 50.0 versus 66.7 %, P = 0.27, respectively). However, IR cytogenetics and negative FLT3-ITD patients with RD levels ≥0.1 % exhibited significantly lower 3y-EFS and 3y-OS than those with RD levels <0.1 % (33.3 versus 83.3 %, P = 0.02 and 20.0 versus 76.9 %, P = 0.005, respectively). Our study suggests that RD shows prognostic relevance in pediatric patients with IR cytogenetics and negative FLT3-ITD AML.
• A Cytokine-Based Diagnostic Program in Pediatric Aplastic Anemia and Hypocellular Refractory Cytopenia of Childhood

  Shaimaa Elmahdi, Asahito Hama, Atsushi Manabe, Daisuke Hasegawa, Hideki Muramatsu, Atsushi Narita, Nobuhiru Nishio, Olfat Ismael, Nozomu Kawashima, Yusuke Okuno, Yinyan Xu, Xinan Wang, Yoshiyuki Takahashi, Masafumi Ito, Seiji Kojima

  Pediatric Blood and Cancer 63 (4) 652 - 658 1545-5017 2016/04/01 [Refereed][Not invited]
   

  Background: Distinguishing hypocellular refractory cytopenia of childhood (RCC) from aplastic anemia (AA) is challenging. Thus far, no studies have compared the cytokine profiles in patients with AA to those with hypocellular RCC. In the present study, we addressed whether thrombopoietin (TPO) and interleukin 17 (IL-17) plasma levels are useful for differentiating between the two diseases. Methods: We measured the endogenous plasma concentrations of TPO and IL-17 in 29 patients with AA, 34 patients with hypocellular RCC, and 31 healthy controls using sensitive enzyme-linked immunosorbent assays. Results: The TPO and IL-17 plasma levels were significantly lower in patients with hypocellular RCC than in patients with AA (P < 0.001 and P = 0.007, respectively). The multivariate logistic regression analysis identified moderate disease severity, TPO levels of < 1,369.8 pg/ml (TPO-low group, n = 32 odds ratio (OR), 13.40 95% confidence intervals (CI), 3.001-51.254 P < 0.001), and IL-17 levels of < 22.2 pg/ml (IL-17-low group, n = 33 OR, 4.11 95% CI, 1.033-19.404 P = 0.031) as independent factors discriminating hypocellular RCC from AA. Importantly, 25 (78.1%) of 32 patients in the TPO-low group and 25 (75.8%) of 33 patients in the IL-17-low group were diagnosed as having hypocellular RCC. Moreover, 22 (71%) of 31 patients in the TPO-high group and 21 (70%) of 30 patients in the IL-17-high group were diagnosed as having AA. Conclusions: TPO and IL-17 levels are useful for differentiating hypocellular RCC from AA. Prospective studies are required to confirm our findings.
• 【小児慢性疾患の成人期移行の現状と問題点】 悪性新生物 血液腫瘍(白血病、悪性リンパ腫)

  吉本 優里, 真部 淳

  小児科臨床 (株)日本小児医事出版社 69 (4) 549  0021-518X 2016/04 [Not refereed][Not invited]
  
• NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity

  Takaya Moriyama, Rina Nishii, Virginia Perez-Andreu, Wenjian Yang, Federico Antillon Klussmann, Xujie Zhao, Ting-Nien Lin, Keito Hoshitsuki, Jacob Nersting, Kentaro Kihira, Ute Hofmann, Yoshihiro Komada, Motohiro Kato, Robert McCorkle, Lie Li, Katsuyoshi Koh, Cesar Rolando Najera, Shirley Kow-Yin Kham, Tomoya Isobe, Zhiwei Chen, Edwynn Kean-Hui Chiew, Deepa Bhojwani, Cynthia Jeffries, Yan Lu, Matthias Schwab, Hiroto Inaba, Ching-Hon Pui, Mary V Relling, Atsushi Manabe, Hiroki Hori, Kjeld Schmiegelow, Allen E.J. Yeoh, William E Evans, Jun J. Yang

  Nature Genetics 48 (4) 367 - 373 1546-1718 2016/03/29 [Refereed][Not invited]
   

  Widely used as anticancer and immunosuppressive agents, thiopurines have narrow therapeutic indices owing to frequent toxicities, partly explained by TPMT genetic polymorphisms. Recent studies identified germline NUDT15 variation as another critical determinant of thiopurine intolerance, but the underlying molecular mechanisms and the clinical implications of this pharmacogenetic association remain unknown. In 270 children enrolled in clinical trials for acute lymphoblastic leukemia in Guatemala, Singapore and Japan, we identified four NUDT15 coding variants (p.Arg139Cys, p.Arg139His, p.Val18Ile and p.Val18-Val19insGlyVal) that resulted in 74.4-100% loss of nucleotide diphosphatase activity. Loss-of-function NUDT15 diplotypes were consistently associated with thiopurine intolerance across the three cohorts (P = 0.021, 2.1 × 10 -5 and 0.0054, respectively meta-analysis P = 4.45 × 10 -8, allelic effect size = -11.5). Mechanistically, NUDT15 inactivated thiopurine metabolites and decreased thiopurine cytotoxicity in vitro, and patients with defective NUDT15 alleles showed excessive levels of thiopurine active metabolites and toxicity. Taken together, these results indicate that a comprehensive pharmacogenetic model integrating NUDT15 variants may inform personalized thiopurine therapy.
• 小児T細胞性ALLにおける既知遺伝子異常の解析 TCCSG-ALL研究

  大木 健太郎, 清河 信敬, 朴 明子, 小林 健一郎, 福島 敬, 康 勝好, 花田 良二, 林 泰秀, 真部 淳, 小原 明, 東京小児がん研究グループ

  日本小児科学会雑誌 (公社)日本小児科学会 120 (2) 259 - 259 0001-6543 2016/02
• Dosage of oral methotrexate/6-mercaptopurine in the maintenance treatment of childhood acute lymphoblastic leukemia: a single-center experience

  Utano Tomoyuki, Tanaka Yoichi, Kizu Junko, Kamiya Takahiro, Ogawa Chitose, Ishida Yasushi, Hosoya Ryota, Manabe Atsushi

  The Japanese Journal of Pediatric Hematology / Oncology (NPO)日本小児血液・がん学会 52 (5) 399 - 404 2187-011X 2016/02 [Not refereed][Not invited]
   

  Background. Mercaptopurine (6-MP) and methotrexate (MTX) form the backbone of maintenance therapy for childhood acute lymphoblastic leukemia (ALL). It is widely noted that the inter- and intrapatient variations in the clinical efficacy and adverse effects of 6-MP and MTX are enormous, and optimal dosage varies considerably. The aim of this study was to elucidate the factors that affect the optimal dosage setting of 6-MP/MTX in the maintenance phase of treatment. Methods. Fifty children (aged 1 to 15) who were diagnosed as having ALL in our institution between April 1995 to March 2010 and who finished maintenance therapy were enrolled in this study. We investigated the 6-MP/MTX dosages from the beginning (6-MP/MTX: 40 mg/m² / 25 mg/m²) and compared patients' characteristics (sex, white blood cell count, age, immunophenotype, body surface area, prednisolone response, risk classification, obesity index) and relapse rates across each category. Results. Thirty-four patients needed to change their 6-MP dosage (increase, n=20; decrease, n=14), whereas 18 patients needed to change their MTX dosage (increase, n=3; decrease, n=15). The patients' characteristics were not significantly different in each category of dosage changes; on the other hand, it was shown that 4 of 7 relapse patients experienced an increase in 6-MP dosage of more than 50% within the first 6 months after the start of maintenance treatment. Conclusions. In this study, we conclude that the patients' characteristics are not related to the 6-MP/MTX dosage change in maintenance therapy, and it is suggested that the major increase in 6-MP dosage may predict the occurrence of relapse.
• 自閉症スペクトラム障害のフォロー中に発作時脳波での鑑別を要した前頭葉てんかん

  角谷 和歌子, 代田 惇朗, 松井 俊大, 田中 育子, 横山 美奈, 長谷川 大輔, 小澤 美和, 荻原 正明, 草川 功, 真部 淳

  日本小児科学会雑誌 (公社)日本小児科学会 120 (2) 516  0001-6543 2016/02 [Not refereed][Not invited]
  
• 水痘感染の既往のない非血縁者間臍帯血移植後男児に生じた帯状疱疹

  木村 俊介, 長谷川 大輔, 代田 惇朗, 松井 俊大, 吉本 優里, 平林 真介, 細谷 要介, 熊本 忠志, 真部 淳

  日本小児科学会雑誌 (公社)日本小児科学会 120 (2) 501  0001-6543 2016/02 [Not refereed][Not invited]
  
• 症例報告の書き方、査読の仕方 論文査読のしかた

  真部 淳

  日本小児科学会雑誌 (公社)日本小児科学会 120 (2) 210  0001-6543 2016/02 [Not refereed][Not invited]
  
• From a paper-based to a web-based Journal

  Atsushi Manabe

  PEDIATRICS INTERNATIONAL 58 (1) 3 - 3 1328-8067 2016/01 [Refereed][Not invited]
  
• ZNF384-related fusion genes consist of a subgroup with a characteristic immunophenotype in childhood B-cell precursor acute lymphoblastic leukemia.

  Hirabayashi Shinsuke, Ohki Kentaro, Nakabayashi Kazuhiko, Ichikawa Hitoshi, Momozawa Yukihide, Okamura Kohji, Yaguchi Akinori, Terada Kazuki, Saito Yuya, Yoshimi Ai, Ogata-Kawata Hiroko, Sakamoto Hiromi, Kato Motohiro, Fujimura Junya, Hino Moeko, Kinoshita Akitoshi, Kakuda Hiromi, Kurosawa Hidemitsu, Kato Keisuke, Kajiwara Ryosuke, Moriwaki Koichi, Morimoto Tsuyoshi, Nakamura Kozue, Noguchi Yasushi, Osumi Tomoo, Sakashita Kazuo, Takita Junko, Yuza Yuki, Matsuda Koich, Yoshida Teruhiko, Matsumoto Kenji, Hata Kenichiro, Kubo Michiaki, Matsubara Yoichi, Fukushima Takashi, Koh Katsuyoshi, Manabe Atsushi, Ohara Akira, Kiyokawa Nobutaka

  ZNF384-related fusion genes consist of a subgroup with a characteristic immunophenotype in childhood B-cell precursor acute lymphoblastic leukemia. 1592-8721 2016 [Not refereed][Not invited]
   

  :Fusion genes involving ZNF384 have recently been identified in B-cell precursor acute lymphoblastic leukemia, and 6 fusion partners have reported. We further characterized this type of fusion gene by whole transcriptome sequencing and/or PCR. In addition to previously reported genes, we identified BMP2K as a novel fusion partner for ZNF384. Including EP300-ZNF384 that we reported recently, the to
• メチルプレドニゾロン・パルス療法とタクロリムスによる治療が奏効した抗MDA5抗体陽性の若年性皮膚筋炎の女児例

  山口 賢一, 横田 俊平, 代田 惇朗, 小澤 美和, 真部 淳, 草川 功

  日本小児科学会雑誌 (公社)日本小児科学会 120 (1) 96  0001-6543 2016/01 [Not refereed][Not invited]
  
• Successful unrelated cord blood transplantation in a child with very severe aplastic anemia

  Kimura Shunsuke, Hasegawa Daisuke, Matsui Toshihiro, Daida Atsuro, Ishida Hisashi, Yoshimoto Yuri, Hirabayashi Shinsuke, Hosoya Yosuke, Yoshihara Hiroki, Kumamoto Tadashi, Mori Shinichiro, Manabe Atsushi

  The Japanese Journal of Pediatric Hematology / Oncology 日本小児血液・がん学会 53 (1) 21 - 25 2187-011X 2016 [Not refereed][Not invited]
   

  Unrelated cord blood transplantation (UCBT) and mismatched related donor stem cell transplantation (MMRD-SCT) have been considered as alternative therapeutic options for patients with very severe aplastic anemia (VSAA) and severe infection when an HLA-matched donor is not available. However, a high rate of graft failure and severe graft-versus-host disease (GVHD) are the major problems in SCT from
• A novel recurrent EP300-ZNF384 gene fusion in B-cell precursor acute lymphoblastic leukemia

  Y. Gocho, N. Kiyokawa, H. Ichikawa, K. Nakabayashi, T. Osumi, T. Ishibashi, H. Ueno, K. Terada, K. Oboki, H. Sakamoto, Y. Shioda, M. Imai, Y. Noguchi, Y. Arakawa, Y. Kojima, D. Toyama, K. Hata, T. Yoshida, K. Matsumoto, M. Kato, T. Fukushima, K. Koh, A. Manabe, A. Ohara

  Leukemia 29 (12) 2445 - 2448 1476-5551 2015/12/01 [Not refereed][Not invited]
  
• 英語論文の書き方

  真部 淳

  日本小児科学会雑誌 (公社)日本小児科学会 119 (12) 1728  0001-6543 2015/12 [Not refereed][Not invited]
  
• 【小児血液・腫瘍性疾患の診断と治療のトピックス】 診断のトピックス 白血病とGWAS(genome-wide association study)

  真部 淳

  小児科診療 (株)診断と治療社 78 (12) 1753  0386-9806 2015/12 [Not refereed][Not invited]
   

  様々な疾患において宿主(患者)の生殖細胞系列の遺伝子変異を網羅的に検索するgenome-wide association study(GWAS:ゲノムワイド関連解析)が行われている。小児の急性リンパ性白血病(acute lymphoblastic leukemia:ALL)ではGWASにより、ALLのなりやすさと関連するARID5Bなどの遺伝子多型ならびに薬物の毒性と関連するNUDT15などの遺伝子多型がわかってきた。近い将来の臨床応用が期待される。(著者抄録)
• Favorable outcome in non-infant children with MLL-AF4-positive acute lymphoblastic leukemia: a report from the Tokyo Children's Cancer Study Group.

  Tomizawa D, Kato M, Takahashi H, Fujimura J, Inukai T, Fukushima T, Kiyokawa N, Koh K, Manabe A, Ohara A

  International journal of hematology 102 (5) 602 - 610 0925-5710 2015/11 [Refereed][Not invited]
   

  Unlike acute lymphoblastic leukemia (ALL) in infants, MLL gene rearrangement (MLL-r) is rare in ALL children (≥1 year old). The outcome and optimal treatment options for MLL-r ALL remain controversial. Among the 1827 children enrolled in the Tokyo Children's Cancer Study Group ALL studies L95-14, L99-15, L99-1502, L04-16, and L07-1602 (1995-2009), 25 MLL-r ALL patients (1.3 %) were identified. Their median age and leukocyte count at diagnosis was 2 years old (range 1-15 years) and 27,690/μL (range 1800-1,113,000/μL), respectively. All but one patient achieved complete remission (CR) after induction therapy, and 19 underwent allogeneic hematopoietic stem cell transplantation (HSCT) in first CR according to the protocol. The 5-year event-free survival (EFS) and overall survival (OS) rate were 60.0 % [standard error (SE), 9.7 %] and 64.0 % (SE 9.6 %), respectively. Notably, 9/12 cases with MLL-AF4-positive ALL are alive in continuous CR with a 75.0 % (SE 12.5 %) EFS rate. The causes of treatment failure were as follows: one induction failure, five relapses, and five transplant-related deaths. With intensive chemotherapy and allogeneic HSCT, favorable outcome of children (≥1 year old) with MLL-AF4-positive ALL was observed. However, considering the risk of acute and late toxicities associated with HSCT, its indication should be restricted.
• 融合遺伝子TCF3-ZNF384陽性B前駆細胞性急性リンパ芽球性白血病5例の臨床的特徴(Clinical characteristics of five cases of B-cell precursor acute lymphoblastic leukemia with TCF3-ZNF384 fusion gene)

  平林 真介, 大木 健太郎, 清河 信敬, 谷口 明徳, 寺田 和樹, 市川 仁, 中林 一彦, 秦 健一郎, 松田 浩一, 桃沢 幸秀, 久保 充明, 松原 洋一, 福島 敬, 康 勝好, 真部 淳, 小原 明

  日本小児血液・がん学会雑誌 52 (4) 260 - 260 2187-011X 2015/10
• 小児T-ALLにおける6qLOHの頻度と予後解析 TCCSG ALL L0416/L0616(Frequency and prognostic impact of loss of heterozygosity at chromosome 6q in pediatric acute T-cell lymphoblastic leukemia: TCCSG ALL-L0416/L0616 Trial)

  大木 健太郎, 清河 信敬, 朴 明子, 小林 健一郎, 福島 敬, 康 勝好, 土田 昌宏, 林 泰秀, 真部 淳, 小原 明

  日本小児血液・がん学会雑誌 52 (4) 267 - 267 2187-011X 2015/10
• 小児B前駆細胞性急性リンパ芽球性白血病における、PAX5の新規融合遺伝子CBFA2T2の同定(Identification of CBFA2T2 as a novel PAX5 fusion partner gene in pediatric B-precursor acute lymphoblastic leukemia)

  寺田 和樹, 清河 信敬, 大木 健太郎, 木川 崇, 櫻井 彩子, 五十嵐 俊二, 谷口 明徳, 石橋 武士, 中林 一彦, 市川 仁, 松本 健治, 福島 敬, 康 勝好, 真部 淳, 小原 明, 角南 勝介

  日本小児血液・がん学会雑誌 52 (4) 349 - 349 2187-011X 2015/10
• TCCSG施設ならびにTCCSG医師における小児がん晩期合併症の経験に関する調査

  清谷 知賀子, 前田 美穂, 青木 由貴, 加藤 陽子, 後藤 晶子, 坂口 佐知, 徳山 美香, 石井 栄三郎, 石田 也寸志, 中舘 尚也, 真部 淳, 小原 明, 東京小児がん研究グループ(TCCSG)QOL委員会

  日本小児血液・がん学会雑誌 (一社)日本小児血液・がん学会 52 (4) 345 - 345 2187-011X 2015/10
• Susceptibility to 6-MP toxicity conferred by a NUDT15 variant in Japanese children with acute lymphoblastic leukaemia

  Yoichi Tanaka, Motohiro Kato, Daisuke Hasegawa, Kevin Y. Urayama, Hisaya Nakadate, Kensuke Kondoh, Kozue Nakamura, Katsuyoshi Koh, Takako Komiyama, Atsushi Manabe

  BRITISH JOURNAL OF HAEMATOLOGY 171 (1) 109 - 115 0007-1048 2015/10 [Refereed][Not invited]
   

  Genotyping of TPMT prior to 6-mercaptopurine (6-MP) administration in acute lymphoblastic leukaemia (ALL) patients has been integrated into clinical practice in some populations of European ancestry. However, the comparable rates of 6-MP myelotoxicity, but rarity of TPMT variants, in Asians suggest that major determinants have yet to be discovered in this population. We genotyped 92 Japanese paediatric ALL patients for NUDT15 rs116855232, a 6-MP toxicity-related locus discovered in Asians. Logistic regression and survival analysis were used to evaluate its association with leucopenia, hepatotoxicity, 6-MP dose reduction, therapy interruption and event-free survival. The allele frequency of rs116855232 was 0.16, and leucopenia was more common in carriers of the T allele (odds ratio, 7.20; 95% confidence interval, 2.49-20.80; P = 2.7 x 10(-4)). As leucopenia results in 6-MP dose reduction, we observed average doses during maintenance therapy of 40.7, 29.3 and 8.8 mg/m(2) for patients with CC, CT and TT genotypes, respectively (P < 0.001). Hepatotoxicity was observed only in CC genotype patients. Event-free survival did not significantly differ by NUDT15 genotype. rs116855232 is an important determinant of 6-MP myelotoxicity in Japanese children with ALL and may represent the most robust toxicity-related locus in Asians to date. Considerations for clinical application may be warranted.
• Susceptibility to 6-MP toxicity conferred by a NUDT15 variant in Japanese children with acute lymphoblastic leukaemia

  Yoichi Tanaka, Motohiro Kato, Daisuke Hasegawa, Kevin Y. Urayama, Hisaya Nakadate, Kensuke Kondoh, Kozue Nakamura, Katsuyoshi Koh, Takako Komiyama, Atsushi Manabe

  British Journal of Haematology 171 (1) 109 - 115 1365-2141 2015/10/01 [Refereed][Not invited]
   

  Genotyping of TPMT prior to 6-mercaptopurine (6-MP) administration in acute lymphoblastic leukaemia (ALL) patients has been integrated into clinical practice in some populations of European ancestry. However, the comparable rates of 6-MP myelotoxicity, but rarity of TPMT variants, in Asians suggest that major determinants have yet to be discovered in this population. We genotyped 92 Japanese paediatric ALL patients for NUDT15 rs116855232, a 6-MP toxicity-related locus discovered in Asians. Logistic regression and survival analysis were used to evaluate its association with leucopenia, hepatotoxicity, 6-MP dose reduction, therapy interruption and event-free survival. The allele frequency of rs116855232 was 0·16, and leucopenia was more common in carriers of the T allele (odds ratio, 7·20 95% confidence interval, 2·49-20·80 P = 2·7 × 10-4). As leucopenia results in 6-MP dose reduction, we observed average doses during maintenance therapy of 40·7, 29·3 and 8·8 mg/m2 for patients with CC, CT and TT genotypes, respectively (P < 0·001). Hepatotoxicity was observed only in CC genotype patients. Event-free survival did not significantly differ by NUDT15 genotype. rs116855232 is an important determinant of 6-MP myelotoxicity in Japanese children with ALL and may represent the most robust toxicity-related locus in Asians to date. Considerations for clinical application may be warranted.
• ダサチニブ投与中に両側肺下胸水を認めたフィラデルフィア染色体陽性急性リンパ性白血病の男児

  吉本 優里, 熊本 忠史, 木村 俊介, 平林 真介, 細谷 要介, 長谷川 大輔, 真部 淳

  日本小児血液・がん学会雑誌 (NPO)日本小児血液・がん学会 52 (4) 309  2187-011X 2015/10 [Not refereed][Not invited]
  
• VincristineとActinomycin Dによる化学療法が奏効し下肢切断を免れているinfantile fibrosarcomaの一例

  細谷 要介, 吉本 優里, 吉原 宏樹, 長谷川 大輔, 熊本 忠史, 川野 孝文, 迫田 晃子, 松藤 凡, 真部 淳

  日本小児血液・がん学会雑誌 (NPO)日本小児血液・がん学会 52 (4) 304  2187-011X 2015/10 [Not refereed][Not invited]
  
• 体細胞ヘテロ接合性CBL変異が長期に残存したJMML(Long-term persistence of somatic heterozygous CBL mutation in JMML)

  平林 真介, 長谷川 大輔, 周尾 卓也, 村松 秀城, 坂下 一夫, 小島 勢二, 小池 健一, 真部 淳

  日本小児血液・がん学会雑誌 (NPO)日本小児血液・がん学会 52 (4) 277  2187-011X 2015/10 [Not refereed][Not invited]
  
• 小児悪性腫瘍患者におけるClostridium Difficile腸炎のリスク(Risk factors for Clostridium difficile associated diarrhea among pediatric cancer patients)

  代田 惇朗, 吉原 宏樹, 稲井 郁子, 吉本 優里, 平林 真介, 細谷 要介, 長谷川 大輔, 石田 也寸志, 浦山 ケビン, 真部 淳

  日本小児血液・がん学会雑誌 (NPO)日本小児血液・がん学会 52 (4) 243  2187-011X 2015/10 [Not refereed][Not invited]
  
• 再生不良性貧血・骨髄増殖性疾患 治療関連骨髄異形成症候群44例の臨床像(Aplastic anemia and myeloproliferative disorder Clinical characteristics of 44 cases with therapy-related myelodysplastic syndrome in childhood)

  長谷川 大輔, 濱 麻人, 野沢 和江, 平林 真介, 渡邉 健一郎, 土田 昌宏, 伊藤 雅文, 小島 勢二, 中畑 龍俊, 真部 淳

  日本小児血液・がん学会雑誌 (NPO)日本小児血液・がん学会 52 (4) 208  2187-011X 2015/10 [Not refereed][Not invited]
  
• わが国の小児がん医療提供体制について考える 小児がんに対するトータルケアと医療提供体制

  長谷川 大輔, 小澤 美和, 真部 淳, 細谷 亮太

  日本小児血液・がん学会雑誌 (NPO)日本小児血液・がん学会 52 (4) 189  2187-011X 2015/10 [Not refereed][Not invited]
  
• Favorable outcome in non-infant children with MLL-AF4-positive acute lymphoblastic leukemia: a report from the Tokyo Children’s Cancer Study Group

  Daisuke Tomizawa, Motohiro Kato, Hiroyuki Takahashi, Junya Fujimura, Takeshi Inukai, Takashi Fukushima, Nobutaka Kiyokawa, Katsuyoshi Koh, Atsushi Manabe, Akira Ohara

  International Journal of Hematology 102 (5) 602 - 610 1865-3774 2015/09/26 [Refereed][Not invited]
   

  Unlike acute lymphoblastic leukemia (ALL) in infants, MLL gene rearrangement (MLL-r) is rare in ALL children (≥1 year old). The outcome and optimal treatment options for MLL-r ALL remain controversial. Among the 1827 children enrolled in the Tokyo Children’s Cancer Study Group ALL studies L95–14, L99–15, L99–1502, L04–16, and L07–1602 (1995–2009), 25 MLL-r ALL patients (1.3 %) were identified. Their median age and leukocyte count at diagnosis was 2 years old (range 1–15 years) and 27,690/μL (range 1800–1,113,000/μL), respectively. All but one patient achieved complete remission (CR) after induction therapy, and 19 underwent allogeneic hematopoietic stem cell transplantation (HSCT) in first CR according to the protocol. The 5-year event-free survival (EFS) and overall survival (OS) rate were 60.0 % [standard error (SE), 9.7 %] and 64.0 % (SE 9.6 %), respectively. Notably, 9/12 cases with MLL-AF4-positive ALL are alive in continuous CR with a 75.0 % (SE 12.5 %) EFS rate. The causes of treatment failure were as follows: one induction failure, five relapses, and five transplant-related deaths. With intensive chemotherapy and allogeneic HSCT, favorable outcome of children (≥1 year old) with MLL-AF4-positive ALL was observed. However, considering the risk of acute and late toxicities associated with HSCT, its indication should be restricted.
• Outcome of adolescent patients with acute myeloid leukemia treated with pediatric protocols

  Daisuke Tomizawa, Tomoyuki Watanabe, Ryoji Hanada, Keizo Horibe, Yasuo Horikoshi, Shotaro Iwamoto, Akitoshi Kinoshita, Hiroshi Moritake, Hideki Nakayama, Akira Shimada, Takashi Taga, Hiroyuki Takahashi, Akio Tawa, Kiminori Terui, Hiroki Hori, Yoshifumi Kawano, Atsushi Kikuta, Atsushi Manabe, Souichi Adachi

  INTERNATIONAL JOURNAL OF HEMATOLOGY 102 (3) 318 - 326 0925-5710 2015/09 [Refereed][Not invited]
   

  As past studies of adolescent and young adults (AYA) with acute myeloid leukemia (AML) reported conflicting results, we conducted a retrospective analysis using data from three Japanese pediatric AML studies. Among the 782 patients with de novo AML, 44 were classified as AYA (age a parts per thousand yen15 years at diagnosis), 164 as infants (0-1 year), 413 as younger children (2-11 years), and 161 as older children (12-14 years). While the 5-year event-free survival rate of AYA was not different among the groups, the five-year survival rate (54.7 %) was significantly lower than that of the other three groups (P = 0.019): 68.7 % for infants, 73.2 % for younger children, and 75.5 % for older children. No difference in the 5-year cumulative incidence of relapse was observed, but treatment-related death (TRD) of AYA was significantly higher (29.4 %) than that in infants (14.8 %), younger children (10.2 %), and older children (13.8 %). Multivariate analysis showed age a parts per thousand yen15 years old at diagnosis was associated with both poor survival rate and high TRD. Adolescents with AML had inferior survival due to a higher incidence of TRD, especially after failure of initial frontline treatment.
• 肋骨の多発溶骨性変化をきたしているGorham病の発症10年後の呼吸機能

  梅原 直, 熊本 忠史, 真部 淳

  日本小児呼吸器学会雑誌 日本小児呼吸器学会 26 (Suppl.) 147  2187-5731 2015/09 [Not refereed][Not invited]
  
• 【内科が使う自己注射薬】 血液に作用する自己注射薬 G-CSF製剤の在宅自己注射

  平林 真介, 真部 淳

  診断と治療 (株)診断と治療社 103 (9) 1223  0370-999X 2015/09 [Not refereed][Not invited]
   

  1 G-CSF製剤は骨髄前駆細胞から顆粒球への増殖分化を促すと同時に顆粒球の機能を高めるバイオ医薬品であり、幅広く臨床応用されている。2 再生不良性貧血と先天性好中球減少症においてG-CSF製剤は有意に感染が減少し、在宅自己注射の適応が承認された。3 G-CSF製剤の長期投与に伴いMDS/AMLへの移行が報告されており、漫然とした使用は避ける必要がある。(著者抄録)
• Multidrug resistance protein 4 (MRP4) polymorphisms impact the 6-mercaptopurine dose tolerance during maintenance therapy in Japanese childhood acute lymphoblastic leukemia

  Y. Tanaka, A. Manabe, H. Fukushima, R. Suzuki, H. Nakadate, K. Kondoh, K. Nakamura, K. Koh, T. Fukushima, M. Tsuchida, K. Koike, N. Kiyokawa, E. Noguchi, R. Sumazaki, T. Komiyama

  Pharmacogenomics Journal 15 (4) 380 - 384 1473-1150 2015/08/25 [Not refereed][Not invited]
   

  Multidrug resistance protein 4 (MRP4) is involved in the efflux of nucleoside derivatives and has a role in the determination of drug sensitivity. We investigated the relationship between MRP4 genetic polymorphisms and doses of the 6-mercaptopurine (6-MP) and methotrexate. Further, we evaluated the frequency of therapeutic interruption during maintenance therapy in Japanese children with acute lymphoblastic leukemia (ALL). Ninety-four patients received an initial 6-MP dose in the range of 30-50 mg m-2 in this analysis. Patients with homozygous variant allele in any of MRP4 G2269A, C912A and G559T required high frequency of 6-MP dose reduction compared with non-homozygous individuals. Average 6-MP dose for patients with homozygous variant allele on either MRP4 or inosine triphosphate pyrophosphatase was significantly lower than that for patients with non-homozygous variant allele during maintenance therapy (30.5 versus 40.0 mg m-2, P=0.024). Therefore, MRP4 genotyping may be useful for personalizing the therapeutic dose of 6-MP during the ALL maintenance therapy in Japanese.
• Review article series on the state of recent evidence in childhood cancer

  Atsushi Manabe

  PEDIATRICS INTERNATIONAL 57 (4) 515 - 515 1328-8067 2015/08 [Refereed][Not invited]
  
• Cytogenetics and clinical features of pediatric myelodysplastic syndrome in Japan (vol 100, pg 478, 2014)

  Koichi Moriwaki, Atsushi Manabe, Takeshi Taketani, Akira Kikuchi, Tatsutoshi Nakahata, Yasuhide Hayashi

  INTERNATIONAL JOURNAL OF HEMATOLOGY 102 (2) 249 - 249 0925-5710 2015/08 [Refereed][Not invited]
  
• Multidrug resistance protein 4 (MRP4) polymorphisms impact the 6-mercaptopurine dose tolerance during maintenance therapy in Japanese childhood acute lymphoblastic leukemia

  Y. Tanaka, A. Manabe, H. Fukushima, R. Suzuki, H. Nakadate, K. Kondoh, K. Nakamura, K. Koh, T. Fukushima, M. Tsuchida, K. Koike, N. Kiyokawa, E. Noguchi, R. Sumazaki, T. Komiyama

  PHARMACOGENOMICS JOURNAL 15 (4) 380 - 384 1470-269X 2015/08 [Refereed][Not invited]
   

  Multidrug resistance protein 4 (MRP4) is involved in the efflux of nucleoside derivatives and has a role in the determination of drug sensitivity. We investigated the relationship between MRP4 genetic polymorphisms and doses of the 6-mercaptopurine (6-MP) and methotrexate. Further, we evaluated the frequency of therapeutic interruption during maintenance therapy in Japanese children with acute lymphoblastic leukemia (ALL). Ninety-four patients received an initial 6-MP dose in the range of 30-50 mg m(-2) in this analysis. Patients with homozygous variant allele in any of MRP4 G2269A, C912A and G559T required high frequency of 6-MP dose reduction compared with non-homozygous individuals. Average 6-MP dose for patients with homozygous variant allele on either MRP4 or inosine triphosphate pyrophosphatase was significantly lower than that for patients with non-homozygous variant allele during maintenance therapy (30.5 versus 40.0 mg m(-2), P = 0.024). Therefore, MRP4 genotyping may be useful for personalizing the therapeutic dose of 6-MP during the ALL maintenance therapy in Japanese.
• CD10陰性B前駆細胞性急性リンパ芽球性白血病の新たな亜群EP300-ZNF384

  寺田 和樹, 清河 信敬, 牛腸 義宏, 谷口 明徳, 石橋 武士, 橋本 亙, 大隅 朋生, 大木 健太郎, 福島 敬, 康 勝好, 真部 淳, 小原 明

  Cytometry Research (一社)日本サイトメトリー学会 25 (Suppl.) 56 - 56 0916-6920 2015/07
• 消化管出血を呈した青色ゴムまり様母斑症候群の1例

  栗山 絢子, 石田 悠志, 吉本 優里, 平林 真介, 細谷 要介, 吉原 宏樹, 長谷川 大輔, 真部 淳

  日本小児科学会雑誌 (公社)日本小児科学会 119 (6) 1029  0001-6543 2015/06 [Not refereed][Not invited]
  
• Long-term outcome of six months maintenance chemotherapy for ALL in children: TCCSG L92-13E study.

  Motohiro Kato, Atsushi Manabe, Sae Ishimaru, Masafumi Seki, Kenichi Yoshida, Daisuke Tomizawa, Daisuke Hasegawa, Takeshi Inukai, Yuki Arakawa, Takahiro Aoki, Mayuko Okuya, Kiyohiko Kaizu, Keisuke Kato, Yuichi Taneyama, Seishi Ogawa, Katsuyoshi Koh, Masahiro Tsuchida, Akira Ohara

  JOURNAL OF CLINICAL ONCOLOGY 33 (15) 0732-183X 2015/05 [Refereed][Not invited]
  
• Imatinib use immediately before stem cell transplantation in children with Philadelphia chromosome-positive acute lymphoblastic leukemia: Results from Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) Study Ph(+)ALL04

  Atsushi Manabe, Hirohide Kawasaki, Hiroyuki Shimada, Itaru Kato, Yuichi Kodama, Atsushi Sato, Kimikazu Matsumoto, Keisuke Kato, Hiromasa Yabe, Kazuko Kudo, Motohiro Kato, Tomohiro Saito, Akiko M. Saito, Masahito Tsurusawa, Keizo Horibe

  CANCER MEDICINE 4 (5) 682 - 689 2045-7634 2015/05 [Refereed][Not invited]
   

  Incorporation of imatinib into chemotherapeutic regimens has improved the prognosis of children with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph(+)ALL). We investigated a role of imatinib immediately before hematopoietic stem cell transplantation (HSCT). Children with Ph(+)ALL were enrolled on JPLSG Ph(+)ALL 04 Study within 1week of initiation of treatment for ALL. Treatment regimen consisted of Induction phase, Consolidation phase, Reinduction phase, 2weeks of imatinib monotherapy phase, and HSCT phase (Etoposide+CY+TBI conditioning). Minimal residual disease (MRD), the amount of BCR-ABL transcripts, was measured with the real-time PCR method. The study was registered in UMIN-CTR: UMIN ID C000000290. Forty-two patients were registered and 36 patients (86%) achieved complete remission (CR). Eight of 17 patients (47%) who had detectable MRD at the beginning of imatinib monotherapy phase showed disappearance or decrease in MRD after imatinib treatment. Consequently, 26 patients received HSCT in the first CR and all the patients had engraftment and no patients died because of complications of HSCT. The 4-year event-free survival rates and overall survival rates among all the 42 patients were 54.1 +/- 7.8% and 78.1 +/- 6.5%, respectively. Four of six patients who did achieve CR and three of six who relapsed before HSCT were salvaged with imatinib-containing chemotherapy and subsequently treated with HSCT. The survival rate was excellent in this study although all patients received HSCT. A longer use of imatinib concurrently with chemotherapy should eliminate HSCT in a subset of patients with a rapid clearance of the disease.
• 周期性好中球減少症合併患者に婦人科手術を施行した一例

  大垣 洋子, 塩田 恭子, 山田 梨紗子, 和泉 紀子, 岩瀬 純, 水野 吉章, 秋谷 文, 平林 真介, 真部 淳

  日本産婦人科・新生児血液学会誌 日本産婦人科・新生児血液学会 25 (1) 32  0916-8796 2015/05 [Not refereed][Not invited]
   

  42歳(0回経妊婦)。周期性好中球減少症の既往があり、今回、卵巣嚢腫摘出術および子宮筋腫核出術目的に当科入院となった。約2ヵ月にわたり好中球の変動を確認し、最低値の時期を過ぎる頃に手術日を設定したが、予定日の3日前よりG-CSF製剤を投与するも好中球数は改善せず、手術は延期となった。遺伝子検査でELA2変異を認め、G-CSF製剤が有効な型であったため、再度手術日を設定し8日前よりG-CSF製剤の投与を行った。周術期の予防的抗生剤はVCM、CFPM、MNZの点滴とし、右卵巣嚢腫摘出と子宮筋腫核出術を施行し得た。術後の経過は良好で、術後5日目に軽快退院した。
• Psychosocial difficulties in adolescent and young adult survivors of childhood cancer

  Yuko Takei, Akiko Ogata, Miwa Ozawa, Hiroshi Moritake, Kei Hirai, Atsushi Manabe, Shin-ichi Suzuki

  PEDIATRICS INTERNATIONAL 57 (2) 239 - 246 1328-8067 2015/04 [Refereed][Not invited]
   

  BackgroundWith a large number of children surviving cancer worldwide, numerous investigations have assessed psychological and social adjustment among childhood cancer survivors. According to these studies, it is unclear whether childhood cancer survivors successfully adjust to daily life after being discharged from hospital, especially for adolescent and young adult survivors who have unique needs and concerns. The primary aim of this study was to identify the factors underlying psychosocial difficulties faced by adolescent and young adult survivors in their day-to-day lives after being discharged from hospital. MethodsSemi-structured interviews were conducted. Twenty-five childhood cancer survivors were recruited from two regional cancer institutions in Japan. Content analysis was applied to the responses. ResultsNineteen attributes were extracted and classified into four categories as follows: physical difficulties, interpersonal difficulties, behavioral difficulties, and uncertainty about the future. The attributes indicated by >50% of the participants were I am worried about not feeling well, I have difficulty continuing treatment in daily life, I have difficulty moving my body, I have to be absent from school or work because of illness, and I am left behind academically. ConclusionsThis study identified important factors of psychosocial day-to-day difficulties. Clinically, these results suggest that it is important to watch for these signs and to provide early support to survivors so that their daily life and development are not hindered by the treatment and its side-effects, and to offer long-term support focusing on individual patient characteristics such as sex, age, and cancer history.
• Acute megakaryoblastic leukemia with acquired trisomy 21 and GATA1 mutations in phenotypically normal children

  Rintaro Ono, Daisuke Hasegawa, Shinsuke Hirabayashi, Takahiro Kamiya, Kenichi Yoshida, Satoko Yonekawa, Chitose Ogawa, Ryota Hosoya, Tsutomu Toki, Kiminori Terui, Etsuro Ito, Atsushi Manabe

  EUROPEAN JOURNAL OF PEDIATRICS 174 (4) 525 - 531 0340-6199 2015/04 [Refereed][Not invited]
   

  GATA1 mutations are found almost exclusively in children with myeloid proliferations related to Down syndrome (DS). Here, we report two phenotypically and cytogenetically normal children with acute megakaryoblastic leukemia (AMKL) whose blasts had both acquired trisomy 21 and GATA1 mutation. Patient 1 was diagnosed with transient abnormal myelopoiesis in the neonatal period. Following spontaneous improvement of the disease, leukemic blasts increased 7 months later. He received less intensive chemotherapy, and he is now 6 years old in complete remission. Patient 2 was diagnosed with AMKL at the age of 18 months. Although he received intensive chemotherapy and a cord blood transplantation, he died without gaining remission. In both cases, trisomy 21 and GATA1 mutation were detected only in leukemic blasts, but not in germline samples. Based on a literature review, we identified reports describing 14 non-DS AMKL with GATA1 mutation and acquired trisomy 21. Of those, 12 cases were diagnosed during the neonatal period, whereas the remaining 2 cases were diagnosed at the age of 22 and 31 months, respectively. Conclusion: These cases suggest that GATA1 mutation may cooperate with the additional chromosome 21 in developing myeloid proliferations even in non-DS patients.
• Acute megakaryoblastic leukemia with acquired trisomy 21 and GATA1 mutations in phenotypically normal children.

  Rintaro Ono, Daisuke Hasegawa, Shinsuke Hirabayashi, Takahiro Kamiya, Kenichi Yoshida, Satoko Yonekawa, Chitose Ogawa, Ryota Hosoya, Tsutomu Toki, Kiminori Terui, Etsuro Ito, Atsushi Manabe

  European journal of pediatrics 174 (4) 525 - 31 1432-1076 2015/04 [Refereed][Not invited]
   

  UNLABELLED: GATA1 mutations are found almost exclusively in children with myeloid proliferations related to Down syndrome (DS). Here, we report two phenotypically and cytogenetically normal children with acute megakaryoblastic leukemia (AMKL) whose blasts had both acquired trisomy 21 and GATA1 mutation. Patient 1 was diagnosed with transient abnormal myelopoiesis in the neonatal period. Following spontaneous improvement of the disease, leukemic blasts increased 7 months later. He received less intensive chemotherapy, and he is now 6 years old in complete remission. Patient 2 was diagnosed with AMKL at the age of 18 months. Although he received intensive chemotherapy and a cord blood transplantation, he died without gaining remission. In both cases, trisomy 21 and GATA1 mutation were detected only in leukemic blasts, but not in germline samples. Based on a literature review, we identified reports describing 14 non-DS AMKL with GATA1 mutation and acquired trisomy 21. Of those, 12 cases were diagnosed during the neonatal period, whereas the remaining 2 cases were diagnosed at the age of 22 and 31 months, respectively. CONCLUSION: These cases suggest that GATA1 mutation may cooperate with the additional chromosome 21 in developing myeloid proliferations even in non-DS patients.
• 小児がん治療の最前線 Pharmacogenomics and Translational Medicine

  真部 淳

  日本薬学会年会要旨集 (公社)日本薬学会 135年会 (1) 348  0918-9823 2015/03 [Not refereed][Not invited]
  
• 小児がん治療30年間の進歩 予後の改善と患者・家族への支援

  真部 淳

  聖路加国際大学紀要 聖路加国際大学 1 29  2189-1591 2015/03 [Not refereed][Not invited]
  
• 小児科領域の国際専門誌に論文を掲載するコツ

  真部 淳

  小児科 金原出版(株) 56 (3) 311  0037-4121 2015/03 [Not refereed][Not invited]
  
• Transplantation for juvenile myelomonocytic leukemia: a retrospective study of 30 children treated with a regimen of busulfan, fludarabine, and melphalan

  Miharu Yabe, Yoshitoshi Ohtsuka, Kenichiro Watanabe, Jiro Inagaki, Nao Yoshida, Kazuo Sakashita, Harumi Kakuda, Hiromasa Yabe, Hidemitsu Kurosawa, Kazuko Kudo, Atsushi Manabe

  INTERNATIONAL JOURNAL OF HEMATOLOGY 101 (2) 184 - 190 0925-5710 2015/02 [Refereed][Not invited]
   

  We report the outcomes of 30 patients with juvenile myelomonocytic leukemia (JMML) who received unmanipulated hematopoietic stem cell transplantation (HSCT) with oral or intravenous busulfan, fludarabine, and melphalan between 2001 and 2011. Mutations in PTPN11 were detected in 15 patients. Six patients received human leukocyte antigen (HLA)-matched HSCT from related donors, and 24 patients received HSCT from alternative donors, including 13 HLA-mismatched donors. Primary engraftment failed in five patients, all of whom had received allografts from HLA-mismatched donors. HLA-mismatched HSCT resulted in poorer event-free survival than HLA-matched HSCT (28.8 vs. 70.6 %). Three patients died of transplantation-related causes, and eight patients experienced hematological relapse (including five patients who died due to disease progression). Eight patients received a second HSCT, and four of these patients have survived. The 5-year estimated overall survival for all patients was 72.4: 88.9 % for the patients without a mutation in PTPN11 (n = 10) and 58.3 % for the patients with a mutation in PTPN11 (n = 15) (P = 0.092). The conditioning regimen reported in the present study achieved hematological and clinical remission in > 50 % of patients with JMML who received HSCT from alternative donors, and may also be effective for JMML patients with PTPN11 mutation.
• 無呼吸、重症下気道感染を来したHuman Rhinovirusの乳児3例

  代田 惇朗, 辻本 信一, 稲井 郁子, 吉本 優里, 石田 悠志, 野村 耕太郎, 梅原 直, 小澤 美和, 真部 淳, 草川 功

  日本小児科学会雑誌 (公社)日本小児科学会 119 (2) 511 - 511 0001-6543 2015/02 [Not refereed][Not invited]
  
• 消化管出血を呈したBlue rubber bleb nevus syndromeの一例

  栗山 絢子, 吉本 優里, 平林 真介, 長谷川 大輔, 小澤 美和, 草川 功, 真部 淳, 嶋田 明, 末延 聡一

  日本小児科学会雑誌 (公社)日本小児科学会 119 (2) 419 - 419 0001-6543 2015/02 [Not refereed][Not invited]
  
• 頸部リンパ節炎の治療に難渋した自己免疫性好中球減少症の2例

  吉本 優里, 代田 惇朗, 平林 真介, 長沖 優子, 細谷 要介, 長谷川 大輔, 稲井 郁子, 小澤 美和, 草川 功, 真部 淳

  日本小児科学会雑誌 (公社)日本小児科学会 119 (2) 414  0001-6543 2015/02 [Not refereed][Not invited]
  
• 英語論文の書き方

  真部 淳

  日本小児科学会雑誌 (公社)日本小児科学会 119 (2) 167  0001-6543 2015/02 [Not refereed][Not invited]
  
• Outcome of pediatric acute lymphoblastic leukemia with very late relapse: a retrospective analysis by the Tokyo Children's Cancer Study Group (TCCSG)

  Motohiro Kato, Atsushi Manabe, Akiko M. Saito, Katsuyoshi Koh, Takeshi Inukai, Chitose Ogawa, Hiroyuki Goto, Masahiro Tsuchida, Akira Ohara

  INTERNATIONAL JOURNAL OF HEMATOLOGY 101 (1) 52 - 57 0925-5710 2015/01 [Refereed][Not invited]
   

  Relapse period is strongly associated with second relapse risk in relapsed acute lymphoblastic leukemia (ALL) in children. In this context, the treatment outcome of very late relapse should be better; however, data regarding very late relapse is limited. We retrospectively analyzed the outcomes of two consecutive Tokyo Children's Cancer Study Group (TCCSG) ALL trials (1995-2004) with a focus on late relapse, which was divided into two categories: late relapse (6-24 months from the end of therapy, n = 48) and very late relapse (> 24 months from the end of therapy, n = 57). Forty-three patients (29 late relapse and 14 very late relapse) received allogeneic hematopoietic stem cell transplantation (HSCT) at second remission. The event-free survival (EFS) probabilities of late relapse and very late relapse were 54.5 +/- A 7.3 and 64.8 +/- A 6.8 % at 7 years, respectively (P = 0.36), and were not significantly different. However, the second relapse incidence of late relapse (34.7 +/- A 7.1 %) was higher than that of very late relapse (15.5 +/- A 5.1 %, P = 0.03). The second relapse risk was low for very late relapse ALL, which suggests that these patients should be treated without allogeneic HSCT.
• Criteria for evaluating response and outcome in clinical trials for children with juvenile myelomonocytic leukemia

  Charlotte M. Niemeyer, Mignon L. Loh, Annamaria Cseh, Todd Cooper, Christopher C. Dvorak, Rebecca Chan, Blanca Xicoy, Ulrich Germing, Seiji Kojima, Atsushi Manabe, Michael Dworzak, Barbara De Moerloose, Jan Stary, Owen P. Smith, Riccardo Masetti, Albert Catala, Eva Bergstraesser, Marek Ussowicz, Oskana Fabri, Andre Baruchel, Helene Cave, Michel Zwaan, Franco Locatelli, Henrik Hasle, Marry M. van den Heuvel-Eibrink, Christian Flotho, Ayami Yoshimi

  HAEMATOLOGICA 100 (1) 17 - 22 0390-6078 2015/01 [Refereed][Not invited]
   

  Juvenile myelomonocytic leukemia is a rare myeloproliferative disease in young children. While hematopoietic stem cell transplantation remains the only curative therapeutic option for most patients, children with juvenile myelomonocytic leukemia increasingly receive novel agents in phase I-II clinical trials as pre-transplant therapy or therapy for relapse after transplantation. However, response criteria or definitions of outcome for standardized evaluation of treatment effect in patients with juvenile myelomonocytic leukemia are currently lacking. Here we propose criteria to evaluate the response to the non-transplant therapy and definitions of remission status after hematopoietic stem cell transplantation. For the evaluation of non-transplant therapy, we defined 6 clinical variables (white blood cell count, platelet count, hematopoietic precursors and blasts in peripheral blood, bone marrow blast percentage, spleen size and extramedullary disease) and 3 genetic variables (cytogenetic, molecular and chimerism response) which serve to describe the heterogeneous picture of response to therapy in each individual case. It is hoped that these criteria will facilitate the comparison of results between clinical trials in juvenile myelomonocytic leukemia.
• Criteria for evaluating response and outcome in clinical trials for children with juvenile myelomonocytic leukemia

  Charlotte M. Niemeyer, Mignon L. Loh, Annamaria Cseh, Todd Cooper, Christopher C. Dvorak, Rebecca Chan, Blanca Xicoy, Ulrich Germing, Seiji Kojima, Atsushi Manabe, Michael Dworzak, Barbara De Moerloose, Jan Starý, Owen P. Smith, Riccardo Masetti, Albert Catala, Eva Bergstraesser, Marek Ussowicz, Oskana Fabri, André Baruchel, Hélène Cavé, Michel Zwaan, Franco Locatelli, Henrik Hasle, Marry M. Van Den Heuvel-Eibrink, Christian Flotho, Ayami Yoshimi

  Haematologica 100 (1) 17 - 22 1592-8721 2015 [Refereed][Not invited]
   

  Juvenile myelomonocytic leukemia is a rare myeloproliferative disease in young children. While hematopoietic stem cell transplantation remains the only curative therapeutic option for most patients, children with juvenile myelomonocytic leukemia increasingly receive novel agents in phase I-II clinical trials as pre-transplant therapy or therapy for relapse after transplantation. However, response criteria or definitions of outcome for standardized evaluation of treatment effect in patients with juvenile myelomonocytic leukemia are currently lacking. Here we propose criteria to evaluate the response to the non-transplant therapy and definitions of remission status after hematopoietic stem cell transplantation. For the evaluation of non-transplant therapy, we defined 6 clinical variables (white blood cell count, platelet count, hematopoietic precursors and blasts in peripheral blood, bone marrow blast percentage, spleen size and extramedullary disease) and 3 genetic variables (cytogenetic, molecular and chimerism response) which serve to describe the heterogeneous picture of response to therapy in each individual case. It is hoped that these criteria will facilitate the comparison of results between clinical trials in juvenile myelomonocytic leukemia.
• Dosage of oral methotrexate/6-mercaptopurine in the maintenance treatment of childhood acute lymphoblastic leukemia: a single-center experience

  Utano Tomoyuki, Tanaka Yoichi, Kizu Junko, Kamiya Takahiro, Ogawa Chitose, Ishida Yasushi, Hosoya Ryota, Manabe Atsushi

  The Japanese Journal of Pediatric Hematology / Oncology 日本小児血液・がん学会 52 (5) 399 - 404 2187-011X 2015 [Not refereed][Not invited]
   

  Background. Mercaptopurine (6-MP) and methotrexate (MTX) form the backbone of maintenance therapy for childhood acute lymphoblastic leukemia (ALL). It is widely noted that the inter- and intrapatient variations in the clinical efficacy and adverse effects of 6-MP and MTX are enormous, and optimal dosage varies considerably. The aim of this study was to elucidate the factors that affect the optimal
• Long-Term Outcome of Six Months Maintenance Chemotherapy for ALL in Children: An Extended Follow up Study of TCCSG L92-13

  Motohiro Kato, Atsushi Manabe, Sae Ishimaru, Daisuke Tomizawa, Daisuke Hasegawa, Takeshi Inukai, Yuki Arakawa, Takahiro Aoki, Mayuko Okuya, Kiyohiko Kaizu, Keisuke Kato, Yuichi Taneyama, Katsuyoshi Koh, Masahiro Tsuchida, Akira Ohara

  BLOOD 124 (21) 0006-4971 2014/12 [Refereed][Not invited]
  
• Hematopoietic Stem Cell Transplantation for Patients with Refractory Cytopenia of Childhood

  Daisuke Hasegawa, Shinsuke Hirabayashi, Shizuka Watanabe, Yuji Zaike, Masahiro Tsuchida, Atsuko Masunaga, Ayami Yoshimi, Asahito Hama, Seiji Kojima, Masafumi Ito, Tatsutoshi Nakahata, Atsushi Manabe

  BLOOD 124 (21) 0006-4971 2014/12 [Refereed][Not invited]
  
• 集学的治療を行った仙尾部原発卵黄嚢腫瘍の1例

  上野 浩生, 長谷川 大輔, 辻本 信一, 小野 林太郎, 吉本 優里, 細谷 要介, 吉原 宏樹, 熊本 忠史, 川野 孝文, 迫田 晃子, 野崎 太希, 関口 建次, 中面 哲也, 真部 淳

  日本小児血液・がん学会雑誌 (NPO)日本小児血液・がん学会 51 (5) 569  2187-011X 2014/12 [Not refereed][Not invited]
  
• Cytogenetics and clinical features of pediatric myelodysplastic syndrome in Japan

  Koichi Moriwaki, Atsushi Manabe, Takeshi Taketani, Akira Kikuchi, Tatsutoshi Nakahata, Yasuhide Hayashi

  INTERNATIONAL JOURNAL OF HEMATOLOGY 100 (5) 478 - 484 0925-5710 2014/11 [Refereed][Not invited]
   

  We analyzed the cytogenetics and clinical features of pediatric myelodysplastic syndrome (MDS) in Japan. Data on patients (<16 years) diagnosed with MDS from 1990 to 2000 were retrospectively collected from pediatric hematologists in 234 institutions. Chromosome analysis was successfully performed in 255 of 277 MDS patients. The numbers of patients with refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess of blasts (RAEB), refractory anemia with excess of blasts in transformation (RAEBt), chronic myelomonocytic leukemia, and juvenile myelomonocytic leukemia were 67 (24 %), 51 (18 %), 51 (18 %), 20 (7 %), and 65 (23 %), respectively. The other 23 patients (8 %) could not be classified specifically. The distribution of childhood MDS in Japan according to the French-American-British subclassification was similar to that in other countries. However, we identified a higher incidence of therapy-related cases. As for relationship between cytogenetics and prognoses, abnormal karyotypes were related to poorer prognoses than normal karyotype (P < 0.01). However, patients with trisomy 8 had prognoses comparable to those with normal karyotypes. Complex karyotypes were associated with poorer prognoses among RAEB and RAEBt patients. In conclusion, prognosis of pediatric MDS is related to cytogenetics. A more precise diagnosis and classification system is needed for childhood MDS.
• 【難治性貧血-診断と病態・治療の進歩-】 小児科領域貧血の診断と病態・治療の進歩 先天性疾患

  真部 淳

  最新医学 (株)最新医学社 69 (11) 2159  0370-8241 2014/11 [Not refereed][Not invited]
   

  小児の先天性骨髄不全は,頻度はまれながら多くの疾患がある.先天性骨髄不全症候群は臨床症状や通常の臨床検査では診断が困難であり,遺伝子の検索が重要であるが,近年多くの疾患で責任遺伝子が同定されてきた.小児の先天性骨髄不全症候群は再生不良性貧血あるいは骨髄異形成症候群とのオーバーラップも多く,中央診断を通じた丁寧な診断と多施設共同治療研究が必須である.(著者抄録)
• 無症候の母から出生した新生児ループスの1例

  岡崎 幹子, 吉本 優里, 代田 惇朗, 石田 悠志, 島袋 林秀, 稲井 郁子, 小澤 美和, 草川 功, 真部 淳

  日本小児科学会雑誌 (公社)日本小児科学会 118 (11) 1667  0001-6543 2014/11 [Not refereed][Not invited]
  
• 【急性リンパ性白血病をめぐる最近の進歩】 小児急性リンパ性白血病の治療戦略

  石田 悠志, 真部 淳

  血液内科 (有)科学評論社 69 (5) 637  2185-582X 2014/11 [Not refereed][Not invited]
  
• 小児がん診断後の二次がん発症に関する疫学研究 15病院における後ろ向きコホート(Secondary cancers after cancer diagnosis in childhood: A hospital-based retrospective cohort study in Japan)

  石田 也寸志, 邱 冬梅, 前田 美穂, 藤本 純一郎, 気賀沢 寿人, 小林 良二, 佐藤 真穂, 岡村 純, 吉永 信治, 力石 健, 七野 浩之, 清谷 知賀子, 工藤 寿子, 浅見 恵子, 堀 浩樹, 川口 浩史, 稲田 浩子, 足立 壮一, 真部 淳, 黒田 達夫

  日本小児血液・がん学会雑誌 51 (4) 261 - 261 2187-011X 2014/10
• 小児がん患児のきょうだいと母親のサポート知覚の特徴

  長尾 愛美, 小澤 美和, 小川 祐子, 武井 優子, 竹内 恵美, 長谷川 由美, 真部 淳, 鈴木 伸一

  日本小児血液・がん学会雑誌 (一社)日本小児血液・がん学会 51 (4) 375 - 375 2187-011X 2014/10
• 長期入院中の兄弟に対する集学的サポート(part 1) PedsQL 4.0総合コア尺度を用いた兄弟のQOL評価(Multidisciplinary support for siblings of long-term inpatients(part 1): Evaluation of siblings' quality of life using the PedsQL 4.0 Generic Core Scales)

  野村 耕太郎, 若林 優, 植松 温子, 春山 智恵子, 三浦 絵莉子, 石田 智美, 後藤 真弥, 北川 千恵, 山本 光映, 小澤 美和, 真部 淳

  日本小児血液・がん学会雑誌 (NPO)日本小児血液・がん学会 51 (4) 375 - 375 2187-011X 2014/10 [Not refereed][Not invited]
  
• 高機能自閉症スペクトラム障害を抱える3歳男児の、入院中の心理的支援 骨髄移植をチームで支える

  阿佐美 百合子, 春山 智恵子, 後藤 真弥, 北川 知恵, 熊谷 祐美, 平田 美佳, 山本 光映, 小澤 美和, 長谷川 大輔, 真部 淳

  日本小児血液・がん学会雑誌 (NPO)日本小児血液・がん学会 51 (4) 374  2187-011X 2014/10 [Not refereed][Not invited]
  
• 神経下垂体部胚細胞腫瘍の化学療法中に点鼻あるいは経口デスモプレシン製剤を用いて尿崩症管理を行った5例

  木村 俊介, 細谷 要介, 石田 悠志, 野村 耕太郎, 吉本 優里, 吉原 宏樹, 長谷川 大輔, 伊藤 純子, 真部 淳

  日本小児血液・がん学会雑誌 (NPO)日本小児血液・がん学会 51 (4) 335  2187-011X 2014/10 [Not refereed][Not invited]
  
• 小児がん患者における長期留置型中心静脈カテーテル合併症のリスクファクターについて(Risk factors of long-term central venous catheters (CVCS) complication in children with hemato-oncological disorders)

  迫田 晃子, 川野 孝文, 細谷 要介, 吉原 宏樹, 平林 真介, 長谷川 大輔, 小澤 美和, 真部 淳, 松藤 凡

  日本小児血液・がん学会雑誌 (NPO)日本小児血液・がん学会 51 (4) 334 - 334 2187-011X 2014/10 [Not refereed][Not invited]
  
• 当院で経験した神経芽腫Stage 4Sの2例

  吉本 優里, 野村 耕太郎, 石田 悠志, 平林 真介, 細谷 要介, 吉原 宏樹, 長谷川 大輔, 細谷 亮太, 真部 淳

  日本小児血液・がん学会雑誌 (NPO)日本小児血液・がん学会 51 (4) 287  2187-011X 2014/10 [Not refereed][Not invited]
  
• 急性前骨髄球性白血病M3 variantの2例

  石田 悠志, 松井 俊大, 木村 俊介, 野村 耕太郎, 吉本 優里, 平林 真介, 細谷 要介, 吉原 宏樹, 長谷川 大輔, 熊本 忠史, 真部 淳

  日本小児血液・がん学会雑誌 (NPO)日本小児血液・がん学会 51 (4) 269  2187-011X 2014/10 [Not refereed][Not invited]
  
• 多職種による長期入院児のきょうだい支援(part 2) きょうだいと医療者、きょうだい同士をつなげる取り組み(Multidisciplinary team approach to sibling support: The bridge-building of siblings, and of siblings and medical staff)

  若林 優, 植松 温子, 春山 智恵子, 三浦 絵莉子, 石田 智美, 後藤 真弥, 北川 千恵, 野村 耕太郎, 山本 光映, 真部 淳, 小澤 美和

  日本小児血液・がん学会雑誌 (NPO)日本小児血液・がん学会 51 (4) 259 - 259 2187-011X 2014/10 [Not refereed][Not invited]
  
• 小児がん患者における精神身体症状発現のリスク因子の検討(Risk factors for psychosomatic symptoms among pediatric cancer patients)

  前田 謙一, 辻本 信一, 長谷川 大輔, 浦山 ケビン, 阿佐美 百合子, 小澤 美和, 真部 淳

  日本小児血液・がん学会雑誌 (NPO)日本小児血液・がん学会 51 (4) 258 - 258 2187-011X 2014/10 [Not refereed][Not invited]
  
• 消化管出血を伴う青色ゴムまり様母斑症候群の乳児例(An infant of blue rubber bleb nevus syndrome with gastrointestinal bleeding)

  平林 真介, 栗山 絢子, 石田 悠志, 吉本 優里, 細谷 要介, 吉原 宏樹, 川野 孝文, 迫田 晃子, 森田 有香, 中村 仁美, 衛藤 光, 鈴木 高祐, 末延 聡一, 長谷川 大輔, 真部 淳

  日本小児血液・がん学会雑誌 (NPO)日本小児血液・がん学会 51 (4) 242  2187-011X 2014/10 [Not refereed][Not invited]
  
• 【小児血液疾患-よくわかる最新知見-】 造血器悪性疾患 若年性骨髄単球性白血病

  平林 真介, 真部 淳

  小児科 金原出版(株) 55 (11) 1745  0037-4121 2014/10 [Not refereed][Not invited]
  
• Genomic evaluations of childhood acute lymphoblastic leukemia susceptibility across race/ethnicities

  URAYAMA Kevin Y, MANABE Atsushi

  Rinsho Ketsueki The Japanese Society of Hematology 55 (10) 2242 - 2248 0485-1439 2014/10 [Refereed][Not invited]
  
• Clinical characteristics and treatment outcome in 65 cases with refractory cytopenia of childhood defined according to the WHO 2008 classification

  Daisuke Hasegawa, Xiaojuan Chen, Shinsuke Hirabayashi, Yasushi Ishida, Shizuka Watanabe, Yuji Zaike, Masahiro Tsuchida, Atsuko Masunaga, Ayami Yoshimi, Asahito Hama, Seiji Kojima, Masafumi Ito, Tatsutoshi Nakahata, Atsushi Manabe

  BRITISH JOURNAL OF HAEMATOLOGY 166 (5) 758 - 766 0007-1048 2014/09 [Refereed][Not invited]
   

  This study analysed 65 children who were prospectively registered between 1999 and 2008 and fulfilled the World Health Organization 2008 criteria of refractory cytopenia of childhood (RCC). First-line therapy was determined by the treating physicians: 25 patients received immunosuppressive therapy (IST), 12 patients received haematopoietic stem cell transplantation (HSCT) and one patient received intensive chemotherapy. The remaining 27 patients were followed without treatment for more than 2 years (watch and wait; WW). In the WW group, 18 patients had stable disease without further intervention. Thirteen of 29 patients (45%) who ended up receiving IST showed response. The combination of ciclosporin and antithymocyte globulin was not shown to be superior to ciclosporin alone with regard to response rate or survival. Of 28 patients who ended up undergoing HSCT, 17 patients are alive in complete remission, whereas nine patients died mostly due to transplantation-related mortality. The 5-year overall survival for all patients was 82 +/- 5%. Eight patients suffered from disease progression. Patients with monosomy 7 or multilineage-dysplasia had a significantly higher incidence of disease progression. This analysis revealed heterogeneity in the clinical course of RCC, varying from those who remained stable for long periods to those who progressed to advanced disease.
• Clinical characteristics and treatment outcome in 65 cases with refractory cytopenia of childhood defined according to the WHO 2008 classification.

  Daisuke Hasegawa, Xiaojuan Chen, Shinsuke Hirabayashi, Yasushi Ishida, Shizuka Watanabe, Yuji Zaike, Masahiro Tsuchida, Atsuko Masunaga, Ayami Yoshimi, Asahito Hama, Seiji Kojima, Masafumi Ito, Tatsutoshi Nakahata, Atsushi Manabe

  British journal of haematology 166 (5) 758 - 66 1365-2141 2014/09 [Refereed][Not invited]
   

  This study analysed 65 children who were prospectively registered between 1999 and 2008 and fulfilled the World Health Organization 2008 criteria of refractory cytopenia of childhood (RCC). First-line therapy was determined by the treating physicians: 25 patients received immunosuppressive therapy (IST), 12 patients received haematopoietic stem cell transplantation (HSCT) and one patient received intensive chemotherapy. The remaining 27 patients were followed without treatment for more than 2 years (watch and wait; WW). In the WW group, 18 patients had stable disease without further intervention. Thirteen of 29 patients (45%) who ended up receiving IST showed response. The combination of ciclosporin and antithymocyte globulin was not shown to be superior to ciclosporin alone with regard to response rate or survival. Of 28 patients who ended up undergoing HSCT, 17 patients are alive in complete remission, whereas nine patients died mostly due to transplantation-related mortality. The 5-year overall survival for all patients was 82 ± 5%. Eight patients suffered from disease progression. Patients with monosomy 7 or multilineage-dysplasia had a significantly higher incidence of disease progression. This analysis revealed heterogeneity in the clinical course of RCC, varying from those who remained stable for long periods to those who progressed to advanced disease.
• Treatment outcomes of adolescent acute lymphoblastic leukemia treated on Tokyo Children's Cancer Study Group (TCCSG) clinical trials

  Motohiro Kato, Atsushi Manabe, Katsuyoshi Koh, Takeshi Inukai, Nobutaka Kiyokawa, Takashi Fukushima, Hiroaki Goto, Daisuke Hasegawa, Chitose Ogawa, Kazutoshi Koike, Setsuo Ota, Yasushi Noguchi, Akira Kikuchi, Masahiro Tsuchida, Akira Ohara

  INTERNATIONAL JOURNAL OF HEMATOLOGY 100 (2) 180 - 187 0925-5710 2014/08 [Refereed][Not invited]
   

  There is no standard treatment for adolescents aged 15 years or older with acute lymphoblastic leukemia (ALL), although this age group has been reported as having a poorer prognosis compared to younger patients. We retrospectively analyzed the outcomes of three consecutive Tokyo Children's Cancer Study Group ALL trials (1995-2006) of 373 patients aged 10 years or older, with particular focus on adolescents aged 15-18 years (older-adolescents n = 41), compared to those aged 10-14 years (younger-adolescents n = 332). The probability of event-free survival at 8 years was 67.5 +/- A 7.4 % for the older-adolescents and 66.5 +/- A 2.6 % for the younger-adolescents (p = 0.95). Overall survival was 70.7 +/- A 7.1 % for the older-adolescents and 74.3 +/- A 2.4 % for the younger-adolescents (p = 0.48). The differences between groups in relapse incidence, non-relapse mortality, and death rate during induction were not statistically significant, although the older-adolescents trended towards a higher frequency of having stem-cell transplantation during the first remission. In conclusion, our treatment strategy, which consists of intensive induction and block-type consolidation, provided improved outcomes for patients aged 15-18 years, comparable to those for patients aged 10-14 years.
• Prognostic impact of gained chromosomes in high-hyperdiploid childhood acute lymphoblastic leukaemia: a collaborative retrospective study of the Tokyo Children's Cancer Study Group and Japan Association of Childhood Leukaemia Study

  Motohiro Kato, Toshihiko Imamura, Atsushi Manabe, Yoshiko Hashii, Katsuyoshi Koh, Atsushi Sato, Hiroyuki Takahashi, Hiroki Hori, Tomohiko Taki, Masami Inoue, Yasuhide Hayashi, Keizo Horibe, Masahiro Tsuchida, Seiji Kojima, Megumi Oda, Akira Ohara

  BRITISH JOURNAL OF HAEMATOLOGY 166 (2) 295 - 298 0007-1048 2014/07 [Refereed][Not invited]
  
• Clinicians' perspectives on support for children with a parent who is diagnosed with breast cancer

  Yuko Takei, Miwa Ozawa, Yasushi Ishida, Shin-ichi Suzuki, Shinji Ohno, Atsushi Manabe

  BREAST CANCER 21 (4) 463 - 471 1340-6868 2014/07 [Refereed][Not invited]
   

  There are few data on clinicians' perspectives regarding support for children who have a parent who has been diagnosed with breast cancer. The purpose of this study was to survey the attitudes of physicians and nurses regarding the care of children who had a parent diagnosed with breast cancer. A survey was mailed to 898 physicians and 135 nurses who were members of the Japanese Breast Cancer Society in 2009. They were asked to answer questions about their attitudes toward and current practice regarding care for children who had a parent with breast cancer. A total of 340 surveys (284 physicians and 56 nurses) were used in this analysis. The mean age of the respondents was 47.2 years, and their mean number of years of practice was 21.7 years. While 69.1 % of them reported that they felt it important for people in their roles to provide support for children, 84.4 % felt they could not provide sufficient support. The results also suggested that female gender in practitioners and nurses as opposed to doctor status seemed to be associated with preference for intervention, current practice of intervention, and recognition of difficulty to support. Physicians and nurses express a variety of opinions with regard to support for children with a parent who has breast cancer. It is important to cooperate with other specialists including physicians, nurses, and psychologists and allocate roles appropriately among them to improve outcomes for these children.
• Clinical characteristics of 15 children with juvenile myelomonocytic leukaemia who developed blast crisis: MDS Committee of Japanese Society of Paediatric Haematology/Oncology

  Yuko Honda, Masahiro Tsuchida, Yuji Zaike, Atsuko Masunaga, Ayami Yoshimi, Seiji Kojima, Masafumi Ito, Akira Kikuchi, Tatsutoshi Nakahata, Atsushi Manabe

  BRITISH JOURNAL OF HAEMATOLOGY 165 (5) 682 - 687 0007-1048 2014/06 [Refereed][Not invited]
   

  Juvenile myelomonocytic leukaemia (JMML) is a rare haematopoietic stem cell disease of early childhood, which can progress to blast crisis in some children. A total of 153 children diagnosed with JMML were reported to the Myelodysplastic Syndrome Committee in Japan between 1989 and 2007; 15 of them (9<bold>8</bold>%) had 20% or more blasts in the bone marrow (blast crisis) during the disease course. Blast crisis occurred during observation without therapy (n=3) or with oral 6-mercaptopurine treatment (n=9) and in relapse after haematopoietic stem cell transplantation (HSCT; n=3). Six patients had a complex karyotype (5 including monosomy 7) and an additional three patients had isolated monosomy 7 at blast crisis. Seven patients received HSCT after blast crisis and four of them achieved remission. Eleven out of the 15 patients died; the cause of death was disease progression in 10 patients and transplant-related complication in one patient. In summary, patients with blast crisis have poor prognosis and can be cured only by HSCT. The emergence of monosomy 7 and complex karyotype may be characteristic of blast crisis in a substantial subset of children.
• Methylenetetrahydrofolate reductase gene haplotypes affect toxicity during maintenance therapy for childhood acute lymphoblastic leukemia in Japanese patients

  Yoichi Tanaka, Atsushi Manabe, Hisaya Nakadate, Kensuke Kondoh, Kozue Nakamura, Katsuyoshi Koh, Akira Kikuchi, Takako Komiyama

  LEUKEMIA & LYMPHOMA 55 (5) 1126 - 1131 1042-8194 2014/05 [Refereed][Not invited]
   

  The aim of this study was to investigate the influence of daily 6-mercaptopurine (6-MP) and low-dose weekly methotrexate (MTX) combination treatment and methylenetetrahydrofolate reductase (MTHFR) haplotypes on toxicity during maintenance therapy in Japanese childhood acute lymphoblastic leukemia (ALL). We retrospectively analyzed the MTHFR C677T and A1298C polymorphisms and influence of haplotypes on toxicity in 73 patients. Patients with the MTHFR 677TT and 677CT + 1298AC were associated with severe liver toxicity (p = 0.014, odds ratio [OR] = 3.82, 95% confidence interval [CI] = 1.27-11.46) and more rapid onset of liver toxicity (p = 0.010). Patients with MTHFR 677TT and 677CT + 1298AC were associated with lower frequency of 6-MP and MTX dose reduction due to leukopenia (p < 0.05). No difference was observed in average drug doses in the MTHFR genotypes. In conclusion, the MTHFR C677T and A1298C haplotypes might be useful for monitoring adverse effects in childhood ALL maintenance therapy in Japanese patients.
• 【血管腫・血管奇形2014:診断からIVR・治療まで】画像診断

  野崎 太希, 松迫 正樹, 衛藤 光, 松井 瑞子, 新見 康成, 真部 淳, 草川 功, 鈴木 高祐, 栗原 泰之

  臨床画像 (株)メジカルビュー社 30 (5) 492 - 504 0911-1069 2014/05
• Parents' perception of pediatric cancer centers in Japan

  Sachi Sakaguchi, Megumi Oda, Yuichi Shinkoda, Atsushi Manabe

  PEDIATRICS INTERNATIONAL 56 (2) 196 - 199 1328-8067 2014/04 [Refereed][Not invited]
   

  BackgroundIn Japan, more than 160 hospitals provide care for approximately 2500 pediatric patients diagnosed with cancer each year. Not all hospitals, however, are fully capable of providing state-of-the-art care due to a lack of experienced personnel or up-to-date facilities. The aim of this study was to solicit parents' experiences during their children's cancer treatment and opinions about the centralization of medical resources to core pediatric cancer centers. MethodsA structured questionnaire was sent to parents of children who had received cancer treatment. ResultsEighty-two questionnaires were completed and analyzed. Parents reported a need for improved psychological support for their children and family members as well as accommodation for families during cancer therapy. Most parents had positive opinions about the centralization of medical resources to core centers but were concerned about the accessibility of the centers and increasing burdens placed on families living in remote areas. ConclusionThe demand for psychological care for families during children's cancer treatment is highlighted. Improved accommodation and greater financial and social support for families living in remote areas should be preconditions for the future centralization of core pediatric cancer centers.
• Allogeneic stem cell transplantation for patients with acute myeloid leukaemia developing from severe congenital neutropenia

  Yasuhiro Ebihara, Kumiko Ishikawa, Shinji Mochizuki, Ryuhei Tanaka, Atsushi Manabe, Tohru Iseki, Taira Maekawa, Kohichiro Tsuji

  BRITISH JOURNAL OF HAEMATOLOGY 164 (3) 459 - 461 0007-1048 2014/02 [Refereed][Not invited]
  
• No impact of high-dose cytarabine and asparaginase as early intensification with intermediate-risk paediatric acute lymphoblastic leukaemia: results of randomized trial TCCSG study L99-15

  Motohiro Kato, Katsuyoshi Koh, Atsushi Manabe, Tomohiro Saito, Daisuke Hasegawa, Keiichi Isoyama, Akitoshi Kinoshita, Miho Maeda, Yuri Okimoto, Michiko Kajiwara, Takashi Kaneko, Kanji Sugita, Akira Kikuchi, Masahiro Tsuchida, Akira Ohara

  BRITISH JOURNAL OF HAEMATOLOGY 164 (3) 376 - 383 0007-1048 2014/02 [Refereed][Not invited]
   

  The Tokyo Children's Cancer Study Group conducted a randomized controlled study to evaluate the effect of experimental early intensification using high-dose cytarabine and L-asparaginase in paediatric intermediate-risk (IR) acute lymphoblastic leukaemia (ALL). A total of 310 IR ALL patients were randomized to receive either experimental early intensification (n=156) or standard early intensification including standard-dose cytarabine arm (n=154) after induction therapy. The experimental arm consisted of high-dose cytarabine and L-asparaginase, while the standard arm consisted of standard-dose cytarabine, oral 6-mercaptopurine and cyclophosphamide. The probabilities of event-free survival at 8years in the experimental and standard arms were 723 +/- 37% and 775 +/- 35%, respectively (P=032). The 8-year overall survival rates for these two arms were 850 +/- 30% and 869 +/- 28%, respectively (P=072). The frequency of infectious events was significantly higher in the experimental arm (664%) than in the standard arm (246%) (P<0001). In conclusion, experimental early intensification including high-dose cytarabine followed by L-asparaginase had no advantage over standard early intensification in paediatric IR ALL patients.
• 蛋白漏出性胃腸症で発症したHenoch-Schoenlein紫斑病の一例

  孫 楽, 吉本 優里, 小野 林太郎, 長谷川 大輔, 小澤 美和, 真部 淳, 草川 功

  日本小児科学会雑誌 (公社)日本小児科学会 118 (2) 398 - 398 0001-6543 2014/02
• 熱性痙攣に対する抗ヒスタミン薬の影響についての検討

  辻本 信一, 吉本 優里, 小野 林太郎, 小澤 美和, 真部 淳, 草川 功, 石田 也寸志, 荻原 正明

  日本小児科学会雑誌 (公社)日本小児科学会 118 (2) 230 - 230 0001-6543 2014/02
• Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group

  Trudy D. Buitenkamp, Shai Izraeli, Martin Zimmermann, Erik Forestier, Nyla A. Heerema, Marry M. van den Heuvel-Eibrink, Rob Pieters, Carin M. Korbijn, Lewis B. Silverman, Kjeld Schmiegelow, Der-Cheng Liang, Keizo Horibe, Maurizio Arico, Andrea Biondi, Giuseppe Basso, Karin R. Rabin, Martin Schrappe, Gunnar Cario, Georg Mann, Maria Morak, Renate Panzer-Grumayer, Veerle Mondelaers, Tim Lammens, Helene Cave, Batia Stark, Ithamar Ganmore, Anthony V. Moorman, Ajay Vora, Stephen P. Hunger, Ching-Hon Pui, Charles G. Mullighan, Atsushi Manabe, Gabriele Escherich, Jerzy R. Kowalczyk, James A. Whitlock, C. Michel Zwaan

  BLOOD 123 (1) 70 - 77 0006-4971 2014/01 [Refereed][Not invited]
   

  Children with Down syndrome (DS) have an increased risk of B-cell precursor (BCP) acute lymphoblastic leukemia (ALL). The prognostic factors and outcome of DS-ALL patients treated in contemporary protocols are uncertain. We studied 653 DS-ALL patients enrolled in 16 international trials from 1995 to 2004. Non-DS BCP-ALL patients from the Dutch Child Oncology Group and Berlin-Frankfurt-Munster were reference cohorts. DS-ALL patients had a higher 8-year cumulative incidence of relapse (26% +/- 2% vs 15% +/- 1%, P < .001) and 2-year treatment-related mortality (TRM) (7% +/- 1% vs 2.0% +/- < 1%, P < .0001) than non-DS patients, resulting in lower 8-year event-free survival (EFS) (64% +/- 2% vs 81% +/- 2%, P < .0001) and overall survival (74% +/- 2% vs 89% +/- 1%, P < .0001). Independent favorable prognostic factors include age <6 years (hazard ratio [HR] = 0.58, P = .002), white blood cell (WBC) count <10 x 10(9)/L (HR = 0.60, P = .005), and ETV6-RUNX1 (HR = 0.14, P = .006) for EFS and age (HR = 0.48, P < .001), ETV6-RUNX1 (HR = 0.1, P = .016) and high hyperdiploidy (HeH) (HR = 0.29, P = .04) for relapse-free survival. TRM was the major cause of death in ETV6-RUNX1 and HeH DS-ALLs. Thus, while relapse is the main contributor to poorer survival in DS-ALL, infection-associated TRM was increased in all protocol elements, unrelated to treatment phase or regimen. Future strategies to improve outcome in DS-ALL should include improved supportive care throughout therapy and reduction of therapy in newly identified good-prognosis subgroups.
• 血液検査所見が正常で骨病変にて発見されたB前駆細胞性急性リンパ性白血病(ALL)の1例

  原 朋子, 長谷川 大輔, 小野 林太郎, 居石 崇志, 吉本 優里, 上野 浩生, 細谷 要介, 吉原 宏樹, 真部 淳

  日本小児科学会雑誌 (公社)日本小児科学会 118 (1) 77 - 77 0001-6543 2014/01
• Significance of CD66c expression in childhood acute lymphoblastic leukemia

  Nobutaka Kiyokawa, Kazutoshi Iijima, Osamu Tomita, Masashi Miharu, Daisuke Hasegawa, Kenichiro Kobayashi, Hajime Okita, Michiko Kajiwara, Hiroyuki Shimada, Takeshi Inukai, Atsushi Makimoto, Toru Nanmoku, Katsuyoshi Koh, Atsushi Manabe, Akira Kikuchi, Junichiro Fujimoto, Yasuhicie Hayashi, Akira Ohara

  LEUKEMIA RESEARCH 38 (1) 42 - 48 0145-2126 2014/01 [Refereed][Not invited]
   

  Upon analyze in 695 childhood B-cell precursor acute lymphoblastic leukemia (BCP-ALL) cases, we identified the characteristics of CD36c expression. In addition to the confirmation of wrong correlation with BCR-ABL positivity and hyperdiploid, we further observed that CD66c is frequently expressed in CRLF2-positive (11/15, p < 0.01 against chiineric gene-negative foss ell as hypediploid cases (314 whereas Sic never expressed in ETVA-RUNX1 MLL-AF4, MLL-AF9, MLL-ENL, and E2A-PBX1-positive cases, Although the expression CD66c itself is not directly linked to the prognosis, the accompanying genetic abnormalities are important prognostic factors for BC P-ALL indicating the importance of CD66c expression in the initial diagnosis of BCP-ALL. (C) 2013 Elsevier Ltd. All rights reserved.
• Significance of CD66c expression in childhood acute lymphoblastic leukemia

  Nobutaka Kiyokawa, Kazutoshi Iijima, Osamu Tomita, Masashi Miharu, Daisuke Hasegawa, Kenichiro Kobayashi, Hajime Okita, Michiko Kajiwara, Hiroyuki Shimada, Takeshi Inukai, Atsushi Makimoto, Takashi Fukushima, Toru Nanmoku, Katsuyoshi Koh, Atsushi Manabe, Akira Kikuchi, Kanji Sugita, Junichiro Fujimoto, Yasuhide Hayashi, Akira Ohara

  Leukemia Research 38 (1) 42 - 48 0145-2126 2014/01 [Refereed][Not invited]
   

  Upon analyzing 696 childhood B-cell precursor acute lymphoblastic leukemia (BCP-ALL) cases, we identified the characteristics of CD66c expression. In addition to the confirmation of strong correlation with BCR-ABL positivity and hyperdiploid, we further observed that CD66c is frequently expressed in CRLF2-positive (11/15, p < 0.01 against chimeric gene-negative) as well as hypodiploid cases (3/4), whereas it is never expressed in ETV6-RUNX1, MLL-AF4, MLL-AF9, MLL-ENL, and E2A-PBX1-positive cases. Although the expression of CD66c itself is not directly linked to the prognosis, the accompanying genetic abnormalities are important prognostic factors for BCP-ALL, indicating the importance of CD66c expression in the initial diagnosis of BCP-ALL. © 2013 Elsevier Ltd.
• Imaging of vascular tumors with an emphasis on ISSVA classification

  Taiki Nozaki, Masaki Matsusako, Hidefumi Mimura, Keigo Osuga, Mizuko Matsui, Hikaru Eto, Naoyuki Ohtake, Atsushi Manabe, Isao Kusakawa, Yoshiyuki Tsutsumi, Shunsuke Nosaka, Minobu Kamo, Yukihisa Saida

  JAPANESE JOURNAL OF RADIOLOGY 31 (12) 775 - 785 1867-1071 2013/12 [Refereed][Not invited]
   

  The International Society for the Study of Vascular Anomalies (ISSVA) classification is becoming the international standard classification system for vascular tumors and vascular malformations. The ISSVA classification strictly distinguishes vascular tumors (neoplastic lesions) from vascular malformations (non-neoplastic lesions) based on whether there is a proliferation of vascular endothelial cells present, and it is an extremely useful classification system for determining therapeutic measures. For vascular tumors, it is clinically significant in terms of discriminating infantile hemangioma and rapidly involuting congenital hemangioma, which are expected to spontaneously regress, from other vascular tumors requiring treatment. Needless to say, clinical courses are important for diagnosis, and it is also important for radiologists to understand imaging findings on vascular tumors because such tumors have unique findings on diagnostic images. In this paper, vascular tumors are classified based on the ISSVA classification, and clinical and imaging findings are reviewed.
• 【小児の痛みについて考える】小児の疼痛の緩和 小児がん性疼痛治療

  小澤 美和, 真部 淳

  小児科臨床 (株)日本小児医事出版社 66 (12) 2541 - 2547 0021-518X 2013/12
• Significance Of Minimal Residual Disease Detected By Multi-Color Flow Cytometry In Childhood Acute Myeloid Leukemia With The Intermideate-Risk Cytogenetics and Negative FMS-Like Tyrosine Kinase 3 Internal Tandem Duplication: A Report Of The Tokyo Children's Cancer Study Group

  Dai Keino, Akitoshi Kinoshita, Daisuke Tomizawa, Hiroyuki Takahashi, Kohmei Ida, Hidemitsu Kurosawa, Kazutoshi Koike, Setsuo Ota, Noriyuki Iwasaki, Junya Fujimura, Yuki Yuza, Chikako Kiyotani, Shohei Yamamoto, Tomoo Osumi, Takahiro Ueda, Shinji Mochizuki, Keiichi Isoyama, Ryoji Hanada, Akio Tawa, Akira Kikuchi, Atsushi Manabe, Akira Ohara

  Blood 122 (21) 1416 - 1416 0006-4971 2013/11/15 

  Abstract Background Response to induction chemotherapy is one of the most important predictors of outcome in acute myeloid leukemia (AML) as well as cytogenetics and molecular genetics. Measurement of minimal residual disease (MRD) by flow cytometry is an informative method for assessment of initial treatment response, but the heterogeneity of leukemia-associated antigens and antigen shifts during treatment limit its sensitivity and specificity. We prospectively evaluated the prognostic prevalence of MRD monitoring using multi-color flow cytometry in children with AML treated on the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) AML-05 trial. Patients and methods From January 2007 to October 2010, 34 children with newly diagnosed de novo AML were enrolled on the AML-MRD study conducted by the Tokyo Children's Cancer Study Group. The median age at the diagnosis was 8 years (1 month- 15 years), and 17 patients were boys and 17 were girls. They were all treated with the JPLSG AML-05 trial. In AML-05, enrolled patients received two induction courses and those achieving a complete remission (CR) were treated according to risk classification at which all the core binding factor-AML cases and good initial response based on morphology after induction 1 were assigned to low risk (LR) group, cases presented with FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD), unfavorable cytogenetics including monosomy7, 5q-,t(16;21), and with poor initial response were assigned to high risk (HR) group, the others were assigned to intermediate risk (IR) group. Allogeneic hematopoietic stem cell transplantation (HSCT) was indicated for the HR patients after the third or later treatment courses. Among the 34 patients enrolled on the AML-MRD study, 8 presented with LR, 22 with IR, and 4 with HR regarding the cytogenetics and FLT3-ITD status. MRD of 63 bone marrow samples were analyzed after induction 1 (BMA-2) and induction 2 (BMA-3) by four-color flow cytometry using 9 AML-associated antigens. A threshold level for MRD-positivity was set at the point of 0.1%. Results Sixty-two (98.4%) of 63 bone marrow samples were evaluable for MRD. Thirteen (39.4%) of 33 samples and 8 (27.6%) of 29 showed MRD-positivity at BMA-2 and BMA-3 respectively. Among the patients with MRD-positivity, 12 at BMA-2 and 7 at BMA-3 were diagnosed as achieving CR by morphology. MRD was associated neither specific FAB subtype nor white blood cell count at diagnosis, but all 3 patients with FLT3-ITD showed the MRD-positivity at BMA-2. Although 3-year probability of event free survival (3-yr EFS) at BMA-2 or BMA-3 was similar between patients with and without MRD; 53.8% (n= 13) vs 70.0% (n= 20) (p=0.30) and 50.0% (n= 8)vs 62.0%(n= 21) (p=0.36), respectively, 3-yr EFS of those with MRD at BMA-2 or BMA-3 was significantly worse compared to those without MRD; 33.3% (n= 9) vs 83.3% (n= 12) (p=0.02) and 20.0%(n= 5) vs 76.9% (n= 13) (p=0.04), respectively, in the group of the IR cytogenetics and negative FLT3-ITD. Multivariate analysis indicated that the MRD detected by multi-color flow cytometry was solely associated with worse outcome in this group. Conclusion Highly sensitive detection of MRD by multi-color flow cytometry was possible in children with AML. The present study suggests that MRD monitoring may have a prognostic relevance in childhood AML with the IR cytogenetics and negative FLT3-ITD. Disclosures: No relevant conflicts of interest to declare.
• 骨病変が先行して発症した急性リンパ性白血病の4例

  原 朋子, 長谷川 大輔, 野崎 太希, 小野 林太郎, 吉本 優里, 上野 浩生, 細谷 要介, 吉原 宏樹, 熊本 忠志, 細谷 亮太, 真部 淳

  日本小児血液・がん学会学術集会・日本小児がん看護学会・公益財団法人がんの子どもを守る会公開シンポジウムプログラム総会号 (NPO)日本小児血液・がん学会・(NPO)日本小児がん看護学会・(公財)がんの子供を守る会 55回・11回・18回 284 - 284 2013/11
• MDSに血球貪食症候群を合併し、移植後自己造血回復状態となるも異常クローンを認めず経過観察している1例

  上野 浩生, 石田 悠志, 小野 林太郎, 吉本 優里, 細谷 要介, 吉原 宏樹, 長谷川 大輔, 大島 久美, 熊本 忠史, 森 慎一郎, 細谷 亮太, 真部 淳

  日本小児血液・がん学会学術集会・日本小児がん看護学会・公益財団法人がんの子どもを守る会公開シンポジウムプログラム総会号 (NPO)日本小児血液・がん学会・(NPO)日本小児がん看護学会・(公財)がんの子供を守る会 55回・11回・18回 328 - 328 2013/11
• 初期治療反応性が不良で早期再発を来したDown症候群合併急性巨核芽球性白血病(DS-AMKL)例

  吉本 優里, 小野 林太郎, 上野 浩生, 細谷 要介, 吉原 宏樹, 長谷川 大輔, 小澤 美和, 熊本 忠史, 森 愼一郎, 澤田 明久, 井上 雅美, 細谷 亮太, 真部 淳

  日本小児血液・がん学会学術集会・日本小児がん看護学会・公益財団法人がんの子どもを守る会公開シンポジウムプログラム総会号 (NPO)日本小児血液・がん学会・(NPO)日本小児がん看護学会・(公財)がんの子供を守る会 55回・11回・18回 249 - 249 2013/11
• Ultra low-dose cytarabine(Ara-C)療法で寛解を維持しているDown症合併急性巨核芽球性白血病(DS-AMKL)の一例

  吉本 優里, 吉原 宏樹, 小野 林太郎, 上野 浩生, 細谷 要介, 長谷川 大輔, 熊本 忠史, 小澤 美和, 岩本 彰太郎, 盛武 浩, 細谷 亮太, 真部 淳

  日本小児血液・がん学会学術集会・日本小児がん看護学会・公益財団法人がんの子どもを守る会公開シンポジウムプログラム総会号 (NPO)日本小児血液・がん学会・(NPO)日本小児がん看護学会・(公財)がんの子供を守る会 55回・11回・18回 249 - 249 2013/11
• 寛解状態にある小児がん患者の退院後の生活を支えるソーシャルサポートの特徴

  武井 優子, 小澤 美和, 盛武 浩, 真部 淳, 鈴木 伸一

  日本小児血液・がん学会学術集会・日本小児がん看護学会・公益財団法人がんの子どもを守る会公開シンポジウムプログラム総会号 (NPO)日本小児血液・がん学会・(NPO)日本小児がん看護学会・(公財)がんの子供を守る会 55回・11回・18回 310 - 310 2013/11
• 終末期の子どもをケアする医療者へのグリーフケアの検討

  鳥山 祐子, 齊藤 由華, 小川 恵里子, 植松 温子, 清藤 育子, 高嶋 希世子, 西野 理英, 関冨 晶子, 吉原 宏樹, 小澤 美和, 真部 淳, 細谷 亮太

  日本小児血液・がん学会学術集会・日本小児がん看護学会・公益財団法人がんの子どもを守る会公開シンポジウムプログラム総会号 (NPO)日本小児血液・がん学会・(NPO)日本小児がん看護学会・(公財)がんの子供を守る会 55回・11回・18回 374 - 374 2013/11
• ダウン症児の受容過程について理解し合えなかった両親が、白血病で子どもを亡くした後にむかえた夫婦の危機

  清藤 育子, 植松 温子, 小川 恵理子, 鳥山 裕子, 上野 浩生, 長谷川 大輔, 細谷 要介, 小澤 美和, 真部 淳, 細谷 亮太

  日本小児血液・がん学会学術集会・日本小児がん看護学会・公益財団法人がんの子どもを守る会公開シンポジウムプログラム総会号 (NPO)日本小児血液・がん学会・(NPO)日本小児がん看護学会・(公財)がんの子供を守る会 55回・11回・18回 383 - 383 2013/11
• A review series begins: How much do we know about intractable disease?

  Atsushi Manabe

  PEDIATRICS INTERNATIONAL 55 (5) 541 - 541 1328-8067 2013/10 [Refereed][Not invited]
  
• [Molecular biology in childhood acute lymphoblastic leukemia (ALL)].

  Manabe A

  [Rinsho ketsueki] The Japanese journal of clinical hematology The Japanese Society of Hematology 54 (10) 1999 - 2005 0485-1439 2013/10 [Refereed][Not invited]
  
• Availability of 10 color flow cytometry in childhood leukemia MRD detection

  MIHARU Masashi, KIYOKAWA Nobutaka, KOBAYASHI Kenichiro, OKITA Hajime, LIJIMA Kazutoshi, MORI Tetsuya, SAITO Masahiro, FUKUSHIMA Takashi, KO Katsuyoshi, MANABE Atsushi, KIKUCHI Akira, HAYASHI Yasuhide, OHARA Akira

  Cytometry Research 日本サイトメトリー学会 23 (2) 7 - 14 0916-6920 2013/09/25 

  In childhood acute lymphoblastic leukemia (ALL), the clinical significance of minimal residual disease (MRD) has been demonstrated. Polymerase chain reaction assays based on the detection of clonal rearrangement of immunoglobulin and T-cell receptor genes are most established method for MRD analysis. However, the flow cytometric detection of MRD also has advantages in simplicity of the method as well as a low-cost, high-performance. Conventionally, 3 or 4 color analysis employing multiple test tubes of the panel of antibodies is used for the detection of leukemia-associated immunophenotypes, whereas we developed 10 color methods of MRD detection for both BCP-ALL and T-ALL. Our methods are able to take effect easily and exhibit high performance. To put it to practical use, further investigations are now underway.

• Overview

  MANABE Atsushi

  Rinsho Ketsueki The Japanese Society of Hematology 54 (8) 719 - 720 0485-1439 2013/08/30
• [What we can learn from childhood leukemology: focusing on ALL].

  Manabe A

  [Rinsho ketsueki] The Japanese journal of clinical hematology The Japanese Society of Hematology 54 (8) 744 - 748 0485-1439 2013/08 [Refereed][Not invited]
  
• [Retrospective analysis of treatment strategy and prognosis in childhood myelodysplastic syndromes from China and Japan].

  Chen XJ, Manabe A, Yang WY, Zhang PH, Wang SC, Guo Y, Liu F, Chang LX, Wei W, Wan Y, Zhu XF

  Zhongguo shi yan xue ye xue za zhi 21 (4) 940 - 947 1009-2137 2013/08 [Refereed][Not invited]
  
• [Information on pediatric hematology necessary for hematology internists. Overview].

  Manabe A

  [Rinsho ketsueki] The Japanese journal of clinical hematology 54 (8) 719 - 720 0485-1439 2013/08 [Refereed][Not invited]
  
• Incidence and survival rates of hematological malignancies in Japanese children and adolescents (2006-2010): based on registry data from the Japanese Society of Pediatric Hematology

  Keizo Horibe, Akiko M. Saito, Tetsuya Takimoto, Masahiro Tsuchida, Atsushi Manabe, Midori Shima, Akira Ohara, Shuki Mizutani

  INTERNATIONAL JOURNAL OF HEMATOLOGY 98 (1) 74 - 88 0925-5710 2013/07 [Refereed][Not invited]
   

  Neither accurate incidence nor survival data for pediatric patients with hematological malignancies (HM) have been available in Japan to date. Incidence of patients under 20 years of age, who were diagnosed with HM from 2006 to 2010, and their two-year survival rate (2y-OS) were obtained from disease registry data maintained by the Japan Society of Pediatric Hematology (JSPH). A total of 5,287 cases of HM were identified during this period. Acute lymphoblastic leukemia (ALL, 46.6 %) showed the highest incidence, followed by acute myeloid leukemia (AML, 16.7 %), non-Hodgkin lymphoma (NHL, 11.9 %), and histiocytosis (11.8 %). ALL, AML and histiocytosis were common in younger patients aged 1-4, while NHL tended to occur more frequently in older patients aged 5-14. The 2y-OS of HM was 91.6 %, with that for the most common B-precursor ALL rising to 96.2 %. The 2y-OS for M3 AML, lymphoblastic-B-precursor or diffuse large B cell NHL, Hodgkin lymphoma, myeloproliferative disorders, and Langerhans cell histiocytosis was > 95 %. There were no gender differences in prognosis, while infants (88.0 %) and adolescents aged 15-19 (90.6 %) tended toward a poorer prognosis. This is the first report to describe incidence and survival times from the nationwide JSPH disease registry. More precise data with longer follow-up is needed.
• Temporal Lobe Epilepsy With Hippocampal Sclerosis in Acute Lymphoblastic Leukemia

  Emi Kasai-Yoshida, Masaaki Ogihara, Miwa Ozawa, Taiki Nozaki, Michiharu Morino, Atsushi Manabe, Ryota Hosoya

  PEDIATRICS 132 (1) E252 - E256 0031-4005 2013/07 [Refereed][Not invited]
   

  Of 71 acute lymphoblastic leukemia survivors at our hospital over the past 10 years, 2 children developed mesial temporal lobe epilepsy with hippocampal sclerosis (MTLE-HS). This is the first report to describe the clinical course of MTLE-HS observed longitudinally by EEG and MRI. Patient 1 experienced a seizure during chemotherapy involving intrathecal methotrexate. Postseizure MRI suggested methotrexate encephalopathy or leukemic invasion. Anticonvulsant therapy was initiated; subsequent EEGs and MRIs revealed normal results. Three years after chemotherapy, a diffuse, irregular spike-and-wave pattern was observed on interictal EEG. Five years after chemotherapy, the patient developed MTLE-HS comprising complex partial seizures, typical temporal spikes on EEG, and hippocampal sclerosis (HS). Patient 2 did not experience seizures during chemotherapy. Four years later, the patient started experiencing complex partial seizures, and a diffuse, irregular spike-and-wave pattern was observed on interictal EEG. A clinical picture of MTLE-HS developed 2 years later. In both patients, nonspecific EEG abnormalities (ie, diffuse, irregular spike-and-wave activity) preceded the appearance of HS on MRI by 2 years, suggesting an insidious advance of HS during the latent period. Such atypical EEG findings may indicate MTLE-HS during follow-up of leukemia patients. MTLE-HS develops several years after an initial precipitating incident such as prolonged seizures, central nervous system infection, and brain trauma. In our cases, the initial precipitating incident may have been chemotherapy and/or prolonged seizures. Thus, MTLE-HS associated with leukemia may not be as rare as generally believed. A large cohort study of late neurologic complications is warranted.
• Li Fraumeni症候群に発症したGlioblastomaの1男児例

  上野 浩生, 小野 林太郎, 吉本 優里, 細谷 要介, 吉原 宏樹, 長谷川 大輔, 熊本 忠史, 真部 淳, 細谷 亮太, 野崎 太希, 萩原 英樹, 師田 信人

  日本小児血液・がん学会雑誌 (一社)日本小児血液・がん学会 50 (2) 284 - 284 2187-011X 2013/07
• Aggressive Transformation of Juvenile Myelomonocytic Leukemia Associated with Duplication of Oncogenic KRAS due to Acquired Uniparental Disomy

  Motohiro Kato, Naoko Yasui, Masafumi Seki, Hiroshi Kishimoto, Aiko Sato-Otsubo, Daisuke Hasegawa, Nobutaka Kiyokawa, Ryoji Hanada, Seishi Ogawa, Atsushi Manabe, Junko Takita, Katsuyoshi Koh

  JOURNAL OF PEDIATRICS 162 (6) 1285 - + 0022-3476 2013/06 [Refereed][Not invited]
   

  A small fraction of cases of juvenile myelomonocytic leukemia (JMML) develop massive disease activation. Through genomic analysis of JMML, which developed in an individual with mosaicism for oncogenic KRAS mutation with rapid progression, we identified acquired uniparental disomy at 12p. We demonstrated that duplication of oncogenic KRAS is associated with rapid JMML progression.
• Magnetic resonance imaging appearance of primary spinal extradural Ewing's sarcoma: Case report and literature review

  S. Tsutsumi, Y. Yasumoto, A. Manabe, I. Ogino, H. Arai, M. Ito

  Clinical Neuroradiology 23 (2) 81 - 85 1869-1439 2013/06 [Refereed][Not invited]
   

  Purpose: Primary spinal extradural Ewing's sarcoma (PSEES) or primitive neuroectodermal tumor (PNET) is uncommon. The present study summarizes the magnetic resonance (MR) imaging appearance of PSEES. Methods: Literature search from 1994 to 2012 with our representative case presentation. Results: Twenty-one patients, 12 males and 9 females, aged 3 weeks to 44 years, were identified. The thoracic spine was most frequently affected, followed by the cervical, cervicothoracic, and thoracolumbar spine. Superior-inferior extension of lesions was three vertebral levels in 7, two in 7, five in 4, four in 1, one in 1 and unknown in 1. PSEESs appeared isointense in 9 cases, hypointense in 2, hyperintense in 1, and no description in 9 on T1-weighted imaging, while hyperintense in 6, hypointense in 3, heterogeneous in 1, and no description in 11 on T2-weighted imaging. Varying enhancement was noted in 13 cases (62 %), with no description of contrast study in the other 8 cases. Dumbbell-shaped configuration of PSEES was found in 5 cases, foraminal widening in 4, and erosions or scalloping of the adjacent vertebral bodies in 4. Conclusion: The MR imaging appearance of PSEESs is indistinguishable from other tumors. PSEES should be assumed as the differential diagnosis of spinal extradural tumors in pediatric, adolescent, and young adult patients, and prompt surgical exploration should be performed. © 2013 Springer-Verlag Berlin Heidelberg.
• IDEAL‐IQで鉄含有量の半定量化を試みたヘモクロマトーシスの3例

  森田有香, 野崎太希, 小野林太郎, 長谷川大輔, 吉原宏樹, 細谷要介, 真部淳, 齋田幸久

  日本小児放射線学会雑誌 29 20  0918-8487 2013/05/20 [Not refereed][Not invited]
  
• Association between parental preference and head computed tomography in children with minor blunt head trauma.

  Yasushi Ishida, Atsushi Manabe, Aya Oizumi, Norio Otani, Michio Hirata, Kevin Urayama, Yukihisa Saida, Isao Kusakawa, Tsuguya Fukui

  JAMA pediatrics 167 (5) 491 - 2 2168-6203 2013/05 [Refereed][Not invited]
  
• WiskottAldrich syndrome presenting with a clinical picture mimicking juvenile myelomonocytic leukaemia

  Ayami Yoshimi, Yoshiro Kamachi, Kosuke Imai, Nobuhiro Watanabe, Hisaya Nakadate, Takashi Kanazawa, Shuichi Ozono, Ryoji Kobayashi, Misa Yoshida, Chie Kobayashi, Asahito Hama, Hideki Muramatsu, Yoji Sasahara, Marcus Jakob, Tomohiro Morio, Stephan Ehl, Atsushi Manabe, Charlotte Niemeyer, Seiji Kojima

  PEDIATRIC BLOOD & CANCER 60 (5) 836 - 841 1545-5009 2013/05 [Refereed][Not invited]
   

  Background WiskottAldrich syndrome (WAS) is a rare X-linked immunodeficiency caused by defects of the WAS protein (WASP) gene. Patients with WAS typically demonstrate micro-thrombocytopenia. Procedures The report describes seven male infants with WAS that initially presented with leukocytosis, monocytosis, and myeloid and erythroid precursors in the peripheral blood (PB) and dysplasia in the bone marrow (BM), which was initially indistinguishable from juvenile myelomonocytic leukaemia (JMML). Results The median age of affected patients was 1 month (range, 14 months). Splenomegaly was absent in four of these patients, which was unusual for JMML. A mutation analysis of genes in the RAS-signalling pathway did not support a diagnosis of JMML. Non-haematological features, such as eczema (n=7) and bloody stools (n=6), ultimately led to the diagnosis of WAS at a median age of 4 months (range, 38 months), which was confirmed by absent (n=6) or reduced (n=1) WASP expression in lymphocytes by flow cytometry (FCM) and a WASP gene mutation. Interestingly, mean platelet volume (MPV) was normal in three of five patients and six of seven patients demonstrated occasional giant platelets, which was not compatible with WAS. Conclusions These data suggest that WAS should be considered in male infants presenting with JMML-like features if no molecular markers of JMML can be detected. Pediatr Blood Cancer 2013; 60: 836841. (c) 2012 Wiley Periodicals, Inc.
• Wiskott-Aldrich syndrome presenting with a clinical picture mimicking juvenile myelomonocytic leukaemia

  Ayami Yoshimi, Yoshiro Kamachi, Kosuke Imai, Nobuhiro Watanabe, Hisaya Nakadate, Takashi Kanazawa, Shuichi Ozono, Ryoji Kobayashi, Misa Yoshida, Chie Kobayashi, Asahito Hama, Hideki Muramatsu, Yoji Sasahara, Marcus Jakob, Tomohiro Morio, Stephan Ehl, Atsushi Manabe, Charlotte Niemeyer, Seiji Kojima

  Pediatric Blood and Cancer 60 (5) 836 - 841 1545-5009 2013/05 [Refereed][Not invited]
   

  Background: Wiskott-Aldrich syndrome (WAS) is a rare X-linked immunodeficiency caused by defects of the WAS protein (WASP) gene. Patients with WAS typically demonstrate micro-thrombocytopenia. Procedures: The report describes seven male infants with WAS that initially presented with leukocytosis, monocytosis, and myeloid and erythroid precursors in the peripheral blood (PB) and dysplasia in the bone marrow (BM), which was initially indistinguishable from juvenile myelomonocytic leukaemia (JMML). Results: The median age of affected patients was 1 month (range, 1-4 months). Splenomegaly was absent in four of these patients, which was unusual for JMML. A mutation analysis of genes in the RAS-signalling pathway did not support a diagnosis of JMML. Non-haematological features, such as eczema (n=7) and bloody stools (n=6), ultimately led to the diagnosis of WAS at a median age of 4 months (range, 3-8 months), which was confirmed by absent (n=6) or reduced (n=1) WASP expression in lymphocytes by flow cytometry (FCM) and a WASP gene mutation. Interestingly, mean platelet volume (MPV) was normal in three of five patients and six of seven patients demonstrated occasional giant platelets, which was not compatible with WAS. Conclusions: These data suggest that WAS should be considered in male infants presenting with JMML-like features if no molecular markers of JMML can be detected. © 2012 Wiley Periodicals, Inc.
• [Current national and international status of supportive therapy for the coagulopathy associated with L-asparaginase containing regimen for acute lymphoblastic leukemia].

  Ogawa C, Manabe A, Ohara A, Ishiguro A

  [Rinsho ketsueki] The Japanese journal of clinical hematology The Japanese Society of Hematology 54 (3) 316 - 318 0485-1439 2013/03 [Refereed][Not invited]
   

  We investigated supportive therapy against coagulopathy associated with L-asparaginase treatment in patients with acute lymphoblastic leukemia who were enrolled in the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG), Japan Adult Leukemia Study Group (JALSG), and foreign institutes. Fresh frozen plasma (FFP) was administered as a supplement in 46% patients in the JPLSG and 86% in the JALSG. The threshold level of FFP infusion was less than 100 mg/dl plasma fibrinogen in 70% of the JALSG and 20% of the JPLSG, while in another 20% of the JPLSG, FFP was administered when the fibrinogen level was less than 50 mg/dl. The preventive use of antithrombin products (AT) was prescribed in 93% of the JPLSG and 63% of the JALSG: The threshold level of AT supplementation was less than 70% of plasma antithrombin activity, which was similar in both groups. Most foreign institutes do not routinely use FFP or AT.
• Resetting the course for Pediatrics International

  Atsushi Manabe

  PEDIATRICS INTERNATIONAL 55 (1) 1 - 1 1328-8067 2013/02 [Refereed][Not invited]
  
• 小児がん患者に併発したClostridium difficile腸炎の再発のリスク因子の検討

  吉原 宏樹, 代田 惇朗, 稲井 郁子, 小野 林太郎, 細谷 要介, 長谷川 大輔, 石田 也寸志, 真部 淳, 細谷 亮太

  日本小児科学会雑誌 (公社)日本小児科学会 117 (2) 345 - 345 0001-6543 2013/02
• 小児慢性良性好中球減少症患者24名の臨床経過についての検討

  上野 浩生, 小野 林太郎, 細谷 要介, 吉原 宏樹, 長谷川 大輔, 真部 淳, 細谷 亮太

  日本小児科学会雑誌 (公社)日本小児科学会 117 (2) 370 - 370 0001-6543 2013/02
• Characteristics of Illness Perception and Psychosocial Adaptation of Survivors of Childhood Cancer

  TAKEI Yuko, OGATA Akiko, OZAWA Miwa, MORITAKE Hiroshi, HIRAI Kei, MANABE Atsushi, SUZUKI Shin-ichi

  Japanese journal of behavior therapy 一般社団法人日本認知・行動療法学会 39 (1) 23 - 33 0910-6529 2013/01/31 [Not refereed][Not invited]
   

  The purpose of the present study was to examine the correlation between perceived illness experiences and psychosocial adaptation in adolescent childhood cancer survivors. The participants, 21 youth (7 boys, 14 girls; average age 15.8 years, SD 2.1) who were cancer patients attending pediatric outpatient clinics, were asked to participate in a semi-structured interview and complete the Pediatric Quality of Life (QOL) Inventory. The results indicated that psychosocial daily difficulties influenced their illness perception. Although the results were not statistically significant, positive perception might correlate positively with QOL, and negative perception or a despairing attitude might correlate negatively with QOL. Future research should investigate those influences in a quantitative study.
• [Childhood acute lymphoblastic leukemia (ALL)].

  Manabe A, Hasegawa D

  [Rinsho ketsueki] The Japanese journal of clinical hematology 54 (1) 100 - 108 0485-1439 2013/01 [Refereed][Not invited]
  
• Current evidence for an inherited genetic basis of childhood acute lymphoblastic leukemia

  Kevin Y. Urayama, Anand P. Chokkalingam, Atsushi Manabe, Shuki Mizutani

  INTERNATIONAL JOURNAL OF HEMATOLOGY 97 (1) 3 - 19 0925-5710 2013/01 [Refereed][Not invited]
   

  Acute lymphoblastic leukemia (ALL) is the most common cancer in children, and efforts to understand its etiology has followed a paradigm that common genetic variation in the presence of modifiable environmental factors contribute to disease risk. To date, there are numerous reports of candidate gene association studies suggesting an involvement of genetic loci in childhood ALL risk, but the general lack of consistency in results has underscored the need for careful interpretation and confirmation in additional well-designed studies. Complementary efforts using the genome-wide association study approach have shown indisputable evidence that common low penetrance genetic polymorphisms contribute to childhood ALL risk. However, current calculations show that these established disease loci only explain a portion of the total estimated contribution of common genetic variation on childhood ALL risk. Certain candidate gene loci previously examined likely contribute to this unexplained variation in risk, but the challenge moving forward will be to establish which ones based on the accumulating evidence. In this review, we describe the results of the most recent gene association studies in childhood ALL and discuss options for future efforts to advance this area of research.
• Clinical and genetic characteristics of congenital sideroblastic anemia: comparison with myelodysplastic syndrome with ring sideroblast (MDS-RS)

  Rie Ohba, Kazumichi Furuyama, Kenichi Yoshida, Tohru Fujiwara, Noriko Fukuhara, Yasushi Onishi, Atsushi Manabe, Etsuro Ito, Keiya Ozawa, Seiji Kojima, Seishi Ogawa, Hideo Harigae

  ANNALS OF HEMATOLOGY 92 (1) 1 - 9 0939-5555 2013/01 [Refereed][Not invited]
   

  Sideroblastic anemia is characterized by anemia with the emergence of ring sideroblasts in the bone marrow. There are two forms of sideroblastic anemia, i.e., congenital sideroblastic anemia (CSA) and acquired sideroblastic anemia. In order to clarify the pathophysiology of sideroblastic anemia, a nationwide survey consisting of clinical and molecular genetic analysis was performed in Japan. As of January 31, 2012, data of 137 cases of sideroblastic anemia, including 72 cases of myelodysplastic syndrome (MDS)-refractory cytopenia with multilineage dysplasia (RCMD), 47 cases of MDS-refractory anemia with ring sideroblasts (RARS), and 18 cases of CSA, have been collected. Hemoglobin and MCV level in CSA are significantly lower than those of MDS, whereas serum iron level in CSA is significantly higher than those of MDS. Of 14 CSA for which DNA was available for genetic analysis, 10 cases were diagnosed as X-linked sideroblastic anemia due to ALAS2 gene mutation. The mutation of SF3B1 gene, which was frequently mutated in MDS-RS, was not detected in CSA patients. Together with the difference of clinical data, it is suggested that genetic background, which is responsible for the development of CSA, is different from that of MDS-RS.
• 小児急性リンパ性白血病の維持療法における副作用発現および投与量へのMRP4遺伝子多型の影響

  田中 庸一, 真部 淳, 中舘 尚也, 近藤 健介, 康 勝好, 中村 こずえ, 菊池 陽, 小宮山 貴子

  日本小児血液・がん学会学術集会・日本小児がん看護学会・公益財団法人がんの子どもを守る会公開シンポジウムプログラム総会号 (NPO)日本小児血液・がん学会・(NPO)日本小児がん看護学会・(公財)がんの子供を守る会 54回・10回・17回 287 - 287 2012/11
• 初発時に多発する頭蓋内出血を来したPh陽性急性リンパ性白血病の10歳女児の1例

  小野 林太郎, 長谷川 大輔, 石田 悠志, 細谷 要介, 吉原 宏樹, 熊本 忠史, 小川 千登世, 真部 淳, 細谷 亮太

  日本小児血液・がん学会学術集会・日本小児がん看護学会・公益財団法人がんの子どもを守る会公開シンポジウムプログラム総会号 (NPO)日本小児血液・がん学会・(NPO)日本小児がん看護学会・(公財)がんの子供を守る会 54回・10回・17回 320 - 320 2012/11
• 当院における小児がんの患児への告知に関する過去20年の検討

  吉本 優里, 上野 浩生, 吉原 宏樹, 細谷 要介, 長谷川 大輔, 小澤 美和, 石田 也寸志, 真部 淳, 細谷 亮太

  日本小児血液・がん学会学術集会・日本小児がん看護学会・公益財団法人がんの子どもを守る会公開シンポジウムプログラム総会号 (NPO)日本小児血液・がん学会・(NPO)日本小児がん看護学会・(公財)がんの子供を守る会 54回・10回・17回 267 - 267 2012/11
• 思春期患者のEnd-of-Lifeケアにおけるチーム医療の課題

  小川 恵理子, 植松 温子, 鳥山 祐子, 高嶋 希世子, 齋藤 由華, 清藤 育子, 西野 理英, 長谷川 大輔, 小澤 美和, 真部 淳, 細谷 亮太

  日本小児血液・がん学会学術集会・日本小児がん看護学会・公益財団法人がんの子どもを守る会公開シンポジウムプログラム総会号 (NPO)日本小児血液・がん学会・(NPO)日本小児がん看護学会・(公財)がんの子供を守る会 54回・10回・17回 307 - 307 2012/11
• VDC/ICE療法及び放射線照射を行なった腎悪性ラブドイド腫瘍(MRTK)の一例

  辻本 信一, 上野 浩生, 細谷 要介, 吉原 宏樹, 長谷川 大輔, 真部 淳, 細谷 亮太

  日本小児血液・がん学会学術集会・日本小児がん看護学会・公益財団法人がんの子どもを守る会公開シンポジウムプログラム総会号 (NPO)日本小児血液・がん学会・(NPO)日本小児がん看護学会・(公財)がんの子供を守る会 54回・10回・17回 354 - 354 2012/11
• 高リスク神経芽腫に対するWT1ペプチドワクチン投与の経験

  細谷 要介, 吉原 宏樹, 長谷川 大輔, 西川 英里, 谷ヶ崎 博, 鈴木 涼子, 小林 千恵, 橋井 佳子, 杉山 治夫, 真部 淳, 細谷 亮太

  日本小児血液・がん学会学術集会・日本小児がん看護学会・公益財団法人がんの子どもを守る会公開シンポジウムプログラム総会号 (NPO)日本小児血液・がん学会・(NPO)日本小児がん看護学会・(公財)がんの子供を守る会 54回・10回・17回 408 - 408 2012/11
• WT1ペプチドワクチンによる再発抑制効果を期待した小児悪性骨・軟部腫瘍対象多施設共同臨床試験

  橋井 佳子, 坪井 昭博, 尾路 祐介, 中島 博子, 岡 芳弘, 岩城 拓磨, 岩瀬 孝志, 細谷 要介, 真部 淳, 辻 尚子, 湯坐 有希, 杉山 治夫, 大薗 恵一

  日本小児血液・がん学会学術集会・日本小児がん看護学会・公益財団法人がんの子どもを守る会公開シンポジウムプログラム総会号 (NPO)日本小児血液・がん学会・(NPO)日本小児がん看護学会・(公財)がんの子供を守る会 54回・10回・17回 426 - 426 2012/11
• Outcome of children with refractory anaemia with excess of blast (RAEB) and RAEB in Transformation (RAEB-T) in the Japanese MDS99 study

  Akira Kikuchi, Daisuke Hasegawa, Yoshitoshi Ohtsuka, Kazuko Hamamoto, Seiji Kojima, Jun Okamura, Tatsutoshi Nakahata, Atsushi Manabe

  BRITISH JOURNAL OF HAEMATOLOGY 158 (5) 657 - 661 0007-1048 2012/09 [Refereed][Not invited]
   

  We report the outcome of 16 children with refractory anaemia with excess of blasts (RAEB; n similar to=similar to 4) and RAEB in transformation (RAEB-T; n similar to=similar to 12) following induction therapy with etoposide, cytarabine and mitoxantrone (ECM) prior to haematopoietic stem cell transplantation (HSCT). The median observation period was 77 similar to months (range 5123). Complete remission rate was 81% following induction; no toxic deaths occurred. Eight-year event-free survival and overall survival was 50% and 56%, respectively. None of the three patients with a complex karyotype survived, suggesting karyotype is a crucial prognostic factor for survival. This study indicates the safety and high remission rate of ECM and high survival rates after HSCT for paediatric RAEB and RAEB-T.
• [Molecular mechanism and treatment of juvenile myelomonocytic leukemia (JMML)].

  Manabe A

  [Rinsho ketsueki] The Japanese journal of clinical hematology 53 (8) 729 - 733 0485-1439 2012/08 [Refereed][Not invited]
  
• The Perceived Cancer Experience in Japanese Childhood Cancer Patients : A Qualitative Study

  Takei Yuko, Ogata Akiko, Hirai Kei, Ozawa Miwa, Moritake Hiroshi, Manabe Atushi, Suzuki Shin-ichi

  Japanese Journal of Psychosomatic Medicine 日本心身医学会 52 (7) 638 - 645 0385-0307 2012/07/01 [Not refereed][Not invited]
   

  Objectives : Experience of cancer has been linked to post-traumatic stress disorder for childhood cancer survivors. However, it is also an opportunity for personal growth (Jim & Jacobsen., 2008). Evaluating the long-term effects of cancer and its treatment, we have to investigate the impact of cancer in life domains. The purpose of this study was to explore the perception of the cancer experience in Japanese childhood cancer patients. Methods : Subjects were 25 childhood cancer patients attending the pediatric outpatient clinics (8 male and 17 female), median age at survey was 16.8 yrs (13.8-28.8 yrs), median age at diagnosis was 8.0 yrs (2.3-15.0 yrs). Approximately 18 patients had leukemia, 4 suffered from malignant lymphoma and 3 suffered from osteosarcoma, respectively. They were asked to participate in a semi-structured interview regarding the perception of the cancer experience. The data was analyzed with the content analysis, chi-square test and Fisher's exact test. Results: A total of 11 attributes were extracted. The attributes indicated by many of the participants were "having cancer brought my family closer together (n=14)", "I have met various people (n=12)", "can
• Physician Preferences and Knowledge Regarding the Care of Childhood Cancer Survivors in Japan: A Mailed Survey of the Japanese Society of Pediatric Oncology

  Yasushi Ishida, Miyako Takahashi, Mitsue Maru, Michiko Mori, Tara O. Henderson, Christopher K. Daugherty, Atsushi Manabe

  JAPANESE JOURNAL OF CLINICAL ONCOLOGY 42 (6) 513 - 521 0368-2811 2012/06 [Refereed][Not invited]
   

  Japanese physicians attitudes regarding the health-care needs of young adult childhood cancer survivors (CCSs) are not well described. Thus, we examined the self-reported preferences and knowledge of pediatric oncologists and surgeons. A mailed survey was sent to 858 physician members of the Japanese Society of Pediatric Oncology. We compared the responses of pediatric oncologists and pediatric surgeons. The pediatric oncologists response rate was 56 (300 out of 533) and that of pediatric surgeons 32 (105 out of 325). The median age of respondents was 46 and 48 years, respectively; 79 and 84 were men. When comfort levels in caring for CCSs were described (i.e. 1 very uncomfortable; 7 very comfortable), the mean levels were 4.4 and 3.8 with CCSs 21 years, 3.6 and 3.6 with 21 years CCSs 30 years, and 2.8 and 3.3 with CCSs 30 years, respectively. In clinical vignette questions, 62 of the pediatric oncologists and 43 of the surgeons answered three or more questions appropriately. Pediatric surgeons reported significantly lower familiarity with long-term follow-up guidelines than pediatric oncologists. Most pediatric oncologists and many surgeons conducted truth-telling of cancer diagnosis to adult CCSs now. They thought that the most important issues are an original long-term follow-up guideline suitable for the Japanese situation and collaborations with adult-based general physicians. Many Japanese pediatric oncologists are uncomfortable with caring for survivors as they age and have suboptimal knowledge regarding late effects. The change in truth-telling situation and preference for collaboration with adult-based physicians was demonstrated also in Japan.
• Long-term haematological improvement after non-intensive or no chemotherapy in juvenile myelomonocytic leukaemia and poor correlation with adult myelodysplasia spliceosome-related mutations

  Kazuyuki Matsuda, Nao Yoshida, Shuhei Miura, Yozo Nakazawa, Kazuo Sakashita, Nobuyuki Hyakuna, Masahiro Saito, Fumiyo Kato, Atsushi Ogawa, Akihiro Watanabe, Manabu Sotomatsu, Chie Kobayashi, Toshiro Ito, Fumihiro Ishida, Atsushi Manabe, Seiji Kojima, Kenichi Koike

  BRITISH JOURNAL OF HAEMATOLOGY 157 (5) 647 - 650 0007-1048 2012/06 [Refereed][Not invited]
  
• The activity of the inosine triphosphate pyrophosphatase affects toxicity of 6-mercaptopurine during maintenance therapy for acute lymphoblastic leukemia in Japanese children

  Yoichi Tanaka, Atsushi Manabe, Hisaya Nakadate, Kensuke Kondoh, Kozue Nakamura, Katsuyoshi Koh, Tomoyuki Utano, Akira Kikuchi, Takako Komiyama

  LEUKEMIA RESEARCH 36 (5) 560 - 564 0145-2126 2012/05 [Refereed][Not invited]
   

  The association between inosine triphosphate pyrophosphatase (ITPA) activity and toxicity of 6-mercaptopurine (6-MP) was retrospectively evaluated in 65 Japanese children with acute lymphoblastic leukemia (ALL). Patients with an ITPA activity of less than 126 mu mol/h/gHb presented with hepatotoxicity more frequently than those with higher ITPA activity (p < 0.01). The average 6-MP dose during maintenance therapy administered to two patients with the ITPA deficiency was lower than that given to the other patients. Measuring ITPA activity is important for ensuring the safety of maintenance therapy for Asians with ALL because thiopurine S-methyl transferase mutations are rare in the Asian population. (C) 2011 Elsevier Ltd. All rights reserved.
• 乳癌患者の子どもへの支援に関する医師・看護師の意識調査

  小澤 美和, 大野 真司, 石田 也寸志, 武井 優子, 真部 淳

  日本乳癌学会総会プログラム抄録集 (一社)日本乳癌学会 20回 521 - 521 2012/05
• [Myelodysplastic syndrome in childhood and juvenile myelomonocytic leukemia].

  Hasegawa D, Manabe A

  Nihon rinsho. Japanese journal of clinical medicine 70 Suppl 2 681 - 686 0047-1852 2012/04 [Refereed][Not invited]
  
• [Acute lymphoblastic leukemia (ALL)].

  Manabe A

  Nihon rinsho. Japanese journal of clinical medicine 70 Suppl 2 670 - 675 0047-1852 2012/04 [Refereed][Not invited]
  
• CBL mutation in chronic myelomonocytic leukemia secondary to familial platelet disorder with propensity to develop acute myeloid leukemia (FPD/AML)

  Norio Shiba, Daisuke Hasegawa, Myoung-ja Park, Chisato Murata, Aiko Sato-Otsubo, Chitose Ogawa, Atsushi Manabe, Hirokazu Arakawa, Seishi Ogawa, Yasuhide Hayashi

  BLOOD 119 (11) 2612 - 2614 0006-4971 2012/03 [Refereed][Not invited]
   

  Familial platelet disorder with a propensity to develop acute myeloid leukemia (FPD/AML) is a rare autosomal dominant disease characterized by thrombocytopenia, abnormal platelet function, and a propensity to develop myelodysplastic syndrome (MDS) and AML. So far,> 20 affected families have been reported. Recently, a second RUNX1 alteration has been reported; however, no additional molecular abnormalities have been found so far. We identified an acquired CBL mutation and 11q-acquired uniparental disomy (11q-aUPD) in a patient with chronic myelomonocytic leukemia (CMML) secondary to FPD with RUNX1 mutation but not in the same patient during refractory cytopenia. This finding suggests that alterations of the CBL gene and RUNX1 gene may cooper-ate in the pathogenesis of CMML in patients with FPD/AML. The presence of CBL mutations and 11q-aUPD was an important "second hit" that could be an indicator of leukemic transformation of MDS or AML in patients with FPD/AML. (Blood. 2012;119(11):2612-2614)
• Clinical significance of early T-cell precursor acute lymphoblastic leukaemia: results of the Tokyo Children's Cancer Study Group Study L99-15

  Takeshi Inukai, Nobutaka Kiyokawa, Dario Campana, Elaine Coustan-Smith, Akira Kikuchi, Miyuki Kobayashi, Hiroyuki Takahashi, Katsuyoshi Koh, Atsushi Manabe, Masaaki Kumagai, Koichiro Ikuta, Yasuhide Hayashi, Masahiro Tsuchida, Kanji Sugita, Akira Ohara

  BRITISH JOURNAL OF HAEMATOLOGY 156 (3) 358 - 365 0007-1048 2012/02 [Refereed][Not invited]
   

  Early T-cell precursor acute lymphoblastic leukaemia (ETP-ALL) is a recently identified subtype of T-ALL with distinctive gene expression and cell marker profiles, poor response to chemotherapy and a very high risk of relapse. We determined the reliability of restricted panel of cell markers to identify EPT-ALL using a previously classified cohort. Then, we applied the cell marker profile that best discriminated ETP-ALL to a cohort of 91 patients with T-ALL enrolled in the Tokyo Childrens Cancer Study Group L99-15 study, which included allogeneic stem cell transplantation (allo-SCT) for patients with poor prednisone response. Five of the 91 patients (5.5%) met the ETP-ALL criteria. There were no significant differences in presenting clinical features between these and the remaining 86 patients. Response to early remission induction therapy was inferior in ETP-ALL as compared with T-ALL. The ETP-ALL subgroup showed a significantly poorer event-free survival (4-year rate; 40%) than the T-ALL subgroup (70%, P = 0.014). Of note, three of four relapsed ETP-ALL patients survived after allo-SCT, indicating that allo-SCT can be effective for this drug-resistant subtype of T-ALL.
• TCCSGの小児B前駆細胞型急性リンパ性白血病におけるCRLF2とIKZF1、JAK遺伝子解析

  大木 健太郎, 大喜多 肇, 清河 信敬, 朴 明子, 康 勝好, 花田 良二, 真部 淳, 菊地 陽, 小原 明, 林 泰秀

  日本小児科学会雑誌 (公社)日本小児科学会 116 (2) 246 - 246 0001-6543 2012/02
• 二相性の経過をとったHHV6脳症4症例の後方視的検討

  小野 林太郎, 居石 崇志, 稲井 郁子, 石田 也寸志, 真部 淳, 草川 功, 細谷 亮太

  日本小児科学会雑誌 (公社)日本小児科学会 116 (2) 367 - 367 0001-6543 2012/02
• 小児がん患児のきょうだいへの心理的サポート PTSD-RIを用いた縦断研究

  東 飛鳥, 小澤 美和, 小林 明雪子, 細谷 要介, 吉原 宏樹, 長谷川 大輔, 小川 千登勢, 石田 也寸志, 真部 淳, 細谷 亮太

  日本小児科学会雑誌 (公社)日本小児科学会 116 (2) 310 - 310 0001-6543 2012/02
• The Utility of Performing the Initial Lumbar Puncture on Day 8 in Remission Induction Therapy for Childhood Acute Lymphoblastic Leukemia: TCCSG L99-15 Study

  Daisuke Hasegawa, Atsushi Manabe, Akira Ohara, Akira Kikuchi, Katsuyoshi Koh, Nobutaka Kiyokawa, Takashi Fukushima, Yasushi Ishida, Tomohiro Saito, Ryoji Hanada, Masahiro Tsuchida

  PEDIATRIC BLOOD & CANCER 58 (1) 23 - 30 1545-5009 2012/01 [Refereed][Not invited]
   

  Background. Traumatic lumbar puncture with leukemic blasts (TLP+), which has been reported to occur 5-10%, in the previous studies, adversely affects the outcome of children with acute lymphoblasticleukemia(ALL). Based on the results from our previous study, we deferred the initial lumbar puncture until day 8 in remission induction therapy in order to reduce the frequency of cases with TLP+.. Procedure. The study was conducted as a prospective cohort study within the Tokyo Children's Cancer Study Group (TCCSG) L99-15 study. Between April 1999 and June 2003, 754 children with newly diagnosed ALL enrolled. The patients received the initial intrathecal chemotherapy after 7 days of prednisolonetreatment. The incidence of central nervous system (CNS)-positive (the presence of leukemicblasts in cerebrospinal fluid or cranial nerve palsy) including TLP+ cases and cumulative incidence of CNS relapse were examined. Results. The incidence of CNS-positive and TLP+ was 2.9% (n = 22) and 0.8% (n = 6), respectively. These incidencesweremuchlower than those in the representative study groups employing the initial IT on day 1. Of 22 patients with CNS-positive, only one patient relapsed in CNS, whereas 22 of the remaining CNS-negative 723 patients suffered from CNS relapse. Overall, event-free survival at 4 year was 78.2 +/- 1.6%. Four-year cumulative incidence of any CNS relapse was 3.3 +/- 0.7%, which improved from our previous study in spite of limiting the use of cranial irradiation. Conclusions. Our strategy reduced the frequency of CNS-positive patients who required reinforcement of CNS-directed therapy without compromising overall outcome. Pediatr Blood Cancer 2012; 58: 23-30. (C) 2011 Wiley Periodicals, Inc.
• プライマリケア・マスターコース 小児科診療のすすめ 乳幼児突然死症候群(SIDS)

  宮下 文織, 小野 林太郎, 長沖 優子, 石田 也寸志, 真部 淳, 細谷 亮太

  日本医事新報 (株)日本医事新報社 (4578) 46 - 49 0385-9215 2012/01
• [Prognosis of 75 patients with juvenile myelomonocytic leukemia: prospective study by MDS committee in the Japanese Society of Pediatric Hematology].

  Nao Yoshida, Shinsuke Hirabayashi, Shizuka Watanabe, Yuji Zaike, Masahiro Tsuchida, Ayami Yoshimi, Atsuko Masunaga, Yoshitoshi Otsuka, Masafumi Ito, Seiji Kojima, Tatsutoshi Nakahata, Atsushi Manabe

  [Rinsho ketsueki] The Japanese journal of clinical hematology 52 (12) 1853 - 8 0485-1439 2011/12 [Refereed][Not invited]
   

  Juvenile myelomonocytic leukemia (JMML) is a myelodysplastic/myeloproliferative disorder of young children. Because the disease is rare and the diagnosis is difficult, a prospective registration of patients suspected of having JMML with a pathological central review have been conducted by the MDS Committee of the Japanese Society of Pediatric Hematology. Between 1999 and 2006, 75 children with JMML were enrolled and diagnosed through this system. Median age at diagnosis was 20 months (1∼85 months). Cytogenetic abnormalities were detected in 21 patients, including 11 with monosomy 7. The 5-year overall survival (OS) was 60%. Regarding the treatment, 61 of the 75 patients received stem cell transplantation (SCT). Conditioning regimen varied widely, and the source of grafts was bone marrow for 43 patients, peripheral blood for 5, and cord blood for 13. The 5-year OS after SCT was 61%. Notably, patients who received cord blood transplantation had inferior survival than those who received grafts from other sources (38 vs. 68%; P=0.03). Given better recognition of the disease, a multi-center protocol study on SCT, JMML11, is now being planned by the Japanese Pediatric Leukemia/Lymphoma Study Group.
• 急性リンパ性白血病の維持療法における6-メルカプトプリン関連副作用発現へのTPMT、ITPA、MTHFR遺伝子型の影響

  田中 庸一, 真部 淳, 中舘 尚也, 近藤 健介, 中村 こずえ, 康 勝好, 菊地 陽, 歌野 智之, 小宮山 貴子

  小児がん (NPO)日本小児がん学会 48 (プログラム・総会号) 248 - 248 0389-4525 2011/11
• 高2倍体(hyperdiploid)小児急性リンパ性白血病における増加染色体と予後との関連

  加藤 元博, 高橋 浩之, 清河 信敬, 福島 敬, 康 勝好, 真部 淳, 土田 昌宏, 小原 明, 東京小児がん研究グループ(TCCSG)

  小児がん (NPO)日本小児がん学会 48 (プログラム・総会号) 248 - 248 0389-4525 2011/11
• TCCSG-L0416臨床試験にみる完全寛解の定義が寛解割合に及ぼす影響

  牧本 敦, 小原 明, 花田 良二, 角南 勝介, 金子 隆, 熊谷 昌明, 真部 淳, 福島 敬, 磯山 恵一, 康 勝好, 井田 孔明, 前田 美穂, 黒澤 秀光, 後藤 裕明, 松井 敦, 菊地 陽, 土田 昌宏, 東京小児がん研究グループ(TCCSG)

  小児がん (NPO)日本小児がん学会 48 (プログラム・総会号) 249 - 249 0389-4525 2011/11
• 小児急性リンパ性白血病高危険群に対するBFM95-HR強化療法 TCCSG ALL L99-1502研究

  康 勝好, 小原 明, 小川 千登世, 加藤 元博, 清河 信敬, 福島 敬, 嶋田 博之, 高橋 浩之, 梶原 道子, 菊地 陽, 真部 淳, 熊谷 昌明, 花田 良二, 林 泰秀, 土田 昌宏, 東京小児がん研究グループ(TCCSG)

  小児がん (NPO)日本小児がん学会 48 (プログラム・総会号) 250 - 250 0389-4525 2011/11
• 小児ALL関連キメラ遺伝子発現量の末梢血中推移と既知リスク因子との関連について

  福島 敬, 南木 融, 清河 信敬, 小林 千恵, 福島 紘子, Shaza Mahmoud, 康 勝好, 菊地 陽, 真部 淳, 熊谷 昌明, 土田 昌宏, 林 泰秀, 小原 明, 東京小児がん研究グループ(TCCSG)

  小児がん (NPO)日本小児がん学会 48 (プログラム・総会号) 250 - 250 0389-4525 2011/11
• 小児急性リンパ性白血病(ALL)症例における寛解導入不能例の検討 東京小児がん研究グループ(TCCSG)からの報告

  細谷 要介, 望月 慎史, 加藤 啓輔, 長谷川 大輔, 清河 信敬, 福島 敬, 康 勝好, 真部 淳, 土田 昌宏, 小原 明, 東京小児がん研究グループ(TCCSG)

  小児がん (NPO)日本小児がん学会 48 (プログラム・総会号) 313 - 313 0389-4525 2011/11
• 小児急性リンパ性白血病(ALL)における低強度寛解導入療法に対する反応性 TCCSG L99-15研究より

  長谷川 大輔, 真部 淳, 小原 明, 菊地 陽, 康 勝好, 清河 信敬, 福島 敬, 石田 也寸志, 斎藤 友博, 花田 良二, 土田 昌宏, 東京小児がん研究グループ

  小児がん (NPO)日本小児がん学会 48 (プログラム・総会号) 314 - 314 0389-4525 2011/11
• 対照的な経過をとったGATA-1変異陽性の非ダウン症AMKLの2症例

  小野 林太郎, 馬場 徳朗, 齋藤 怜, 米川 聡子, 吉原 宏樹, 神谷 尚宏, 長谷川 大輔, 小川 千登世, 真部 淳, 細谷 亮太

  小児がん (NPO)日本小児がん学会 48 (プログラム・総会号) 321 - 321 0389-4525 2011/11
• 小児がん患者が退院後に抱える心理社会的問題に関するパンフレット作成の試み

  武井 優子, 小澤 美和, 樋口 明子, 片山 麻子, 斎藤 秀子, 横川 めぐみ, 真部 淳, 尾形 明子, 鈴木 伸一

  小児がん (NPO)日本小児がん学会 48 (プログラム・総会号) 245 - 245 0389-4525 2011/11
• 小児がん経験者の晩期合併症の予測は可能か 聖路加国際病院小児科の経験

  石田 也寸志, 渡辺 静, 小澤 美和, 米川 聡子, 小川 千登世, 長谷川 大輔, 細谷 要介, 吉原 宏樹, 真部 淳, 森本 克, 西村 昂三, 細谷 亮太

  小児がん (NPO)日本小児がん学会 48 (プログラム・総会号) 252 - 252 0389-4525 2011/11
• 小児がん患者に対する妊孕性温存の現状についての検討

  米川 聡子, 小川 千登世, 小澤 美和, 齋藤 怜, 細谷 要介, 吉原 宏樹, 長谷川 大輔, 塩田 恭子, 石田 也寸志, 真部 淳, 細谷 亮太

  小児がん (NPO)日本小児がん学会 48 (プログラム・総会号) 253 - 253 0389-4525 2011/11
• 高機能広汎性発達障害を有する子どもの、小児がん入院治療への心理的サポート

  阿佐美 百合子, 小澤 美和, 小林 明雪子, 吉原 広樹, 長谷川 大輔, 小川 千登世, 真部 淳, 関富 晶子, 西野 理英, 細谷 亮太

  小児がん (NPO)日本小児がん学会 48 (プログラム・総会号) 353 - 353 0389-4525 2011/11
• WT1ワクチンを用いて寛解を保っている横紋筋肉腫の2例

  吉原 宏樹, 細谷 要介, 神谷 尚宏, 長谷川 大輔, 小川 千登世, 澤田 明久, 井上 雅美, 橋井 佳子, 杉山 治夫, 真部 淳, 細谷 亮太

  小児がん (NPO)日本小児がん学会 48 (プログラム・総会号) 303 - 303 0389-4525 2011/11
• Clinical Characteristics and Treatment Outcome of Refractory Cytopenia of Childhood (RCC): A Prospective Registration Through the Japanese Society of Pediatric Hematology

  Daisuke Hasegawa, Xiaojuan Chen, Shinsuke Hirabayashi, Yasushi Ishida, Shizuka Watanabe, Yuji Zaike, Masahiro Tsuchida, Atsuko Masunaga, Ayami Yoshimi, Asahito Hama, Seiji Kojima, Masafumi Ito, Tatsutoshi Nakahata, Atsushi Manabe

  BLOOD 118 (21) 1199 - 1199 0006-4971 2011/11 [Refereed][Not invited]
  
• Intellectual development after treatment in children with acute leukemia and brain tumor

  Shizuka Watanabe, Yuriko Azami, Miwa Ozawa, Takahiro Kamiya, Daisuke Hasegawa, Chitose Ogawa, Yasushi Ishida, Ryota Hosoya, Junko Kizu, Atsushi Manabe

  PEDIATRICS INTERNATIONAL 53 (5) 694 - 700 1328-8067 2011/10 [Refereed][Not invited]
   

  Background: The influence of central nervous system (CNS)-directed chemotherapy on intelligence remains controversial. In this study, we investigated the influence of treatment on intellectual development in acute lymphoblastic leukemia (ALL) and brain tumor patients undergoing CNS-directed treatments. Methods: Among patients treated in the Department of Pediatrics, St Luke's International Hospital between April 2000 and March 2009, the subjects were 38 patients with ALL or brain tumors who underwent regular Wechsler intelligence tests. Results: The subjects consisted of 26 patients with ALL and 12 with brain tumors. Prophylactic cranial irradiation was not performed in patients with ALL, whereas it was done for all those with brain tumor. In patients with ALL, the IQ 1 year later was not changed from the start of treatment. In those with brain tumors, the verbal IQ 1 year later was significantly lower than that at the start of treatment. In patients with ALL, intelligence tests were performed 3 years after the start of treatment and there were no marked changes between the two time-points (n = 11). In those with a brain tumor, intellectual functions further decreased after the completion of treatment to as late as 5 years after the initiation of treatment (n = 7). Conclusions: There is no intellectual impairment in any patient with ALL at post-treatment follow-up 3 years after the start of treatment, while intelligence is serially reduced in brain tumor patients. An innovative intervention may be needed for this group of patients.
• MLL関連キメラが検出されないCD10陰性ALLのマーカーと発現遺伝子の特徴(Molecular characteristics and gene expression profiles of CD10-negative B-cell precursor ALL without MLL-rearrangements)

  清河 信敬, 飯島 一智, 加藤 元博, 福島 敬, 康 勝好, 真部 淳, 菊地 陽, 熊谷 昌明, 藤本 純一郎, 林 泰秀, 小原 明

  日本癌学会総会記事 70回 201 - 201 0546-0476 2011/09
• [Bone marrow findings of childhood aplastic anemia: analyses of 140 cases by central reviewers].

  Hama A, Yoshimi A, Sakaguchi H, Doisaki S, Muramatsu H, Shimada A, Takahashi Y, Nozawa K, Ito M, Tsuchida M, Manabe A, Ohara A, Kojima S

  [Rinsho ketsueki] The Japanese journal of clinical hematology 52 (8) 653 - 658 0485-1439 2011/08 [Refereed][Not invited]
   

  The revised WHO classification proposed the term "refractory cytopenia of childhood (RCC)" for children with myelodysplastic syndrome (MDS) with a low blast count. The differential diagnosis between RCC and aplastic anemia (AA) is challenging, especially when bone marrow is hypoplastic and there is no detectable chromosomal abnormality. To reveal the difference between AA and RCC with respect to the clinical and biological features, we retrospectively reviewed the bone marrow smears of 140 patients registered for childhood AA-97 study, which were classified into three groups as follows; the AA group was defined as having no morphologically dysplastic changes; the AA-RCC borderline group was defined as having <10% dysplastic changes in the erythroid lineage only; and the RCC group was defined as having dysplastic changes in more than two cell lineages or >10% in a single cell lineage. The patients were classified into the AA group (n=96, 69%), AA-RCC borderline group (n=20, 14%) and RCC group (n=24, 17%). Most of the patients in the AA group were classified as having very severe disease, whereas most of the patients in the RCC group were classified as non-severe disease. Only 2 patients in the AA group developed acute myeloid leukemia. The response rate to immunosuppressive therapy did not differ among the 3 groups. To demonstrate whether the two diseases are truly different entities, it is necessary to compare molecular backgrounds between the AA and RCC groups.
• がんを持つ親の子どもへのサポートグループに関する研究

  小林 真理子, 大沢 かおり, 小澤 美和, 石田 也寸志, 真部 淳

  日本緩和医療学会学術大会プログラム・抄録集 (NPO)日本緩和医療学会 16回 424 - 424 2011/06
• がんになった患者の子どもへの病気説明に関する実態調査(その3) 説明を受けた子どもの反応(アンケートからの質的分析)

  井上 絵未, 大沢 かおり, 小林 真理子, 村瀬 有紀子, 茶園 美香, 井上 実穂, 衛藤 美穂, 三浦 絵莉子, 小澤 美和, 石田 也寸志, 真部 淳

  日本緩和医療学会学術大会プログラム・抄録集 (NPO)日本緩和医療学会 16回 487 - 487 2011/06
• がんになった患者の子どもへの病気説明に関する実態調査(その1) 患者へのアンケート・量的分析

  大沢 かおり, 井上 実穂, 小林 真理子, 石田 也寸志, 小澤 美和, 真部 淳

  日本緩和医療学会学術大会プログラム・抄録集 (NPO)日本緩和医療学会 16回 488 - 488 2011/06
• がんになった患者の子どもへの病気説明に関する実態調査(その2) がん患者が子供に病気を説明する背景

  村瀬 有紀子, 井上 実穂, 茶園 美香, 大沢 かおり, 井上 絵未, 衛藤 美穂, 小林 真理子, 三浦 絵莉子, 小澤 美和, 石田 也寸志, 真部 淳

  日本緩和医療学会学術大会プログラム・抄録集 (NPO)日本緩和医療学会 16回 488 - 488 2011/06
• 肝芽腫を合併したUPD‐14の2例

  野崎太希, 河野達夫, 清水光政, 草川功, 平田倫生, 槇殿文香理, 真部淳, 平林健, 細谷亮太, 齋田幸久

  日本小児放射線学会雑誌 27 31  0918-8487 2011/05/20 [Not refereed][Not invited]
  
• Low dose cytarabine therapy for transient abnormal myelopoiesis (TAM)

  NAKAGAWA Machiko, KUSAKAWA Isao, HIRATA Michio, SAITO Rei, KASAI Emi, HASEGAWA Daisuke, MANABE Atsushi, HOSOYA Ryota

  日本周産期・新生児医学会雑誌 = Journal of Japan Society of Perinatal and Neonatal Medicine (一社)日本周産期・新生児医学会 47 (1) 161 - 164 1348-964X 2011/05/01 [Not refereed][Not invited]
   

  妊娠35週0日、児心音異常のため母体搬送となり同日緊急帝王切開となった。児は血液検査にて著明な白血球数増加と血小板の増加、LDHの増加を認め一過性骨髄増殖症(TAM)が疑われたため日齢1に新生児搬送となった。白血球、血小板とも減少傾向で、補液、尿アルカリ化、アロプリノール投与のみで経過観察した。日齢1の血清総ビリルビン値は14.9mg/dlであったため光線療法を行い、SpO2の軽度低下に対し酸素投与を行った。染色体検査で21トリソミーと診断遺伝子検査でTAMと診断した。末梢血芽球の消失を認めず、日齢11より少量Ara-C療法を7日間行い日齢31に芽球消失を確認した。化学療法中全身状態は安定し、有害事象としては骨髄抑制を認め、濃厚赤血球の輸血を必要とした。日齢23には表皮ブドウ球菌菌血症に罹患したが抗菌薬投与にて改善した。日齢62に退院し、月齢10ヵ月現在も経過良好である。
• Validation of the Japanese version of the Pediatric Quality of Life Inventory (PedsQL) Cancer Module

  Naoko Tsuji, Naoko Kakee, Yasushi Ishida, Keiko Asami, Ken Tabuchi, Hisaya Nakadate, Tsuyako Iwai, Miho Maeda, Jun Okamura, Takuro Kazama, Yoko Terao, Wataru Ohyama, Yuki Yuza, Takashi Kaneko, Atsushi Manabe, Kyoko Kobayashi, Kiyoko Kamibeppu, Eisuke Matsushima

  HEALTH AND QUALITY OF LIFE OUTCOMES 9 22  1477-7525 2011/04 [Refereed][Not invited]
   

  Background: The PedsQL 3.0 Cancer Module is a widely used instrument to measure pediatric cancer specific health-related quality of life (HRQOL) for children aged 2 to 18 years. We developed the Japanese version of the PedsQL Cancer Module and investigated its reliability and validity among Japanese children and their parents. Methods: Participants were 212 children with cancer and 253 of their parents. Reliability was determined by internal consistency using Cronbach's coefficient alpha and test-retest reliability using intra-class correlation coefficient (ICC). Validity was assessed through factor validity, convergent and discriminant validity, concurrent validity, and clinical validity. Factor validity was examined by exploratory factor analysis. Convergent and discriminant validity were examined by multitrait scaling analysis. Concurrent validity was assessed using Spearman's correlation coefficients between the Cancer Module and Generic Core Scales, and the comparison of the scores of child self-reports with those of other self-rating depression scales for children. Clinical validity was assessed by comparing the on-and off-treatment scores using Kruskal-Wallis and Mann-Whitney U tests. Results: Cronbach's coefficient alpha was over 0.70 for the total scale and over 0.60 for each subscale by age except for the 'pain and hurt' subscale for children aged 5 to 7 years. For test-retest reliability, the ICC exceeded 0.70 for the total scale for each age. Exploratory factor analysis demonstrated sufficient factorial validity. Multitrait scaling analysis showed high success rates. Strong correlations were found between the reports by children and their parents, and the scores of the Cancer Module and the Generic Core Scales except for 'treatment anxiety' subscales for child reports. The Depression Self-Rating Scale for Children (DSRS-C) scores were significantly correlated with emotional domains and the total score of the cancer module. Children who had been off treatment over 12 months demonstrated significantly higher scores than those on treatment. Conclusions: The results demonstrate the reliability and validity of the Japanese version of the PedsQL Cancer Module among Japanese children.
• 10カラーフローサイトメトリー解析による小児白血病のマーカー診断

  清河 信敬, 山田 浩之, 康 勝好, 福島 敬, 真部 淳, 菊地 陽, 熊谷 昌明, 小原 明, 林 泰秀, 土田 昌宏

  日本小児科学会雑誌 (公社)日本小児科学会 115 (2) 328 - 328 0001-6543 2011/02
• Early T-cell precursor ALL同定のための汎用抗原を用いたスコアリング・システム

  犬飼 岳史, 清河 信敬, 高橋 浩之, 康 勝好, 真部 淳, 熊谷 昌明, 小原 明, Dario Campana, 杉田 完爾

  小児がん (NPO)日本小児がん学会 47 (プログラム・総会号) 282 - 282 0389-4525 2010/12
• 小児急性リンパ性白血病中間危険群に対する早期強化療法としての大量cytarabine療法の意義 TCCSG L99-15研究

  康 勝好, 小原 明, 小川 千登世, 加藤 元博, 清河 信敬, 福島 敬, 嶋田 博之, 高橋 浩之, 梶原 道子, 菊地 陽, 真部 淳, 熊谷 昌明, 生田 孝一郎, 花田 良二, 林 泰秀, 土田 昌宏

  小児がん (NPO)日本小児がん学会 47 (プログラム・総会号) 285 - 285 0389-4525 2010/12
• 東京小児がん研究グループ急性リンパ性白血病中央診断におけるEarly T-cell precursor ALLのマーカーの特徴

  清河 信敬, 犬飼 岳史, 高橋 浩之, 康 勝好, 杉田 完爾, 真部 淳, 菊地 陽, 熊谷 昌明, 小原 明, 林 泰秀, 土田 昌宏

  小児がん (NPO)日本小児がん学会 47 (プログラム・総会号) 396 - 396 0389-4525 2010/12
• 東京小児がん研究グループ(TCCSG)ALL L07-1602の寛解導入療法におけるL-アスパラギナーゼの有害事象

  小川 千登世, 太田 節雄, 熊谷 昌明, 牧本 敦, 清河 信敬, 福島 敬, 康 勝好, 真部 淳, 花田 良二, 小原 明, 土田 昌宏

  小児がん (NPO)日本小児がん学会 47 (プログラム・総会号) 397 - 397 0389-4525 2010/12
• MLL関連キメラ遺伝子陽性小児急性白血病におけるMCSP抗原発現

  山田 浩之, 清河 信敬, 橋本 亙, 恩田 恵子, 飯島 一智, 福島 敬, 康 勝好, 真部 淳, 菊地 陽, 熊谷 昌明, 小原 明

  小児がん (NPO)日本小児がん学会 47 (プログラム・総会号) 427 - 427 0389-4525 2010/12
• 急性骨髄性白血病に対して化学療法施行中にα-Streptoccusによる髄膜炎、感染性心内膜炎を呈した1例

  小野 林太郎, 居石 崇志, 森山 貴也, 米川 聡子, 山本 剛士, 神谷 尚宏, 小川 千登世, 真部 淳, 野崎 太希, 篠田 正樹, 細谷 亮太

  小児がん (NPO)日本小児がん学会 47 (プログラム・総会号) 419 - 419 0389-4525 2010/12
• 小児病棟の入院生活に対する悪性腫瘍児および家族の意識調査 付き添い家族の生活について考える

  吉川 久美子, 関冨 晶子, 永瀬 恭子, 天野 こころ, 平田 美佳, 石井 里奈, 大野 尚子, 神谷 尚宏, 長谷川 大輔, 真部 淳, 石田 也寸志, 細谷 亮太

  小児がん (NPO)日本小児がん学会 47 (プログラム・総会号) 273 - 273 0389-4525 2010/12
• 小児病棟での生活に対する悪性腫瘍患児およびに家族の意識調査 携帯電話・ポータブルゲームを考える

  芹澤 裕子, 天野 こころ, 前田 邦枝, 永瀬 恭子, 関冨 晶子, 平田 美佳, 吉川 久美子, 大野 尚子, 石井 里奈, 長谷川 大輔, 神谷 尚宏, 石田 也寸志, 真部 淳, 細谷 亮太

  小児がん (NPO)日本小児がん学会 47 (プログラム・総会号) 295 - 295 0389-4525 2010/12
• 小児がん患者における知的発達のフォローアップ(第2報)

  渡辺 静, 阿佐美 百合子, 神谷 尚宏, 長谷川 大輔, 小川 千登世, 小澤 美和, 石田 也寸志, 木津 純子, 後藤 一美, 真部 淳, 細谷 亮太

  小児がん (NPO)日本小児がん学会 47 (プログラム・総会号) 253 - 253 0389-4525 2010/12
• 骨髄移植のドナー候補となったきょうだいの心理的現状に関する検討

  小林 明雪子, 小澤 美和, 阿佐美 百合子, 東 飛鳥, 神谷 尚宏, 小川 千登世, 石田 也寸志, 真部 淳, 細谷 亮太

  小児がん (NPO)日本小児がん学会 47 (プログラム・総会号) 385 - 385 0389-4525 2010/12
• 急性リンパ性白血病患児の同胞への心理的援助 弟を亡くした9歳女子の事例から

  阿佐美 百合子, 小澤 美和, 小林 明雪子, 長谷川 大輔, 小川 千登世, 真部 淳, 大野 尚子, 吉川 久美子, 細谷 亮太

  小児がん (NPO)日本小児がん学会 47 (プログラム・総会号) 386 - 386 0389-4525 2010/12
• 小児がん患者における病気のとらえ方と退院後の困難の関連性の検討

  武井 優子, 尾形 明子, 小澤 美和, 盛武 浩, 真部 淳, 平井 啓, 鈴木 伸一

  日本行動療法学会大会発表論文集 (一社)日本認知・行動療法学会 36回 164 - 165 2010/12
• Clinical Outcome of Children With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Treated Between 1995 and 2005

  Maurizio Arico, Martin Schrappe, Stephen P. Hunger, William L. Carroll, Valentino Conter, Stefania Galimberti, Atsushi Manabe, Vaskar Saha, Andre Baruchel, Kim Vettenranta, Keizo Horibe, Yves Benoit, Rob Pieters, Gabriele Escherich, Lewis B. Silverman, Ching-Hon Pui, Maria Grazia Valsecchi

  JOURNAL OF CLINICAL ONCOLOGY 28 (31) 4755 - 4761 0732-183X 2010/11 [Refereed][Not invited]
   

  Purpose In a previous analysis of 326 children with Philadelphia chromosome (Ph) -positive acute lymphoblastic leukemia (ALL) treated between 1986 and 1996, hematopoietic stem-cell transplantation from HLA-matched related donors, but not from unrelated donors, offered a superior outcome than chemotherapy alone. To evaluate the impact of recent improvements in chemotherapy and transplantation, we performed a similar analysis on patients treated in the following decade. Patients and Methods We analyzed 610 patients with Ph-positive ALL treated between 1995 and 2005 without tyrosine kinase inhibitor therapy. The median follow-up duration was 6.3 years. Results Complete remission was achieved in 89% of patients. The 7-year event-free survival and overall survival rates were superior in the present cohort compared with the previous cohort (32.0% +/- 2.0% v 25.0% +/- 3.0, respectively, P = .007; and 44.9% +/- 2.2% v 36.0% +/- 3.0%, respectively, P = .017). Compared with chemotherapy alone, transplantation with matched related donors or unrelated donors in first remission (325 patients) showed an advantage with increasing follow-up, suggesting greater protection against late relapses (hazard ratio at 5 years, 0.37; P < .001). In the multivariate Cox regression analysis accounting for treatment (transplantation v no transplantation), age, leukocyte count, and early response had independent impact on treatment outcome. Conclusion Clinical outcome of children and adolescents with Ph-positive ALL has improved with advances in transplantation and chemotherapy. Transplantations with matched related donors and unrelated donors were equivalent and offered better disease control compared with chemotherapy alone. Age, leukocyte count, and early treatment response were independent prognostic indicators. The results of this study will serve as a historical reference to evaluate the therapeutic impact of tyrosine kinase inhibitors on the outcome of Ph-positive ALL. J Clin Oncol 28: 4755-4761. (C) 2010 by American Society of Clinical Oncology
• [Recent progress in acute lymphoblastic leukemia in childhood].

  Manabe A

  [Rinsho ketsueki] The Japanese journal of clinical hematology 一般社団法人 日本血液学会 51 (10) 1558 - 1563 0485-1439 2010/10 [Refereed][Not invited]
  
• Bullous exudative retinal detachment due to infiltration of leukemic cells in a child with acute lymphoblastic leukemia

  Kenichi Yoshida, Daisuke Hasegawa, Ayako Takusagawa, Itaru Kato, Chitose Ogawa, Nariaki Echizen, Kishiko Ohkoshi, Tatsuo Yamaguchi, Ryota Hosoya, Atsushi Manabe

  INTERNATIONAL JOURNAL OF HEMATOLOGY 92 (3) 535 - 537 0925-5710 2010/10 [Refereed][Not invited]
   

  Acute lymphoblastic leukemia (ALL) is known to cause several ocular involvements, but exudative retinal detachment is a rare complication. We describe a case report of a 4-year-old boy with T cell ALL who developed bilateral exudative retinal detachment caused by leukemic infiltration in the retinas after achieving hematological remission. Intravenous steroid pulse therapy and local irradiation reversed the condition, but it recurred concurrently with disease progression after a second relapse in the bone marrow. It is suggested that ophthalmic examination is crucial for ALL patients, especially for those whose white blood cell count is very high at onset.
• Congenital dyserythropoietic anemia

  Takahiro Kamiya, Atsushi Manabe

  INTERNATIONAL JOURNAL OF HEMATOLOGY 92 (3) 432 - 438 0925-5710 2010/10 [Refereed][Not invited]
   

  Congenital dyserythropoietic anemias (CDAs) are a heterogeneous group of rare hereditary disorders of erythropoiesis characterized by morphologic abnormal erythroblasts in the bone marrow. Three types of the disease are known as type I, II and III, and the variant type of CDA and several minor subgroups of CDA have been also reported since the first classification. Recently, responsible genes for type I (CDAN1) and type II (SEC23B) have been identified and the molecular pathogenesis of the disease is currently being explored. Although CDAs rarely transform to myelodysplastic syndrome or leukemia, the disease is important to understand the mechanism of hemopoiesis in humans.
• 小児白血病のマーカー中央診断に対する10カラーフローサイトメトリー解析の有用性

  清河 信敬, 恩田 恵子, 橋本 亙, 長谷川 大輔, 飯島 一智, 福島 敬, 齋藤 正博, 藤本 純一郎, 康 勝好, 真部 淳, 菊地 陽, 熊谷 昌明, 小原 明, 林 泰秀, 土田 昌宏

  臨床血液 (一社)日本血液学会-東京事務局 51 (9) 1153 - 1153 0485-1439 2010/09
• 急性リンパ節白血病(ALL)治療後に海馬硬化を伴う難治性側頭葉てんかんを発症した女児例

  笠井 恵美, 荻原 正明, 小澤 美和, 真部 淳, 草川 功, 野崎 太希, 森本 克, 細谷 亮太

  てんかん研究 (一社)日本てんかん学会 28 (2) 300 - 300 0912-0890 2010/09
• [Molecular biology of juvenile myelomonocytic leukemia (JMML)].

  Manabe A

  [Rinsho ketsueki] The Japanese journal of clinical hematology 51 (7) 526 - 531 0485-1439 2010/07 [Refereed][Not invited]
  
• Spectrum of molecular defects in juvenile myelomonocytic leukaemia includes ASXL1 mutations

  Yuka Sugimoto, Hideki Muramatsu, Hideki Makishima, Courtney Prince, Anna M. Jankowska, Nao Yoshida, Yinyan Xu, Nobuhiro Nishio, Asahito Hama, Hiroshi Yagasaki, Yoshiyuki Takahashi, Koji Kato, Atsushi Manabe, Seiji Kojima, Jaroslaw P. Maciejewski

  BRITISH JOURNAL OF HAEMATOLOGY 150 (1) 83 - 87 0007-1048 2010/07 [Refereed][Not invited]
   

  P>Mutations in NF1, PTPN11, NRAS, KRAS and CBL have been reported to play a pathogenetic role in juvenile myelomonocytic leukaemia (JMML), a rare myelodyplastic/myeloproliferative neoplasm occurring in children. Recently, mutations in ASXL1 were identified in chronic myelomonocytic leukaemia and other myeloid malignancies. We sequenced exon 12 of ASLX1 in 49 JMML patients, and found 2 novel heterozygous (nonsense and frameshift) mutations, one occurring as a sole lesion, the other was in conjunction with a PTPN11 mutation. ASXL1 cooperates with KDM1A in transcriptional repression and thereby ASXL1 mutations may synergize with or mimic other JMML-related mutations.
• 5カラーおよび10カラーによる小児白血病のマーカー中央診断

  清河 信敬, 恩田 恵子, 橋本 亙, 山田 浩之, 高野 邦彦, 飯島 一智, 福島 敬, 藤本 純一郎, 康 勝好, 真部 淳, 菊地 陽, 熊谷 昌明, 小原 明, 林 泰秀, 土田 昌宏

  Cytometry Research (一社)日本サイトメトリー学会 20 (Suppl.) 65 - 65 0916-6920 2010/06
• 小児白血病におけるCD244の発現

  山田 浩之, 清河 信敬, 恩田 恵子, 橋本 亙, 飯島 一智, 福島 敬, 斎藤 正博, 藤本 純一郎, 康 勝好, 真部 淳, 菊地 陽, 熊谷 昌明, 小原 明, 林 泰秀, 土田 昌宏

  Cytometry Research (一社)日本サイトメトリー学会 20 (Suppl.) 65 - 65 0916-6920 2010/06
• がんを持つ親の子どもへの支援に関する活動報告

  大沢 かおり, 藤井 あけみ, 村瀬 有紀子, 伊藤 ゆかり, 井上 絵未, 中島 美鈴, 村田 和恵, 小林 真理子, 小澤 美和, 石田 也寸志, 真部 淳

  日本緩和医療学会学術大会プログラム・抄録集 (NPO)日本緩和医療学会 15回 212 - 212 2010/06
• がんを持つ親の子どもへの介入に関する実態調査 医療関係者へのアンケート分析(その1) 量的分析

  小林 真理子, 石田 也寸志, 茶園 美香, 小澤 美和, 井上 実穂, 大沢 かおり, 村田 和恵, 真部 淳

  日本緩和医療学会学術大会プログラム・抄録集 (NPO)日本緩和医療学会 15回 214 - 214 2010/06
• がんを持つ親の子どもへの介入に関する実態調査 医療関係者へのアンケート分析(その2) 量的分析

  衛藤 美穂, 小澤 美和, 井上 実穂, 小林 真理子, 西野 なお子, 茶園 美香, 大沢 かおり, 石田 也寸志, 真部 淳

  日本緩和医療学会学術大会プログラム・抄録集 (NPO)日本緩和医療学会 15回 214 - 214 2010/06
• 乳がん患者とその子どもへのサポートを考える CLS介入事例

  衛藤 美穂, 伊藤 ゆかり, 小澤 美和, 中島 美鈴, 小林 真理子, 真部 淳

  日本乳癌学会総会プログラム抄録集 (一社)日本乳癌学会 18回 655 - 655 2010/05
• 乳がん患者とその子どもへのサポートを考える 親子で乳がんを考える絵本の作成

  中島 美鈴, 小澤 美和, 伊藤 ゆかり, 衛藤 美穂, 小林 真理子, 真部 淳

  日本乳癌学会総会プログラム抄録集 (一社)日本乳癌学会 18回 656 - 656 2010/05
• 急速に呼吸障害が進行した小児のパンデミック(H1N1)2009による急性肺炎の2例

  神谷 尚宏, 森山 貴也, 中島 健太郎, 佐藤 真洋, 山本 剛士, 斎藤 怜, 笠井 恵美, 吉田 健一, 中川 真智子, 長谷川 大輔, 小松 なぎさ, 稲井 郁子, 平田 倫生, 小川 千登世, 小澤 美和, 真部 淳, 草川 功, 細谷 亮太, 片山 正夫

  日本小児科学会雑誌 (公社)日本小児科学会 114 (4) 746 - 746 0001-6543 2010/04
• Mutations of an E3 ubiquitin ligase c-Cbl but not TET2 mutations are pathogenic in juvenile myelomonocytic leukemia

  Hideki Muramatsu, Hideki Makishima, Anna M. Jankowska, Heather Cazzolli, Christine O'Keefe, Nao Yoshida, Yinyan Xu, Nobuhiro Nishio, Asahito Hama, Hiroshi Yagasaki, Yoshiyuki Takahashi, Koji Kato, Atsushi Manabe, Seiji Kojima, Jaroslaw P. Maciejewski

  BLOOD 115 (10) 1969 - 1975 0006-4971 2010/03 [Refereed][Not invited]
   

  Juvenile myelomonocytic leukemia (JMML) is a rare pediatric myeloid neoplasm characterized by excessive proliferation of myelomonocytic cells. When we investigated the presence of recurrent molecular lesions in a cohort of 49 children with JMML, neurofibromatosis phenotype (and thereby NF1 mutation) was present in 2 patients (4%), whereas previously described PTPN11, NRAS, and KRAS mutations were found in 53%, 4%, and 2% of cases, respectively. Consequently, a significant proportion of JMML patients without identifiable pathogenesis prompted our search for other molecular defects. When we applied single nucleotide polymorphism arrays to JMML patients, somatic uniparental disomy 11q was detected in 4 of 49 patients; all of these cases harbored RING finger domain c-Cbl mutations. In total, c-Cbl mutations were detected in 5 (10%) of 49 patients. No mutations were identified in Cbl-b and TET2. c-Cbl and RAS pathway mutations were mutually exclusive. Comparison of clinical phenotypes showed earlier presentation and lower hemoglobin F levels in patients with c-Cbl mutations. Our results indicate that mutations in c-Cbl may represent key molecular lesions in JMML patients without RAS/PTPN11 lesions, suggesting analogous pathogenesis to those observed in chronic myelomonocytic leukemia (CMML) patients. (Blood. 2010; 115: 1969-1975)
• 当院における小児のインフルエンザA(H1N1)pdm感染症の受診動向および重症例のまとめ

  神谷 尚宏, 中島 健太郎, 笠井 恵美, 中川 真智子, 長谷川 大輔, 稲井 郁子, 小澤 美和, 真部 淳, 草川 功, 細谷 亮太

  日本小児科学会雑誌 (公社)日本小児科学会 114 (2) 215 - 215 0001-6543 2010/02
• Long-term results of Tokyo Children's Cancer Study Group trials for childhood acute lymphoblastic leukemia, 1984-1999

  M. Tsuchida, A. Ohara, A. Manabe, M. Kumagai, H. Shimada, A. Kikuchi, T. Mori, M. Saito, M. Akiyama, T. Fukushima, K. Koike, M. Shiobara, C. Ogawa, T. Kanazawa, Y. Noguchi, S. Oota, Y. Okimoto, H. Yabe, M. Kajiwara, D. Tomizawa, K. Ko, K. Sugita, T. Kaneko, M. Maeda, T. Inukai, H. Goto, H. Takahashi, K. Isoyama, Y. Hayashi, R. Hosoya, R. Hanada

  LEUKEMIA 24 (2) 383 - 396 0887-6924 2010/02 [Refereed][Not invited]
   

  We report the long-term results of Tokyo Children's Cancer Study Group's studies L84-11, L89-12, L92-13, and L95-14 for 1846 children with acute lymphoblastic leukemia, which were conducted between 1984 and 1999. The value of event-free survival (EFS) +/- s.e. was 67.2 +/- 2.2% at 10 years in L84-11, which was not improved in the following two studies, and eventually improved to 75.0 +/- 1.8% at 10 years in L95-14 study. The lower EFS of the L89-12 reflected a high rate of induction failure because of infection and delayed remission in very high-risk patients. The L92-13 study was characterized by short maintenance therapy; it resulted in poor EFS, particularly in the standard-risk (SR) group and boys. Females did significantly better than males in EFS in the early three studies. The gender difference was not significant in overall survival, partly because 460% of the males survived after the testicular relapse. Randomized studies in the former three protocols revealed that intermediate-or high-dose methotrexate therapy significantly reduced the testicular relapse rate. In the L95-14 study, gender difference disappeared in EFS. Contrary to the results of larger-scale studies, the randomized control study in the L95-14 reconfirmed with updated data that dexamethasone 8mg/m(2) had no advantage over prednisolone 60mg/m(2) in the SR and intermediate-risk groups. Prophylactic cranial irradiation was assigned to 100, 80, 44, and 44% of the patients in the studies, respectively. Isolated central nervous system relapse rates decreased to <2% in the last two trials. Secondary brain tumors developed in 12 patients at 8-22 years after cranial irradiation. Improvement of the remission induction rates and the complete omission of irradiation are currently main objectives in our studies. Leukemia (2010) 24, 383-396; doi: 10.1038/leu.2009.260; published online 24 December 2009
• 小児がん患者が退院後に抱える心理社会的問題に関する研究の現状と課題

  武井優子, 尾形明子, 小澤美和, 真部淳, 鈴木伸一

  小児がん 47 (1) 84 - 90 2010 [Refereed][Not invited]
  
• Cytomegalovirus Infection Mimicking Juvenile Myelomonocytic Leukemia Showing Hypersensitivity to Granulocyte-Macrophage Colony Stimulating Factor

  Hiroshi Moritake, Toshio Ikeda, Atsushi Manabe, Sachiyo Kamimura, Hiroyuki Nunoi

  PEDIATRIC BLOOD & CANCER 53 (7) 1324 - 1326 1545-5009 2009/12 [Refereed][Not invited]
   

  We describe an infant with cytomegalovirus (CMV) infection presenting as transient myeloproliferation resembling juvenile myelomonocytic leukemia (JMML). The patient fulfilled the international diagnostic criteria of JMML, including hypersensitivity to granulocyte-macrophage colony-stimulating factor (GM-CSF). Viral studies using serologic assays and polymerase chain reaction (PCR) were positive for CMV. Clinical symptoms disappeared and laboratory values returned to normal without specific treatment within I year. Follow-up showing a decrease in viral titers Suggested CMV infection as an etiologic factor for the development of myeloproliferative features. We conclude that the CMV infection transiently induced abnormal myelopoiesis in this infant. Pediatr Blood Cancer 2009;53:1324-1326. (C) 2009 Wiley-Liss, Inc.
• Treatment of Children With Refractory Anemia: The Japanese Childhood MDS Study Group Trial (MDS99)

  Daisuke Hasegawa, Atsushi Manabe, Hiroshi Yagasaki, Yoshitoshi Ohtsuka, Masami Inoue, Akira Kikuchi, Akira Ohara, Masahiro Tsuchida, Seiji Kojima, Tatsutoshi Nakahata

  PEDIATRIC BLOOD & CANCER 53 (6) 1011 - 1015 1545-5009 2009/12 [Refereed][Not invited]
   

  Background Although hematopoietic stern cell transplantation (HSCT) is offered as a Curative therapy for pediatric myelodysplastic syndrome (MDS), it may Cause severe complications and mortality. Several reports have shown the efficacy of immunosuppressive therapy (IST) in adult patients with refractory anemia (RA), but its safety and efficacy remains to be fully elucidated in childhood RA. Procedure. Eleven children diagnosed with RA and enrolled on a prospective multicenter trial conducted by the Japanese Childhood MDS Study Group were eligible for analysis. if patients showed transfusion dependent or suffered from infection due to neutropenia, they received IST consisting of antithymocyte globulin (ATG), cyclosporine (CyA), and methylprednisolone (mPSL.). Results. Eight children received IST, 2 received Only Supportive therapy, and one underwent HSCT without IST. Five (63%) of eight children who received IST showed hematological response. Of note, one patient showed the disappearance of monosomy 7 after IST. Responders were significantly younger than non-responders (29 months vs. 140 months; P=0.03). No severe adverse events related to IST were reported in this study. Of 6 children with chromosomal abnormalities who received IST, four showed hematological response. The probability of failure-free and overall survival at 5 years was 63 +/- 17% and 90 +/- 9% respectively. Conclusion. IST is likely to be a safe and effective modality for childhood RA. Pediatr Blood Cancer 2009;53:1011-1015. (C) 2009 Wiley-Liss, Inc.
• 泌尿生殖器領域の横紋筋肉腫に対する外科の役割について

  中村 晃子, 平林 健, 松藤 凡, 小川 千登世, 真部 淳, 細谷 亮太

  小児がん (NPO)日本小児がん学会 46 (プログラム・総会号) 218 - 218 0389-4525 2009/11
• 脾臓摘出術後に同種臍帯血移植を行なった再発RBM15-MKL1陽性急性巨核芽球性白血病の一例

  長谷川 大輔, 神谷 尚宏, 吉田 健一, 中島 健太郎, 有馬 慶太郎, 平林 真介, 中村 晃子, 平林 健, 松藤 凡, 小川 高史, 藤原 美恵子, 鈴木 高祐, 小川 千登世, 真部 淳, 細谷 亮太

  小児がん (NPO)日本小児がん学会 46 (プログラム・総会号) 407 - 407 0389-4525 2009/11
• 東京小児がん研究グループ急性リンパ性白血病第16次治療研究におけるマーカー中央診断

  清河 信敬, 恩田 恵子, 平林 真介, 飯島 一智, 福島 敬, 齋藤 正博, 藤本 純一郎, 真部 淳, 康 勝好, 熊谷 昌明, 小原 明, 林 泰秀, 花田 良二, 土田 昌宏

  小児がん (NPO)日本小児がん学会 46 (プログラム・総会号) 226 - 226 0389-4525 2009/11
• 日本人小児ALLにおけるBFM95 protocol Mに基づいた5g/m2 MTX投与の安全性に関する検討

  大隅 朋生, 小川 千登世, 康 勝好, 嶋 晴子, 三春 晶嗣, 大久保 淳, 真部 淳, 嶋田 博之

  小児がん (NPO)日本小児がん学会 46 (プログラム・総会号) 229 - 229 0389-4525 2009/11
• 治療中再発に対してimatinib併用Hyper-CVAD療法による第2寛解導入後にHLA一致同胞間移植を行ったPh+ALLの2例

  有馬 慶太郎, 長谷川 大輔, 中島 健太郎, 吉田 健一, 平林 真介, 神谷 尚宏, 小川 千登世, 小澤 美和, 真部 淳, 細谷 亮太

  小児がん (NPO)日本小児がん学会 46 (プログラム・総会号) 231 - 231 0389-4525 2009/11
• Parvovirus B19感染によりaplastic crisisを来たしたcongenital dyserythropoietic anemia type 2の1例

  笠井 恵美, 神谷 尚宏, 長谷川 大輔, 中島 健太郎, 吉田 健一, 小川 千登世, 小澤 美和, 真部 淳, 細谷 亮太

  小児がん (NPO)日本小児がん学会 46 (プログラム・総会号) 302 - 302 0389-4525 2009/11
• 小児がん患児のきょうだいにおける心理・社会的問題の検討 きょうだいの心理的現状

  小林 明雪子, 小澤 美和, 阿佐美 百合子, 長谷川 大輔, 小川 千登世, 石田 也寸志, 真部 淳, 細谷 亮太

  小児がん (NPO)日本小児がん学会 46 (プログラム・総会号) 346 - 346 0389-4525 2009/11
• 小児がん患児のきょうだいにおける心理・社会的問題の検討 きょうだい自身の意見

  小林 明雪子, 小澤 美和, 阿佐美 百合子, 長谷川 大輔, 小川 千登世, 石田 也寸志, 真部 淳, 細谷 亮太

  小児がん (NPO)日本小児がん学会 46 (プログラム・総会号) 346 - 346 0389-4525 2009/11
• 家族性網膜芽細胞腫の治療後に2次性の横紋筋肉腫を発症した一例

  中島 健太郎, 山本 剛士, 笠井 恵美, 吉田 健一, 平林 真介, 神谷 尚宏, 長谷川 大輔, 小川 千登世, 石田 也寸志, 小澤 美和, 真部 淳, 細谷 亮太

  小児がん (NPO)日本小児がん学会 46 (プログラム・総会号) 369 - 369 0389-4525 2009/11
• MYCN増幅の獲得とともに進行性の経過をたどった神経芽腫StageIVの乳児例

  吉田 健一, 真部 淳, 山本 剛士, 中島 健太郎, 平林 真介, 神谷 尚宏, 長谷川 大輔, 小川 千登世, 小澤 美和, 中村 晃子, 平林 健, 藤原 美恵子, 鈴木 高祐, 中川 温子, 上條 岳彦, 中川原 章, 細谷 亮太

  小児がん (NPO)日本小児がん学会 46 (プログラム・総会号) 370 - 370 0389-4525 2009/11
• 小児がんに罹患した子どもの同胞への心理面でのケア 弟を亡くした3歳児の事例から

  武田 洋子, 小澤 美和, 相良ローゼンマイヤ みはる, 真部 淳, 小川 千登世, 長谷川 大輔, 神谷 尚宏, 平林 真介, 吉田 健一, 中島 健太郎, 山本 剛士, 細谷 亮太

  小児がん (NPO)日本小児がん学会 46 (プログラム・総会号) 416 - 416 0389-4525 2009/11
• 小児がん患者が退院後に抱える病気や体調面に関する困難の検討

  武井 優子, 尾形 明子, 鈴木 伸一, 小澤 美和, 盛武 浩, 平井 啓, 真部 淳

  小児がん (NPO)日本小児がん学会 46 (プログラム・総会号) 419 - 419 0389-4525 2009/11
• The ex vivo production of ammonia predicts L-asparaginase biological activity in children with acute lymphoblastic leukemia

  Shizuka Watanabe, Kumiko Miyake, Chitose Ogawa, Haruna Matsumoto, Kenichi Yoshida, Shinsuke Hirabayashi, Daisuke Hasegawa, Tadao Inoue, Junko Kizu, Reiko Machida, Akira Ohara, Ryota Hosoya, Atsushi Manabe

  INTERNATIONAL JOURNAL OF HEMATOLOGY 90 (3) 347 - 352 0925-5710 2009/10 [Refereed][Not invited]
   

  Patients with acute lymphoblastic leukemia (ALL), who develop antiasparaginase antibodies without clinical allergic reactions ("silent inactivation'') during L-asparaginase (L-Asp) treatment, have poor outcomes. Ammonia is produced by hydrolysis of asparagine by L-Asp. We postulated that plasma ammonia level might reflect the biological activity of L-Asp. Five children with ALL treated according to the Tokyo Children's Cancer Study Group (TCCSG) protocol were enrolled. Plasma ammonia levels were analyzed immediately and 1 h after incubation at room temperature and "ex vivo ammonia production'' was defined as increase in ammonia concentration. Ex vivo ammonia production well correlated with L-Asp activity (r = 0.882, P < 0.01, n = 23). It always exceeded 170 mu g/dL (170-345 mu g/dL) in induction therapy. We found 3 patients whose ammonia production was negligible during later phases of therapy. Antiasparaginase antibody was detected and L-Asp activity decreased in these patients. Ex vivo ammonia production is a surrogate marker of L-Asp biological activity.
• Detection of submicroscopic disease in the bone marrow and unaffected testis of a child with T-cell acute lymphoblastic leukemia who experienced "isolated" testicular relapse

  Keitaro Arima, Daisuke Hasegawa, Chitose Ogawa, Itaru Kato, Toshihiro Imamura, Ayako Takusagawa, Hiroka Takahashi, Yoshiro Kitagawa, Toshinari Hori, Masahito Tsurusawa, Atsushi Manabe, Ryota Hosoya

  INTERNATIONAL JOURNAL OF HEMATOLOGY 90 (3) 370 - 373 0925-5710 2009/10 [Refereed][Not invited]
   

  Testicular relapse has an impact on the prognosis of boys with acute lymphoblastic leukemia (ALL). Because isolated testicular relapse often precedes hematological relapse, systemic therapy is required in addition to local therapy. However, a rationale for the use of a combination of systemic chemotherapy and local therapy is unclear. A 12-year-old boy with T-ALL suffered from isolated testicular relapse at 27 months after diagnosis. He was successfully treated with systemic chemotherapy with orchiectomy and prophylactic irradiation to the contralateral testis. We retrospectively estimated the minimal residual disease in the bone marrow (BM) and the testis by detection of clone-specific T-cell receptor rearrangement of leukemic cells. We detected leukemic cells in the affected testis at relapse, as well as in the BM at initial diagnosis. In addition, we confirmed submicroscopic disease in the unaffected testis and the BM at relapse. We conclude that molecular analysis could reveal the submicroscopic disease in the patient with apparently isolated testicular relapse. This finding may provide a rationale for intensified systemic treatment of patients with isolated testicular relapse.
• 乳癌患者の闘病生活がその子どもへ与える心理・行動学影響

  小澤 美和, 伊藤 ゆかり, 真部 淳, 山内 英子, 中村 清吾, 細谷 亮太

  日本癌治療学会誌 (一社)日本癌治療学会 44 (2) 845 - 845 0021-4671 2009/09
• 発作性の左下肢感覚異常に引き続いて部分運動発作重積状態を呈した右頭頂葉てんかんの一例(A case of right parietal lobe epilepsy showing repetitive paroxysmal irritation of left lower extremity developing clonic seizure of left leg)

  笠井 恵美, 山本 剛士, 吉田 健一, 中島 健太郎, 小澤 美和, 真部 淳, 草川 功, 細谷 亮太, 荻原 正明

  てんかん研究 27 (2) 266 - 266 0912-0890 2009/09
• Metachronous gliomas following cranial irradiation for mixed germ cell tumors

  Akari Makidono, Nobuo Kobayashi, Yukihisa Saida, Atsushi Manabe, Jiro Kawamori, Koyu Suzuki

  CHILDS NERVOUS SYSTEM 25 (6) 713 - 718 0256-7040 2009/06 [Refereed][Not invited]
   

  Cranial irradiation has been widely used as a therapeutic tool for treating various lesions, particularly neoplastic diseases. Even though radiation therapy is usually well-tolerated, it occasionally causes clinically significant long-term toxicity such as radiation necrosis and irradiation-related arteriopathy with stroke. The development of neoplasms following therapeutic cranial irradiation is also rare, but may cause serious and potentially fatal complications. Various radiation-induced tumors, including meningioma, glioma, and sarcoma have been reported (Child Nerv Syst 24:793-805, 12). However, metachronous intracranial double tumors induced by radiation therapy are extremely rare. In here, we report a case of metachronous different gliomas including astrocytoma and glioblastoma following irradiation therapy after 41 and 46 months, respectively.
• 9 colorフローサイトメトリーによる小児白血病のマーカー解析

  清河 信敬, 恩田 恵子, 高野 邦彦, 藤本 純一郎, 真部 淳, 康 勝好, 小原 明, 林 泰秀, 花田 良二, 土田 昌宏

  Cytometry Research (一社)日本サイトメトリー学会 19 (抄録集) 56 - 56 0916-6920 2009/06
• Correlation of Clinical Features With the Mutational Status of GM-CSF Signaling Pathway-Related Genes in Juvenile Myelomonocytic Leukemia

  Nao Yoshida, Hiroshi Yagasaki, Yinyan Xu, Kazuyuki Matsuda, Ayami Yoshimi, Yoshiyuki Takahashi, Asahito Hama, Nobuhiro Nishio, Hideki Muramatsu, Nobuhiro Watanabe, Kimikazu Matsumoto, Koji Kato, Junichi Ueyama, Hiroko Inada, Hiroaki Goto, Miharu Yabe, Kazuko Kudo, Junichi Mimaya, Akira Kikuchi, Atsushi Manabe, Kenichi Koike, Seiji Kojima

  PEDIATRIC RESEARCH 65 (3) 334 - 340 0031-3998 2009/03 [Refereed][Not invited]
   

  Mutations in RAS, neurofibromatosis type 1 (NF1), and PTPN11, constituents of the granulocyte-macrophage colony-stimulating factor signaling pathway, have been recognized in patients with juvenile myelomonocytic leukemia (JMML). We assessed 71 children with JMML for NRAS, KRAS. and PTPN11 mutations and evaluated their clinical significance. Of the 71 patients, three had been clinically diagnosed with neurofibromatosis type 1, and PTPN11 and NRAS/KRAS mutations were found in 32 (45%) and 13 (18%) patients, respectively. No Simultaneous aberrations were found. Compared with patients with RAS Mutation or without any aberrations, patients with PTPN11 mutation were significantly older at diagnosis and had higher fetal Hb levels, both of which have been recognized as poor prognostic factors. As was expected, overall survival was lower for patients with the PTPN11 mutation than for those without (25 versus 64%; p = 0.0029). In an analysis of 48 patients who received hematopoietic stein cell transplantation, PTPN11 mutations were also associated with poor prognosis for survival. Mutation in PTPN11 was the only unfavorable factor for relapse after hematopoietic stem cell transplantation (p = 0.001). All patients who died after relapse had PTPN11 mutation. These results suggest that JMML with PTPN11 mutation might be a distinct subgroup with specific clinical characteristics and poor outcome.
• 当院乳児健診受診児における排便状況と関連因子の検討

  中川 真智子, 鶴田 志緒, 中村 晃子, 小澤 美和, 真部 淳, 草川 功, 松藤 凡, 細谷 亮太

  日本小児科学会雑誌 (公社)日本小児科学会 113 (2) 350 - 350 0001-6543 2009/02
• 頸部絞扼事故を契機に診断した広範性発達障害の一例

  山本 剛士, 笠井 恵美, 吉田 健一, 中島 健太郎, 平林 真介, 有馬 慶太郎, 小澤 美和, 真部 淳, 草川 功, 細谷 亮太

  日本小児科学会雑誌 (公社)日本小児科学会 113 (2) 359 - 359 0001-6543 2009/02
• 親と死別する子どもへの介入の経験

  小澤 美和, 真部 淳, 石田 也寸志, 草川 功, 細谷 亮太

  日本小児科学会雑誌 (公社)日本小児科学会 113 (2) 457 - 457 0001-6543 2009/02
• 聖路加国際病院のレジデント教育(第14報) 後期研修医の受け入れを開始してから

  比嘉 千明, 吉田 健一, 中島 健太郎, 有馬 慶太郎, 平林 信介, 小澤 美和, 真部 淳, 草川 功, 細谷 亮太

  日本小児科学会雑誌 (公社)日本小児科学会 113 (2) 464 - 464 0001-6543 2009/02
• 01. 脾臓摘出術を先行して同種臍帯血移植を行った再発急性巨核芽球性白血病の1例(一般演題,第22回日本小児脾臓研究会)

  長谷川 大輔, 神谷 尚宏, 吉田 健一, 中島 健太郎, 有馬 健太郎, 平林 真介, 中村 晃子, 平林 健, 松藤 凡, 小川 高史, 藤原 美恵子, 鈴木 高祐, 小川 千登世, 真部 淳, 細谷 亮太

  日本小児外科学会雑誌 特定非営利活動法人 日本小児外科学会 45 (4) 803 - 803 2009
• A conditioning regimen of busulfan, fludarabine, and melphalan for allogeneic stem cell transplantation in children with juvenile myelomonocytic leukemia

  Miharu Yabe, Masahiro Sako, Hiromasa Yabe, Yuko Osugi, Hidemitsu Kurosawa, Taemi Nara, Mika Tokuyama, Souichi Adachi, Chie Kobayashi, Masakatsu Yanagimachi, Yoshitoshi Ohtsuka, Yozo Nakazawa, Chitose Ogawa, Atsushi Manabe, Seiji Kojima, Tatsutoshi Nakahata

  PEDIATRIC TRANSPLANTATION 12 (8) 862 - 867 1397-3142 2008/12 [Refereed][Not invited]
   

  A pilot study was undertaken using a myeloablative conditioning with fludarabine, busulfan, and melphalan to improve the outcome of HSCT in 10 children, aged six months to six yr, with JMML. All patients were conditioned with oral busulfan (560 mg/m(2)), fludarabine (120 mg/m(2)), and melphalan (180-210 mg/m(2)) prior to HSCT, and received stem cells from bone marrow in seven cases, and from cord blood in three cases. Engraftment was documented in eight patients, whereas graft failure occurred in two, one of whom had received HLA-mismatched cord blood and other had received bone marrow from HLA-mismatched mother. Three patients, including two in who graft failure had occurred, relapsed. Five patients developed acute GVHD and two developed chronic GVHD. Seven patients are alive and in remission 27-69 months after transplantation. Thus, our study showed that HSCT following conditioning with fludarabine, busulfan, and melphalan was well tolerated and appeared to be effective for JMML.
• Clinicopathological characteristics of erythroblast-rich RAEB and AML M6a in children

  Yuko Honda, Atsushi Manabe, Masahiro Tsuchida, Yuji Zaike, Atsuko Masunaga, Masami Inoue, Ryoji Kobayashi, Yoshitoshi Ohtsuka, Akira Kikuchi, Tatsutoshi Nakahata

  INTERNATIONAL JOURNAL OF HEMATOLOGY 88 (5) 524 - 529 0925-5710 2008/12 [Refereed][Not invited]
   

  The distinction between RAEB, RAEB-T and AML M6a is difficult when erythroblasts in the bone marrow (BM) exceed 50%. We analyzed 19 children (2 RAEB, 13 RAEB-T and 4 AML M6a) enrolled in a prospective pathological central review in Japan and divided them into two groups according to the myeloblasts percentage among non-erythroid cells in BM: group A (n = 8), 5-19% myeloblasts; group B (n = 11), 20% or more myeloblasts. Their characteristics were very similar except for the number of myeloblasts. The median WBC was in the range of 1.0-5.0 x 10(9) L(-1), the median Hb was around 7.5 g/dL, the median MCV was greater than 90 fL and both group had Auer rods at 60-65%. Severe multi-lineage dysplasia was observed in most of the patients in two groups. Six with group A and seven with group B treated with AML type chemotherapy achieved complete remission. Five with group A and seven with group B undergoing SCT are alive at a median of 3 years after diagnosis. Erythroblast-rich RAEB and AML M6a in children have similar characteristics and may belong to a single disease entity.
• Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts

  Ghulam J. Mufti, John M. Bennett, Jean Goasguen, Barbara J. Bain, Irith Baumann, Richard Brunning, Mario Cazzola, Pierre Fenaux, Ulrich Germing, Eva Hellstrom-Lindberg, Itsuro Jinnai, Atsushi Manabe, Akira Matsuda, Charlotte M. Niemeyer, Guillermo Sanz, Masao Tomonaga, Teresa Vallespi, Ayami Yoshimi

  HAEMATOLOGICA-THE HEMATOLOGY JOURNAL 93 (11) 1712 - 1717 0390-6078 2008/11 [Refereed][Not invited]
   

  The classification of myelodysplastic syndromes is based on the morphological criteria proposed by the French-American-British (FAB) and World Health Organization (WHO) groups. Accurate enumeration of blast cells, although essential for diagnosis of myelodysplastic syndrome and for assignment to prognostic groups, is often difficult, due to imprecise criteria for the morphological definition of blasts and promyelocytes. An International Working Group on Morphology of Myelodysplastic Syndrome (IWGM-MDS) of hematopathologists and hematologists expert in the field of myelodysplastic syndrome reviewed the morphological features of bone marrows from all subtypes of myelodysplastic syndrome and agreed on a set of recommendations, including recommendations for the definition and enumeration of blast cells and ring sideroblasts. It is recommended that (1) agranular or granular blast cells be defined (replacing the previous type I, II and III blasts), (2) dysplastic promyelocytes be distinguished from cytologically normal promyelocytes and from granular blast cells, (3) sufficient cells be counted to give a precise blast percentage, particularly at thresholds that are important for diagnosis or prognosis and (4) ring sideroblasts be defined as erythroblasts in which there are a minimum of 5 siderotic granules covering at least a third of the nuclear circumference. Clear definitions and a differential count of a sufficient number of cells is likely to improve precision in the diagnosis and classification of myelodysplastic syndrome. Recommendations should be applied in the context of the WHO classification.
• 肺転移を伴う骨肉腫症例に対する外科的肺転移巣切除の意義

  中村 晃子, 松藤 凡, 平林 健, 小川 千登世, 真部 淳, 細谷 亮太

  小児がん (NPO)日本小児がん学会 45 (プログラム・総会号) 317 - 317 0389-4525 2008/11
• 自家および同種造血幹細胞移植を含む集学的治療を行った右胸壁原発PNETの一例

  神谷 尚宏, 真部 淳, 小川 千登世, 有馬 慶太郎, 平林 真介, 長谷川 大輔, 河守 次郎, 関口 建次, 中村 晃子, 松藤 凡, 細谷 亮太

  小児がん (NPO)日本小児がん学会 45 (プログラム・総会号) 400 - 400 0389-4525 2008/11
• ALL標準危険群に対するTCCSG治療戦略の変遷 TCCSG ALL L-89-12,92-13,95-14,99-15研究

  康 勝好, 小原 明, 磯山 恵一, 梶原 道子, 小池 和俊, 金澤 崇, 嶋田 博之, 田中 竜平, 熊谷 昌明, 木下 明俊, 杉田 完爾, 杉田 憲一, 真部 淳, 林 泰秀, 前田 美穂, 花田 良二, 土田 昌宏

  小児がん (NPO)日本小児がん学会 45 (プログラム・総会号) 189 - 189 0389-4525 2008/11
• 東京小児がん研究グループ(TCCSG)急性リンパ性白血病(ALL)マーカー中央診断におけるT-ALLのマーカー解析

  恩田 恵子, 清河 信敬, 藤本 純一郎, 齋藤 正博, 大喜多 肇, 梶原 道子, 福島 敬, 犬飼 岳史, 牧本 敦, 真部 淳, 康 勝好, 中川 温子, 小原 明, 林 泰秀, 花田 良二, 土田 昌宏

  小児がん (NPO)日本小児がん学会 45 (プログラム・総会号) 190 - 190 0389-4525 2008/11
• 小児急性リンパ性白血病に対する寛解導入療法・早期強化療法の安全性に関する検討 TCCSG L04-16研究

  小嶋 靖子, 太田 節雄, 牧本 敦, 小原 明, 福島 啓太郎, 福島 敬, 犬飼 岳史, 秋山 政晴, 子川 和宏, 矢部 普正, 康 勝好, 清河 信敬, 真部 淳, 林 泰秀, 花田 良二, 土田 昌宏, 東京小児がん研究グループALL委員会・支持療法委員会

  小児がん (NPO)日本小児がん学会 45 (プログラム・総会号) 194 - 194 0389-4525 2008/11
• 小児急性リンパ性白血病標準危険群治療における入院期間の後方視的検討

  望月 慎史, 菊地 陽, 後藤 裕明, 太田 節雄, 富澤 大輔, 廣瀬 衣子, 加藤 陽子, 前田 美穂, 磯山 恵一, 小原 明, 真部 淳, 花田 良二, 土田 昌宏

  小児がん (NPO)日本小児がん学会 45 (プログラム・総会号) 193 - 193 0389-4525 2008/11
• 小児がん経験者のPosttraumatic stress symptomsの時間経過による変化

  小澤 美和, 阿佐美 百合子, 平林 真介, 神谷 尚宏, 長谷川 大輔, 小川 千登勢, 石田 也寸志, 真部 淳, 細谷 亮太

  小児がん (NPO)日本小児がん学会 45 (プログラム・総会号) 222 - 222 0389-4525 2008/11
• 化学療法施行に際してClostridium difficile関連下痢症を発症した6例の検討

  吉田 健一, 長谷川 大輔, 笠井 恵美, 山本 剛士, 中島 健太郎, 比嘉 千明, 平林 真介, 有馬 慶太郎, 神谷 尚宏, 小川 千登世, 稲井 郁子, 小澤 美和, 真部 淳, 細谷 亮太

  小児がん (NPO)日本小児がん学会 45 (プログラム・総会号) 249 - 249 0389-4525 2008/11
• 小児がん患者における知的発達のフォローアップ

  渡辺 静, 阿佐美 百合子, 真部 淳, 長谷川 大輔, 小川 千登世, 小澤 美和, 石田 也寸志, 木津 純子, 細谷 亮太

  小児がん (NPO)日本小児がん学会 45 (プログラム・総会号) 254 - 254 0389-4525 2008/11
• 医療従事者のグリーフケアについての検討

  山本 光映, 永瀬 恭子, 宮坂 真紗規, 中村 かおり, 吉川 久美子, 阿佐美 百合子, 小川 千登世, 小澤 美和, 真部 淳, 細谷 亮太

  小児がん (NPO)日本小児がん学会 45 (プログラム・総会号) 257 - 257 0389-4525 2008/11
• germ cell tumorに対する治療終了から3年後に発症したglioblastomaの症例

  比嘉 千明, 中島 健太郎, 有馬 慶太郎, 平林 真介, 長谷川 大輔, 小川 千登世, 真部 淳, 小澤 美和, 関口 建次, 細谷 亮太, 伊藤 昌徳

  小児がん (NPO)日本小児がん学会 45 (プログラム・総会号) 293 - 293 0389-4525 2008/11
• 川崎病と同時に発症したMyeloid/NK前駆細胞性急性白血病の例

  有馬 慶太郎, 真部 淳, 吉田 健一, 平林 真介, 神谷 尚宏, 長谷川 大輔, 小川 千登世, 小澤 美和, 海老原 康博, 土屋 恵司, 細谷 亮太

  小児がん (NPO)日本小児がん学会 45 (プログラム・総会号) 301 - 301 0389-4525 2008/11
• 小児がん経験者の身体的晩期合併症 身長と体重に対する検討

  小松 なぎさ, 吉田 健一, 中島 健太郎, 平林 真介, 有馬 慶太郎, 神谷 尚宏, 長谷川 大輔, 小川 千登世, 小澤 美和, 真部 淳, 石田 也寸志, 細谷 亮太

  小児がん (NPO)日本小児がん学会 45 (プログラム・総会号) 380 - 380 0389-4525 2008/11
• Successful Reduction of Cranial Irradiation in Children with B Cell Precursor Acute Lymphoblastic Leukemia(ALL) through Four Consecutive ALL Studies: Long-Term Follow-up of ALL in Tokyo Children's Cancer Study Group (TCCSG) L89-12, 92-13, 95-14 and 99-15 Studies

  Chitose Ogawa, Akira Ohara, Atsushi Manabe, Akira Kikuchi, Katsuyoshi Koh, Daisuke Tomizawa, Junya Fujimura, Hiroyasu Inoue, Syosuke Sunami, Eizaburo Ishii, Masaaki Shiohara, Tetsuya Mori, Hiroyuki Takahashi, Yasuhide Hayashi, Ryoji Hanada, Masahiro Tsuchida

  BLOOD 112 (11) 338 - 339 0006-4971 2008/11 [Refereed][Not invited]
  
• Myelodysplastic Syndrome (MDS) and Myeloproliferative Disease (MPD) in Children: A Prospective Registration of 222 Cases

  Shinsuke Hirabayashi, Atsushi Manabe, Shizuka Watanabe, Yuji Zaike, Masahiro Tsuchida, Atsuko Masunaga, Ayami Yoshimi, Masafumi Ito, Akira Kikuchi, Kohichiro Tsuji, Akira Ohara, Seiji Kojima, Tatsutoshi Nakahata

  BLOOD 112 (11) 926 - 926 0006-4971 2008/11 [Refereed][Not invited]
  
• [Pediatric hematology for internists].

  Manabe A

  [Rinsho ketsueki] The Japanese journal of clinical hematology 49 (10) 1341 - 1348 0485-1439 2008/10 [Refereed][Not invited]
  
• Mutation analysis of SIPA1 in patients with juvenile myelomonocytic leukemia

  Hugues de lavallade, Philippe A. Cassier, Reda Bouabdallah, Jean El-Cheikh, Catherine Faucher, Sabine Fuerst, Diane Coso, Danielle Sainty, Christine Arnoulet, Jean-Albert Gastaut, Bruno Chetaille, Luc Xerri, Didier Blaise, Mohamad Mohty

  BRITISH JOURNAL OF HAEMATOLOGY 142 (5) 850 - 851 0007-1048 2008/09 [Refereed][Not invited]
  
• 小児急性リンパ性白血病におけるDay8ITの意義 東京小児がん研究グループ(TCCSG)L99-15研究より

  長谷川 大輔, 真部 淳, 小原 明, 富澤 大輔, 康 勝好, 小川 千登世, 花田 良二, 土田 昌宏

  臨床血液 (一社)日本血液学会-東京事務局 49 (9) 921 - 921 0485-1439 2008/09
• 小児ALLに対する化学療法早期の有効性と安全性の検討 TCCSG ALL L04-16研究

  小原 明, 真部 淳, 牧本 敦, 康 勝好, 小川 千登世, 磯山 恵一, 杉田 憲一, 杉田 完爾, 野口 靖, 太田 節雄, 前田 美穂, 矢部 普正, 金子 隆, 熊谷 昌明, 梶原 道子, 高橋 浩之, 菊地 陽, 嶋田 博之, 外松 学, 福島 敬, 齋藤 正博, 林 泰秀, 花田 良二, 土田 昌宏

  臨床血液 (一社)日本血液学会-東京事務局 49 (9) 921 - 921 0485-1439 2008/09
• 高密度SNPマイクロアレイを用いた本邦の小児急性リンパ芽球性白血病のmolecular karyotyping

  清河 信敬, 加藤 元博, 藤本 純一郎, 宮川 世志幸, 恩田 恵子, 大喜多 肇, 齋藤 正博, 牧本 敦, 真部 淳, 康 勝好, 小原 明, 林 泰秀, 花田 良二, 土田 昌宏, 小川 誠司

  臨床血液 (一社)日本血液学会-東京事務局 49 (9) 1203 - 1203 0485-1439 2008/09
• Significance of the complete clearance of peripheral blasts after 7 days of prednisolone treatment in children with acute lymphoblastic leukemia: the Tokyo Children's Cancer Study Group Study L99-15

  Atsushi Manabe, Akira Ohara, Daisuke Hasegawa, Katsuyoshi Koh, Tomohiro Saito, Nobutaka Kiyokawa, Akira Kikuchi, Hiroyuki Takahashi, Koichiro Ikuta, Yasuhide Hayashi, Ryoji Hanada, Masahiro Tsuchida

  HAEMATOLOGICA-THE HEMATOLOGY JOURNAL 93 (8) 1155 - 1160 0390-6078 2008/08 [Refereed][Not invited]
   

  Background Treatment response has become one of the most important prognostic factors in childhood acute lymphoblastic leukemia. We evaluated the significance of the complete clearance of peripheral leukemic blasts on survival in children with acute lymphoblastic leukemia. Design and Methods Seven hundred and fifty-four children diagnosed with acute lymphoblastic leukemia, consecutively enrolled from 1999 to 2003 in the TCCSG L99-15 study, were eligible for analysis. Patients were stratified into three risk groups based on presenting features, such as age and the leukocyte count before starting the treatment, followed by reclassification into three categories 7 days after prednisolone monotherapy based on the peripheral blast count; 0/mu L (Day8NoBlasts), 1-999/mu L and >= 1,000/mu L. Results After 7 days of prednisolone monotherapy, 249 patients (33%) were classified as Day8NoBlasts, 392 patients (52%) had blast counts of 1-999/mu L, and 113 patients (15%) had blast counts >= 1,000/mu L. The event-free survival for all patients was 79.6 +/- 1.6 (SE)% at 4 years, whereas that for patients with Day8NoBlasts was 90.4 +/- 2.0% (n=249) and the event-free survival for the other patients was 74.2 +/- 2.2% (n=504) (log rank p < 0.001). The event-free survival for Day8NoBlasts patients with B-lineage acute lymphoblastic leukemia and T-cell acute lymphoblastic leukemia was 89.8 +/- 2.1% (n=226) and 95.7 +/- 4.3% (n=23), respectively. In a multivariate analysis, age at diagnosis, the initial white blood cell count, immunophenotype, and gender did not remain as independent risk factors for treatment failure, whereas Day8NoBlasts and marked hyperdiploidy (more than 50 chromosomes) became statistically significant. Conclusions Children with Day8NoBlasts constituted one third of all the cases with childhood acute lymphoblastic leukemia with an excellent outcome, and should be candidates for curative management with less intensive treatment.
• Mutation analysis of AML1 gene in pediatric primary myelodysplastic syndrome and juvenile myelomonocytic leukemia

  Atsuko Masunaga, Toshiyuki Mitsuya, Tsuyoki Kadoftiku, Sanju Iwamoto, Akira Miyazaki, Atsushi Manabe, Yuji Zaike, Masahiro Tsuchida, Tatsutoshi Nakahata

  LEUKEMIA RESEARCH 32 (6) 995 - 997 0145-2126 2008/06 [Refereed][Not invited]
  
• 小児がんの治療における中枢神経障害の検討.

  渡辺静, 阿佐美百合子, 真部淳, 小川千登世, 長谷川大輔, 小澤美和, 木津純子, 井上忠夫, 細谷亮太

  日本小児がん学会雑誌 45(2) 45(2)  2008/06 [Refereed][Not invited]
  
• Picture in Clinical Hematology No. 25

  平林 真介, 吉田 健一, 中島 健太郎, 有馬 慶太郎, 長谷川 大輔, 小川 千登世, 真部 淳, 細谷 亮太

  Rinsho Ketsueki The Japanese Society of Hematology 49 (3) 139 - 139 0485-1439 2008/03/30
• Iodine-131-metaiodobenzyguanidine therapy with reduced-intensity allogeneic stem cell transplantation in recurrent neuroblastoma

  Hiroka Takahashi, Atsushi Manabe, Chiaki Aoyama, Takahiro Kamiya, Itaru Kato, Ayako Takusagawa, Chitose Ogawa, Miwa Ozawa, Ryota Hosoya, Kunihiko Yokoyama

  PEDIATRIC BLOOD & CANCER 50 (3) 676 - 678 1545-5009 2008/03 [Refereed][Not invited]
   

  Neuroblastoma is the most common extracranial solid tumor of childhood, and iodine-131-metaiodobenzylguanidine (MIBG) therapy is a new approach for grade IV neuroblastoma. We describe the case history of a 3-year-old girl with recurrent neuroblastoma who received MIBG therapy with reduced-intensity allogeneic stein cell transplantation (RIST) because of an extensive bone marrow involvement. The post-transplant Course was uneventful and complete chimerism was obtained. Neither acute nor chronic graft-versus-host disease (GVHD) was observed. The patient remained in remission for 3 months after RIST until the second relapse. MIBG therapy combined with RIST warrants further trials.
• Desmoplastic small round cell tumorが疑われた縦隔肉腫の乳児例

  平林 真介, 青山 千晶, 伊藤 雄伍, 今村 壽宏, 加藤 格, 神谷 尚宏, 藤田 真智子, 小澤 美和, 真部 淳, 細谷 亮太, 森本 克, 松藤 凡, 鈴木 高祐, 田中 祐吉, 秦 順一

  小児がん (NPO)日本小児がん学会 45 (1) 36 - 40 0389-4525 2008/02 

  生後3ヵ月女児。呼吸困難を主訴に来院、精査にて左縦隔に巨大腫瘤を認めた。生検を行い、Desmoplastic small round cell tumor(DSRCT)と診断された。化学療法にて腫瘍は縮小傾向を示したが、水頭症を発症、頸椎への浸潤と髄膜播種の所見が認められた。VPシャント挿入後、末梢血幹細胞移植を含む化学療法を施行したが、不幸な転帰を辿った。極めて稀な縦隔原発DSRCTの乳児例を報告する。(著者抄録)
• 小児がん経験者のsexualityを支援するフォローアップ外来を立ち上げて

  巷岡 彩子, 小澤 美和, 鈴木 麻水, 塩田 恭子, 佐藤 孝道, 有馬 慶太郎, 平林 真介, 小川 千登世, 真部 淳, 細谷 亮太

  日本小児科学会雑誌 (公社)日本小児科学会 112 (2) 278 - 278 0001-6543 2008/02
• 聖路加国際病院小児科レジデント教育の現況(第13報) 電子カルテが教育へ及ぼす影響

  有馬 慶太郎, 平林 真介, 中川 真智子, 長谷川 大輔, 小川 千登世, 稲井 郁子, 小澤 美和, 真部 淳, 草川 功, 細谷 亮太

  日本小児科学会雑誌 (公社)日本小児科学会 112 (2) 329 - 329 0001-6543 2008/02
• Wiskott-Aldrich syndrome is an important differential diagnosis in male infants with juvenile myelomonocytic leukemialike features

  Nobuhiro Watanabe, Ayami Yoshimi, Yoshiro Kamachi, Takashi Kawabe, Hideki Muramatsu, Kimikazu Matsumoto, Atsushi Manabe, Seiji Kojima, Koji Kato

  JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY 29 (12) 836 - 838 1077-4114 2007/12 [Refereed][Not invited]
   

  A newborn presented with thrombocytopenia at birth and subsequently developed leukocytosis, monocytosis, and mild hepatomegaly. The bone marrow was normocellular with dysplasia and spontaneous granulocyte-monocyte colony formation was demonstrated. These findings fulfilled the diagnostic criteria of juvenile myelomonocytic leukemia. Then he developed atopic dermatitislike eczema, which led to the consideration of Wiskott-Aldrich syndrome (WAS). Lack of intracellular WASP expression and WASP gene mutation confirmed the diagnosis of WAS. After stem cell transplantation, he is alive in good condition with normal WASP expression. WAS should be considered as a differential diagnosis in male infants with juvenile myelomonocytic leukemialike features.
• The effect of donor leukocyte infusion on refractory pure red blood cell aplasia after allogeneic stem cell transplantation in a patient with myelodysplastic syndrome developing from Kostmann syndrome

  Yasuhiro Ebihara, Atsushi Manabe, Toshihisa Tsuruta, Kumiko Ishikawa, Daisuke Hasegawa, Yoshitoshi Ohtsuka, Hirohide Kawasaki, Kazuo Ogami, Yuka Wada, Tadayasu Kanda, Kohichiro Tsuji

  INTERNATIONAL JOURNAL OF HEMATOLOGY 86 (5) 446 - 450 0925-5710 2007/12 [Refereed][Not invited]
   

  We describe the clinical course of a patient who experienced refractory pure red cell aplasia (PRCA) after undergoing HLA-matched allogeneic peripheral blood stem cell transplantation (allo-PBSCT) for refractory anemia with an excess of blasts in transformation that had evolved from Kostmann syndrome. The treatment for patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) developing from Kostmann syndrome has not been standardized. We treated this patient with allo-PBSCT using a regimen combining high-dose cytosine arabinoside with granulocyte colony-stimulating factor, in addition to total body irradiation and cyclophosphamide without preceding intensive chemotherapy. The donor was ABO incompatible. Myeloid and platelet recoveries were achieved rapidly. Erythroid engraftment was not evident, however, and the patient was given a diagnosis of PRCA. Regimen-related toxicity and graft-versus-host disease (GVHD) were limited. The PRCA did not respond to various therapies, including the discontinuation of immunosuppressants for the induction of chronic GVHD, human recombinant erythropoietin, immunosuppressive treatment with steroids, cyclosporin A, and human anti-CD20 antibody (rituximab). The patient received transfusions 48 times until the resolution of his anemia by donor leukocyte infusion (DLI) at 25 months after PBSCT. He is now clinically well (performance status, 100%) with normal blood cell counts at 5 years after SCT An in vitro study demonstrated that serum from the recipient blocked the differentiation of erythroid cells in the bone marrow. The results indicate that the conditioning regimen we describe seems safe and effective for those who have MDS/AML and that DLI might be a valuable approach for refractory PRCA after ABO-incompatible SCT.
• 小児Castleman病の2例

  有馬 慶太郎, 稲井 郁子, 真部 淳, 長谷川 大輔, 小川 千登世, 細谷 亮太, 荒木 夕宇子, 中村 晃子, 松藤 凡, 竹内 敏雄, 三輪 操子, 上松 一永

  小児感染免疫 (一社)日本小児感染症学会 19 (4) 490 - 490 0917-4931 2007/12
• 自家末梢血幹細胞移植後に消化管出血、VOD、肺出血を来たし死亡した神経芽腫の1例

  吉田 健一, 長谷川 大輔, 平林 真介, 有馬 慶太郎, 小川 千登世, 真部 淳, 中村 晃子, 松藤 凡, 細谷 亮太

  小児がん (NPO)日本小児がん学会 44 (プログラム・総会号) 237 - 237 0389-4525 2007/12
• 肺転移を伴ったWilms腫瘍に対して治療終了のタイミングを開胸肺生検で決定した2例についての検討

  中村 晃子, 松藤 凡, 平林 健, 小川 千登世, 真部 淳, 細谷 亮太

  小児がん (NPO)日本小児がん学会 44 (プログラム・総会号) 356 - 356 0389-4525 2007/12
• 診断に難渋した左上顎洞腫瘍の1女児例

  苛原 香, 真部 淳, 小川 千登世, 長谷川 大輔, 田草川 彩子, 高橋 宏佳, 今西 康次, 有馬 慶太郎, 平林 真介, 細谷 亮太, 中村 晃子, 荒木 夕宇子, 松藤 凡, 鈴木 高祐, 岸本 誠司

  小児がん (NPO)日本小児がん学会 44 (プログラム・総会号) 367 - 367 0389-4525 2007/12
• 急性リンパ性白血病の染色体・遺伝子異常と予後 TCCSG ALL L95-14・L99-15研究

  高橋 浩之, 小原 明, 齋藤 正博, 福島 敬, 梶原 道子, 小嶋 靖子, 菊地 陽, 小川 千登世, 前田 美穂, 塩原 正明, 康 勝好, 真部 淳, 林 泰秀, 花田 良二, 土田 昌宏, 東京小児がん研究グループ(TCCSG)ALL委員会

  小児がん (NPO)日本小児がん学会 44 (プログラム・総会号) 179 - 179 0389-4525 2007/12
• 東京小児がん研究グループALL治療第16次研究(TCCSG L04-16/06-16)におけるマーカー中央診断

  清河 信敬, 藤本 純一郎, 田口 智子, 塩沢 裕介, 斉藤 洋平, 大喜多 肇, 梶原 道子, 福島 敬, 河崎 裕英, 犬飼 岳史, 牧本 敦, 真部 淳, 康 勝好, 小原 明, 林 泰秀, 花田 良二, 土田 昌宏

  小児がん (NPO)日本小児がん学会 44 (プログラム・総会号) 180 - 180 0389-4525 2007/12
• 1歳の小児急性リンパ性白血病の臨床像及び治療成績の検討 東京小児がん研究グループ(TCCSG)からの報告

  富澤 大輔, 磯山 恵一, 小原 明, 福島 啓太郎, 金子 隆, 加藤 陽子, 野口 靖, 太田 節雄, 嶋田 博之, 矢部 普正, 康 勝好, 真部 淳, 林 泰秀, 花田 良二, 土田 昌宏

  小児がん (NPO)日本小児がん学会 44 (プログラム・総会号) 172 - 172 0389-4525 2007/12
• 骨・軟部腫瘍患児の術前/術後の面接から疾患の受け止め方を考える

  小澤 美和, 阿佐美 百合子, 有馬 慶太郎, 平林 真介, 長谷川 大輔, 小川 千登勢, 真部 淳, 細谷 亮太

  小児がん (NPO)日本小児がん学会 44 (プログラム・総会号) 206 - 206 0389-4525 2007/12
• 小児がん患者長期フォローアップの実践 当院の最近20年間の実態調査

  渡辺 静, 真部 淳, 長谷川 大輔, 小川 千登世, 小澤 美和, 井上 忠夫, 木津 純子, 森本 克, 西村 昴三, 細谷 亮太

  小児がん (NPO)日本小児がん学会 44 (プログラム・総会号) 245 - 245 0389-4525 2007/12
• Acute myeloid leukemia with multifineage dysplasia in children

  Souichi Adachi, Atsushi Manabe, Masue Imaizumi, Takashi Taga, Akio Tawa, Masahito Tsurusawa, Akira Kikuchi, Atsuko Masunaga, Masahiro Tsuchida, Tatsutoshi Nakahata

  INTERNATIONAL JOURNAL OF HEMATOLOGY 86 (4) 358 - 363 0925-5710 2007/11 [Refereed][Not invited]
   

  We retrospectively surveyed pediatric acute myeloid leukemia (AML) patients with multilineage dysplasia treated with the AML 99 and the Children's Cancer and Leukemia Study Group (CCLSG) AML 9805 protocols. We found only 9 AML patients (2.6%) with multilineage dysplasia among the 341 patients with newly diagnosed de novo AML. Eight of the 9 patients obtained complete remission (CR) following the intensive AML-oriented treatments. Three of 7 patients who underwent stem cell transplantation were alive in CR for more than 4 years, and the 2 patients treated only with chemotherapy were alive in CR for more than 30 months. We did not identify any particular chromosomal abnormalities or differentiation according to the French-American-British classification in these 9 patients. No reports have described AML with multilineage dysplasia in children, and the incidence of the disease is expected to be very low. We plan to conduct a prospective pathologic review to select cases with this disease entity in the next Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) AML-05 protocol.
• 上顎洞原発粘液性軟骨肉腫の1女児例

  苛原 香, 真部 淳, 小川 千登世, 平林 真介, 田草川 彩子, 高橋 宏佳, 今西 康次, 有賀 慶太郎, 長谷川 大輔, 細谷 亮太, 中村 晃子, 荒木 夕宇子, 松藤 凡, 鈴木 高祐, 岸本 誠司

  小児がん (NPO)日本小児がん学会 44 (2) 198 - 198 0389-4525 2007/09
• TCCSG L95-14およびL99-15にて治療後に再発した小児急性リンパ性白血病の予後

  小川 千登世, 康 勝好, 金子 隆, 後藤 裕明, 太田 節雄, 真部 淳, 小原 明, 花田 良二, 土田 昌宏

  臨床血液 (一社)日本血液学会-東京事務局 48 (9) 936 - 936 0485-1439 2007/09
• 小児がん経験者のsexualityを支援するfollow up外来を立ち上げて

  巷岡 彩子, 小澤 美和, 鈴木 麻水, 塩田 恭子, 佐藤 孝道, 有馬 慶太郎, 長谷川 大輔, 小川 千登世, 真部 淳, 細谷 亮太

  臨床血液 (一社)日本血液学会-東京事務局 48 (9) 975 - 975 0485-1439 2007/09
• 小児Castleman病の2例

  有馬 慶太郎, 稲井 郁子, 真部 淳, 平林 真介, 高橋 宏佳, 田草川 彩子, 長谷川 大輔, 小川 千登世, 荒木 夕宇子, 中村 晃子, 松藤 凡, 細谷 亮太, 竹内 敏雄, 三輪 操子, 上松 一永

  日本小児科学会雑誌 (公社)日本小児科学会 111 (7) 912 - 912 0001-6543 2007/07
• 小児がん患児のきょうだいにおける心理的問題の検討

  小澤 美和, 泉 真由子, 森本 克, 真部 淳, 細谷 亮太

  日本小児科学会雑誌 (公社)日本小児科学会 111 (7) 847 - 854 0001-6543 2007/07 

  小児がん患児のきょうだい23人を対象に、心理的な現状を知るため、きょうだい自身のself-reportを用いた面接調査を行った。きょうだいへは、特性不安検査、ソーシャルサポート授与感、バウムテスト、ベンダーベシュタルトテストを行い、母親へはきょうだいの背景について問う質問紙とTS式幼児・児童性格診断を行った。その結果、きょうだいは、小児がん患児や慢性疾患々児らと同等で、とくに不安が高い集団ではなかった。誰からのソーシャルサポートを実感しているかという項目に注目すると、きょうだいは、先生や友人からのサポートを患児よりもより高く実感していた。投影法によると、生活年齢に比して理性よりも感情優位の状況であり、心理学的には年齢相当の成長をしていないことが示唆された。更に、精神的エネルギーが少なく、自己存在感が乏しいことがわかった。また、ベンダーゲシュタルトテストから抽出された彼らの情緒指標から、約2分の1のきょうだいたちは精神的に混乱し、情緒不安定な状態であり、約4分の1が逸脱行動をとる可能性が示された。しかし、親から観察されるきょうだいの情動、対人関係、体質についてはすべて年齢相当で問題ないと評価されており、親は患児のことで頭がいっぱいで、きょうだいの不安定感や行動の問題などに気づいていない傾向が示された。
• Spontaneous improvement of hematologic abnormalities in patients having juvenile myelomonocytic leukemia with specific RAS mutations

  Kazuyuki Matsuda, Akira Shimada, Nao Yoshida, Atsushi Ogawa, Akihiro Watanabe, Shuhei Yajima, Susumu Iizuka, Kazutoshi Koike, Fumio Yanai, Keiichiro Kawasaki, Masakatsu Yanagimachi, Akira Kikuchi, Yoshitoshi Ohtsuka, Eiko Hidaka, Kazuyoshi Yamauchi, Miyuki Tanaka, Ryu Yanagisawa, Yozo Nakazawa, Masaaki Shiohara, Atsushi Manabe, Seiji Kojima, Kenichi Koike

  BLOOD 109 (12) 5477 - 5480 0006-4971 2007/06 [Refereed][Not invited]
   

  Of 11 children with juvenile myelomonocytic leukemia (JMML) carrying RAS mutations (8 with NRAS mutations, 3 with KRAS2 mutations), 5 had a profound elevation in either or both the white blood cells and spleen size at diagnosis. Three patients had no or modest hepatosplenomegaly and mild leukocytosis at presentation but subsequently showed a marked increase in spleen size with or without hematologic exacerbation, for which nonintensive chemotherapy was initiated. The other three patients with NRAS or KRAS2 glycine to serine substitution received no chemotherapy, but hematologic improvement has been observed during a 2- to 4-year follow up. In the third group, all hematopoletic cell lineages analyzed had the RAS mutations at the time of hematologic improvement, whereas DNA obtained from the nails had the wild type. Additionally, numbers of circulating granulocyte-macrophage progenitors were significantly reduced during the clinical course. Thus, some patients with JMMIL with specific RAS mutations may have spontaneously improving disease.
• 当科で経験したOncologic surgical emergencyについての検討

  中村 晃子, 松藤 凡, 荒木 夕宇子, 真部 淳, 草川 功, 細谷 亮太

  日本小児救急医学会雑誌 (一社)日本小児救急医学会 6 (1) 116 - 116 1346-8162 2007/06
• Development of diffuse large B cell lymphoma during the maintenance therapy for B-lineage acute lymphoblastic leukemia

  Itaru Kato, Atsushi Manabe, Chiaki Aoyama, Takahiro Kamiya, Tsuyoshi Morimoto, Hiroshi Matsufuji, Koyu Suzuki, Yoshiro Kitagawa, Toshinori Hori, Masahito Tsurusawa, Nobutaka Kiyokawa, Junichiro Fujimoto, Ryota Hosoya

  PEDIATRIC BLOOD & CANCER 48 (2) 230 - 232 1545-5009 2007/02 [Refereed][Not invited]
   

  Non-Hodgkin lymphoma (NHL) is a very rare complication of acute lymphoblastic leukemia (ALL). A Japanese boy presented with B-lineage ALL at the age of 2.5. He was treated with chemotherapy for standard-risk ALL. While he was receiving maintenance treatment 2 years and 9 months after the diagnosis of ALL, diffuse large B cell lymphoma(DLBL) was diagnosed from a biopsy of an abdominal mass. DLBL was treated by surgical resection followed by chemotherapy for 6 months. The patient has been free from the recurrence of ALL or DLBL for 16 months after the development of DLBL.
• 小児Castleman病の2例

  有馬 慶太郎, 稲井 郁子, 真部 淳, 小川 千登世, 荒木 夕宇子, 松藤 凡, 竹内 敏雄, 三輪 操子, 上松 一永, 細谷 亮太

  日本小児科学会雑誌 (公社)日本小児科学会 111 (2) 249 - 249 0001-6543 2007/02
• 聖路加国際病院小児科レジデント教育の現況(第12報) 新臨床研修制度への対応

  今村 壽宏, 有馬 慶太郎, 平林 真介, 高橋 宏佳, 田草川 彩子, 小澤 美和, 真部 淳, 草川 功, 細谷 亮太

  日本小児科学会雑誌 (公社)日本小児科学会 111 (2) 316 - 316 0001-6543 2007/02
• Immunosuppressive therapy in children with refractory anemia: Results of Japanese childhood MDS study group trial (MDS99).

  Daisuke Hasegawa, Hiroshi Yagasaki, Yoshitoshi Ohtsuka, Masami Inoue, Akira Kikuchi, Akira Ohara, Masahiro Tsuchida, Seiji Kojima, Atsushi Manabe, Tatsutoshi Nakahata

  BLOOD 108 (11) 756A - 756A 0006-4971 2006/11 [Refereed][Not invited]
  
• 健常腎温存のための治療方針選択に苦慮した、両側ウィルムス腫瘍(stage V,FRN)の1例

  荒木 夕宇子, 松藤 凡, 中村 晃子, 細谷 亮太, 真部 淳, 小川 千登世

  日本小児血液学会雑誌 日本小児血液学会 20 (5) 332 - 332 0913-8706 2006/10
• 当院で経験したユーイング肉腫ファミリー腫瘍10例の治療についての検討

  中村 晃子, 松藤 凡, 荒木 夕宇子, 道川 武紘, 小川 千登世, 真部 淳, 細谷 亮太

  日本小児血液学会雑誌 日本小児血液学会 20 (5) 402 - 402 0913-8706 2006/10
• 下大静脈合併切除を行ったStageIVのWilms腫瘍

  道川 武紘, 松藤 凡, 荒木 夕宇子, 中村 晃子, 小川 千登世, 真部 淳, 細谷 亮太

  日本小児血液学会雑誌 日本小児血液学会 20 (5) 411 - 411 0913-8706 2006/10
• TEL/AML1陽性急性リンパ性白血病におけるday15BM芽球比率の重要性

  野口 靖, 小原 明, 真部 淳, 太田 節雄, 高橋 浩之, 福島 啓太郎, 杉田 憲一, 小川 千登世, 菊池 陽, 康 勝好, 生田 孝一郎, 林 泰秀, 花田 良二, 土田 昌宏

  日本小児血液学会雑誌 日本小児血液学会 20 (5) 500 - 500 0913-8706 2006/10
• TCCSG L95-14およびL99-15にて治療後に再発した小児急性リンパ性白血病の予後

  小川 千登世, 康 勝好, 金子 隆, 太田 節雄, 後藤 裕明, 真部 淳, 小原 明, 花田 良二, 土田 昌宏

  日本小児血液学会雑誌 日本小児血液学会 20 (5) 505 - 505 0913-8706 2006/10
• 急性リンパ性白血病標準危険群・中間危険群に対する6MP/MTX漸増間歇維持療法の有効性の検討

  外松 学, 小原 明, 真部 淳, 金子 隆, 前田 美穂, 中舘 尚也, 福島 敬, 熊谷 昌明, 三浦 信之, 加藤 陽子, 生田 孝一郎, 林 泰秀, 花田 良二, 土田 昌宏, 東京小児がん研究グループ

  日本小児血液学会雑誌 日本小児血液学会 20 (5) 360 - 360 0913-8706 2006/10
• 最近当院で経験した骨肉腫の10症例

  田草川 彩子, 真部 淳, 加藤 格, 高橋 宏佳, 今村 壽宏, 有馬 慶太郎, 平林 真介, 長谷川 大輔, 小林 明雪子, 小川 千登世, 小澤 美和, 細谷 亮太, 真鍋 淳, 松本 誠一, 川口 智義

  日本小児血液学会雑誌 日本小児血液学会 20 (5) 398 - 398 0913-8706 2006/10
• 小児期に発症し、成人に持ち越した急性リンパ性白血病の2症例

  高橋 宏佳, 小澤 美和, 田草川 彩子, 長谷川 大輔, 小川 千登世, 真部 淳, 細谷 亮太, 塚崎 百合子, 西田 知佳子

  日本小児血液学会雑誌 日本小児血液学会 20 (5) 425 - 425 0913-8706 2006/10
• 小児悪性腫瘍患者における中枢神経障害の検討

  渡辺 静, 塚崎 百合子, 田草川 彩子, 長谷川 大輔, 小林 明雪子, 小川 千登世, 小澤 美和, 真部 淳, 細谷 亮太, 井上 忠夫, 木津 純子

  日本小児血液学会雑誌 日本小児血液学会 20 (5) 435 - 435 0913-8706 2006/10
• 心タンポナーデを合併したリンパ管腫症の1例

  田草川 彩子, 小川 千登世, 高橋 宏佳, 加藤 格, 今村 壽宏, 小澤 美和, 真部 淳, 細谷 亮太

  日本小児血液学会雑誌 日本小児血液学会 20 (5) 454 - 454 0913-8706 2006/10
• 東京小児がん研究グループTCCSG小児急性リンパ性白血病プロトコールALL L99-15研究中間解析

  小原 明, 真部 淳, 康 勝好, 磯山 恵一, 杉田 憲一, 杉田 完爾, 太田 節雄, 沖本 由理, 木下 明俊, 前田 美穂, 矢部 普正, 金子 隆, 熊谷 昌明, 上條 岳彦, 梶原 道子, 高橋 浩之, 菊地 陽, 小川 千登世, 外松 学, 福島 敬, 齋藤 正博, 別所 文雄, 生田 孝一郎, 齋藤 友博, 林 泰秀, 花田 良二, 土田 昌宏, 東京小児がん研究グループ

  臨床血液 (一社)日本血液学会-東京事務局 47 (9) 1013 - 1013 0485-1439 2006/09
• 小児ALLにおけるPred反応性最良好群(Day8末梢血芽球ゼロ)の治療成績 TCCSG L99-15研究

  真部 淳, 小原 明, 康 勝好, 太田 節雄, 小川 千登世, 加藤 陽子, 後藤 裕明, 齋藤 正博, 嶋田 博之, 高橋 浩之, 富沢 大輔, 中舘 尚也, 野口 靖, 福島 啓太郎, 福島 敬, 牧本 敦, 三浦 信之, 林 泰秀, 生田 孝一郎, 齋藤 友博, 熊谷 昌明, 花田 良二, 土田 昌宏

  臨床血液 (一社)日本血液学会-東京事務局 47 (9) 1030 - 1030 0485-1439 2006/09
• 初発時hyperleukocytosisをきたしたT cell ALLの3例

  田草川 彩子, 真部 淳, 高橋 宏佳, 今村 壽宏, 加藤 格, 神谷 尚宏, 長谷川 大輔, 小林 明雪子, 稲井 郁子, 小川 千登世, 小澤 美和, 細谷 亮太

  臨床血液 (一社)日本血液学会-東京事務局 47 (9) 1257 - 1257 0485-1439 2006/09
• Picture in Clinical Hematology

  真部 淳

  Rinsho Ketsueki The Japanese Society of Hematology 47 (4) 255 - 255 0485-1439 2006/04/30
• Irinotecan for children with relapsed solid tumors

  T Shitara, A Shimada, R Hanada, T Matsunaga, K Kawa, H Mugishima, T Sugimoto, JI Mimaya, A Manabe, M Tsurusawa, Y Tsuchida

  PEDIATRIC HEMATOLOGY AND ONCOLOGY 23 (2) 103 - 110 0888-0018 2006/03 [Refereed][Not invited]
   

  Irinotecan is expected to become a new drug for childhood solid tumors. Sixteen children with relapsed solid tumors received irinotecan 180 mg/m(2)/day for 3 consecutive days, repeated once after 25 days off. Their original tumors were neuroblastoma in 7, rhabdomyosarcoma in 3, nephroblastoma and undifferentiated sarcoma in 2 each, and primitive neuroectodermal tumor and leiomyosarcoma in I each. The average age at trials was 6 years. Partial response was achieved in 5 (31.3 %) (neuroblastoma, rhabdomyosarcoma, nephroblastoma, undifferentiated sarcoma, and leiomyosarcoma), and decrease in tumor marker in the other 2. Irinotecan appears promising, and could become included in the first-line treatment.
• 聖路加国際病院小児科レジデント教育の現況(第11報) 新臨床研修制度が始まって

  神谷 尚宏, 伊藤 雄伍, 今村 寿宏, 加藤 格, 小川 千登世, 稲井 郁子, 小澤 美和, 真部 淳, 草川 功, 細谷 亮太

  日本小児科学会雑誌 (公社)日本小児科学会 110 (2) 282 - 282 0001-6543 2006/02
• 学童期に経験した親との喪失体験の違いによる受容過程についての考察

  小澤 美和, 一ノ橋 祐子, 小川 千登世, 稲井 郁子, 森本 克, 真部 淳, 草川 功, 細谷 亮太

  日本小児科学会雑誌 (公社)日本小児科学会 110 (2) 330 - 330 0001-6543 2006/02
• P-52 最近10年間に当院で経験した10例のEwing肉腫/pPNETについての検討(示説13 腫瘍2・代謝,第43回 日本小児外科学会総会)

  中村 晃子, 松藤 凡, 荒木 夕宇子, 細谷 亮太, 真部 淳

  日本小児外科学会雑誌 特定非営利活動法人 日本小児外科学会 42 (3) 445 - 445 2006
• 眼窩周囲炎・副鼻腔炎に続発した眼窩蜂窩織炎の1例

  加藤 格, 今村 壽宏, 伊藤 雄伍, 神谷 尚宏, 藤田 真智子, 青山 千昌, 安西 有紀, 稲井 郁子, 小澤 美和, 森本 克, 真部 淳, 草川 功, 細谷 亮太, 小暮 朗子, 大越 貴志子, 山口 達夫

  小児科臨床 (株)日本小児医事出版社 59 (1) 131 - 136 0021-518X 2006/01 

  左眼窩周囲の腫脹を主訴に入院した1歳男児.左眼窩蜂窩織炎の診断にて抗生剤投与開始するものの,左眼窩内の脂肪織に炎症が波及し圧迫による視神経への影響を認めた.外科的処置まで考慮されたが抗生剤の追加投与,ステロイド投与にて症状改善を認めた.年少児の眼窩蜂窩織炎では眼球突出や眼球運動制限といった眼窩内病変によって起こる症状が評価しにくいため,不可逆的な視神経障害を来す前にCT,MRIなどによる速やかな画像検索を行い,的確な治療が必要である(著者抄録)
• RAS-blocking bisphosphonate zoledronic acid inhibits the abnormal proliferation and differentiation of juvenile myelomonocytic leukemia cells in vitro

  Y Ohtsuka, A Manabe, H Kawasaki, D Hasegawa, Y Zaike, S Watanabe, T Tanizawa, T Nakahata, K Tsuji

  BLOOD 106 (9) 3134 - 3141 0006-4971 2005/11 [Refereed][Not invited]
   

  Juvenile myelomonocytic leukemia (JMML) is a clonal myeloproliferative/myelodysplastic disorder of early childhood with a poor prognosis. JMML cells are characterized by hypersensitivity to granulocyte-macrophage colony-stimulating factor (GMCSF) caused by a continuously activated GM-CSF receptor-retrovirus-associated sequence (RAS) signal transduction pathway through various molecular mechanisms, resulting in spontaneous GM colony formation in vitro. Bisphosphonate zoledronic acid (ZOL), a RAS-blocking compound, suppressed colony formation from bone marrow (BM) cells of 8 patients with JMML and 5 healthy control subjects without and with GM-CSF (10 ng/mL), respectively, in a dose-dependent manner in clonal culture. At 10 mu M ZOL, however, spontaneous GM colony formation from JMML BM cells decreased to 3%, but the formation of G colonies containing granulocytes, but no macrophages, was enhanced, whereas 40% of GM colonies were retained and G colony formation was not affected in culture of normal BM cells with GM-CSF. In suspension culture, cytochemical and flow cytometric analyses showed that 10 mu M ZOL also inhibited spontaneous proliferation and differentiation along monocyte/macrophage lineage of JMML BM cells but not the development of normal BM cells by GM-CSF. The inhibitory effect of ZOL on JMML cells was confirmed at a single-clone level and observed even at 3 mu M. The current result offers a novel approach to therapy in JMML.
• 眼窩周囲炎・副鼻腔炎に続発した眼窩蜂窩織炎の1例

  加藤 格, 今村 壽宏, 伊藤 雄伍, 神谷 尚宏, 藤田 真智子, 青山 千昌, 安西 有紀, 稲井 郁子, 小澤 美和, 森本 克, 真部 淳, 草川 功, 細谷 亮太

  日本小児科学会雑誌 (公社)日本小児科学会 109 (11) 1383 - 1383 0001-6543 2005/11
• 鎖骨に生じたMRSA骨髄炎の1例

  平林 真介, 高橋 宏佳, 田草川 彩子, 伊藤 雄伍, 今村 壽宏, 加藤 格, 神谷 尚宏, 一ノ橋 裕子, 小川 千登世, 稲井 郁子, 小澤 美和, 真部 淳, 草川 功, 細谷 亮太

  日本小児科学会雑誌 (公社)日本小児科学会 109 (11) 1390 - 1390 0001-6543 2005/11
• 11th symposium on aplastic anemia and 9th symposium on myelodysplastic syndromes in children

  Atsushi Manabe, Seiji Kojima

  Pediatrics International 47 (5) 572 - 574 1328-8067 2005/10 [Refereed][Not invited]
  
• トータルケアの心と実践 地域共同診療(ウォーターフロント小児がん共同治療計画) 手術,化学療法,移植治療の分担と支援グループの共有

  松藤 凡, 荒木 夕宇子, 中村 晃子, 細谷 亮太, 真部 淳, 川口 智義, 高上 洋一, 牧本 敦

  日本小児血液学会雑誌 日本小児血液学会 19 (5) 278 - 278 0913-8706 2005/10
• MDSの中央診断 骨髄生検の実施状況

  増永 敦子, 在家 裕司, 菅原 幸子, 土田 昌宏, 河崎 裕英, 真部 淳

  日本小児血液学会雑誌 日本小児血液学会 19 (5) 299 - 299 0913-8706 2005/10
• 小児11q23転座型急性リンパ性白血病(ALL)の第一寛解期移植による治療成績の向上

  齋藤 正博, 林 泰秀, 康 勝好, 高橋 浩之, 福島 敬, 太田 節雄, 真部 淳, 杉田 憲一, 杉田 完爾, 矢部 普正, 菊地 陽, 野口 靖, 生田 孝一郎, 小原 明, 花田 良二, 土田 昌宏, 東京小児がん研究グループ(TCCSG)ALL委員会

  日本小児血液学会雑誌 日本小児血液学会 19 (5) 355 - 355 0913-8706 2005/10
• CD10陽性T細胞型急性リンパ性白血病(T-ALL)の臨床像および予後

  三浦 信之, 真部 淳, 嶋田 博之, 熊谷 昌明, 金子 隆, 前田 美穂, 木下 明俊, 沖本 由理, 加藤 陽子, 上條 岳彦, 豊田 恭徳, 生田 孝一郎, 小原 明, 花田 良二, 土田 昌宏, 東京小児がん研究グループALL委員会

  日本小児血液学会雑誌 日本小児血液学会 19 (5) 500 - 500 0913-8706 2005/10
• 131I-MIBG療法を2回施行し,良好なQOLを得られた再発神経芽腫の1例

  神谷 尚宏, 青山 千晶, 藤田 真智子, 伊藤 雄伍, 今村 壽宏, 加藤 格, 真部 淳, 小川 千登世, 小澤 美和, 細谷 亮太, 横山 邦彦

  日本小児血液学会雑誌 日本小児血液学会 19 (5) 331 - 331 0913-8706 2005/10
• No advantage of dexamethasone over prednisolone for the outcome of standard- and intermediate-risk childhood acute lymphoblastic leukemia in the Tokyo Children's Cancer Study Group L95-14 protocol

  S Igarashi, A Manabe, A Ohara, M Kumagai, T Saito, Y Okimoto, T Kamijo, K Isoyama, M Kajiwara, M Sotomatsu, K Sugita, K Sugita, M Maeda, H Yabe, A Kinoshita, T Kaneko, Y Hayashi, K Ikuta, R Hanada, M Tsuchida

  JOURNAL OF CLINICAL ONCOLOGY 23 (27) 6489 - 6498 0732-183X 2005/09 [Refereed][Not invited]
   

  Purpose To evaluate whether dexamethasone (DEXA) yields a better outcome than prednisolone (PRED) in a prospective, randomized, controlled trial for the treatment of childhood acute lymphoblastic leukemia (ALL). Patients and Methods Two hundred thirty-one standard-risk (SR) patients and 128 intermediate-risk (IR) non-B-cell ALL patients were registered from March 1995 to March 1999. After random assignment in each group, the PRED arm patients received PRED 60 mg/m(2) during induction followed by PRED 40 mg/m(2) over four intensifications in the SR group and three intensifications in the IR group. DEXA arm patients received DEXA 8 mg/m(2) during induction and DEXA 6 mg/m(2) during the intensifications. The maintenance phase was continued until week 104. Results Event-free survival rates at 8 years in the DEXA and PRED arms were 81.1% +/- 3.9% (n = 117) and 84.4% +/- 5.2% (n = 114), respectively, in the SR group (P = .217) and 84.9% +/- 4.6% (n = 62) and 80.4% +/- 5.1 % (n = 66), respectively, in the IR group (P = .625). The primary reason for treatment failure was marrow relapse. Only two extramedullary relapses occurred in the DEXA arm compared with seven relapses in the PRED arm. Although complications were more prevalent in the DEXA arm than in the PRED arm, fatal toxicity was rare both groups. Conclusion DEXA administered at 8 mg/m(2) during induction and 6 mg/m(2) during intensification showed no advantage over PRED administered at 60 mg/m(2) during induction and 40 mg/m(2) during intensification in both the SR and IR groups.
• 若年性骨髄単球性白血病(JMML)における赤芽球コロニー形成に対するビスフォスフォネート製剤の効果

  大塚 欣敏, 浅野 由美, 金田 由美, 竹田 洋樹, 森田 直子, 長谷川 大輔, 河崎 裕英, 真部 淳, 辻 浩一郎, 谷澤 隆邦

  日本血液学会・日本臨床血液学会総会プログラム・抄録集 日本臨床血液学会 67回・47回 824 - 824 2005/09
• 小児急性リンパ性白血病(ALL)診断時・寛解導入期にみられる凝固異常と治療の必要性

  加藤 格, 神谷 尚宏, 田草川 彩子, 高橋 宏佳, 小澤 美和, 森本 克, 小川 千登世, 真部 淳, 細谷 亮太

  日本血液学会・日本臨床血液学会総会プログラム・抄録集 日本臨床血液学会 67回・47回 750 - 750 2005/09
• 海外で処方された睡眠薬により中毒症状を来した1例

  今村 壽宏, 伊藤 雄伍, 加藤 格, 神谷 尚宏, 青山 千晶, 藤田 真智子, 安西 有紀, 稲井 郁子, 小澤 美和, 森本 克, 真部 淳, 草川 功, 細谷 亮太

  日本小児科学会雑誌 (公社)日本小児科学会 109 (7) 901 - 901 0001-6543 2005/07
• 脾臓摘出術を行い貧血が改善したCDA Type IIの1例

  藤田 真智子, 森本 克, 真部 淳, 小澤 美和, 細谷 亮太

  日本小児外科学会雑誌 (一社)日本小児外科学会 41 (4) 712 - 712 0288-609X 2005/06
• Therapy-related myelodysplastic syndrome in childhood: A retrospective study of 36 patients in Japan

  M Tsurusawa, A Manabe, Y Hayashi, Y Akiyama, H Kigasawa, H Inada, Y Noguchi, N Sawai, R Kobayashi, Y Nagatoshi, K Kawakami, S Kojima, T Nakahata

  LEUKEMIA RESEARCH 29 (6) 625 - 632 0145-2126 2005/06 [Refereed][Not invited]
   

  We report here a retrospective analysis of 36 children with therapy-related rnyelodysplastic syndrome (t-MDS) diagnosed between 1990 and 1999 in Japan. Their median age was 7.7 years and the median latency period for the development of t-MDS was 38.5 months. The primary tumors were hematologic in 15 of the cases and nonhematologic in 21. Chromosomal abnormalities were detected in 32/34(94%) patients: abnormalities of chromosomes 5 and/or 7 in 41% and notably. 11q23 abnormalities in 31%. The prognosis of children with t-MDS was very poor as compared to children with primary MDS (5 year survival: 16% versus 54%, p < 0.0001). (c) 2005 Elsevier Ltd. All rights reserved.
• Methylation status of the p15 and p16 genes in paediatric myelodysplastic syndrome and juvenile myelomonocytic leukaemia

  D Hasegawa, A Manabe, T Kubota, H Kawasaki, Hirose, I, Y Ohtsuka, T Tsuruta, Y Ebihara, Y Goto, XY Zhao, K Sakashita, K Koike, M Isomura, S Kojima, A Hoshika, K Tsuji, T Nakahata

  BRITISH JOURNAL OF HAEMATOLOGY 128 (6) 805 - 812 0007-1048 2005/03 [Refereed][Not invited]
   

  Aberrant DNA methylation is frequently observed in adults with myelodysplastic syndrome (MDS), and is recognized as a critical event in the disease's pathogenesis and progression. This is the first report to investigate the methylation status of p15 and p16, cell cycle regulatory genes, in children with MDS (n = 9) and juvenile myelomonocytic leukaemia (JMML; n = 18) by using a methylation-specific polymerase chain reaction. The frequency of p15 hypermethylation in paediatric MDS was 78% (7/9), which was comparable to that in adult MDS. In contrast, p15 hypermethylation in JMML was a rare event (17%; 3/18). In JMML, clinical and laboratory characteristics including PTPN11 mutations and aberrant colony formation were not different between the three patients with hypermethylated p15 and the others. Aberrant methylation of p16 was not detected in children with either MDS or JMML. Since p15 and p16 genes were unmethylated in two children with JMML, in whom the disease had progressed with an increased number of blasts, a condition referred to as blastic crisis, we infer that the aberrant methylation of these genes is not responsible for the progression of JMML. The results suggest that demethylating agents may be effective in most children with MDS and a few patients with JMML.
• 非血縁者間同種骨髄移植後の再発に対するドナーリンパ球輸注(DLI)の臨床検討

  河崎 裕英, 長谷川 大輔, 大塚 欣敏, 鶴田 敏久, 真部 淳, 海老原 康博, 辻 浩一郎

  日本小児科学会雑誌 (公社)日本小児科学会 109 (2) 132 - 132 0001-6543 2005/02
• V-15 Liver hanging maneuver; 切除困難な肝芽腫への適応とその有用性

  荒木 夕宇子, 松藤 凡, 堀田 亮, 細谷 亮太, 草川 功, 真部 淳, 青山 千晶, 藤田 真智子

  日本小児外科学会雑誌 特定非営利活動法人 日本小児外科学会 41 (3) 416 - 416 2005
• フィラデルフィア染色体陽性急性リンパ性白血病(Ph+ALL)の治療 TCCSG L99-15

  真部 淳, 河崎 裕英, 矢部 普正, 小原 明, 高橋 浩之, 生田 孝一郎, 齋藤 友博, 土田 昌宏

  小児がん (NPO)日本小児がん学会 41 (3) 558 - 558 0389-4525 2004/11
• 非血縁者間同種骨髄移植後の再発に対してドナーリンパ球輸注(DLI)を行った3例

  河崎 裕英, 長谷川 大輔, 大塚 欣敏, 海老原 康博, 鶴田 敏久, 真部 淳, 辻 浩一郎

  小児がん (NPO)日本小児がん学会 41 (3) 705 - 705 0389-4525 2004/11
• 初診ALLにおけるdelayed lumbar puctureの妥当性

  康 勝好, 野口 靖, 福島 敬, 富澤 大輔, 太田 節雄, 齋藤 正博, 高橋 裕之, 真部 淳, 小原 明, 生田 孝一郎, 花田 良二, 土田 昌宏, 東京小児がん研究グループ

  小児がん (NPO)日本小児がん学会 41 (3) 557 - 557 0389-4525 2004/11
• 縦隔原発Desmoplastic small round cell tumorの乳児例

  青山 千晶, 伊藤 雄伍, 今村 壽宏, 加藤 格, 神谷 尚宏, 藤田 真智子, 小澤 美和, 森本 克, 真部 淳, 細谷 亮太, 松藤 凡, 鈴木 高祐

  小児がん (NPO)日本小児がん学会 41 (3) 631 - 631 0389-4525 2004/11
• 急性リンパ性白血病治療中腸重積を機に悪性リンパ腫が発見された5歳男児例

  加藤 格, 伊藤 雄伍, 今村 壽宏, 神谷 尚宏, 青山 千晶, 藤田 真智子, 小澤 美和, 森本 克, 真部 淳, 細谷 亮太, 清川 信敬, 藤本 純一郎

  小児がん (NPO)日本小児がん学会 41 (3) 727 - 727 0389-4525 2004/11
• Viral infections in juvenile myelomonocytic leukemia: Prevalence and clinical implications

  A Manabe, T Yoshimasu, Y Ebihara, H Yagasaki, M Wada, K Ishikawa, J Hara, K Koike, H Moritake, YD Park, K Tsuji, T Nakahata

  JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY 26 (10) 636 - 641 1077-4114 2004/10 [Refereed][Not invited]
   

  Objectives: Viral infections may complicate the diagnosis of juvenile myelomonocytic leukemia (JMML) in a substantial proportion of patients, but this possibility has not been tested in a prospective study. The authors therefore measured the cellular expression of the MxA protein, a reliable marker of viral infection, at diagnosis in children with JMML to estimate the prevalence of such infections. Methods: Eighteen children, aged 1 to 69 months, who met the diagnostic criteria of the International JMML Working Group were prospectively studied. MxA expression was assessed by flow cytometric analysis of peripheral blood mononuclear cells stained with an antihuman MxA antibody. All data were obtained through the MDS Committee of the Japanese Society of Pediatric Hematology. Results: Twelve patients (67%) had elevated levels of the MxA protein, with rotavirus, RS virus, or CMV infection documented in three of these patients. Although none of the patients had primary Epstein-Barr virus (EBV) infection, reactivation of the virus was strongly suspected in four children, including two with monosomy 7, each having increased levels of MxA. Southern blot analysis revealed monoclonal integration of the EBV genome into bone marrow mononuclear cells from one of these patients. There was no discernible correlation between increases in the marker protein and the presenting features or course of the disease. Conclusions: Viral infection may be present in two thirds of children with newly diagnosed JMML, but it does not constitute a basis for revising clinical management. The possibility that EBV or other viruses contribute to JMML pathogenesis by stimulating pre-exiting malignant clones warrants further investigation.
• Viral infections in juvenile myelomonocytic leukemia: Prevalence and clinical implications

  A Manabe, T Yoshimasu, Y Ebihara, H Yagasaki, M Wada, K Ishikawa, J Hara, K Koike, H Moritake, YD Park, K Tsuji, T Nakahata

  JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY 26 (10) 636 - 641 1077-4114 2004/10 [Refereed][Not invited]
   

  Objectives: Viral infections may complicate the diagnosis of juvenile myelomonocytic leukemia (JMML) in a substantial proportion of patients, but this possibility has not been tested in a prospective study. The authors therefore measured the cellular expression of the MxA protein, a reliable marker of viral infection, at diagnosis in children with JMML to estimate the prevalence of such infections. Methods: Eighteen children, aged 1 to 69 months, who met the diagnostic criteria of the International JMML Working Group were prospectively studied. MxA expression was assessed by flow cytometric analysis of peripheral blood mononuclear cells stained with an antihuman MxA antibody. All data were obtained through the MDS Committee of the Japanese Society of Pediatric Hematology. Results: Twelve patients (67%) had elevated levels of the MxA protein, with rotavirus, RS virus, or CMV infection documented in three of these patients. Although none of the patients had primary Epstein-Barr virus (EBV) infection, reactivation of the virus was strongly suspected in four children, including two with monosomy 7, each having increased levels of MxA. Southern blot analysis revealed monoclonal integration of the EBV genome into bone marrow mononuclear cells from one of these patients. There was no discernible correlation between increases in the marker protein and the presenting features or course of the disease. Conclusions: Viral infection may be present in two thirds of children with newly diagnosed JMML, but it does not constitute a basis for revising clinical management. The possibility that EBV or other viruses contribute to JMML pathogenesis by stimulating pre-exiting malignant clones warrants further investigation.
• 若年性骨髄単球性白血病(JMML)におけるビスフォスフォネート製剤の検討

  大塚 欣敏, 真部 淳, 長谷川 大輔, 河崎 裕英, 辻 浩一郎

  日本血液学会・日本臨床血液学会総会プログラム・抄録集 日本臨床血液学会 66回・46回 951 - 951 2004/09
• 有害事象によりL-asparaginase投与を中止した小児急性リンパ性白血病症例の予後

  小川 千登世, 生田 孝一郎, 高橋 浩之, 梶原 道子, 前田 美穂, 杉田 憲一, 康 勝好, 菊地 陽, 磯山 恵一, 野口 靖, 矢部 普正, 豊田 恭徳, 真部 淳, 小原 明, 花田 良二, 土田 昌宏, 東京小児がん研究グループALL委員会

  日本血液学会・日本臨床血液学会総会プログラム・抄録集 日本臨床血液学会 66回・46回 751 - 751 2004/09
• 小児の低2倍体急性リンパ性白血病(ALL)68例の検討

  福島 敬, 康 勝好, 高橋 浩之, 真部 淳, 小原 明, 竹 泰秀, 外松 学, 金子 隆, 上條 岳彦, 磯山 恵一, 木下 明俊, 後藤 裕明, 豊田 恭徳, 前田 美穂, 嶋田 博之, 杉田 憲一, 齋藤 正博, 杉田 完爾, 梶原 道子, 矢部 晋正, 菊地 陽, 中舘 尚也, 野口 靖, 牧本 敦, 柳沢 隆昭, 生田 孝一郎, 花田 良二, 土田 昌宏, 東京小児がん研究グループ

  日本血液学会・日本臨床血液学会総会プログラム・抄録集 日本臨床血液学会 66回・46回 752 - 752 2004/09
• フィラデルフィア染色体陽性急性リンパ性白血病(Ph+ALL)の治療 TCCSG L99-15

  真部 淳, 河崎 裕英, 矢部 普正, 小原 明, 高橋 浩之, 生田 孝一郎, 齋藤 友博, 土田 昌宏

  日本小児血液学会雑誌 日本小児血液学会 18 (4) 301 - 301 0913-8706 2004/08
• 非血縁者間同種骨髄移植後の再発に対してドナーリンパ球輸注(DLI)を行った3例

  河崎 裕英, 長谷川 大輔, 大塚 欣敏, 海老原 康博, 鶴田 敏久, 真部 淳, 辻 浩一郎

  日本小児血液学会雑誌 日本小児血液学会 18 (4) 444 - 444 0913-8706 2004/08
• 初診ALLにおけるdelayed lumbar puctureの妥当性

  康 勝好, 野口 靖, 福島 敬, 富澤 大輔, 太田 節雄, 齋藤 正博, 高橋 裕之, 真部 淳, 小原 明, 生田 孝一郎, 花田 良二, 土田 昌宏, 東京小児がん研究グループ

  日本小児血液学会雑誌 日本小児血液学会 18 (4) 300 - 300 0913-8706 2004/08
• 縦隔原発Desmoplastic small round cell tumorの乳児例

  青山 千晶, 伊藤 雄伍, 今村 壽宏, 加藤 格, 神谷 尚宏, 藤田 真智子, 小澤 美和, 森本 克, 真部 淳, 細谷 亮太, 松藤 凡

  日本小児血液学会雑誌 日本小児血液学会 18 (4) 370 - 370 0913-8706 2004/08
• 急性リンパ性白血病治療中腸重積を機に悪性リンパ腫が発見された5歳男児例

  加藤 格, 伊藤 雄伍, 今村 壽宏, 神谷 尚宏, 青山 千晶, 藤田 真智子, 小澤 美和, 森本 克, 真部 淳, 細谷 亮太, 清川 信敬

  日本小児血液学会雑誌 日本小児血液学会 18 (4) 466 - 466 0913-8706 2004/08
• 神経芽腫に対する遺伝子治療(第I相臨床試験)の問題点

  大塚 欣敏, 長谷川 大輔, 鶴田 敏久, 河崎 裕英, 海老原 康博, 広瀬 偉美子, 真部 淳, 辻 浩一郎, 黒田 達夫, 佐藤 雄也, 谷澤 昭彦, 山下 直秀

  小児がん (NPO)日本小児がん学会 40 (3) 448 - 448 0389-4525 2003/11
• Myelodysplastic Syndrome : MDS

  MANABE Atsushi

  J.J.P.H. THE JAPANESE SOCIETY OF PEDIATRIC HEMATOLOGY/ONCOLOGY 17 (5) 429 - 432 0913-8706 2003/10/30
• AMLI/RUNXI mutations are infrequent, but related to AML-M0, acquired trisomy 21, and leukemic transformation in pediatric hematologic malignancies

  T Taketani, T Taki, J Takita, M Tsuchida, R Hanada, T Hongo, T Kaneko, A Manabe, K Ida, Y Hayashi

  GENES CHROMOSOMES & CANCER 38 (1) 1 - 7 1045-2257 2003/09 [Refereed][Not invited]
   

  AML1/RUNX1, located on chromosome band 21 q22, is one of the most important hematopoietic transcription factors. AML1 is frequently affected in leukemia and myelodysplastic syndrome with 21 q22 translocations. Recently, AML1 mutations were found in adult hematologic malignancies, especially acute myeloid leukemia (AML)-M0 or leukemia with acquired trisomy 21, and familial platelet disorder with a predisposition toward AML. Through the use of polymerase chain reaction-single-strand conformation polymorphism analysis, we examined the AML1 gene for mutations in 241 patients with pediatric hematologic malignancies, and we detected AML1 mutations in seven patients (2.9%). Deletion was found in one patient, and point mutations in four patients, including three missense mutations, two silent mutations, and one mutation within an intron resulting in an abnormal splice acceptor site. All of the mutations except for one were heterozygous. Mutations within the runt domain were found in six of seven patients. Six of seven patients with AML1 mutations were diagnosed with AML, and one had acute lymphoblastic leukemia. In three of these seven patients, AML evolved from other hematologic disorders. AML1 mutations were found in two of four AML-M0 and two of three patients with acquired trisomy 21. Patients with AML1 mutations tended to be older children. Three of four patients with AML1 mutations who received stem cell transplantation (SCT) are alive, whereas the remaining three patients with mutations without SCT died. These results suggest that AML1 mutations in pediatric hematologic malignancies are infrequent, but are possibly related to All acquired trisomy 2 1, and leukemic transformation. These patients may have a poor clinical outcome. (C) 2003 Wiley-Liss, Inc.
• ALLに対するVP-16を含まないレジメンによる化学療法後に発症したtopoisomerase II阻害剤関連性急性骨髄性白血病

  長谷川 大輔, 真部 淳, 大塚 欣敏, 鶴田 敏久, 河崎 裕英, 海老原 康博, 辻 浩一郎, 前田 美穂

  臨床血液 (一社)日本血液学会-東京事務局 44 (9) 975 - 975 0485-1439 2003/09
• CD7/CD13陽性急性白血病の1例

  長谷川 大輔, 真部 淳, 鶴田 敏久, 大塚 欣敏, 海老原 康博, 河崎 裕英, 有瀧 健太郎, 松浦 恵子, 辻 浩一郎

  日本小児血液学会雑誌 日本小児血液学会 17 (4) 263 - 263 0913-8706 2003/08
• DIC,高カルシウム血症を合併した(17;19)番転座を伴った急性リンパ性白血病の1例

  大塚 欣敏, 長谷川 大輔, 鶴田 敏久, 河崎 裕英, 海老原 康博, 真部 淳, 杉田 記代子, 田中 葉子, 稲葉 俊哉, 本郷 輝明, 辻 浩一郎

  日本小児血液学会雑誌 日本小児血液学会 17 (4) 283 - 283 0913-8706 2003/08
• Successful treatment of natural killer (NK) cell leukemia following a long-standing chronic active Epstein-Barr virus (CAEBV) infection with allogeneic bone marrow transplantation

  Y Ebihara, A Manabe, R Tanaka, T Yoshimasu, K Ishikawa, T Iseki, J Hayakawa, M Maeda, S Asano, K Tsuji

  BONE MARROW TRANSPLANTATION 31 (12) 1169 - 1171 0268-3369 2003/06 [Refereed][Not invited]
   

  The optimal treatment for natural killer (NK) cell leukemia after chronic active Epstein-Barr virus (CAEBV) infection has not been determined. A 15-year-old boy presented with NK cell leukemia following CAEBV infection for 5 years. The peripheral blood and BM had an increased number of CD3(-)CD56(+) large granular lymphocytes and a monoclonal integration of the EBV genome was detected. Chemotherapy was not sufficiently effective to control the disease. Allogeneic BMT from an HLA-identical sister was performed using a conditioning regimen consisting of total body irradiation, cyclophosphamide and thiotepa. The patient is disease-free with a perfect performance status 24 months after BMT. This is the first report to show that allogeneic BMT is potentially able to cure NK cell leukemia after CAEBV infection.
• Effects of sodium in hydration solution on plasma methotrexate concentrations following high-dose methotrexate in children with acute lymphoblastic leukemia

  A Kinoshita, Y Kurosawa, K Kondoh, T Suzuki, A Manabe, T Inukai, K Sugita, S Nakazawa

  CANCER CHEMOTHERAPY AND PHARMACOLOGY 51 (3) 256 - 260 0344-5704 2003/03 [Refereed][Not invited]
   

  Purpose: To test whether a higher sodium dose in the hydration solution may facilitate faster methotrexate (MTX) elimination as compared with a lower sodium dose following high-dose MTX (HDMTX) treatment. Methods: Intravenous solutions with alternate doses of sodium (regimen A 70 mEq/l, regimen B 100 mEq/l) were given to 30 children with acute lymphoblastic leukemia in two courses of HDMTX in a randomized crossover fashion. The plasma MTX concentrations every 24 h from the beginning of MTX administration and the adverse events associated with HDMTX were compared between the two hydration regimens. Results: The plasma MTX concentrations were similar in the two hydration regimens at 24 h (A 50.9 +/- 7.4 vs B 40.9 +/- 5.4 muM, means +/- SE, P = 0.17), but was significantly lower in regimen B at 48 and 72 h (A 0.65 +/- 0.17 vs B 0.27 +/- 0.03 muM, P=0.04; and A 0.14 +/- 0.03 vs B 0.05 +/- 0.01 muM, P=0.003). The time during which MTX plasma concentrations exceeded 0.1 muM was significantly longer in regimen A than in regimen B (A 3.83 +/- 0.18 vs B 3.13 +/- 0.06 days, P = 0.001). The incidences of adverse events were similar between the two regimens (P=0.78), and severe adverse events were not seen in either regimen. Conclusions: Hydration with a higher sodium dose facilitated faster MTX elimination following HDMTX. Sodium may have a beneficial effect on MTX-induced nephrotoxicity.
• Third International Symposium on Myelodysplastic Syndromes in Childhood

  Atsushi Manabe, Yoshitoshi Ohtsuka

  International Journal of Hematology 78 (5) 475 - 476 0925-5710 2003 [Refereed][Not invited]
   

  This article summarizes presentations from the Third International Symposium on Myelodysplastic Syndromes in Childhood, April 27-29, 2003, in Stresa, Italy. Topics included epidemiology, pathology, cytogenetics, molecular biology, pathophysiology, and treatment. Dr. Susanna Fenu was the Meeting Chair. ©2003 The Japanese Society of Hematology.
• Reconstitution of human haematopoiesis in non-obese diabetic/severe combined immunodeficient mice by clonal cells expanded from single CD34(+) CD38(-) cells expressing Flk2/Flt3

  Y Ebihara, M Wada, T Ueda, MJ Xu, A Manabe, R Tanaka, M Ito, H Mugishima, S Asano, T Nakahata, K Tsuji

  BRITISH JOURNAL OF HAEMATOLOGY 119 (2) 525 - 534 0007-1048 2002/11 [Refereed][Not invited]
   

  In the present study, we examined the expression of Flk2/Flt3, a tyrosine kinase receptor, on human cord blood CD34(+) haematopoietic progenitor/stem cells. In flow cytometric analysis, Flk2/Flt3 was expressed on 80% of CD34(+) cells and their immature subpopulations, CD34(+) CD33(-) and CD34(+) CD38(-) cells. Methycellulose clonal culture of sorted CD34(+) Flk2/ Flt3(+) and CD34(+) Flk2/Flt3(-) cells showed that most of myelocytic progenitors expressed Flk2/Flt3, but erythroid and haematopoietic multipotential progenitors were shared by both fractions. When 1 x 10(4) lineage marker-negative (Lin(-))CD34(+)Flk2/Flt3(-) cells were transplanted into non-obese diabetic/severe combined immunodeficient (NOD/SCID) mice, none of the recipients possessed human CD45(+) cells in bone marrow 11-12 weeks after the transplantation. In contrast, all recipients transplanted with 1 x 10(4) Lin(-) CD34(+) Flk2/Flt3(+) cells showed successful engraftment. Furthermore, clonal cells expanded from single Lin(-) CD34(+) CD38(-) Flk2/Flt3(+) cells in the culture with Flk2/Flt3 ligand, stem cell factor, thrombopoietin, and a complex of interleukin 6/soluble interleukin 6 receptor were individually transplanted into NOD/SCID mice. At 20 to 21 weeks after the transplantation, three out of 10 clones harvested at d 7 of culture, and three out of six clones at d 14 could reconstitute human haematopoiesis in recipient marrow. These results demonstrated that Flk2/Flt3 was expressed on a wide variety of human haematopoietic cells including long-term-repopulating haematopoietic stem cells.
• 短期決戦型TCCSG ALL L92-13再発例の救済とQOLについて

  杉田 憲一, 土田 昌宏, 生田 孝一郎, 花田 良二, 金子 隆, 小池 和俊, 角南 勝介, 矢部 みはる, 菊地 陽, 木下 俊明, 渋谷 温, 藤田 宏夫, 高山 順, 外松 学, 加藤 陽子, 森本 克, 沖本 由理, 豊田 恭徳, 小森 功夫, 前田 美穂, 真部 淳, 斉藤 友博, 中澤 眞平, 東京小児がん研究グループ

  臨床血液 (一社)日本血液学会-東京事務局 43 (8) 327 - 327 0485-1439 2002/08
• 溶血性貧血,血小板減少にて発症したALPSの一例

  稲井 郁子, 森本 克, 小澤 美和, 真部 淳, 金兼 弘和, 宮脇 利男, 三輪 操子, 細谷 亮太

  日本小児血液学会雑誌 日本小児血液学会 16 (4) 267 - 267 0913-8706 2002/08
• Successful treatment of relapsed blastic natural killer cell lymphoma with unrelated cord blood transplantation

  T Yoshimasu, A Manabe, R Tanaka, S Mochizuki, Y Ebihara, K Ishikawa, T Iseki, N Oyaizu, K Aritaki, K Tanaka, T Tsuruta, A Hoshika, S Asano, K Tsuji

  BONE MARROW TRANSPLANTATION 30 (1) 41 - 44 0268-3369 2002/07 [Refereed][Not invited]
   

  The prognosis for blastic natural killer (NK) cell lymphoma is generally dismal. We report a patient who was successfully treated with unrelated cord blood transplantation (UCBT). A 15-year-old boy was diagnosed as having blastic NK cell lymphoma in the cervical lymph nodes. Autologous peripheral blood stem cell transplantation was performed on achieving a complete remission. However, the disease recurred in the bone marrow 6 months later. Chemotherapy induced a second remission and the patient received UCBT with a conditioning regimen consisting of total body irradiation, thiotepa and cyclophosphamide. Chronic GVHD of the lung occurred, but it was well controlled with steroids. At the time of writing, he remains in remission 18 months after UCBT with an excellent performance status. UCBT may be an option for patients with blastic NK cell lymphoma.
• Generation of definitive hematopoietic stem cells from murine early yolk sac and paraaortic splanchnopleures by aorta-gonad-mesonephros region-derived stromal cells

  S Matsuoka, K Tsuji, H Hisakawa, MJ Xu, Y Ebihara, T Ishii, D Sugiyama, A Manabe, R Tanaka, Y Ikeda, S Asano, T Nakahata

  BLOOD 98 (1) 6 - 12 0006-4971 2001/07 [Refereed][Not invited]
   

  There is controversy as to whether murine definitive hematopoiesis originates from yolk sac (YS) or the intraembryonic region. This study reports the generation of definitive hematopoietic stem cells (HSCs) from both early YS and infraembryonic paraaortic splanchnopleures (P-Sp) on AGM-S3 stromal cells derived from:the aorta-gonad-mesonephros (AGM) region at 10.5 days post coitum (dpc). YS and P-Sp cells at 8.5 dpc generated no definitive hematopoiesis-derived colony-forming cells in: cocultures with AGM-S3 cells, but spleen colony-forming cells and HSCs capable of reconstituting definitive hematopoiesis In adult mice simultaneously appeared on day 4 of coculture. Precursors for definitive HSCs were present in YS and P-Sp at 8.0 dpc, a time when YS and embryo were not connected by blood vessels. It is proposed that precursors with the potential to generate definitive HSCs appear independently in YS and intraembryonic P-Sp and that the P-Sp or AGM region affords the microenvironment that facilitates generation of definitive hematopoiesis from precursors. (C) 2001 by The American Society of Hematology.
• Surfactant protein D and KL-6 as serologic indicators of Pneumocystis carinii pneumonia in a child with acute lymphoblastic leukemia

  Takashi Takahashi, Yasuhiro Ebihara, Atsushi Manabe, Kohichiro Tsuji, Tetsuya Nakamura, Tatsutoshi Nakahata, Aikichi Iwamoto

  Journal of Medicine 32 (1-2) 41 - 51 0025-7850 2001 [Refereed][Not invited]
   

  Pneumocystis carinii pneumonia (PCP) in immunocompromised patients is one of the important causes of morbidity and mortality. Serum levels of surfactant protein D (SP-D) and KL-6 are useful biomarkers for understanding some pulmonary inflammatory responses in patients with idiopathic pulmonary fibrosis (IPF). We present a child with PCP following bone marrow transplantation (BMT) for acute lymphoblastic leukemia (ALL), for whom both SP-D and KL-6 in sera were simultaneously measured through the clinical course of PCP. Both serum levels of SP-D and KL-6 were rapidly elevated reflecting some inflammatory processes in the lung that chest X-ray films and CT scans showed as ground-glass attenuations. He died due to respiratory failure 40 days after PCP developed. A combination of the assays for SP-D and KL-6 in sera may be helpful in predicting the treatment results for PCP.
• C67 進行神経芽腫に対する樹状細胞を用いた免疫療法の基礎的研究

  中原 さおり, 真部 淳, 浅野 茂隆, 辻 浩一郎, 橋都 浩平

  日本小児外科学会雑誌 特定非営利活動法人 日本小児外科学会 36 (3) 250 - 250 2000
• Second international symposium on myelodysplastic syndromes in childhood

  Atsushi Manabe

  International Journal of Hematology 72 (4) 522 - 524 0925-5710 2000 [Refereed][Not invited]
   

  This article summarizes presentations from the Second International Symposium on Myelodysplastic Syndromes in Childhood, May 11 to 14,2000, in Funen, Denmark. Topics included epidemiology, pathology, pathophysiology, cytogenetics, congenital neutropenia, transplantation, and classification. Dr. Henrik Hasle was the Meeting Chair and Dr. Gitte Kerndrup was the Co-Chair. © 2000 The Japanese Society of Hematology.
• ヒト臍帯血CD34陽性細胞におけるFlk2/Flt3の発現

  海老原 康博, 植田 高弘, 吉野 浩, 石井 武文, 谷ヶ崎 博, 久川 浩章, 三井 哲夫, 郡司 勇治, 田中 竜平, 真部 淳

  臨床血液 (一社)日本血液学会-東京事務局 40 (9) 921 - 921 0485-1439 1999/09
• 治療後期のL-アスパラギナーゼにより重症膵炎を発症したALLの1女児例

  石井 武文, 真部 淳, 海老原 康博, 植田 高弘, 吉野 浩, 三井 哲夫, 久川 浩章, 谷ヶ崎 博, 菊地 陽, 辻 浩一郎

  日本小児血液学会雑誌 日本小児血液学会 13 (4) 261 - 261 0913-8706 1999/08
• 再生不良性貧血と骨髄異形成症候群の境界例と考えられた1例

  吉野 浩, 植田 高弘, 真部 淳, 菊地 陽, 海老原 康博, 三井 哲夫, 久川 浩章, 石井 武文, 谷ヶ崎 博, 辻 浩一郎

  日本小児血液学会雑誌 日本小児血液学会 13 (4) 320 - 320 0913-8706 1999/08
• 再発急性骨髄性白血病患児にみられたNeutropenic enterocolitis(Typhlitis)の1例

  吉野 浩, 真部 淳, 海老原 康博, 植田 高弘, 石井 武文, 江口 直宏, 三井 哲夫, 久川 浩章, 谷ヶ崎 博, 菊地 陽

  日本小児科学会雑誌 (公社)日本小児科学会 103 (4) 478 - 479 0001-6543 1999/04
• Fifth international symposium on myelodysplastic syndromes

  Atsushi Manabe

  International Journal of Hematology 70 (4) 296 - 300 0925-5710 1999 [Refereed][Not invited]
  
• ステロイドが奏効した同種骨髄移植後Bronchiolitis Obliterans Organizing Pneumonia(BOOP)の一例

  石井 武文, 真部 淳, 海老原 康博, 植田 高弘, 吉野 浩, 江口 直宏, 三井 哲夫, 久川 浩章, 谷ヶ崎 博, 菊地 陽

  日本小児血液学会雑誌 日本小児血液学会 12 (4) 221 - 221 0913-8706 1998/08
• Hydroxyureaで芽球のコントロールを行い,非血縁者間骨髄移植(uBMT)を施行した再発急性骨髄性白血病の一例

  吉野 浩, 真部 淳, 海老原 康博, 植田 高弘, 石井 武文, 江口 直宏, 三井 哲夫, 久川 浩章, 谷ヶ崎 博, 菊地 陽

  日本小児血液学会雑誌 日本小児血液学会 12 (4) 231 - 231 0913-8706 1998/08
• Ph1 ALL症例の造血幹細胞移植における多分割高線量の全身照射(TBI)の試み

  菊地 陽, 海老原 康博, 植田 高弘, 吉野 浩, 石井 武文, 江口 直宏, 三井 哲夫, 久川 浩章, 谷ヶ崎 博, 真部 淳

  日本小児血液学会雑誌 日本小児血液学会 12 (4) 227 - 227 0913-8706 1998/08
• G-CSF投与中に脳梗塞をきたしたT-ALLの1例

  小澤 美和, 真部 淳, 海老原 康博

  日本小児血液学会雑誌 日本小児血液学会 11 (6) 436 - 440 0913-8706 1997/12 

  14歳女児,寛解導入療法中,白血球数が300/μlと減少し,第5週よりG-CSFの投与を開始後,15日目に白血球数が39,300/μlと急激に上昇した時点で投与を中止した.同日,Jacksonian typeの間代性けいれんを認めた.4日目の頭部CT,8日目のMRI所見で梗塞が疑われ,12日目の脳血流シンチグラムでも一過性の血流低下を示した.約5週後のhigh dose AraC(3g/m2)終了後,再度G-CSFの投与を3日間行い白血球数が300/μlから2,800/μlとなったところで頭部CTと血流シンチグラムを行ったところ,再び虚血性変化を認めた.G-CSFにより正常顆粒球が急激に増加したことが血液の粘稠度を上昇させたと考えられた
• Etiologic correlation between streptococcal infection and anaphylactoid purpura....a study of anaphylactoid purpura in recent 10 years in St. Luke's International Hospital.

  折居建治, 大矢達男, 大山栄作, 平田倫生, 斎藤昭彦, 海老原康博, 渡部玉蘭, 真部淳, 西村昂三

  聖路加健康科学誌 4/5(1994/1995) 30 - 34 1341-0415 1997/07 [Not refereed][Not invited]
  
• A Case of Acute Lymphoblastic Leukemia Showing Markedly Increased Uptake in the Bone without Uptake in the Liver by ^<67> Ga Scintigraphy

  ORII Kenji, MANABE Atsushi, HIRATA Michio, EBIHARA Yasuhiro, WATANABE Gokuran, NISHIMURA Kozo, HOSOYA Ryota

  日本小児血液学会雑誌 日本小児血液学会 11 (2) 120 - 124 0913-8706 1997/04/30 [Not refereed][Not invited]
   

  5歳女児.急性リンパ性白血病の発症初期に67Gaシンチグラフィーを施行され,骨への異常集積を認めた.その機序としては白血病細胞に67Ga-citrateが取り込まれ,そのために骨髄への集積をきたしたと考えられた.本例では治療に伴う画像所見の正常化が認められ,67Gaシンチグラフィーが発症初期の白血病細胞量の変化を推察する上で有用な補助検査法になり得ることを示唆している
• Human B-cell progenitors and bone marrow microenvironment.

  Campana D, Coustan-Smith E, Manabe A, Kumagai M, Murti KG, Silvennoinen O, Nishigaki H, Kitanaka A, Ito C

  Human cell 9 (4) 317 - 322 1996/12 [Refereed][Not invited]
  
• 52. 先天性神経芽腫 (NB) stage III の1例(第30回日本小児外科学会関東甲信越地方会)

  加地 展之, 松藤 凡, 真部 淳, 細谷 亮太, 横山 穣太郎

  日本小児外科学会雑誌 特定非営利活動法人 日本小児外科学会 32 (7) 1161 - 1161 1996
• 26 神経芽腫の年齢とステージ別の治療方法と成績(乳児例(非MS)、進行例の手術はどうあるべきか, V.神経芽腫, 第11回日本小児外科学会秋季シンポジウム)

  松藤 凡, 細谷 亮太, 真部 淳, 横山 穣太郎

  日本小児外科学会雑誌 特定非営利活動法人 日本小児外科学会 31 (6) 871 - 871 1995
• 63. 多発皮下転移を認めた小円形細胞肉腫の1例(第29回関東甲信越地方会)

  澤村 聡美, 松藤 凡, 細谷 亮太, 真部 淳, 植草 利公, 横山 譲太郎, 秦 順一

  日本小児外科学会雑誌 特定非営利活動法人 日本小児外科学会 31 (1) 127 - 127 1995
• Effects of Atrial Natriuretic Peptide on Hepatic Tissue Blood Flow in Rats

  MANABE Atsushi

  JOURNAL OF THE KYORIN MEDICAL SOCIETY 杏林医学会 21 (4) 477 - 486 1990 

  Effects of intra-arterial injection of rat-atrial natriuretic peptide on hepatic tissue blood flow (HTBF) and mean blood pressure (MBP) were evaluated in normal and cirrhotic rats. HTBF was measured by the electrolytic hydrogen clearance method at, 0, 1, 10 and 20 min after bolus injection of ANP into the femoral artery. In normal rats, no significant changes was observed after injection of 10, 100 and 1000 μg/kg of ANP on HTBF. However, MBP fell significantly for 20 min after injection of 1000 μg/kg of ANP, while no significant change was observed with 10, or 100 μg/kg of ANP. In cirrhotic rats, HTBF increased by 20 % at 1 min after injection of 100 μg/kg of ANP (p<0.05), whereas it decreased by 17 % at 1 min after injection of 1000 μg/kg of ANP. No significant change was observed with 10 μg/kg of ANP. MBP fell significantly at 1 min after injection of 100 μg/kg of ANP and 20 min after injection of 1000 μg/kg of ANP respectively (p<0.01, p<0.01), while no significant change was observed with 10 μg/kg of ANP. These results indicate that the effect of ANP on HTBF is more prominent in cirrhotic than normal rats, and that the injection of ANP in a case of optimal dose induces an increase of HTBF in cirrhotic rats. Concerning THBF, ANP may be benefit in the therapy of patients with cirrhosis.
• I-E-41 小児急性リンパ性白血症同胞発生のみられた2家族における両親の心理的反応(腫瘍・死の臨床)(一般口演)

  細谷 亮太, 真部 淳, 岩堀 晃, 西村 昂三

  心身医学 一般社団法人 日本心身医学会 28 108 - 108 1988

MISC

• Treatment of intracranial immature teratoma with serum AFP elevation

  山口秀, 伊師雪友, 大木聡悟, 茂木洋晃, 長谷河昌孝, 寺下友佳代, 平林真介, 西岡健太郎, 橋本孝之, 真部淳, 藤村幹  小児の脳神経(Web)  49-  (2)  2024
• Report of Comprehensive Genomic Profiling (CGP) for the Patients with Primary Brain Tumors in Hokkaido Univ. Hospital

  山口秀, 茂木洋晃, 澤谷亮佑, 伊師雪友, 寺下友佳代, 平林真介, 杉山未奈子, 齋藤祐介, 木下一郎, 真部淳, 藤村幹  日本脳腫瘍学会学術集会プログラム・抄録集  41st-  2023
• IMMUNOPHENOTYPIC AND CHROMOSOMAL CHARACTERIZATION OF KMT2A GERMLINE ACUTE LYMPHOBLASTIC LEUKEMIA IN INFANTS

  Hiroki Yoshihara, Takako Miyamura, Takao Deguchi, Toshinori Hori, Tomohiko Taki, Kunihiko Moriya, Yuki Arakawa, Mariko Eguchi, Kunihiro Shinoda, Yuhki Koga, Katsuyoshi Koh, Atsushi Manabe, Keizo Horibe, Daisuke Tomizawa  PEDIATRIC BLOOD & CANCER  69-  2022/11
• 乳児へのボリコナゾール投与中に、代謝機能の発達によると考えられる著しい血中濃度低下が認められた1例

  山口 敦史, 田澤 佑基, 武隈 洋, 植木 将弘, 山田 雅文, 真部 淳, 菅原 満  TDM研究  39-  (2)  136  -136  2022/05
• 早産出生の乳幼児の睡眠と精神発達

  太田 英伸, 安藤 明子, 吉村 優子, 中川 真智子, 安積 陽子, 中澤 貴代, 三谷 裕介, 大石 芳久, 水島 正人, 安達 裕行, 兼次 洋介, 森岡 圭太, 島袋 林秀, 平田 倫生, 池田 尊司, 福冨 理佳, 小林 京子, 小澤 美和, 竹島 正浩, 真部 淳, 高橋 勉, 三島 和夫, 草川 功, 與田 仁志, 菊知 充, 長 和俊  精神神経学雑誌  124-  (4付録)  S  -517  2022/04
• How should we manage multiple intracerebral hemorrhage and brain death in a patient with T-ALL?

  長祐子, 澤井彩織, 原和也, 寺下友佳代, 杉山未奈子, 平林真介, 真部淳, 杉山拓, 方波見謙一, 浜崎和朗  日本小児科学会雑誌  126-  (2)  2022
• Chemotherapy with the Use of TKIs Based on MRD Has the Potential to Avoid Hematopoietic Stem Cell Transplantation in Treatment for Children with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph plus ALL). Results of the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) Study ALL-Ph13

  Atsushi Sato, Hirohide Kawasaki, Takao Deguchi, Yoshiko Hashii, Yuka Iijima-Yamashita, Sachiko Yonezawa, Chiyo K. Imamura, Haruko Shima, Hirotoshi Sakaguchi, Yuichi Kodama, Keisuke Kato, Motohiro Kato, Hidefumi Hiramatsu, Nobutaka Kiyokawa, Akiko Kada, Akiko M. Saito, Keizo Horibe, Atsushi Manabe, Hiroyuki Shimada  BLOOD  138-  2021/11  

  0
• 新規の白血病特性を有するmyeloid/natural killer cell precursor acute leukemia(Myeloid/natural killer(NK) cell precursor acute leukemia as a novel distinctive leukemia entity)

  西村 聡, 横山 和明, 成戸 卓也, 中園 博仁, 木村 俊介, 今村 俊彦, 森尾 友宏, 金井 昭教, 松井 啓隆, 梅田 雄嗣, 佐野 秀樹, 小池 隆志, 頼 晋也, 關中 悠仁, 小川 淳, 木下 明俊, 柴 徳生, 三木 瑞香, 木村 文彦, 中山 秀樹, 中沢 洋三, 多賀 崇, 滝 智彦, 足立 壯一, 真部 淳, 康 勝好, 石田 也寸志, 滝田 順子, 東條 有伸, 高木 正稔  日本血液学会学術集会  83回-  PL  -4  2021/09
• Comprehensive Genetic Analysis Revealed Myeloid/Natural Killer (NK) Cell Precursor Acute Leukemia As a Novel Distinctive Leukemia Entity

  Akira Nishimura, Kazuaki Yokoyama, Chika Yamagishi, Toshihiko Imamura, Takuya Naruto, Tomohiro Morio, Yukie Tanaka, Akinori Kanai, Hirotaka Matsui, Naoko Higuchi, Akiko Takada, Haruna Okuno, Shoji Saito, Shuhei Karakawa, Shogo Kobayashi, Daisuke Hasegawa, Hiroyuki Fujisaki, Daiichiro Hasegawa, Kazutoshi Koike, Takashi Koike, Shinya Rai, Katsutsugu Umeda, Hideki Sano, Yujin Sekinaka, Atsushi Ogawa, Akitoshi Kinoshita, Norio Shiba, Mizuka Miki, Fumihiko Kimura, Hideki Nakayama, Yozo Nakazawa, Takashi Taga, Tomohiko Taki, Souichi Adachi, Atsushi Manabe, Katsuyoshi Koh, Yasushi Ishida, Arinobu Tojo, Masatoshi Takagi  BLOOD  136-  2020/11  

  0
• 小児血液・腫瘍性疾患の治療中にPRESによる非けいれん性てんかん重積を認めた2例

  山本 薫, 代田 惇朗, 長谷川 大輔, 木村 俊介, 吉本 優里, 平林 真介, 細谷 要介, 野崎 太希, 横山 美奈, 真部 淳, 荻原 正明  日本小児科学会雑誌  124-  (9)  1391  -1396  2020/09  

  症例1(4歳女児)。急性リンパ性白血病に対する寛解導入療法開始31日に意識障害、右下肢間代発作を認めた。その後も意識障害が持続し、3日後の脳波検査およびMRI検査にて可逆性後部白質脳症(PRES)による非けいれん性てんかん重積状態(NCSE)と診断された。クロバザム(CLB)を投与するもNCSEのコントロールに苦慮し、白血病の治療後も焦点てんかんが後遺症として残った。現在、CLBのの内服を継続し、てんかん発作は消失している。症例2(7歳女児)。全身転移を有する治療抵抗性横紋筋肉腫へのパゾパニブの投与中に左上肢の間代発作が出現し、頭部MRI検査にてPRESと診断された。その後は意識障害が遷延し、脳波検査でNCSEと判明、抗てんかん薬を投与したところ、NCSEは消失し、意識状態の改善が得られた。
• NUDT15 Variants Confer High Incidence of Secondary Malignancies of ALL in Children

  Masanori Yoshida, Kazuhiko Nakabayashi, Aiko Sato-Otsubo, Shinichi Tsujimoto, Kaoru Yoshida, Ryota Shirai, Tomoo Osumi, Yuki Yuza, Masatoshi Takagi, Hiroyuki Takahashi, Katsuyoshi Koh, Akitoshi Kinoshita, Moeko Hino, Toshihiko Imamura, Yozo Nakazawa, Okuya Mayuko, Harumi Kakuda, Masashi Sanada, Kimikazu Matsumoto, Daisuke Tomizawa, Nobutaka Kiyokawa, Akira Ohara, Atsushi Manabe, Kenichiro Hata, Jun J. Yang, Motohiro Kato  BLOOD  134-  2019/11  

  0
• 多彩な自己炎症性疾患を紐解く Linear ubiquitin assembly complexとOTULINによる炎症と細胞死の制御 OTULIN-related autoinflammatory syndrome患者の解析を通して

  植木 将弘, 松廣 淳平, 竹崎 俊一郎, 藤田 宏明, 三宅 紀子, 戸澤 雄介, 山田 雅文, 小林 一郎, 松本 直通, 有賀 正, 岩井 一宏, 真部 淳  日本小児リウマチ学会総会・学術集会プログラム・抄録集  29回-  52  -52  2019/10  [Not refereed][Not invited]
  
• 大頭症、軽度運動発達遅滞、白質信号異常を呈し、PTEN遺伝子変異を認めた男児例

  黒子 由梨香, 山本 薫, 横山 美奈, 代田 惇朗, 平林 真介, 真部 淳, 荻原 正明, 草川 功, 青木 洋子, 小崎 里華  脳と発達  51-  (Suppl.)  S359  -S359  2019/05  [Not refereed][Not invited]
  
• 造血細胞移植後に生じた腸管気腫症に対して間欠的酸素投与が有効であった3例

  足洗美穂, 西村聡, 西村聡, 神谷尚宏, 山本俊亮, 小野林太郎, 友田昴宏, 山本薫, 井上健斗, 井上真依子, 廣木遥, 宮本智史, 星野顕宏, 梅原直, 平林真介, 岡本健太郎, 柳町昌克, 磯田健志, 細谷要介, 長谷川大輔, 今井耕輔, 高木正稔, 金兼弘和, 森尾智宏, 真部淳  日本造血細胞移植学会総会プログラム・抄録集  41st-  2019
• A case of neuroblastoma diagnosed by growth failure and hyperhidrosis

  橋本 佳帆子, 中山 加奈子, 山口 健史, 原 和也, 寺下 友佳代, 杉山 未奈子, 長 祐子, 井口 晶裕, 本多 昌平, 中村 明枝, 真部 淳  臨床小児医学 = The Journal of clinical pediatrics, Sapporo  67-  (1)  84  -89  2019  [Not refereed][Not invited]
  
• Characteristics and Treatment Outcome of Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia not Enrolled on Clinical Trials in TKI-era

  Keisuke Kato, Hirotoshi Sakaguchi, Yuichi Kodama, Yuichi Shinkoda, Akira Shimada, Takashi Iwase, Junko Takita, Chitose Ogawa, Hidefumi Hiramatsu, Motohiro Kato, Atsushi Sato, Hideko Uryu, Tsuyako Iwai, Akiko Saito, Hirohide Kawasaki, Katsuyoshi Koh, Atsushi Manabe, Keizo Horibe, Hiroyuki Shimada  PEDIATRIC BLOOD & CANCER  65-  S64  -S65  2018/11
• Clinical Feature and Genetic Alterations in Myeloid/Natural Killer (NK) Cell Precursor Acute Leukemia and Myeloid/NK Cell Acute Leukemia

  Akira Nishimura, Kazuaki Yokoyama, Chika Yamagishi, Takuya Naruto, Tomohiro Morio, Akinori Kanai, Hirotaka Matsui, Naoko Higuchi, Akiko Takada, Haruna Okuno, Shoji Saito, Shuhei Karakawa, Shogo Kobayashi, Hideki Sano, Takashi Koike, Daisuke Hasegawa, Hiroyuki Fujisaki, Daiichiro Hasegawa, Kazutoshi Koike, Atsushi Ogawa, Akitoshi Kinoshita, Norio Shiba, Mizuka Miki, Hideki Nakayama, Yozo Nakazawa, Toshihiko Imamura, Takashi Taga, Souichi Adachi, Katsuyoshi Koh, Atsushi Manabe, Tomohiko Taki, Yasushi Ishida, Arinobu Tojo, Masatoshi Takagi  BLOOD  132-  2018/11  

  0
• DNA Methylation-Based Characterization of T-cell Acute Lymphoblastic Leukemia Well Correlated with Genetic Features, Prognosis and Differentiation Stages

  Shunsuke Kimura, Masafumi Seki, Tomoko Kawai, Kenichi Yoshida, Tomoya Isobe, Hiroo Ueno, Yusuke Shiozawa, Hiromichi Suzuki, Yuichi Shiraishi, Kentaro Ohki, Motohiro Kato, Katsuyoshi Koh, Ryoji Kobayashi, Takao Deguchi, Yoshiko Hashii, Toshihiko Imamura, Atsushi Sato, Nobutaka Kiyokawa, Atsushi Manabe, Masashi Sanada, Akira Ohara, Keizo Horibe, Masao Kobayashi, Akira Oka, Yasuhide Hayashi, Satoru Miyano, Kenichiro Hata, Seishi Ogawa, Junko Takita  PEDIATRIC BLOOD & CANCER  65-  S21  -S22  2018/11
• The Prognostic Value of TP53 Mutations Depends on Clinical Backgrounds in Pediatric Patients with Acute Lymphoblastic Leukemia

  Hiroo Ueno, Kenichi Yoshida, Yusuke Shiozawa, Yasuhito Nannya, Yuka Iijima-Yamashita, Nobutaka Kiyokawa, Yuichi Shiraishi, Kenichi Chiba, Hiroko Tanaka, Tomoya Isobe, Masafumi Seki, Shunsuke Kimura, Hideki Makishima, Nobuyuki Kakiuchi, Keisuke Kataoka, Tetsuichi Yoshizato, Hiroyuki Tsukamoto, Dai Nishijima, Takao Deguchi, Kentaro Ohki, Atsushi Sato, Hiroyuki Takahashi, Yoshiko Hashii, Sadao Tokimasa, Junichi Hara, Yoshiyuki Kosaka, Koji Kato, Takeshi Inukai, Junko Takita, Toshihiko Imamura, Satoru Miyano, Atsushi Manabe, Keizo Horibe, Seishi Ogawa, Masashi Sanada  BLOOD  132-  2018/11  [Not refereed][Not invited]
   

  0
• Tolerable Dose of 6-Mercaptopurine and Prognostic Impact of NUDT15-Deficient Genotype in Childhood Acute Lymphoblastic Leukemia

  Yoichi Tanaka, Motohiro Kato, Takaya Moriyama, Yuki Arakawa, Daisuke Hasegawa, Junya Fujimura, Dai Keino, Atsushi Sato, Takahiro Ueda, Yuichi Taneyama, Masatoshi Takagi, Masaki Yamamoto, Masaki Matsuoka, Moeko Hino, Hiroki Hori, Katsuyoshi Koh, Allen Eng Juh Yeoh, Jun J. Yang, Atsushi Manabe  BLOOD  132-  2018/11  

  0
• Dasatinib-Combined Less Intensive Chemotherapy for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in Down Syndrome

  Hirabayashi Shinsuke, Yamamoto Shunsuke, Yamamoto Kaoru, Yamamoto Kazuki, Aiga Saori, Daida Atsuro, Ono Rintaro, Ashiarai Miho, Nishimura Akira, Hosoya Yosuke, Hasegawa Daisuke, Manabe Atsushi  PEDIATRIC BLOOD & CANCER  65-  S97  2018/11  [Refereed][Not invited]
  
• Successful Inhaled Nitric Oxide Therapy for Severe Acute Respiratory Failure Due to Alveolar Hemorrhage During Induction Phase in AML M5

  Ashiarai Miho, Umehara Naoki, Kuroko Yurika, Yamamoto Kaoru, Yamamoto Shunsuke, Ono Rintaro, Hirabayashi Shinsuke, Hosoya Yosuke, Hasegawa Daisuke, Manabe Atsushi  PEDIATRIC BLOOD & CANCER  65-  S55  -S56  2018/11  [Refereed][Not invited]
  
• 小児T細胞性急性リンパ性白血病におけるNOTCH1シグナル活性化変異の種類と臨床的特徴の解析(Analysis of features of alterations leading to activate NOTCH1 signaling in pediatric T-ALL)

  木村 俊介, 関 正史, 吉田 健一, 上野 浩生, 塩澤 裕介, 磯部 知弥, 大木 健太郎, 加藤 元博, 康 勝好, 小林 良二, 出口 隆生, 橋井 佳子, 今村 俊彦, 佐藤 篤, 清河 信敬, 真部 淳, 堀部 敬三, 小原 明, 眞田 昌, 小林 正夫, 岡 明, 林 泰秀, 宮野 悟, 小川 誠司, 滝田 順子  臨床血液  59-  (9)  1585  -1585  2018/09  [Not refereed][Not invited]
  
• 小児ALLにおける高用量メトトレキサート療法時の薬物クリアランスへ影響を及ぼす因子の検討(The between MTX clearance and genetic variants in high-dose MTX therapy for ALL)

  田中 庸一, 浦山 ケビン, 森 麻希子, 長谷川 大輔, 赤羽 弘資, 太田 節雄, 康 勝好, 真部 淳  臨床血液  59-  (9)  1533  -1533  2018/09  [Not refereed][Not invited]
  
• Clinical Sequencing of 347 Children with Acquired and Inherited Bone Marrow Failure Syndromes

  Hideki Muramatsu, Yusuke Okuno, Kenichi Yoshida, Yuichi Shiraishi, Sayoko Doisaki, Atsushi Narita, Hirotoshi Sakaguchi, Nozomu Kawashima, Xinan Wang, Yinyan Xu, Kenichi Chiba, Hiroko Tanaka, Asahito Hama, Masashi Sanada, Yoshiyuki Takahashi, Hitoshi Kanno, Hiroki Yamaguchi, Shouichi Ohga, Atsushi Manabe, Hideo Harigae, Shinji Kunishima, Eiichi Ishii, Masao Kobayashi, Kenichi Koike, Kenichiro Watanabe, Etsuro Ito, Minoru Takata, Miharu Yabe, Seishi Ogawa, Satoru Miyano, Seiji Kojima  BLOOD  130-  2017/12  

  0
• Comprehensive Immunophenotyping Panel in Japan Enables to Detect Rare Subtypes in Childhood Leukemia

  Takao Deguchi, Nobutaka Kiyokawa, Kentaro Ohki, Yoshiko Hashii, Atsushi Manabe, Souichi Adachi, Akiko Moriya Saito, Keizo Horibe  BLOOD  130-  2017/12  

  0
• Integrated Genetic and Epigenetic Analysis in Pediatric T-Cell Acute Lymphoblastic Leukemia (T-ALL)

  S. Kimura, M. Seki, T. Kawai, K. Yoshida, T. Isobe, H. Ueno, H. Suzuki, K. Oki, T. Imamura, N. Kiyokawa, M. Kobayashi, K. Koh, A. Manabe, A. Ohara, M. Sanada, Y. Hayashi, K. Hata, S. Miyano, S. Ogawa, J. Takita  PEDIATRIC BLOOD & CANCER  64-  S31  -S31  2017/11  [Not refereed][Not invited]
  
• Close Correlation Between Immunophenotype and Genetic Abnormalities in Childhood Acute Lymphoblastic Leukemia: Results from TCCSG Study L04-16

  Nobutaka Kiyokawa, Takashi Fukushima, Kentaro Ohki, Motohiro Kato, Takeshi Ishibashi, Ai Yoshimi, Yuya Saito, Takahiro Aoki, Kazuki Terada, Osamu Tomita, Keiko Onda, Yoshihiro Gocho, Shinsuke Hirabayashi, Daisuke Hasegawa, Hiroyuki Takahahsi, Katsuyoshi Koh, Atsushi Manabe, Akira Ohara  PEDIATRIC BLOOD & CANCER  64-  S17  -S17  2017/11  [Not refereed][Not invited]
  
• Multimodality Treatment for Pelvic Ewing Sarcoma

  Akira Nishimura, Ayumu Arakawa, Yosuke Hosoya, Shinsuke Hirabayashi, Hiroki Yoshihara, Atsushi Kikuta, Seiichi Matsumoto, Jiro Kawamori, Daisuke Hasegawa, Tadashi Kumamoto, Chitose Ogawa, Atsushi Manabe  PEDIATRIC BLOOD & CANCER  64-  S58  -S58  2017/11  [Not refereed][Not invited]
  
• Asymptomatic Cerebral Microhemorrhage in Adolescent and Young Adult Survivors of Childhood Cancer: Five Patients Examined Using Magnetic Resonance Imaging

  Yosuke Hosoya, Yasushi Ishida, Miwa Ozawa, Taiki Nozaki, Kyoko Nagase, Michiyo Gunji, Kunie Maeda, Kyoko Kobayashi, Yuri Yoshimoto, Daisuke Hasegawa, Atsushi Manabe, Ryota Hosoya  PEDIATRIC BLOOD & CANCER  64-  S100  -S100  2017/11  [Not refereed][Not invited]
  
• The Feasibility of a Comprehensive Medical Check-up in Adolescent and Young Adult Survivors of Childhood Cancer

  Miwa Ozawa, Yasushi Ishida, Kyoko Kobayashi, Kyoko Nagase, Michiyo Gunzi, Kunie Maeda, Yuri Yoshimoto, Yosuke Hosoya, Daisuke Hasegawa, Atsushi Manabe, Ryota Hosoya  PEDIATRIC BLOOD & CANCER  64-  S101  -S101  2017/11  [Not refereed][Not invited]
  
• The Association Between Plasma Methotrexate Concentration and Genetic Variant in High-dose Methotrexate Therapy for Childhood Acute Lymphoblastic Leukemia

  Yoichi Tanaka, Kevin Urayama, Makiko Mori, Daisuke Hasegawa, Koshi Akahane, Setsuo Ota, Katsuyoshi Koh, Atsushi Manabe  PEDIATRIC BLOOD & CANCER  64-  S97  -S98  2017/11  [Not refereed][Not invited]
  
• IDH1 and KRAS Mutations are Involved in Acute Lymphoblastic Leukemia in Maffucci Syndrome

  S. Hirabayashi, M. Seki, D. Hasegawa, M. Kato, N. Hyakuna, T. Shuo, S. Kimura, K. Yoshida, K. Kataoka, Y. Fujii, Y. Shiraishi, K. Chiba, H. Tanaka, N. Kiyokawa, S. Miyano, S. Ogawa, J. Takita, A. Manabe  PEDIATRIC BLOOD & CANCER  64-  S179  -S180  2017/11  [Not refereed][Not invited]
  
• Correlation of Bone Marrow Morphology with Clinical Findings and Gene Alterations in Patients with Diamond-Blackfan Anemia

  Asahito Hama, Tsutomu Toki, Akie Kobayashi, Hideki Muramatsu, Yusuke Okuno, Daisuke Hasegawa, Kazue Nozawa, Yoshiyuki Takahashi, Kenichiro Watanabe, Atsushi Manabe, Masafumi Ito, Etsuro Ito, Seiji Kojima  PEDIATRIC BLOOD & CANCER  64-  S28  -S28  2017/11  [Not refereed][Not invited]
  
• Characteristics of Childhood Mixed Phenotype Acute Leukemia Diagnosed By Nation-Wide Immunophenotyping in Japan

  Takao Deguchi, Nobutaka Kiyokawa, Kentaro Ohki, Yoshiko Hashii, Atsushi Manabe, Souichi Adachi, Akiko Saito, Keizou Horibe  PEDIATRIC BLOOD & CANCER  64-  S16  -S16  2017/11  [Not refereed][Not invited]
  
• 先天性および後天性造血不全375例に対するクリニカルシーケンス(Clinical sequencing of 375 patients with inherited and acquired bone marrow failure syndromes)

  Muramatsu Hideki, Okuno Yusuke, Yoshida Kenichi, Shiraishi Yuichi, Narita Atsushi, Sakaguchi Hirotoshi, Kawashima Nozomu, Xu Yinyan, Chiba Kenichi, Tanaka Hiroko, Hama Asahito, Sanada Masashi, Takahashi Yoshiyuki, Kanno Hitoshi, Yamaguchi Hiroki, Ohga Shouichi, Manabe Atsushi, Harigae Hideo, Kunishima Shinji, Ishii Eiichi, Kobayashi Masao, Koike Kenichi, Watanabe Kenichiro, Ito Etsuro, Takata Minoru, Yabe Miharu, Miyano Satoru, Ogawa Seishi, Kojima Seiji  臨床血液  58-  (9)  1519  -1519  2017/09
• Congenetal dyserythropoietic anemia 10例の全エクソーム解析結果(Whole exome sequency analysis of congenital dyserythropoietic anemia in Japan)

  Hamada Motoharu, Doisaki Sayoko, Okuno Yusuke, Muramatsu Hideki, Hama Asahito, Kataoka Shinsuke, Ichikawa Daisuke, Taniguchi Rieko, Suzuki Kyogo, Kojima Daiei, Sekiya Yuko, Kawashima Nozomu, Narita Atsushi, Yoshida Kenichi, Shiraishi Yuichi, Sanada Masashi, Chiba Kenichi, Tanaka Hiroko, Manabe Atsushi, Taga Takashi, Takahashi Yoshiyuki, Miyano Satoru, Ogawa Seishi, Kojima Seiji  臨床血液  58-  (9)  1477  -1477  2017/09
• "つつうらうら"の小児救急事情 小児救急医療の現況 多角的な視点から課題を共有する 当院の小児救急医療の10年間の動向 都市部の立場から

  梅原 直, 草川 功, 真部 淳, 小澤 美和, 稲井 郁子, 平田 倫生, 吉良 登志子, 山田 奈生子, 塙 佳生, 日原 真理子, 小森 信政, 渡辺 浩志, 小坂 和輝, 松藤 凡  日本小児救急医学会雑誌  16-  (2)  232  -232  2017/05  [Not refereed][Not invited]
  
• 過去10年間に当院外来を受診した、異物・誤飲患児に関する検討

  山本 俊亮, 山本 薫, 相賀 咲央莉, 山本 一希, 梅原 直, 島袋 林秀, 平田 倫生, 小澤 美和, 真部 淳, 草川 功, 右田 美里, 松藤 凡  日本小児救急医学会雑誌  16-  (2)  312  -312  2017/05  [Not refereed][Not invited]
  
• ターゲットシーケンス解析を施行した小児造血不全移植例の解析

  村松秀城, 奥野友介, 吉田健一, 白石友一, 濱麻人, 真田昌, 高橋義行, 菅野仁, 山口博樹, 大賀正一, 真部淳, 張替秀郎, 國島伸治, 石井榮一, 小林正夫, 小池健一, 渡邉健一郎, 伊藤悦朗, 高田穣, 矢部みはる, 小川誠司, 宮野悟, 小島勢二  日本造血細胞移植学会総会プログラム・抄録集  40th-  2017
• 特発性造血障害に関する調査研究 先天性造血不全症候群の研究

  中畑龍俊, 真部淳  特発性造血障害に関する調査研究 平成28年度 総括・分担研究報告書(Web)  201610059A0012 (WEB ONLY)  2017  [Not refereed][Not invited]
  
• Five Cases of Pediatric-Onset Bechet’s disease complicated with Myelodysplastic Syndrome.

  Kanamitsu K, Shimada A, Nishiuchi R, Shigemura T, Nakazawa Y, Koike K, Kodama Y, Shinkoda Y, Kawano Y, Yasui K, Sasaki K, Kajiwara R, Tsukahara H, Manabe A  International Journal of Hematology  105-  (3)  377  -382  2017  [Not refereed][Not invited]
  
• TAL1 Super Enhancer Aberration and Stil-TAL1 Fusion in Pediatric T Cell Acute Lymphoblastic Leukemia

  Shunsuke Kimura, Masafumi Seki, Kenichi Yoshida, Hiroo Ueno, Yuichi Shiraishi, Kenichi Chiba, Hiroko Tanaka, Hiromichi Suzuki, Keisuke Kataoka, Kentaro Ohki, Motohiro Kato, Katsuyoshi Koh, Ryoji Hanada, Nobutaka Kiyokawa, Masao Kobayashi, Atsushi Manabe, Akira Ohara, Yasuhide Hayashi, Satoru Miyano, Seishi Ogawa, Junko Takita  BLOOD  128-  (22)  2016/12  [Not refereed][Not invited]
  
• Clusters of Childhood Mixed Phenotype Acute Leukemia Diagnosed By Nation-Wide Immunophenotyping in Japan

  Takao Deguchi, Nobutaka Kiyokawa, Kentaro Ohki, Yoshiko Hashii, Atsushi Manabe, Souichi Adachi, Akiko M. Saito, Keizo Horibe, Yoshihiro Komada  BLOOD  128-  (22)  2016/12  [Not refereed][Not invited]
   

  0
• Genetic Abnormalities and Prognosis in Pediatric B-Precursor Acute Lymphoblastic Leukemia without Conventional Genetic Abnormalities; Tokyo Children's Cancer Study Group

  Kenro Ohki, Shinsuke Hirabayashi, Akinori Yaguchi, Akinori Yaguchi, Kazuki Terada, Jun Ohkubo, Norio Shiba, Motohiro Kato, Takashi Fukushima, Katsuyoshi Koh, Hayashi Yasuhide, Atsushi Manabe, Akira Ohara, Nobutaka Kiyokawa  BLOOD  128-  (22)  2016/12  [Not refereed][Not invited]
  
• Comparison of Clinical Outcomes Between Pediatric Aplastic Anemia and Refractory Cytopenia of Childhood

  Asahito Hama, Atsushi Manabe, Daisuke Hasegawa, Kazue Nozawa, Atsushi Narita, Hideki Muramatsu, Yoshiyuki Takahashi, Kenichiro Watanabe, Akira Ohara, Masafumi Ito, Seiji Kojima  BLOOD  128-  (22)  2016/12  [Not refereed][Not invited]
  
• TAL1 Abnormalities in Childhood T-Cell Acute Lymphoblastic Leukemia

  M. Seki, K. Yoshida, S. Kimura, Y. Shiraishi, M. Kato, K. Koh, R. Hanada, T. Deguchi, T. Imamura, K. Horibe, N. Kiyokawa, A. Manabe, A. Ohara, M. Sanada, H. Mano, Y. Hayashi, S. Miyano, A. Oka, S. Ogawa, J. Takita  PEDIATRIC BLOOD & CANCER  63-  S117  -S117  2016/11  [Not refereed][Not invited]
  
• 小児造血器腫瘍の分子遺伝学の進歩 : WHO分類第4版2016改訂 (特集 小児造血器腫瘍の特色 : 分子的理解から治療開発まで)

  平林 真介, 真部 淳  血液フロンティア  26-  (11)  1561  -1568  2016/11
• Risk Factors for Psychosomatic Symptoms in Patients with Paediatric Cancers

  D. Hasegawa, K. I. Maeda, K. Urayama, S. I. Tsujimoto, Y. Azami, M. Ozawa, A. Manabe  PEDIATRIC BLOOD & CANCER  63-  S280  -S281  2016/11  [Not refereed][Not invited]
  
• 本邦での骨髄浸潤を伴わない小児顆粒球肉腫の後方視的研究(Retrospective study for pediatric myeloid sarcoma without bone marrow involvement in Japan)

  多賀 崇, 今村 俊彦, 中島 健太郎, 前田 尚子, 渡辺 輝浩, 宮島 雄二, 藤村 純也, 佐野 仁志, 長谷川 大一郎, 河崎 裕英, 足立 壮一, 高木 正稔, 康 勝好, 真部 淳, 滝 智彦, 石田 也寸志, 日本小児血液・がん学会白血病リンパ腫委員会  日本小児血液・がん学会雑誌  53-  (4)  251  -251  2016/11  [Not refereed][Not invited]
  
• mTOR阻害剤が有効であった血管奇形の3例

  平林 真介, 長谷川 大輔, 吉本 優里, 細谷 要介, 熊本 忠史, 真部 淳, 鮫島 麗子, 藤村 純也  日本小児血液・がん学会雑誌  53-  (4)  282  -282  2016/11  [Not refereed][Not invited]
  
• 日本人小児ALLのL-アスパラギナーゼアレルギー発現におけるNFATC2 rs6021191多型の影響(Lack of association between L-asparaginase allergy and rs6021191 variant in NFATC2 in Japanese children with acute lymphoblastic leukemia)

  田中 庸一, ウラヤマ・ケビン, 森 麻希子, 長谷川 大輔, 石丸 紗恵, 寺田 和樹, 柳町 昌克, 太田 節雄, 高橋 浩之, 外山 大輔, 慶野 大, 森脇 浩一, 高木 正稔, 藤村 純也, 関中 悠仁, 中村 こずえ, 佐藤 雄弥, 小原 明, 康 勝好, 真部 淳  日本小児血液・がん学会雑誌  53-  (4)  342  -342  2016/11  [Not refereed][Not invited]
  
• 改訂版長期フォローアップ手帳(Follow Up Diary)の使用感に関する全国調査(A nation-wide survey of usability assessment for the revised version of the "Long-Term Follow Up Diary")

  大園 秀一, 石田 也寸志, 清谷 知賀子, 岩井 艶子, 黒田 達夫, 藤 浩, 佐藤 伊織, 前田 美穂, 細井 創, 足立 壯一, 真部 淳, 福澤 正洋, 水谷 修紀, JCCG長期フォローアップ委員会  日本小児血液・がん学会雑誌  53-  (4)  265  -265  2016/11  [Not refereed][Not invited]
  
• 小児における特発性骨髄不全症候群の遺伝的背景(Genetic background of idiopathic bone marrow failure syndromes in children)

  Narita Atsushi, Okuno Yusuke, Muramatsu Hideki, Yoshida Kenichi, Shiraishi Yuichi, Chiba Kenichi, Tanaka Hiroko, Wang Xinan, Kawashima Nozomu, Nishio Nobuhiro, Hama Asahito, Takahashi Yoshiyuki, Hasegawa Daisuke, Manabe Atsushi, Sakaguchi Hirotoshi, Yoshida Nao, Kato Koji, Miyano Satoru, Ito Masafumi, Ogawa Seishi, Kojima Seiji  臨床血液  57-  (9)  1490  -1490  2016/09
• 非血縁同種骨髄移植後に重症腎TMAを発症した骨髄異形成症候群の8歳女児例

  宮本智史, 宮本智史, 木村俊介, 石田悠志, 代田惇朗, 松井俊大, 吉本優里, 平林真介, 細谷要介, 藤丸拓也, 長谷川大輔, 熊本忠史, 森慎一郎, 鈴木高祐, 真部淳  日本造血細胞移植学会総会プログラム・抄録集  38th-  2016
• 小児最重症再生不良性貧血に対する非血縁者間臍帯血移植

  木村俊介, 長谷川大輔, 松井俊大, 代田惇朗, 石田悠志, 吉本優里, 平林真介, 細谷要介, 吉原宏樹, 熊本忠史, 森愼一郎, 真部淳  日本小児血液・がん学会雑誌(Web)  53-  (1)  2016
• Mechanisms of clonal evolution in childhood acute lymphoblastic leukemia : Swaminathan S. (Journal club : 抄読会(第52回))

  吉本 優里, 真部 淳  小児科臨床  69-  (1)  149  -152  2016/01
• Lack of association between L-asparaginase allergy and rs6021191 variant in NFATC2 in Japanese children with acute lymphoblastic leukemia

  田中庸一, ウラヤマ ケビン, 森麻希子, 長谷川大輔, 石丸紗恵, 寺田和樹, 柳町昌克, 太田節雄, 高橋浩之, 外山大輔, 慶野大, 森脇浩一, 高木正稔, 藤村純也, 関中悠仁, 中村こずえ, 佐藤雄弥, 小原明, 康勝好, 真部淳  日本小児血液・がん学会雑誌(Web)  53-  (4)  2016
• Two cases of pediatric BCL2 and MYC dual-hit leukemia between 2002 and 2011 in Japan

  坂口公祥, 今村俊彦, 石丸紗恵, 今井千速, 下之段秀美, 岡田恵子, 出口隆生, 橋井佳子, 清河信敬, 齋藤明子, 真部淳, 佐藤篤, 康勝好  日本小児血液・がん学会雑誌(Web)  53-  (4)  2016
• The characteristics of Bilineal Leukemia diagnosed by nationwide immunophenotyping for pediatric hematological malignancy in Japan

  出口隆生, 清河信敬, 大木健太郎, 橋井佳子, 真部淳, 足立壯一, 齋藤明子, 堀部敬三, 駒田美弘  日本小児血液・がん学会雑誌(Web)  53-  (4)  2016
• 特発性造血障害に関する調査研究 先天性造血不全症候群の研究

  中畑龍俊, 真部淳, 長谷川大輔, 小島勢二, 矢部普正, 小原明  特発性造血障害に関する調査研究 平成27年度 総括・分担研究報告書  45‐48  2016  [Not refereed][Not invited]
  
• The Outcome of Relapsed Childhood Core Binding Factor Acute Myeloid Leukemia: A Report from the JPLSG AML-05R Study

  Hiroshi Moritake, Shiro Tanaka, Hideki Nakayama, Takako Miyamura, Shotaro Iwamoto, Akira Shimada, Kiminori Terui, Akiko M. Saito, Norio Shiba, Yasuhide Hayashi, Daisuke Tomizawa, Takashi Taga, Hiroaki Goto, Atsushi Manabe, Keizo Horibe, Shuki Mizutani, Souichi Adachi  BLOOD  126-  (23)  2015/12  [Not refereed][Not invited]
  
• TAL1 and MYB Abnormalities in Childhood T-Cell Acute Lymphoblastic Leukemia

  Masafumi Seki, Kenichi Yoshida, Yuichi Shiraishi, Kenichi Chiba, Hiroko Tanaka, Motohiro Kato, Shunsuke Kimura, Ryoji Hanada, Katsuyoshi Koh, Satoru Miyano, Toshihiko Imamura, Keizo Horibe, Nobutaka Kiyokawa, Atsushi Manabe, Akira Ohara, Yasuhide Hayashi, Akira Oka, Seishi Ogawa, Junko Takita  BLOOD  126-  (23)  2015/12  [Not refereed][Not invited]
  
• The Characteristics of Blastic Plasmacytoid Dendritic Cell Neoplasms Presenting Leukemia Dissemination, Diagnosed By Nation-Wide Immunophenotyping for Pediatric Hematological Malignancy in Japan

  Takao Deguchi, Nobutaka Kiyokawa, Yoshiko Hashii, Akiko M. Saito, Atsushi Manabe, Keizo Horibe, Yoshihiro Komada  BLOOD  126-  (23)  2015/12  [Not refereed][Not invited]
  
• Genetic Susceptibility Loci for Childhood Acute Lymphoblastic Leukemia Among Japanese

  Kevin Y. Urayama, Masatoshi Takagi, Takahisa Kawaguchi, Keitaro Matsuo, Yoichi Tanaka, Yuki Arakawa, Daisuke Hasegawa, Yuki Yuza, Takashi Kaneko, Yasushi Noguchi, Yuichi Taneyama, Setsuo Ota, Takeshi Inukai, Masakatsu Yanagimachi, Dai Keino, Kazutoshi Koike, Daisuke Toyama, Yozo Nakazawa, Hidernitsu Kurosawa, Kozue Nakamura, Koichi Moriwaki, Hiroaki Goto, Yujin Sekinaka, Daisuke Morita, Motohiro Kato, Katsuyoshi Koh, Yasushi Ishida, Akira Ohara, Shuki Mizutani, Fumihiko Matsuda, Atsushi Manabe  BLOOD  126-  (23)  2015/12  [Not refereed][Not invited]
  
• A novel recurrent EP300-ZNF384 gene fusion in B-cell precursor acute lymphoblastic leukemia

  Y. Gocho, N. Kiyokawa, H. Ichikawa, K. Nakabayashi, T. Osumi, T. Ishibashi, H. Ueno, K. Terada, K. Oboki, H. Sakamoto, Y. Shioda, M. Imai, Y. Noguchi, Y. Arakawa, Y. Kojima, D. Toyama, K. Hata, T. Yoshida, K. Matsumoto, M. Kato, T. Fukushima, K. Koh, A. Manabe, A. Ohara  LEUKEMIA  29-  (12)  2445  -2448  2015/12  [Not refereed][Not invited]
  
• Comparison of Clinical and Laboratory Features Between Pediatric Aplastic Anemia and Refractory Cytopenia of Childhood

  Asahito Hama, Atsushi Manabe, Daisuke Hasegawa, Hideki Muramatsu, Yoshiyuki Takahashi, Kenichiro Watanabe, Akira Ohara, Masafumi Ito, Seiji Kojima  BLOOD  126-  (23)  2015/12  [Not refereed][Not invited]
  
• FIVE CASES OF PEDIATRIC-ONSET BEHCET DISEASE COMPLICATED WITH MYELODYSPLASTIC SYNDROME

  K. Kanamitsu, R. Nishiuchi, K. Yamato, T. Shigemura, Y. Nakazawa, K. Koike, Y. Shinkoda, Y. Kawano, H. Ueno, A. Manabe, K. Yasui, H. Goto, K. Sasaki, S. Yokota, A. Shimada  LEUKEMIA RESEARCH  39-  S96  -S96  2015/04  [Not refereed][Not invited]
  
• Blast crisis of juvenile myelomonocytic leukemia

  本田 裕子, 真部 淳  血液内科  70-  (3)  397  -402  2015/03
• 小児不応性血球減少症に対する造血幹細胞移植;日本小児血液学会前方視的登録例より

  長谷川大輔, 平林真介, 渡辺静, 在家裕司, 土田昌宏, 増永敦子, 吉見礼美, 濱麻人, 小島勢二, 伊藤雅文, 中畑龍俊, 真部淳  日本造血細胞移植学会総会プログラム・抄録集  37th-  251  2015/02/06  [Not refereed][Not invited]
  
• 非血縁者間臍帯血移植を行った小児最重症再生不良性貧血の1例

  木村俊介, 長谷川大輔, 松井俊大, 小野沙裕子, 石田悠志, 吉本優里, 平林真介, 細谷要介, 吉原宏樹, 熊本忠志, 真部淳  日本造血細胞移植学会総会プログラム・抄録集  37th-  2015
• 小児再生不良性貧血におけるリンパ球テロメア長と造血幹細胞移植予後との関連

  成田敦, 坂口大俊, 関屋由子, 奥野友介, 村松秀城, 川島希, 土居崎小夜子, 濱麻人, 高橋義行, 吉田奈央, 伊藤雅文, 長谷川大輔, 真部淳, 矢部普正, 小林良二, 小島勢二  日本造血細胞移植学会総会プログラム・抄録集  37th-  2015
• 特発性造血障害に関する調査研究 先天性造血不全症候群の研究

  中畑龍俊, 真部淳, 小島勢二, 矢部普正, 小原明  特発性造血障害に関する調査研究 平成26年度 総括・分担研究報告書  76‐79  2015  [Not refereed][Not invited]
  
• SECONDARY CANCERS AFTER CANCER DIAGNOSIS IN CHILDHOOD: A HOSPITAL-BASED RETROSPECTIVE COHORT STUDY IN JAPAN

  Y. Ishida, D. Qiu, M. Maeda, J. Fujimoto, H. Kigasawa, R. Kobayashi, M. Sato, J. Okamura, S. Yoshinaga, T. Rikiishi, H. Shichino, C. Kiyotani, K. Kudo, K. Asami, H. Hori, H. Kawaguchi, H. Inada, S. Adachi, A. Manabe, T. Kuroda  PEDIATRIC BLOOD & CANCER  61-  S198  -S198  2014/12  [Not refereed][Not invited]
  
• Phase I/II Clinical Trial of Erwinia Asparaginase (Erwinase(R)) in Combination with Prednisolone, Vincristine and Pirarubicin in Children and Young Adults with Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)

  Chitose Ogawa, Atsushi Manabe, Hiroaki Goto, Katsuyoshi Koh, Daisuke Tomizawa, Keitaro Fukushima, Ken-ichiro Watanabe, Keizo Horibe, Atsushi Kikuta, Mitsuma Hamada, Akira Ohara  BLOOD  124-  (21)  2014/12  [Not refereed][Not invited]
  
• Outcome of Adolescent and Young Adults with Acute Myeloid Leukemia Treated with Pediatric Protocols: A Report from the 3 Japanese Cooperative Studies

  Daisuke Tomizawa, Tomoyuki Watanabe, Ryoji Hanada, Keizo Horibe, Yasuo Horikoshi, Shotaro Iwamoto, Akitoshi Kinoshita, Hiroshi Moritake, Hideki Nakayama, Akira Shimada, Takashi Taga, Hiroyuki Takahashi, Akio Tawa, Kiminori Terui, Hiroki Hori, Yoshifumi Kawano, Atsushi Kikuta, Atsushi Manabe, Souichi Adachi  BLOOD  124-  (21)  2014/12  [Not refereed][Not invited]
  
• Central Morphology Review of Childhood Bone Marrow Failure in Japan

  Asahito Hama, Manabe Atsushi, Daisuke Hasegawa, Kazue Nozawa, Yusuke Okuno, Masahiro Irie, Hideki Muramatsu, Yoshiyuki Takahashi, Kenichiro Watanabe, Akira Ohara, Masafumi Ito, Seiji Kojima  BLOOD  124-  (21)  2014/12  [Not refereed][Not invited]
  
• RISK FACTORS OF LONG-TERM CENTRAL VENOUS CATHETERS (CVCS) COMPLICATION IN CHILDREN WITH HEMATO-ONCOLOGICAL DISORDERS

  A. Sakoda, T. Kawano, Y. Hosoya, H. Yoshiwara, S. Hirabayashi, D. Hasegawa, M. Ozawa, H. Matsufuji, A. Manabe, O. Takahashi  PEDIATRIC BLOOD & CANCER  61-  S353  -S353  2014/12  [Not refereed][Not invited]
  
• Genetic Abnormalities and Prognosis in Pediatric B-precursor Acute Lymphoblastic Leukemia Treated on Tokyo Children's Cancer Study Group Protocol

  Kentaro Ohki, Myoung-ja Park, Yusuke Hara, Norio Shiba, Takashi Fukushima, Katsuyoshi Koh, Atsushi Manabe, Akira Ohara, Nobutaka Kiyokawa, Yasuhide Hayashi  BLOOD  124-  (21)  2014/12  [Not refereed][Not invited]
  
• 小児急性リンパ性白血病における6-メルカプトプリン/メトトレキサート関連遺伝子の再発リスクへの影響(The influence of genetic polymorphisms related with 6-mercaptopurine and methotrexate on the risk of relapse in childhood acute lymphoblastic leukemia)

  田中 庸一, 真部 淳, 中舘 尚也, 慶野 大, 中村 こずえ, 康 勝好, 秋山 政晴, 植田 高弘, 小宮山 貴子  日本小児血液・がん学会雑誌  51-  (4)  235  -235  2014/10  [Not refereed][Not invited]
  
• B前駆細胞性急性リンパ芽球性白血病の新規融合遺伝子EP300-ZNF384 BCP-ALLの新たなサブグループ(Identification of a novel subset of B-cell precursor acute lymphoblastic leukemia with EP300-ZNF384 fusion gene)

  牛腸 義宏, 清河 信敬, 市川 仁, 中林 一彦, 上野 瞳, 大隅 朋生, 石橋 武士, 寺田 和樹, 大保木 啓介, 坂本 裕美, 塩田 曜子, 今井 雅子, 野口 靖, 外山 大輔, 秦 健一郎, 吉田 輝彦, 松本 健治, 福島 敬, 康 勝好, 真部 淳, 小原 明  日本小児血液・がん学会雑誌  51-  (4)  238  -238  2014/10  [Not refereed][Not invited]
  
• 小児Ph-like ALL症例の表面マーカー、遺伝子発現解析

  飯島 一智, 清河 信敬, 吉原 宏樹, 富田 理, 小林 健一郎, 福島 敬, 林 泰秀, 菊地 陽, 康 勝好, 真部 淳, 小原 明  日本小児血液・がん学会雑誌  51-  (3)  200  -205  2014/09  [Not refereed][Not invited]
   

  近年、B前駆細胞性急性リンパ芽球性白血病(BCP-ALL)症例の中で、BCR-ABL1陰性にもかかわらずPh1 ALLに類似した遺伝子発現プロファイルを示し、予後も同程度不良な亜群であるPh-like ALLが注目されている。現状では多数の症例の遺伝子発現データに基づいたクラスタリング解析により判定されていることから、より簡便、迅速に症例毎に適用可能な診断法が求められている。我々はGene Set Enrichment Analysisを用いて単一症例でのPh-like ALL判定法を確立し、東京小児がん研究グループ(TCCSG)ALL治療研究L0416/0616登録BCP-ALL 235例に対してマイクロアレイによる遺伝子発現解析を行ない、14例(6.0%)がPh-like ALLと判断され、予後不良であることを報告している。そこで、今回はフローサイトメトリーによるマーカー所見と遺伝子発現に基づき、特異的マーカーの探索を行なった。表面マーカー所見としては、全例がCD10陽性のcommon-ALL型で、約7割の症例でCD66cが陽性であった。種々のMyeloid系マーカーのaberrantな発現を認めたものの、マーカー所見のみでPh-like ALLを判定するのは困難であった。また、Ph-like ALLとPh1 ALL症例に共通して特徴的に発現する遺伝子やPh-like ALLのみで特徴的に発現する遺伝子を同定した。(著者抄録)
• INVESTIGATION OF PH-LIKE ALL BY GENE SET ENRICHMENT ANALYSIS AND IDENTIFICATION OF THEIR SPECIFIC EXPRESSION GENES

  K. Iijima, N. Kiyokawa, K. Nakabayashi, H. Ichikawa, T. Osumi, H. Yoshihara, K. Ohki, M. Kato, T. Fukushima, H. Shimada, T. Mori, A. Kinoshita, K. Matsumoto, K. Koh, A. Kikuchi, Y. Hayashi, A. Manabe, A. Ohara  HAEMATOLOGICA  99-  5  -5  2014/06  [Not refereed][Not invited]
  
• Management of germinoma-induced diabetes insipidus with DDAVP during hydration for chemotherapy

  木村 俊介, 伊藤 純子, 吉本 優里, 平林 真介, 細谷 要介, 吉原 宏樹, 長谷川 大輔, 真部 淳  ホルモンと臨床  62-  (5)  367  -371  2014/05
• 小児急性リンパ性白血病のキメラ遺伝子スクリーニング検査

  大木 圭子, 南木 融, 福島 敬, 清河 信敬, 康 勝好, 小原 明, 真部 淳, 川上 康  医学検査  63-  (学会特集号)  175  -175  2014/04  [Not refereed][Not invited]
  
• 点鼻あるいは経口デスモプレシン製剤を用いて化学療法中の尿崩症を管理した神経下垂体部胚細胞腫瘍の5例

  木村俊介, 細谷要介, 石田悠志, 野村耕太郎, 吉本優里, 吉原宏樹, 長谷川大輔, 伊藤純子, 真部淳  日本小児内分泌学会学術集会プログラム・抄録集  48th-  2014
• 変異KRASの片親性ダイソミーにより急性転化したJMML

  加藤 元博, 安井 直子, 関 正史, 岸本 宏志, 佐藤 亜以子, 長谷川 大輔, 清河 信敬, 小川 誠司, 真部 淳, 滝田 順子, 康 勝好, 花田 良二  日本小児血液・がん学会雑誌  50-  (4)  651  -651  2013/12  [Not refereed][Not invited]
  
• B前駆細胞性ALL再発症例のマーカーの特徴に関する検討

  牛腸 義宏, 清河 信敬, 富田 理, 飯島 一智, 吉原 宏樹, 石橋 武士, 小林 健一郎, 福島 敬, 前田 美穂, 林 泰秀, 菊地 陽, 康 勝好, 真部 淳, 小原 明  日本小児血液・がん学会学術集会・日本小児がん看護学会・公益財団法人がんの子どもを守る会公開シンポジウムプログラム総会号  55回・11回・18回-  202  -202  2013/11  [Not refereed][Not invited]
  
• 小児B前駆細胞型ALLにおけるEBF1-PDGFRB融合遺伝子の解析 TCCSG-ALL研究

  大木 健太郎, 朴 明子, 原 勇介, 柴 徳生, 大喜多 肇, 小林 健一郎, 外松 学, 福島 敬, 康 勝好, 花田 良二, 真部 淳, 菊地 陽, 土田 昌宏, 小原 明, 清河 信敬, 林 泰秀  日本小児血液・がん学会学術集会・日本小児がん看護学会・公益財団法人がんの子どもを守る会公開シンポジウムプログラム総会号  55回・11回・18回-  244  -244  2013/11  [Not refereed][Not invited]
  
• 変異KRASの片親性ダイソミーにより急性転化したJMML

  加藤 元博, 安井 直子, 関 正史, 岸本 宏志, 佐藤 亜以子, 長谷川 大輔, 清河 信敬, 小川 誠司, 真部 淳, 滝田 順子, 康 勝好, 花田 良二  日本小児血液・がん学会雑誌  50-  (3)  496  -496  2013/10  [Not refereed][Not invited]
  
• Myelodysplastic syndrome and aplastic anemia in childhood : recent advances

  上野 浩生, 真部 淳  血液内科  67-  (3)  404  -410  2013/09
• REAPPRAISAL OF NCI/ROME CRITERIA IN CHILDHOOD B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA: TOKYO CHILDREN'S CANCER STUDY GROUP STUDIES BETWEEN 1989 AND 2003

  A. Manabe, K. Koh, K. Oshima, J. Fujimura, K. Ikuta, T. Saito, A. Kikuchi, R. Hanada, M. Tsuchida, A. Ohara  PEDIATRIC BLOOD & CANCER  60-  66  -66  2013/09  [Not refereed][Not invited]
  
• HYPERSENSITIVITY TO ASPARAGINASE IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)

  D. Hasegawa, S. Watanabe, H. Yoshihara, Y. Hosoya, C. Ogawa, K. Goto, R. Hosoya, A. Manabe  PEDIATRIC BLOOD & CANCER  60-  63  -63  2013/09  [Not refereed][Not invited]
  
• NURSING CARE FOR CHILDREN WITH DOWN SYNDROME (DS) AND LEUKEMIA

  J. Iida, M. Hirata, D. Hasegawa, A. Sekitomi, Y. Toriyama, W. Irie, R. Nishino, M. Ozawa, A. Manabe, R. Hosoya  PEDIATRIC BLOOD & CANCER  60-  41  -41  2013/09  [Not refereed][Not invited]
  
• 小児Ph-like ALLのマーカー所見の検討

  清河 信敬, 飯島 一智, 富田 理, 吉原 宏樹, 三春 晶嗣, 大隅 朋生, 嶋田 博之, 福島 敬, 森 鉄也, 斎藤 正博, 康 勝好, 真部 淳, 菊地 陽, 林 泰秀, 小原 明  Cytometry Research  23-  (Suppl.)  57  -57  2013/06  [Not refereed][Not invited]
  
• Cytomtric Bead Arrayを用いたBCR-ABL1蛋白検出の臨床的有用性

  富田 理, 清河 信敬, 三春 晶嗣, 石橋 武士, 大隅 朋生, 嶋田 博之, 福島 敬, 森 鉄也, 斎藤 正博, 康 勝好, 真部 淳, 菊地 陽, 林 泰秀, 小原 明  Cytometry Research  23-  (Suppl.)  58  -58  2013/06  [Not refereed][Not invited]
  
• Morphological differentiation of bone marrow failure syndromes in children according to 2008 WHO classification

  A. Hama, A. Manabe, M. Ito, D. Hasegawa, K. Nozawa, H. Muramatsu, Y. Takahashi, A. Ohara, S. Kojima  LEUKEMIA RESEARCH  37-  S89  -S89  2013/05  [Not refereed][Not invited]
  
• Equivalent outcome between reduced-intensity versus conventional myeloablative conditioning haematopoietic stem cell transplantation for childhood MDS: a report from the MDS working group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT)

  D. Hasegawa, A. Kikuchi, M. Yabe, M. Kato, K. Kudo, Y. Atsuta, J. Inagaki, M. Inoue, R. Nishimura, J. Tanaka, K. Kato, H. Yabe, K. Kawa, A. Manabe, K. Watanabe  BONE MARROW TRANSPLANTATION  48-  S296  -S297  2013/04  [Not refereed][Not invited]
  
• 思春期がん経験者のQOLと病気に関する自己開示

  三井 千佳, 山崎 あけみ, 前田 尚子, 堀部 敬三, 浅見 恵子, 原 純一, 井田 孔明, 康 勝好, 小澤 美和, 真部 淳, 上別府 圭子  日本小児血液・がん学会雑誌  50-  (1)  79  -84  2013/04  [Not refereed][Not invited]
   

  思春期がん経験者31名を対象に病気に関する自己開示とQOLについての調査を行った。開示相手として診断当時は母親を、現在は母親と友人を選択している者が多かった。診断当時も現在も「結婚・子どもを持つこと」が最も開示していない内容であった。また診断当時も現在も開示していること、またはしていないことについて概ね満足しており、現在の満足度の高さが精神的健康を高める可能性が示唆された。(著者抄録)
• A Case of Burkitt Lymphoma with Multifocal Bone Invasion

  TANAKA Chie, NOZAWA Kazue, SANO Akiko, UCHIKAWA Kaori, NAKAJIMA Atsuko, MANABE Atushi, TAKEDA Kyoko  臨床病理  61-  (3)  231  -236  2013/03/25
• 小児B前駆細胞型ALLにおけるCRLF2高発現例の特徴 TCCSG-ALL研究

  大木 健太郎, 朴 明子, 柴 徳生, 清河 信敬, 康 勝好, 花田 良二, 真部 淳, 菊地 陽, 小原 明, 林 泰秀  日本小児科学会雑誌  117-  (2)  345  -345  2013/02  [Not refereed][Not invited]
  
• 小児不応性血球減少症の臨床像の検討 日本小児血液学会前方視的登録例より

  長谷川 大輔, 在家 裕司, 土田 昌宏, 増永 敦子, 吉見 礼美, 濱 麻人, 小島 勢二, 伊藤 雅文, 中畑 龍俊, 真部 淳, 日本小児血液, がん学会MDS委員会  日本小児科学会雑誌  117-  (2)  370  -370  2013/02  [Not refereed][Not invited]
  
• 血球貪食症候群の経過中に中枢神経症状を呈した3例の画像的考察

  石田悠志, 長谷川大輔, 野崎太希, 細谷要介, 吉原宏樹, 平林真介, 神谷尚宏, 熊本忠史, 小川千登世, 細谷亮太, 森愼一郎, 真部淳  日本小児血液・がん学会学術集会・日本小児がん看護学会・がんの子供を守る会公開シンポジウムプログラム・総会号  55th-11th-18th-  2013
• Telomere length as a predictor for the immunosuppressive therapy in acquired aplastic anemia

  SAKAGUCHI Hirotoshi, NISHIO Nobuhiro, KAWASHIMA Nozomu, WANG Xinan, NARITA Atsushi, DOISAKI Sayoko, MURAMATSU Hideki, HAMA Asahito, NAKANISHI Koji, TAKAHASHI Yoshiyuki, TSUCHIDA Masahiro, KOBAYASHI Ryouji, ITOU Etsurou, YABE Hiromasa, OHGA Syouichi, OHARA Akira, HASEGAWA Daisuke, MANABE Atsushi, ITOU Masafumi, KOJIMA Seiji  臨床血液  54-  (9)  2013
• 【臨床血液学 今後の展望(2013年版)-リンパ系疾患-】 小児急性リンパ性白血病

  真部 淳, 長谷川 大輔  臨床血液  54-  (1)  100  -108  2013/01  [Not refereed][Not invited]
  
• POSTTRAUMATIC STRESS SYMPTOMS AS AN IMPORTANT REACTION IN CHILDREN WHO DONATE THEIR STEM CELL TO THEIR SIBLINGS WITH CANCER

  Miwa Ozawa, Asuka Higashi, Akiko Kobayashi, Disuke Hasegawa, Chitose Ogawa, Atsushi Manabe, Ryota Hosoya  ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY  8-  247  -247  2012/11  [Not refereed][Not invited]
  
• CD66c陽性小児急性リンパ芽球性白血病の特徴

  富田 理, 清河 信敬, 三春 晶嗣, 小林 健一郎, 大喜多 肇, 長谷川 大輔, 嶋田 博之, 森 鉄也, 福島 敬, 斎藤 正博, 犬飼 岳史, 康 勝好, 杉田 完爾, 花田 良二, 土田 昌宏, 真部 淳, 菊地 陽, 藤本 純一郎, 林 泰秀, 小原 明, 東京小児がん研究グループ  日本小児血液・がん学会学術集会・日本小児がん看護学会・公益財団法人がんの子どもを守る会公開シンポジウムプログラム総会号  54回・10回・17回-  286  -286  2012/11  [Not refereed][Not invited]
  
• 経過中に急性転化したJMML 23例の検討 MDS委員会のデータベースから

  本田 裕子, 土田 昌宏, 増永 敦子, 吉見 礼美, 小島 勢二, 伊藤 雅文, 菊地 陽, 中畑 龍俊, 真部 淳  日本小児血液・がん学会学術集会・日本小児がん看護学会・公益財団法人がんの子どもを守る会公開シンポジウムプログラム総会号  54回・10回・17回-  251  -251  2012/11  [Not refereed][Not invited]
  
• ダウン症候群に合併した一過性骨髄異常増殖症に対する少量シタラビン療法による腫瘍崩壊症候群

  村松 秀城, 菊地 陽, 林 泰秀, 川村 眞智子, 小島 勢二, 矢部 みはる, 磯山 恵一, 滝 智彦, 辻 浩一郎, 土田 昌宏, 真部 淳  日本小児血液・がん学会学術集会・日本小児がん看護学会・公益財団法人がんの子どもを守る会公開シンポジウムプログラム総会号  54回・10回・17回-  282  -282  2012/11  [Not refereed][Not invited]
  
• 【MDS(骨髄異形成症候群)】 小児のMDS

  長谷川 大輔, 真部 淳  臨床検査  56-  (12)  1377  -1384  2012/11  [Not refereed][Not invited]
  
• 若年性骨髄単球性白血病(JMML)の分子機構と治療

  真部 淳  臨床血液  53-  (8)  729  -733  2012/08/30
• Congenital Dyserythropoietic Anemia : 現状と今後の課題

  多賀 崇, 真部 淳  日本小児科学会雑誌  116-  (7)  1075  -1080  2012/07/01
• FCMによるリンパ系腫瘍への新たなアプローチ 小児白血病MRD検出における10カラーフローサイトメトリーの有用性

  三春 晶嗣, 清河 信敬, 小林 健一郎, 大喜多 肇, 飯島 一智, 森 鉄也, 斎藤 正博, 福島 敬, 康 勝好, 真部 淳, 菊地 陽, 林 泰秀, 小原 明  Cytometry Research  22-  (Suppl.)  44  -44  2012/06  [Not refereed][Not invited]
  
• 小児リンパ芽球性白血病のキメラ遺伝子、細胞マーカーと遺伝子発現プロファイルの特徴

  清河 信敬, 福島 敬, 小林 健一郎, 三春 晶嗣, 大喜多 肇, 飯島 一智, 森 鉄也, 斎藤 正博, 康 勝好, 真部 淳, 菊地 陽, 林 泰秀, 小原 明  Cytometry Research  22-  (Suppl.)  66  -66  2012/06  [Not refereed][Not invited]
  
• A case of Langerhans cell histiocytosis with severe anemia: Letterer-Siwe disease

  Hitomi Nakamura, Yukari Zenke, Yoko Momose, Mamiko Masuzawa, Satoru Arai, Hikaru Eto, Atsushi Manabe, Yosuke Hosoya, Daisuke Hasegawa  JOURNAL OF DERMATOLOGY  39-  118  -118  2012/06  [Not refereed][Not invited]
  
• がんを家族にどう伝えどう支えるか 乳がん患者の子どものこころ

  小澤 美和, 三浦 絵莉子, 石田 也寸志, 山内 英子, 真部 淳  日本緩和医療学会学術大会プログラム・抄録集  17回-  206  -206  2012/06  [Not refereed][Not invited]
  
• 小児がん経験者の晩期合併症の予測は可能か 聖路加国際病院小児科の経験

  石田 也寸志, 渡辺 静, 小澤 美和, 米川 聡子, 小川 千登世, 長谷川 大輔, 細谷 要介, 吉原 宏樹, 真部 淳, 森本 克, 西村 昴三, 細谷 亮太  日本小児血液・がん学会雑誌  49-  (1-2)  31  -39  2012/05  [Not refereed][Not invited]
   

  JPLSG長期フォローアップ(FU)委員会の5段階のFUレベルが、晩期合併症発症の予想に役立つかどうか検証した。【対象と方法】研究デザインはレトロスペクティブコホート研究で、対象は1972年から2011年に当院小児科で診療した小児がん症例で治療を終了しているものである。治療終了時FUレベルと最終観察日の晩期合併症について単変量とロジステック解析を行いオッズ比(OR)を求めた。【結果】2011年3月31日の時点で生存していた388例で、FUレベル判定不能88例を除き、残り300例を解析した。血液がんではレベル3=41%、4=37%、脳腫瘍はレベル4=100%、固形腫瘍はレベル2=25%、レベル3=44%、LCHはレベル1=62%、骨軟部腫瘍はレベル3=36%、4=25%、5=40%であった。晩期合併症は、レベル1:0%、レベル2:15%、レベル3:37%、レベル4:72%、レベル5:100%で、ロジスティク解析では、脳腫瘍(OR:65.4)、固形腫瘍(OR:3.45)、骨軟部腫瘍(OR:10.4)、最終観察年齢26歳以上(OR:6.75)、CPM>5g/m2(OR:5.64)、同種造血細胞移植(OR:10.9)が晩期合併症の独立したリスク因子であった。【結語】治療終了時の5段階のFUレベル評価は晩期合併症の予測に有用であり、この分類を活用することによりリスクに基づいたFU計画の立案が可能である。(著者抄録)
• 血液腫瘍(白血病,悪性リンパ腫) (特集 小児慢性疾患の生活指導 : 最新の知見から) -- (日常生活における管理・指導)

  細谷 要介, 真部 淳  小児科臨床  65-  (4)  615  -621  2012/04
• Significance of TP53 gene abnormalities in childhood acute lymphoblastic leukemia

  熊本 忠史, 真部 淳  血液内科  64-  (4)  508  -512  2012/04
• Wiskott-Aldrich syndrome presenting with a clinical picture resembling juvenile myelomonocytic leukaemia

  A. Yoshimi, Y. Kamachi, K. Imai, T. Morio, N. Watanabe, A. Konoshita, N. Nakadate, K. Tamura, S. Oozono, R. Kobayashi, H. Kigasawa, M. Jakob, S. Nonoyama, A. Manabe, C. Niemeyer, S. Kojima  BONE MARROW TRANSPLANTATION  47-  S69  -S70  2012/04  [Not refereed][Not invited]
  
• プライマリケア・マスターコース 小児科診療のすすめ 小児がん

  真部 淳, 細谷 亮太  日本医事新報  (4586)  46  -49  2012/03/17
• 若年性骨髄単球性白血病75例の予後 小児血液学会MDS委員会の前方視的検討

  吉田 奈央, 平林 真介, 渡辺 静, 在家 裕司, 土田 昌宏, 吉見 礼美, 増永 敦子, 大塚 欣敏, 伊藤 雅文, 小島 勢二, 中畑 龍俊, 真部 淳  臨床血液  52-  (12)  1853  -1858  2011/12  [Not refereed][Not invited]
   

  若年性骨髄単球性白血病(JMML)は乳幼児に好発する稀な骨髄異形成/骨髄増殖性疾患であり,診断が難しいことから小児血液学会MDS委員会において前方視的登録と中央診断を行っている。今回1999年から2006年に本登録を経て診断されたJMML75例を追跡調査した。診断時年齢は中央値20ヵ月(1〜85ヵ月),染色体異常は21例に認め,うち11例がmonosomy7を有した。全体の5年生存率は60%であり,61例で造血幹細胞移植が施行された。移植前処置は多岐にわたり,移植片は骨髄43,末梢血5,臍帯血13例であった。移植例の5年生存率は61%であり,臍帯血移植群の生存率は他の群に比べ有意に低かった(38% vs. 68%;P=0.03)。前方視的登録による症例把握の結果を受け,日本小児白血病リンパ腫研究グループ(JPLSG)では標準的移植法の確立を目的とした多施設共同臨床試験JMML11を計画している。(著者抄録)
• A 9-year-old female with thoracic vertebral fracture

  槇殿 文香理, 野崎 太希, 真部 淳  The Journal of pediatric practice  74-  (11)  1665  -1669  2011/11
• A 8-year-old female with upper arm swelling

  野崎 太希, 槇殿 文香理, 真部 淳  The Journal of pediatric practice  74-  (11)  1835  -1839  2011/11
• A boy with fever and migratory pain

  槇殿 文香理, 野崎 太希, 真部 淳  The Journal of pediatric practice  74-  (11)  1846  -1850  2011/11
• A Brief Use of Imatinib Immediately Before Hematopoietic Stem Cell Transplantation (HSCT) in Children with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph plus ALL). Results of the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) Study Ph+ALL04

  Atsushi Manabe, Hirohide Kawasaki, Motoaki Chin, Atsushi Sato, Kimikazu Matsumoto, Tsutomu Watanabe, Michiko Kajiwara, Hiroyuki Shimada, Itaru Kato, Yuichi Kodama, Noriko Sato, Kazuko Kudo, Atsushi Kikuta, Megumi Oda, Tomoyuki Watanabe, Akiko M. Saito, Masahito Tsurusawa, Keizo Horibe  BLOOD  118-  (21)  1095  -1096  2011/11  [Not refereed][Not invited]
  
• Acute Lymphoblastic Leukemia in Children with Down Syndrome: A Report From the Ponte Di Legno Study Group

  Trudy Buitenkamp, Shai Izraeli, Martin Zimmermann, Erik Forestier, Nyla A. Heerema, Marry M. van den Heuvel, Rob Pieters, Valerie de Haas, Lewis B. Silverman, Kjeld Schmiegelow, Der-Cherng Liang, Keizo Horibe, Maurizio Arico, Giovanni Cazzaniga, Giuseppe Basso, Karen R. Rabin, Martin Schrappe, Gunnar Cario, Georg Mann, Veerle Mondelaers, Tim Lammens, Helene Cave, Batia Stark, Anthony V. Moorman, Ajay J. Vora, Stephen Hunger, Ching-Hon Pui, Charles G. Mullighan, Atsushi Manabe, Gabriele Escherich, Jerzy Kowalczyk, James A. Whitlock, Christian M. Zwaan  BLOOD  118-  (21)  1527  -1528  2011/11  [Not refereed][Not invited]
  
• TCCSG ALL登録症例の細胞抗原とキメラ遺伝子との関連性についての検討

  小林 健一郎, 福島 敬, 南木 融, 清河 信敬, 三春 晶嗣, 山田 浩之, 飯島 一智, 大喜多 肇, 森 鉄也, 熊谷 昌明, 藤本 純一郎, 斎藤 正博, 康 勝好, 真部 淳, 菊地 陽, 林 泰秀, 土田 昌宏, 小原 明, 東京小児がん研究グループTCCSG  小児がん  48-  (プログラム・総会号)  212  -212  2011/11  [Not refereed][Not invited]
  
• 東京小児がん研究グループ(TCCSG)ALL治療研究登録症例の網羅的遺伝子発現解析

  飯島 一智, 清河 信敬, 小林 健一郎, 大喜多 肇, 山田 浩之, 三春 晶嗣, 森 鉄也, 福島 敬, 南木 融, 斎藤 正博, 康 勝好, 真部 淳, 菊地 陽, 熊谷 昌明, 藤本 純一郎, 林 泰秀, 土田 昌宏, 小原 明, 東京小児がん研究グループTCCSG  小児がん  48-  (プログラム・総会号)  211  -211  2011/11  [Not refereed][Not invited]
  
• 10カラーフローサイトメトリーを用いたB前駆細胞急性リンパ芽球性白血病のMRD検出

  三春 晶嗣, 清河 信敬, 小林 健一郎, 大喜多 肇, 山田 浩之, 飯島 一智, 森 鉄也, 福島 敬, 斎藤 正博, 康 勝好, 真部 淳, 菊地 陽, 熊谷 昌明, 藤本 純一郎, 林 泰秀, 土田 昌宏, 小原 明, 東京小児がん研究グループTCCSG  小児がん  48-  (プログラム・総会号)  247  -247  2011/11  [Not refereed][Not invited]
  
• 小児ALLにおけるCRLF2、IKZF1、JAK2遺伝子の臨床的意義 TCCSGの小児B前駆細胞型急性リンパ性白血病におけるCRLF2とIKZF1の解析

  大木 健太郎, 大喜多 肇, 小林 健一郎, 清河 信敬, 朴 明子, 新井 心, 外松 学, 柴 徳生, 福島 敬, 康 勝好, 花田 良二, 真部 淳, 菊地 陽, 小原 明, 土田 昌宏, 林 泰秀  小児がん  48-  (プログラム・総会号)  174  -174  2011/11  [Not refereed][Not invited]
  
• 若い乳がん患者とその子どもへのサポートを考える 子どもの行動・情緒的問題<続報>

  小澤 美和, 三浦 絵莉子, 石田 智美, 石田 也寸志, 真部 淳, 山内 英子  日本乳癌学会総会プログラム抄録集  19回-  428  -428  2011/09  [Not refereed][Not invited]
  
• 日本におけるL-asparaginase(L-asp)療法中の凝固障害に対する支持療法の調査(Survey of supportive therapy for coagulation disorder during L-asparaginase (L-asp) therapy in Japan)

  Ogawa Chitose, Manabe Atsushi, Ohara Akira, Ishiguro Akira  臨床血液  52-  (9)  1078  -1078  2011/09  [Not refereed][Not invited]
  
• 日本人小児における血栓症に関する初の全国調査(The first national survey of thrombotic disorders in Japanese children)

  Ishiguro Akira, Taki Masashi, Manabe Atsushi, Ogawa Chitose, Nakadate Hisaya, Shima Midori  臨床血液  52-  (9)  1138  -1138  2011/09  [Not refereed][Not invited]
  
• The survey of supportive therapy for coagulation disorder during L-asparaginase (L-ASP) therapy in Japan

  C. Ogawa, A. Manabe, A. Ohara, A. Ishiguro  JOURNAL OF THROMBOSIS AND HAEMOSTASIS  9-  227  -227  2011/07  [Not refereed][Not invited]
  
• 小児白血病におけるCD66c発現の意義

  山田 浩之, 清河 信敬, 橋本 亙, 飯島 一智, 嶋 晴子, 嶋田 博之, 森 鉄也, 福島 敬, 康 勝好, 真部 淳, 菊地 陽, 熊谷 昌明, 小原 明, 林 泰秀, 土田 昌宏  Cytometry Research  21-  (Suppl.)  78  -78  2011/06  [Not refereed][Not invited]
  
• カラーフローサイトメトリーを用いた小児白血病MRD検出の試み

  清河 信敬, 三春 晶嗣, 山田 浩之, 橋本 亙, 飯島 一智, 森 鉄也, 斎藤 正博, 福島 敬, 康 勝好, 真部 淳, 菊地 陽, 熊谷 昌明, 林 泰秀, 土田 昌宏, 小原 明  Cytometry Research  21-  (Suppl.)  80  -80  2011/06  [Not refereed][Not invited]
  
• 特発性造血障害に関する調査研究 小児の骨髄不全と骨髄異形成症候群に関する研究

  中畑龍俊, 真部淳  特発性造血障害に関する調査研究 平成22年度 総括・分担研究報告書  39  -45  2011  [Not refereed][Not invited]
  
• 東京小児がん研究グループ急性リンパ性白血病治療研究におけるBCP-ALL-NCI-HR群の治療成績 特に年齢因子の検討

  藤村 純也, 高橋 浩之, 菊地 陽, 清河 信敬, 福島 敬, 康 勝好, 真部 淳, 花田 良二, 小原 明, 土田 昌宏  小児がん  47-  (プログラム・総会号)  396  -396  2010/12  [Not refereed][Not invited]
  
• ダウン症候群に合併した一過性骨髄異常増殖症148例の後方視的解析

  村松 秀城, 菊地 陽, 林 泰秀, 川村 眞智子, 小島 勢二, 矢部 みはる, 磯山 恵一, 滝 智彦, 辻 浩一郎, 土田 昌宏, 真部 淳  小児がん  47-  (プログラム・総会号)  221  -221  2010/12  [Not refereed][Not invited]
  
• Low-Dose Cytosine Arabinoside Therapy for Neonates with Down Syndrome (DS) and Transient Leukemia (TL)

  Hideki Muramatsu, Yasuhide Hayashi, Machiko Kawamura, Seiji Kojima, Miharu Yabe, Keiichi Isoyama, Tomohiko Taki, Kohichiro Tsuji, Masahiro Tsuchida, Atsushi Manabe, Etsuro Ito, Shotaro Iwamoto, Hiromi Kato, Aiko Sumie, Takashi Taga, Keiko Nomura, Daisuke Hasegawa, Ken-ichiro Watanabe, Akira Kikuchi  BLOOD  116-  (21)  469  -470  2010/11  [Not refereed][Not invited]
  
• Epidemiological and Genetic Analysis of Sideroblastic Anemia - Multi-center Study In Japan

  Rie Ohba, Kazumichi Furuyama, Shigeru Tsuchiya, Atsushi Manabe, Etsuro Ito, Seiji Kojima, Keiya Ozawa, Hideo Harigae  BLOOD  116-  (21)  1716  -1717  2010/11  [Refereed][Not invited]
  
• Histopathological review of pediatric bone marrow failures by objective MDS scoring system

  M. Ito, A. Hama, A. Manabe, S. Kojima  HISTOPATHOLOGY  57-  149  -150  2010/10  [Not refereed][Not invited]
  
• 9 colorフローサイトメトリーによる小児白血病のマーカー解析

  清河 信敬, 恩田 恵子, 高野 邦彦, 藤本 純一郎, 真部 淳, 康 勝好, 小原 明, 林 泰秀, 花田 良二, 土田 昌宏  Cytometry Research  20-  (2)  27  -33  2010/09  [Not refereed][Not invited]
   

  白血病細胞株と小児ALL患者の骨髄検体を用いて、市販されている複数の蛍光色素と標識抗体を組み合わせた9カラー・フローサイトメトリーを試み、その実現性と有用性について検討した。その結果、本法は非常に有用性の高い検査手段になりうることが示唆された。1本のチューブで、従来のCD45-gating+2カラー解析の場合の4本分の測定が可能であり、染色過程も含めた検査所要時間が大幅に短縮され、迅速な診断が可能であった。また、使用する検体量も大幅に減量可能であった。
• Myelodysplastic syndrome

  真部 淳  The Journal of pediatric practice  73-  (8)  1352  -1356  2010/08
• THE IMPACT OF THE CANCER IN JAPANESE CHILDHOOD CANCER PATIENTS AFTER DISCHARGE FROM MEDICAL TREATMENT

  Yuko Takei, Akiko Ogata, Miwa Ozawa, Atsushi Manabe, Hiroshi Moritake, Kei Hirai, Shinichi Suzuki  INTERNATIONAL JOURNAL OF BEHAVIORAL MEDICINE  17-  28  -29  2010/08  [Not refereed][Not invited]
  
• Refractory Cytopenia of Childhood anno 2010, State of the Art

  HASEGAWA Daisuke, MANABE Atsushi  日本小児血液学会雑誌  24-  (3)  161  -167  2010/06/30
• 乳がん患者とその子どもへのサポートを考える 子どもの行動・情緒的問題

  小澤 美和, 伊藤 ゆかり, 阿佐美 百合子, 真部 淳, 山内 英子, 中村 清吾  日本乳癌学会総会プログラム抄録集  18回-  656  -656  2010/05  [Not refereed][Not invited]
  
• Clinical Characteristics of Seven Cases with Acute Lymphoblastic Leukemia Unable to Participate in a Clinical Trial because of the Advanced Organ Damage at Diagnosis : TCCSG L99-15 Study

  SOTOMATSU Manabu, KANEKO Takashi, SAITO Masahiro, NOGUCHI Yasushi, TAKAHASHI Hiroyuki, YABE Miharu, MANABE Atsushi, OHARA Akira, HANADA Ryoji, TSUCHIDA Masahiro  日本小児血液学会雑誌  24-  (1)  25  -31  2010/02/28
• 白血病の分子標的療法 (ミニ特集 白血病)

  真部 淳  小児科臨床  63-  (1)  27  -33  2010/01
• 6.多発性骨浸潤により発症したバーキット・リンパ腫の一例(III,2009年度関東甲信越地区小児がん登録研究会)

  斎藤 怜, 笠井 恵美, 神谷 尚宏, 長谷川 大輔, 小川 千登世, 真部 淳, 細谷 亮太  小児がん : 小児悪性腫瘍研究会記録  47-  (3)  478  -478  2010
• 特発性造血障害に関する調査研究 小児の骨髄不全と骨髄異形成症候群に関する研究

  中畑龍俊, 真部淳  特発性造血障害に関する調査研究 平成21年度 総括・分担研究報告書  38  -39  2010  [Not refereed][Not invited]
  
• C-Cbl but Not TET2 Mutations Are Present in Patients with Juvenile Myelomonocytic Leukemia

  Hideki Muramatsu, Hideki Makishima, Anna Malgorzata Jankowska, Heather Cazzolli, Christine O'Keefe, Nao Yoshida, Yinyan Xu, Nobuhiro Nishio, Asahito Hama, Hiroshi Yagasaki, Yoshiyuki Takahashi, Koji Kato, Atsushi Manabe, Seiji Kojima, Jaroslaw P. Maciejewski  BLOOD  114-  (22)  174  -175  2009/11  [Not refereed][Not invited]
  
• A COMPREHENSIVE SUPPORT FOR FAMILIES HAVING CHILDREN WITH CANCER

  Atsushi Manabe, Miwa Ozawa, Akiko Higuchi, Hiroko Kondo, Motohiro Matoba, Makiko Oshikawa, Shinichi Suzuki, Megumi Oda, Kiyoko Kamibeppu, Keizo Horibe, Ryota Hosoya  PEDIATRIC BLOOD & CANCER  53-  (5)  876  -877  2009/11  [Not refereed][Not invited]
  
• 東京小児がん研究グループ急性リンパ性白血病治療12から15次研究におけるBCP-ALL-NCI-SR群治療成績の検討

  大嶋 宏一, 康 勝好, 小川 千登世, 富澤 大輔, 嶋田 博之, 福島 啓太郎, 藤村 純也, 徳山 美香, 長谷川 大輔, 太田 節雄, 高橋 浩之, 真部 淳, 熊谷 昌明, 菊地 陽, 小原 明, 花田 良二, 土田 昌宏  小児がん  46-  (プログラム・総会号)  226  -226  2009/11  [Not refereed][Not invited]
  
• TCCSG-L1602治療研究におけるDay8末梢血-芽球数のフローサイトメトリー測定についての評価

  恩田 恵子, 平林 真介, 清河 信敬, 齊藤 正博, 森 鉄也, 福島 敬, 藤本 純一郎, 真部 淳, 康 勝好, 熊谷 昌明, 小原 明, 林 泰秀, 花田 良二, 土田 昌宏  小児がん  46-  (プログラム・総会号)  228  -228  2009/11  [Not refereed][Not invited]
  
• 東京小児がん研究グループにて1981年から1999年の5つの研究に登録された小児急性リンパ性白血病2035例の長期追跡結果

  土田 昌宏, 小原 明, 花田 良二, 真部 淳, 熊谷 昌明, 高橋 浩之, 金沢 崇, 藤村 純也, 富澤 大輔, 康 勝好, 嶋田 博之, 森 鉄也, 後藤 裕明, 福島 敬, 小池 和俊, 野口 靖, 小川 千登世, 犬飼 岳史, 福島 啓太郎, 塩原 正明, 加藤 陽子, 前田 美穂, 菊地 陽, 梶原 道子, 矢部 晋正, 外松 学, 太田 節雄, 磯山 恵一, 金子 隆, 林 泰秀, 東京小児がん研究グループALL委員会  臨床血液  50-  (9)  904  -904  2009/09  [Not refereed][Not invited]
  
• 小児B細胞性リンパ腫のマイクロアレイを用いたmolecular karyotypingと網羅的発現遺伝子解析

  清河 信敬, 恩田 恵子, 飯島 一智, 長谷川 大輔, 加藤 元博, 大喜多 肇, 齋藤 正博, 森 鉄也, 真部 淳, 康 勝好, 小原 明, 林 泰秀, 花田 良二, 土田 昌宏, 中川 温子, 小川 誠司, 藤本 純一郎  臨床血液  50-  (9)  1268  -1268  2009/09  [Not refereed][Not invited]
  
• Hepatic Veno-Occlusive Disease (VOD) during Early Intensification Therapy of Acute Lymphoblastic Leukemia (ALL)

  YOSHIDA Kenichi, HASEGAWA Daisuke, NAKASHIMA Kentaro, ARIMA Keitaro, HIRABAYASHI Shinsuke, OGAWA Chitose, MANABE Atsushi, HOSOYA Ryota  日本小児血液学会雑誌  23-  (4)  251  -255  2009/08/31
• Treatment of adolescents and young adults with acute lymphoblastic leukemia

  真部 淳  血液・腫瘍科  59-  (1)  88  -92  2009/07
• TCCSG-L1602治療研究/Day8末梢血 芽球数のフローサイトメトリー測定

  恩田 恵子, 清河 信敬, 齋藤 正博, 森 鉄也, 藤本 純一郎, 真部 淳, 康 勝好, 小原 明, 林 泰秀, 花田 良二, 土田 昌宏  Cytometry Research  19-  (抄録集)  57  -57  2009/06  [Not refereed][Not invited]
  
• MYELODYSPLASTIC SYNDROME AND MYELOPROLIFERATIVE DISEASE IN CHILDREN: A PROSPECTIVE REGISTRATION OF 222 CASES

  A. Manabe, S. Hirabayashi, S. Watanabe, Y. Zaike, M. Tsuchida, A. Masunaga, A. Yoshimi, M. Ito, A. Kikuchi, K. Tsuji, A. Ohara, S. Kojima, T. Nakahara  HAEMATOLOGICA-THE HEMATOLOGY JOURNAL  94-  S1  -S1  2009/04  [Not refereed][Not invited]
  
• A JAPANESE PEDIGREE WITH RUNX1 MUTATION RESULTING IN FAMILIAL PLATELET DISORDER WITH PROPENSITY TO ACUTE MYELOGENOUS LEUKEMIA

  D. Hasegawa, C. Ogawa, S. Hirabayashi, M. Park, Y. Hayashi, A. Manabe, R. Hosoya  HAEMATOLOGICA-THE HEMATOLOGY JOURNAL  94-  S24  -S24  2009/04  [Not refereed][Not invited]
  
• CONGENITAL MYELOPROLIFERATIVE DISEASE WITH GATA-1 MUTATION IN A PHENOTYPICALLY NORMAL INFANT

  S. Hirabayashi, K. Arima, T. Kamiya, D. Hasegawa, C. Ogawa, A. Manabe, R. Hosoya, E. Ito  HAEMATOLOGICA-THE HEMATOLOGY JOURNAL  94-  S29  -S29  2009/04  [Not refereed][Not invited]
  
• IMPACT OF GM-CSF SIGNALING PATHWAY-RELATED GENES ON CLINICAL OUTCOME OF CHILDREN WITH JUVENILE MYELOMONOCYTIC LEUKEMIA

  N. Yoshida, H. Yagasaki, Y. Xu, K. Matsuda, A. Yoshimi, Y. Takahashi, K. Matsumoto, K. Kato, J. Ueyama, H. Inada, H. Goto, M. Yabe, K. Kudo, J. Mimaya, A. Kikuchi, K. Koike, A. Manabe, S. Kojima  HAEMATOLOGICA-THE HEMATOLOGY JOURNAL  94-  S15  -S15  2009/04  [Not refereed][Not invited]
  
• ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH FLUDARABINE-CONTAINING REGIMEN IN CHILDREN WITH JUVENILE MYELOMONOCYTIC LEUKEMIA

  N. Yabe, A. Manabe, Y. Ohtsuka, K. Watanabe, M. Imamura, M. Kaneda, R. Miyachi, J. Inagaki, Y. Ebihara, N. Yoshida, K. Sakashita, K. Horibe, M. Tsurusawa  HAEMATOLOGICA-THE HEMATOLOGY JOURNAL  94-  S26  -S27  2009/04  [Not refereed][Not invited]
  
• Pathological Central Review of Myelodysplastic Syndrome in 445 Children

  HIRABAYASHI Shinsuke, MANABE Atsushi  日本小児血液学会雑誌  23-  (1)  53  -57  2009/02/28
• Feasibility of WT1 peptide vaccination for the treatment of refractory hematological and solid malignancies in children

  SAWADA Akihisa, INOUE Masami, KONDO Osamu, KIMOTO Tomiko, YAMADA Kayo, NAKAYAMA Masahiro, KUWAE Yuko, NISHIKAWA Masanori, OKAWA Hiroji, IDA Kohemi, TOKUDA Kiriko, MANABE Atsushi, TSUCHIYA Kunihiko, OKUYAMA Hiroomi, KUBOTA Akio, KAWAHARA Hisayoshi, HASEGAWA Toshimiti, YONEDA Akihiro, TAKEMOTO Osamu, YAMADA Junji, KAWABATA Hidehiko, TAMURA Daisuke, KINOUCHI Keiko, HIRANO Shinya, UNO Makoto, TAKESHITA Yasufumi, ISHIHARA Takashi, OKAMURA Takayuki, SAKATA Naoki, MIZUTANI Syuki, NAKAHATA Tatsutoshi, SAKO Masahiro, TAWA Akio, OJI Yusuke, TSUBOI Akihiro, KOYAMA Maho, OKA Yoshihiro, YASUI Masahiro, SUGIYAMA Haruo, KAWA Keisei  小児がん : 小児悪性腫瘍研究会記録 = Pediatric oncology  46-  (1)  6  -16  2009/02/25  [Not refereed][Not invited]
   

  Purpose: The purpose of this study is to evaluate the safety and efficacy of cancer immunotherapy with WT1 peptide for the treatment of children with refractory hematological and solid malignancies. Methods: The major eligible critria were the expression of the WT1 gene in affected tissues or leukemic cells, and the HLA type of the patients (and donors) being A2402. Vaccination using high-affinity WT1 peptide (CYTWNQMNL) with adjuvant (montanide ISA51) was performed every week for a tatl of 12 times. Results: 15 cases (16 courses) were enrolled. No side effects other than local skin reactions were observed. Out of the 10 cases (11 courses) having measurable residuals, clinical effects were observed in 3 cases, and there was complete remission in 1 case. Massive residual tumors or hematological leukemic burden were correlated with failure in the current setting. Conclusions: WT1 peptide vaccination was performed without serious complications in the present phase I/II study. In order to improve outcomes, WT1 peptide vaccination should be started at the earliest stages of the disease so that there are minimal lingering effects after successfully compteting therapy.
• Myelodysplastic syndromes: focused on refractory anemia/cytopenia

  長谷川 大輔, 真部 淳  The Journal of pediatric practice  72-  (2)  345  -354  2009/02
• 1.膀胱Rhabdoid tumorの女児例(2008年度関東甲信越地区小児がん登録研究会)

  比嘉 千明, 中島 健太郎, 吉田 健一, 平林 真介, 神谷 尚宏, 長谷川 大輔, 小川 千登世, 真部 淳, 細谷 亮太, 中村 晃子, 平林 健, 鈴木 高祐  小児がん : 小児悪性腫瘍研究会記録  46-  (3)  412  -413  2009
• 特発性造血障害に関する調査研究 小児骨髄異形成症候群に関する研究

  中畑龍俊, 真部淳  特発性造血障害に関する調査研究 平成20年度 総括・分担研究報告書  41  -42  2009  [Not refereed][Not invited]
  
• Clinical Outcome of 640 Children with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Treated Between 1995 and 2005

  Maurizio Arica, Martin Schrappe, Stephen Hunger, William L. Carroll, Valentino Conter, Paola Di Lorenzo, Atsushi Manabe, Vaskar Saba, Andre Baruchel, Kim Vettenranta, Masahiro Tsuchida, Yves Benoit, Rob Pieters, Gabriele Escherich, Lewis B. Silverman, Ching-Hon Pui, Maria Grazia Valsecchi  BLOOD  112-  (11)  213  -214  2008/11  [Not refereed][Not invited]
  
• Significance of Initial Lumbar Puncture on Day8 of Remission Induction Therapy in Childhood Acute Lymphoblastic Leukemia: The Results from the Tokyo Children's Cancer Study Group L99-15 Protocol

  Daisuke Hasegawa, Atsushi Manabe, Akira Ohara, Katsuyoshi Koh, Chitose Ogawa, Ryoji Hanada, Masahiro Tsuchida  BLOOD  112-  (11)  339  -339  2008/11  [Not refereed][Not invited]
  
• B precursor-ALLに対する中枢神経白血病予防治療の変遷と成績 TCCSG ALL L89-12,92-13,95-14,99-15研究

  小川 千登世, 小原 明, 真部 淳, 菊地 陽, 康 勝好, 富澤 大輔, 藤村 純也, 井上 裕靖, 角南 勝介, 石井 栄三郎, 塩原 正明, 森 鉄也, 高橋 裕之, 林 泰秀, 花田 良二, 土田 昌宏  小児がん  45-  (プログラム・総会号)  190  -190  2008/11  [Not refereed][Not invited]
  
• MDSセントラルレビュー症例の解析

  平林 真介, 渡辺 静, 真部 淳, 土田 昌宏, 在家 裕司, 増永 敦子, 菅原 幸子, 吉見 礼美, 伊藤 雅文, 辻 浩一郎, 菊地 陽, 中畑 龍俊  小児がん  45-  (プログラム・総会号)  160  -160  2008/11  [Not refereed][Not invited]
  
• 20-P2-324 小児急性リンパ性白血病患者におけるex vivoアンモニア上昇値をパラメータとしたL-アスパラギナーゼの効果評価(がん薬物療法(その他),来るべき時代への道を拓く)

  渡辺 静, 三宅 久美子, 松本 晴菜, 小川 千登世, 長谷川 大輔, 真部 淳, 木津 純子, 細谷 亮太  日本医療薬学会年会講演要旨集  18-  336  -336  2008/09/01
• Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

  MANABE Atsushi  日本小児血液学会雑誌  22-  (4)  306  -311  2008/08/31
• Congenital Dyserythropoietic Anemiaの全国調査

  多賀 崇, 伊藤 剛, 浅見 恵子, 井上 雅美, 吉益 哲, 菊地 陽, 杉田 憲一, 鈴木 信寛, 真部 淳, 岩崎 史記, 小阪 嘉之, 右田 昌宏, 小原 明  日本小児血液学会雑誌  22-  (4)  233  -238  2008/08  [Not refereed][Not invited]
   

  我が国の小児におけるCongenital Dyserythropoietic Anemia(CDA)の全国調査を施行した。全国120施設から回答を得(回答率55%)、12症例を把握した。男女比は6:6、診断時年齢は新生児期〜4歳で、乳児期に診断される症例が多かった。1)家族歴は3例にみられた。CDAのタイプはtype Iが4例、type IIが3例、type IIIが2例、variant typeが3例であった。2)新生児期の異常は8例に認められ、7例が治療を要する黄疸であった。3)12例中10例で赤血球輸血が施行され、調査時点では5例が輸血不要となっていた。輸血不要となった理由は、2例(I型)が自然に、1例(II型)が脾摘後に、1例(亜型)が造血幹細胞移植によるものであった。1例は現在も輸血依存状態で、4例は死亡していた。4)死因は肝硬変が1例、CDA以外の基礎疾患によるものが3例であった。死亡年齢は8ヵ月から15歳であった。
• Diagnosis and treatment of myelodysplastic syndrome in children

  本田 裕子, 真部 淳  The Cell  40-  (6)  234  -237  2008/06
• 標準粒子を用いた小児急性白血病の末梢血残存白血病細胞数絶対値直接算定法

  恩田 恵子, 清河 信敬, 藤本 純一郎, 宮川 世志幸, 大喜多 肇, 森 鉄也, 齋藤 正博, 牧本 敦, 真部 淳, 康 勝好, 小原 明, 林 泰秀, 花田 良二, 土田 昌宏  Cytometry Research  18-  (Suppl.)  69  -69  2008/06  [Not refereed][Not invited]
  
• Transient abnormal myelopoiesis of non-Down syndrome with GATA-1 mutation

  平林 真介, 吉田 健一, 有馬 慶太郎, 中川 真智子, 鶴田 志緒, 長谷川 大輔, 小川 千登世, 真部 淳, 草川 功, 細谷 亮太  日本産婦人科・新生児血液学会誌 = The Japanese journal of obstetrical, gynecological & neonatal hematology  18-  (1)  "S  -133"-"S-134"  2008/06/01
• Benefit and feasibility of initial lumbar puncture and intrathecal chemotherapy on day 8 of remission induction therapy in children with acute lymphoblastic leukaemia (ALL): the results from the Tokyo Children's Cancer Study Group L99-15 protocol

  D. Hasegawa, A. Manabe, A. Ohara, K. Koh, C. Ogawa, R. Hanada, M. Tsuchida  BRITISH JOURNAL OF HAEMATOLOGY  141-  94  -94  2008/04  [Not refereed][Not invited]
  
• The ex vivo production of ammonia predicts biologic activity of L-asparaginase in children with ALL

  C. Ogawa, A. Manabe, S. Watanabe, K. Miyake, K. Arima, S. Hirabayahi, D. Hasegawa, T. Inoue, J. Kizu, R. Hosoya  BRITISH JOURNAL OF HAEMATOLOGY  141-  96  -96  2008/04  [Not refereed][Not invited]
  
• Update on L-asparaginase therapy

  小川 千登世, 真部 淳  血液・腫瘍科  56-  (3)  382  -388  2008/03
• 小児のprimary myelodysplastic syndromeとjuvenile myelomonocytic leukemiaにおけるAML1 geneの変異

  増永 敦子, 巌本 三寿, 門福 強樹, 真部 淳, 宮崎 章, 光谷 俊幸, 中畑 龍俊  日本病理学会会誌  97-  (1)  356  -356  2008/03  [Not refereed][Not invited]
  
• Molecular pathogenesis of inherited bone marrow failure syndromes

  長谷川 大輔, 真部 淳  血液・腫瘍科  56-  (2)  147  -154  2008/02
• 小児MDSのセントラルレビュー 453例の解析

  真部 淳, 土田 昌宏, 在家 裕司, 増永 敦子, 菅原 幸子, 吉見 礼美, 伊藤 雅文, 辻 浩一郎, 菊地 陽, 中畑 龍俊  日本小児科学会雑誌  112-  (2)  234  -234  2008/02  [Not refereed][Not invited]
  
• A novel clinical phenotype with juvenile myelomonocytic leukemia-like features and giant platelets in infancy with Wiskott-Aldrich syndrome

  Yashiro Kamachi, Ayami Yoshimi, Nobuhiro Watanabe, Kazushi Tamura, Shuichi Ozono, Atsushi Manabe, Seiji Kojima  CLINICAL IMMUNOLOGY  127-  S61  -S62  2008  [Not refereed][Not invited]
  
• CHARACTERISTICS OF EPILEPSY IN EIGHT PATIENTS WITH INV DUP (15)

  Hiroka Takahashi, Y. Takahashi, K. Imai, Atsushi Manabe, R. Hosoya, M. Ogiwara, Hironao Numabe, A. Nezu, T. Nagai, Y. Toribe, N. Kondo, T. Fujiwara  EPILEPSIA  49-  250  -250  2008  [Not refereed][Not invited]
  
• TCCSG ALL L99-15治療研究に登録されたAML1 amplificationを有する急性リンパ性白血病3例の臨床的特徴

  徳山 美香, 高橋 浩之, 菊池 陽, 野口 靖, 森 鉄也, 小原 明, 真部 淳, 斎藤 友博, 林 泰秀, 花田 良二, 土田 昌宏  小児がん  44-  (プログラム・総会号)  271  -271  2007/12  [Not refereed][Not invited]
  
• RAEB/AML M6症候群18例の検討

  本田 裕子, 真部 淳, 土田 昌宏, 在家 裕司, 増永 敦子, 井上 雅美, 小林 良二, 大塚 欣敏, 菊地 陽, 中畑 龍俊  小児がん  44-  (プログラム・総会号)  203  -203  2007/12  [Not refereed][Not invited]
  
• Molecular pathogenesis of childhood MDS

  長谷川 大輔, 真部 淳  血液・腫瘍科  55-  (5)  579  -586  2007/11
• Correlation of clinical features with the mutational status of GM-CSF signaling pathway-related genes in children with juvenile myelomonocytic leukemia

  Nao Yoshida, Hiroshi Yagasaki, Ayami Yoshimi, Yoshiyuki Takahashi, Yinyan Xu, Makito Tanaka, Nobuhiro Watanabe, Kimikazu Matsumoto, Koji Kato, Junichi Ueyama, Hiroko Inada, Hiroaki Goto, Miharu Yabe, Junichi Mimaya, Akira Kikuchi, Atsushi Manabe, Seiji Kojima  BLOOD  110-  (11)  457A  -457A  2007/11  [Not refereed][Not invited]
  
• 30-P1-188 小児がん治療における知能障害の検討(がん薬物療法,社会の期待に応える医療薬学を)

  渡辺 静, 阿佐美 百合子, 小川 千登世, 長谷川 大輔, 小澤 美和, 真部 淳, 木津 純子, 井上 忠夫, 細谷 亮太  日本医療薬学会年会講演要旨集  17-  324  -324  2007/09/01
• 小児MDSのセントラルレビュー 453例の解析

  真部 淳, 土田 昌宏, 在家 裕司, 増永 敦子, 菅原 幸子, 吉見 礼美, 伊藤 雅文, 辻 浩一郎, 菊地 陽, 中畑 龍俊  臨床血液  48-  (9)  986  -986  2007/09  [Not refereed][Not invited]
  
• 小児の骨髄異形成症候群--最新の知見

  本田 裕子, 真部 淳  小児科  48-  (6)  905  -911  2007/05
• 7.アスペルガー症候群を持つ脳腫瘍患児へのケアの実際 : 社会性を獲得させるために(一般演題,第13回群馬小児がん研究会抄録)

  伊藤 愛, 永瀬 恭子, 中村 かおり, 吉川 久美子, 塚崎 百合子, 小林 明雪子, 小川 千登世, 真部 淳, 細谷 亮太  The KITAKANTO medical journal  57-  (1)  100  -101  2007/02/01
• 特発性造血障害に関する調査研究 小児骨髄異形成症候群に関する研究

  中畑龍俊, 真部淳, 小島勢二, 小原明  特発性造血障害に関する調査研究 平成18年度 総括・分担研究報告書  37  -40  2007  [Not refereed][Not invited]
  
• The significance of complete clearance of peripheral blasts after 7 days of prednisolone in children with acute lymphoblastic leukemia: Tokyo Children's Cancer Study Group (TCCSG) study L99-15.

  Katsuyoshi Koh, Akira Ohara, Atsushi Manabe, Kouichiro Ikuta, Ryouji Hanada, Hiromasa Yabe, Akitoshi Kinoshita, Kenichi Koike, Yuri Okimoto, Yasushi Noguchi, Michiko Kajiwara, Hiroyuki Takahashi, Kanji Sugita, Takashi Fukushima, Keiichi Isoyama, Masahiro Saito, Akira Kikuchi, Setsuo Ota, Masaaki Kumagai, Yasuhide Hayashi, Tomohiro Saito, Masahiro Tsuchida  BLOOD  108-  (11)  210B  -210B  2006/11  [Not refereed][Not invited]
  
• Prognostic factors for relapsed childhood acute lymphoblastic leukemia (ALL): A report from tokyo children's cancer study group (TCCSG) study L95-14 and L-99-15.

  Chitose Ogawa, Akira Ohara, Atsushi Manabe, Katsuyoshi Koh, Takashi Kaneko, Hiroaki Goto, Setsuo Ota, Ryoji Hanada, Masahiro Tsuchida  BLOOD  108-  (11)  534A  -534A  2006/11  [Not refereed][Not invited]
  
• Correlation of clinical features with mutational status in children with juvenile myelomonocytic leukemia.

  Nan Yoshida, Hiroshi Yagasaki, Yinyan Xu, Makito Tanaka, Nobuhiro Nishio, Hirokazu Hidaka, Asahito Hama, Yoshiyuki Takahashi, Atsushi Manabe, Seiji Kojima  BLOOD  108-  (11)  760A  -760A  2006/11  [Not refereed][Not invited]
  
• Macroscopic Hematuria as the First Clinical Feature of Immune-Mediated Thrombocytopenic Purpura

  KATO Itaru, MANABE Atsushi, OGAWA Chitose, MORIMOTO Tsuyoshi, HOSOYA Ryota  日本小児血液学会雑誌  20-  (2)  98  -100  2006/04/30
• 26HO3-5 自己免疫性リンパ増殖症候群の臨床的検討 : 活性化T細胞Fas誘導性細胞死の有無と臨床症状、検査所見の比較(口演「リンパ腫・HLH・他」,第22回日本小児がん学会 第48回日本小児血液学会 第4回日本小児がん看護研究会 同時期開催)

  徳山 美香, 小原 明, 石田 也寸志, 脇口 宏, 稲井 郁子, 真部 淳, 野田 幸弘, 杉田 完爾, 斉藤 章治, 久間木 悟, 笹原 洋二, 金兼 弘和, 笠原 善仁, 小泉 晶一  小児がん : 小児悪性腫瘍研究会記録  43-  (3)  491  -491  2006
• 24OO1-3 健常腎温存のための治療方針選択に苦慮した,両側ウィルムス腫瘍(stage V,FRN)の1例(口演「QOL」,第22回日本小児がん学会 第48回日本小児血液学会 第4回日本小児がん看護研究会 同時期開催)

  荒木 夕宇子, 松藤 凡, 中村 晃子, 細谷 亮太, 真部 淳, 小川 千登世  小児がん : 小児悪性腫瘍研究会記録  43-  (3)  467  -467  2006
• 24OP5-17 下大静脈合併切除を行ったStageIVのWilms腫瘍(ポスター 横紋筋肉腫・その他,第22回日本小児がん学会 第48回日本小児血液学会 第4回日本小児がん看護研究会 同時期開催)

  道川 武紘, 松藤 凡, 荒木 夕宇子, 中村 晃子, 小川 千登世, 真部 淳, 細谷 亮太  小児がん : 小児悪性腫瘍研究会記録  43-  (3)  548  -548  2006
• 24OP7-8 小児期に発症し、成人に持ち越した急性リンパ性白血病の2症例(ポスター LPD・その他,第22回日本小児がん学会 第48回日本小児血液学会 第4回日本小児がん看護研究会 同時期開催)

  高橋 宏佳, 小澤 美和, 田草川 彩子, 長谷川 大輔, 小川 千登世, 真部 淳, 細谷 亮太, 塚崎 百合子, 西田 知佳子  小児がん : 小児悪性腫瘍研究会記録  43-  (3)  562  -562  2006
• 24OP7-9 精巣単独再発を来たしたT-ALL男児例におけるPCRを用いた腫瘍量の測定の意義(ポスター LPD・その他,第22回日本小児がん学会 第48回日本小児血液学会 第4回日本小児がん看護研究会 同時期開催)

  有馬 慶太郎, 小川 千登世, 田草川 彩子, 加藤 格, 高橋 宏佳, 真部 淳, 細谷 亮太, 北川 好郎, 堀 壽成, 鶴澤 正仁  小児がん : 小児悪性腫瘍研究会記録  43-  (3)  563  -563  2006
• 24OP10-3 心タンポナーデを合併したリンパ管腫症の1例(ポスター その他(臨床)3,第22回日本小児がん学会 第48回日本小児血液学会 第4回日本小児がん看護研究会 同時期開催)

  田草川 彩子, 小川 千登世, 高橋 宏佳, 加藤 格, 今村 壽宏, 小澤 美和, 真部 淳, 細谷 亮太  小児がん : 小児悪性腫瘍研究会記録  43-  (3)  591  -591  2006
• 24OP4-9 最近当院で経験した骨肉腫の10症例(ポスター 骨・軟部腫瘍(臨床),第22回日本小児がん学会 第48回日本小児血液学会 第4回日本小児がん看護研究会 同時期開催)

  田草川 彩子, 真部 淳, 加藤 格, 高橋 宏佳, 今村 壽宏, 有馬 慶太郎, 平林 真介, 長谷川 大輔, 小林 明雪子, 小川 千登世, 小澤 美和, 細谷 亮太, 真鍋 淳, 松本 誠一, 川口 智義  小児がん : 小児悪性腫瘍研究会記録  43-  (3)  535  -535  2006
• 26HO1-4 ras遺伝子変異を示した若年性骨髄単球性白血病(JMML)13例の臨床像(口演「基礎研究」,第22回日本小児がん学会 第48回日本小児血液学会 第4回日本小児がん看護研究会 同時期開催)

  松田 和之, 嶋田 明, 小川 淳, 渡辺 輝浩, 柳井 文男, 菊地 陽, 飯塚 進, 柳町 昌克, 川崎 圭一郎, 矢島 周平, 真部 淳, 小池 和俊, 小島 勢二, 小池 健一  小児がん : 小児悪性腫瘍研究会記録  43-  (3)  487  -487  2006
• 26HP4-7 TEL/AML1陽性急性リンパ性白血病におけるday15BM芽球比率の重要性(ポスター ALL2,第22回日本小児がん学会 第48回日本小児血液学会 第4回日本小児がん看護研究会 同時期開催)

  野口 靖, 小原 明, 真部 淳, 太田 節雄, 高橋 浩之, 福島 啓太郎, 杉田 憲一, 小川 千登世, 菊地 陽, 康 勝好, 生田 孝一郎, 林 泰秀, 花田 良二, 土田 昌宏  小児がん : 小児悪性腫瘍研究会記録  43-  (3)  637  -637  2006
• 24OP8-6 小児悪性腫瘍患者における中枢神経障害の検討(ポスター その他(臨床)1,第22回日本小児がん学会 第48回日本小児血液学会 第4回日本小児がん看護研究会 同時期開催)

  渡辺 静, 塚崎 百合子, 田草川 彩子, 長谷川 大輔, 小林 明雪子, 小川 千登世, 小澤 美和, 真部 淳, 細谷 亮太, 井上 忠夫, 木津 純子  小児がん : 小児悪性腫瘍研究会記録  43-  (3)  572  -572  2006
• 26HP3-6 寛解導入療法終了直後に白血病細胞浸潤を伴う両側漿液性網膜剥離を来したT細胞性急性リンパ性白血病の1例(ポスター ALL1,第22回日本小児がん学会 第48回日本小児血液学会 第4回日本小児がん看護研究会 同時期開催)

  長谷川 大輔, 真部 淳, 小川 千登世, 吉田 健一, 有馬 慶太郎, 高橋 宏佳, 田草川 彩子, 加藤 格, 越前 成旭, 大越 貴志子, 細谷 亮太  小児がん : 小児悪性腫瘍研究会記録  43-  (3)  632  -632  2006
• 26HP5-8 TCCSG L95-14およびL99-15にて治療後に再発した小児急性リンパ性白血病の予後(ポスター ALL3,第22回日本小児がん学会 第48回日本小児血液学会 第4回日本小児がん看護研究会 同時期開催)

  小川 千登世, 康 勝好, 金子 隆, 太田 節雄, 後藤 裕明, 真部 淳, 小原 明, 花田 良二, 土田 昌宏  小児がん : 小児悪性腫瘍研究会記録  43-  (3)  642  -642  2006
• 24OP4-16 当院で経験したユーイング肉腫ファミリー腫瘍10例の治療についての検討(ポスター 骨・軟部腫瘍(臨床),第22回日本小児がん学会 第48回日本小児血液学会 第4回日本小児がん看護研究会 同時期開催)

  中村 晃子, 松藤 凡, 荒木 夕宇子, 道川 武紘, 小川 千登世, 真部 淳, 細谷 亮太  小児がん : 小児悪性腫瘍研究会記録  43-  (3)  539  -539  2006
• 26HO5-4 急性リンパ性白血病標準危険群・中間危険群に対する6MP/MTX漸増間歇維持療法の有効性の検討(口演「ALL」,第22回日本小児がん学会 第48回日本小児血液学会 第4回日本小児がん看護研究会 同時期開催)

  外松 学, 小原 明, 真部 淳, 金子 隆, 前田 美穂, 中舘 尚也, 福島 敬, 熊谷 昌明, 三浦 信之, 加藤 陽子, 生田 孝一郎, 林 泰秀, 花田 良二, 土田 昌宏  小児がん : 小児悪性腫瘍研究会記録  43-  (3)  495  -495  2006
• 特発性造血障害に関する調査研究 小児骨髄異形成症候群に関する研究

  中畑龍俊, 真部淳, 小島勢二, 小原明  特発性造血障害に関する調査研究 平成17年度 総括・分担研究報告書  40  -42  2006  [Not refereed][Not invited]
  
• Treatment outcome of discontinued L-asparaginase in children with standard-risk acute lymphoblastic leukemia: Tokyo Children's Cancer Study Group (TCCSG) study L99-15.

  C Ogawa, A Ohara, A Manabe, R Hanada, H Takahashi, K Koh, M Kajiwara, M Maeda, K Sugita, A Kikuchi, K Isoyama, Y Noguchi, M Saito, S Ota, T Fukushima, H Yabe, Y Toyoda, T Saito, M Tsuchida  BLOOD  106-  (11)  258A  -258A  2005/11  [Not refereed][Not invited]
  
• The JAK2 V617F mutation is uncommon in patients with juvenile myelomonocytic leukemia.

  N Yoshida, H Yagasaki, YY Xu, T Yamamoto, K Kudo, K Kato, K Horibe, A Manabe, S Kojima  BLOOD  106-  (11)  316B  -316B  2005/11  [Not refereed][Not invited]
  
• The effect of early high dose Ara-C in children with high-risk acute lymphoblastic leukemia (ALL): Tokyo Children's Cancer Study Group (TCCSG) study L99-15.

  A Manabe, A Ohara, K Ikuta, R Hanada, H Yabe, A Kinoshita, K Koike, Y Okimoto, Y Noguchi, M Kajiwara, H Takahashi, K Sugita, T Fukushima, K Isoyama, M Saito, A Kikuchi, S Ota, M Kumagai, Y Hayashi, T Saito, M Tsuchida  BLOOD  106-  (11)  255A  -255A  2005/11  [Not refereed][Not invited]
  
• TCCSG ALL L04-16におけるマーカー中央診断と細胞保存の現況

  清河 信敬, 塩沢 裕介, 梶原 道子, 福島 敬, 河崎 裕英, 犬飼 岳史, 真部 淳, 石川 久美子, 川村 眞智子, 牧本 敦, 藤本 純一郎, 林 泰秀, 小原 明, 花田 良, 土田 昌宏  日本小児血液学会雑誌  19-  (5)  349  -349  2005/10  [Not refereed][Not invited]
  
• CD7/CD13陽性急性分類不能型白血病の14歳男児例

  長谷川 大輔, 望月 慎史, 有瀧 健太郎, 松浦 恵子, 宇塚 里奈, 田中 こずえ, 河島 尚志, 星加 明徳, 河崎 裕英, 真部 淳, 辻 浩一郎, 鶴田 敏久  東京医科大学雑誌  63-  (5)  439  -440  2005/09/25
• JMMLにおける赤芽球系コロニー形成能の検討

  長谷川 大輔, 真部 淳, 石川 久美子, 和田 美夏, 谷ヶ崎 博, 吉益 哲, 河崎 裕英, 海老原 康博, 中畑 龍俊, 辻 浩一郎  日本血液学会・日本臨床血液学会総会プログラム・抄録集  67回・47回-  812  -812  2005/09  [Not refereed][Not invited]
  
• 14.神経芽腫に対する同種ミニ移植を併用したMIBG治療の経験(2004年度関東甲信越地区小児がん登録研究会,研究会)

  青山 千晶, 藤田 真智子, 神谷 尚宏, 真部 淳, 細谷 亮太, 横山 邦彦  小児がん : 小児悪性腫瘍研究会記録  42-  (1)  126  -126  2005
• JS6 地域共同診療(ウォーターフロント小児がん共同治療計画) : 手術、化学療法、移植治療の分担と支援グループの共有(合同シンポジウム トータルケアの心と実践,第21回日本小児がん学会 第47回日本小児血液学会 同時期開催)

  松藤 凡, 荒木 夕宇子, 中村 晃子, 細谷 亮太, 真部 淳, 川口 智義, 高上 洋一, 牧本 敦  小児がん : 小児悪性腫瘍研究会記録  42-  (3)  503  -503  2005
• HO4-1 TCCSG ALL L04-16におけるマーカー中央診断と細胞保存の現況(口演 晩期障害・2次がん、ALL,第21回日本小児がん学会 第47回日本小児血液学会 同時期開催)

  清河 信敬, 塩沢 裕介, 梶原 道子, 福島 敬, 河崎 裕英, 犬飼 岳史, 真部 淳, 石川 久美子, 川村 眞智子, 牧本 敦, 藤本 純一郎, 林 泰秀, 小原 明, 花田 良二, 土田 昌宏  小児がん : 小児悪性腫瘍研究会記録  42-  (3)  586  -586  2005
• HO7-2 TCCSGプロトコールによるt(1;19)転座・E2A/PBX1を有する小児急性リンパ性白血病の治療成績(口演 ALL1,第21回日本小児がん学会 第47回日本小児血液学会 同時期開催)

  小嶋 靖子, 林 泰秀, 外松 学, 磯山 恵一, 梶原 道子, 中舘 尚也, 後藤 裕明, 福島 敬, 小川 千登世, 別所 文雄, 斎藤 友博, 生田 孝一郎, 真部 淳, 小原 明, 花田 良二, 土田 昌宏  小児がん : 小児悪性腫瘍研究会記録  42-  (3)  591  -591  2005
• OP55-3 3ヶ月健診で頭囲拡大を指摘され診断されたnodular medulloblastomaの1例(ポスター 小児脳腫瘍4,第21回日本小児がん学会 第47回日本小児血液学会 同時期開催)

  伊藤 雄伍, 加藤 格, 今村 壽宏, 神谷 尚宏, 青山 千晶, 藤田 真智子, 森本 克, 真部 淳, 細谷 亮太, 伊藤 昌徳  小児がん : 小児悪性腫瘍研究会記録  42-  (3)  732  -732  2005
• OO10-2 131I-MIBG療法を2回施行し、良好なQOLを得られた再発神経芽腫の1例(口演 神経芽腫(治療),第21回日本小児がん学会 第47回日本小児血液学会 同時期開催)

  神谷 尚宏, 青山 千晶, 藤田 真智子, 伊藤 雄伍, 今村 壽宏, 加藤 格, 真部 淳, 小川 千登世, 小澤 美和, 細谷 亮太, 横山 邦彦  小児がん : 小児悪性腫瘍研究会記録  42-  (3)  568  -568  2005
• HP4-3 CD10陽性T細胞型急性リンパ性白血病(T-ALL)の臨床像および予後(ポスター 施設共同研究,第21回日本小児がん学会 第47回日本小児血液学会 同時期開催)

  三浦 信之, 真部 淳, 嶋田 博之, 熊谷 昌明, 金子 隆, 前田 美穂, 木下 明俊, 沖本 由理, 加藤 陽子, 上條 岳彦, 豊田 恭徳, 生田 孝一郎, 小原 明, 花田 良二, 土田 昌宏  小児がん : 小児悪性腫瘍研究会記録  42-  (3)  739  -739  2005
• 8.手術時期の決定に苦慮した末,拡大肝左葉切除術を施行したPRETEXT-III肝芽腫の一例(日本小児肝癌スタディグループ研究会2005,研究会)

  荒木 夕宇子, 松藤 凡, 堀田 亮, 細谷 亮太, 草川 功, 真部 淳, 藤田 真智子, 青山 千晶  小児がん : 小児悪性腫瘍研究会記録  42-  (2)  272  -272  2005
• HP10-5 Diamond-Blacfan Anemiaに対するMetoclopramideの効果(ポスター 貧血,第21回日本小児がん学会 第47回日本小児血液学会 同時期開催)

  田草川 彩子, 森本 克, 加藤 格, 伊藤 雄伍, 今村 壽宏, 神谷 尚宏, 小川 千登世, 真部 淳, 細谷 亮太  小児がん : 小児悪性腫瘍研究会記録  42-  (3)  755  -755  2005
• C1-5 MDSの中央診断 : 骨髄生検の実施状況(委員会セッション 骨髄異形成症候群,第21回日本小児がん学会 第47回日本小児血液学会 同時期開催)

  増永 敦子, 在家 裕司, 菅原 幸子, 土田 昌宏, 河崎 裕英, 真部 淳  小児がん : 小児悪性腫瘍研究会記録  42-  (3)  530  -530  2005
• HO7-3 小児11q23転座型急性リンパ性白血病(ALL)の第一寛解期移植による治療成績の向上(口演 ALL1,第21回日本小児がん学会 第47回日本小児血液学会 同時期開催)

  齋藤 正博, 林 泰秀, 康 勝好, 高橋 浩之, 福島 敬, 太田 節雄, 真部 淳, 杉田 憲一, 杉田 完爾, 矢部 普正, 菊地 陽, 野口 靖, 生田 孝一郎, 小原 明, 花田 良二, 土田 昌宏  小児がん : 小児悪性腫瘍研究会記録  42-  (3)  592  -592  2005
• C1-4 De novo AML with trilineage dysplasia症例の予後調査(委員会セッション 骨髄異形成症候群,第21回日本小児がん学会 第47回日本小児血液学会 同時期開催)

  足立 壮一, 今泉 益栄, 真部 淳  小児がん : 小児悪性腫瘍研究会記録  42-  (3)  529  -529  2005
• 1歳未満発症stage III・IV神経芽腫9症例の検討,salvage therapyについて

  熊倉 香, 松藤 凡, 森本 克也, 細谷 亮太, 真部 淳, 堀田 亮  小児がん  41-  (3)  682  -682  2004/11  [Not refereed][Not invited]
  
• Acute myeloid leukemia (AML) - Type chemotherapy for newly diagnosed children with myelodysplastic syndrome (MDS): A Japanese childhood MDS study group trial MDS99.

  Y Ohtsuka, A Manabe, J Okamura, S Kojima, A Ohara, M Tuchida, K Ikuta, S Hibi, K Kawa, M Yabe, A Watanabe, K Ueda, S Nakazawa, S Miyazaki, T Nakahata  BLOOD  104-  (11)  265B  -265B  2004/11  [Not refereed][Not invited]
  
• Bisphosphonate zoledronic acid (ZOL) inhibits the abnormal proliferation and differentiation of juvenile myelomonocytic leukemia (JMML) cells.

  Y Ohtsuka, A Manabe, H Kawasaki, S Watanabe, Y Zaike, D Hasegawa, T Miyazaki, T Tanizawa, T Nakahata, K Tsuji  BLOOD  104-  (11)  265B  -265B  2004/11  [Not refereed][Not invited]
  
• 小児MDS治療研究会 MDS99治療研究における治療成績

  大塚 欣敏, 矢部 みはる, 岡村 純, 真部 淳, 小原 明, 土田 昌宏, 小島 勢二, 日比 成美, 河 敬世, 生田 孝一郎, 渡辺 新, 上田 一博, 中澤 眞平, 宮崎 澄雄, 中畑 龍俊, 小児骨髄異形成症候群治療研究会  小児がん  41-  (3)  519  -519  2004/11  [Not refereed][Not invited]
  
• Monosomy 7を示す小児MDSにおける微小巨核球の増加とdysplasia所見の特徴

  土田 昌宏, 菅原 幸子, 在家 裕司, 真部 淳, 増永 敦子, 生田 孝一郎, 中畑 龍俊, 小児血液学会MDS委員会  日本血液学会・日本臨床血液学会総会プログラム・抄録集  66回・46回-  772  -772  2004/09  [Not refereed][Not invited]
  
• 小児骨髄異形成症候群(MDS)及び若年性骨髄単球性白血病(JMML)におけるp15メチル化の検討

  長谷川 大輔, 真部 淳, 久保田 健夫, 河崎 裕英, 大塚 欣敏, 磯村 万理子, 小島 勢二, 辻 浩一郎, 中畑 龍俊  日本血液学会・日本臨床血液学会総会プログラム・抄録集  66回・46回-  942  -942  2004/09  [Not refereed][Not invited]
  
• 1歳未満発症stage III・IV神経芽腫9症例の検討,salvage therapyについて

  熊倉 香, 松藤 凡, 森本 克也, 細谷 亮太, 真部 淳, 堀田 亮  日本小児血液学会雑誌  18-  (4)  421  -421  2004/08  [Not refereed][Not invited]
  
• 骨髄異形成症候群 小児MDS治療研究会 MDS99治療研究における治療成績

  大塚 欣敏, 矢部 みはる, 岡村 純, 真部 淳, 小原 明, 土田 昌宏, 小島 勢二, 日比 成美, 河 敬世, 生田 孝一郎, 渡辺 新, 上田 一博, 中澤 眞平, 宮崎 澄雄, 中畑 龍俊, 小児骨髄異形成症候群治療研究会  日本小児血液学会雑誌  18-  (4)  268  -268  2004/08  [Not refereed][Not invited]
  
• Risk-Adapted Treatment for Childhood Acute Lymphoblastic Leukemia

  MANABE Atsushi  日本小児血液学会雑誌  18-  (3)  185  -188  2004/06/30
• Acute Unclassified Leukemia with CD7 and CD13 Positivity

  HASEGAWA Daisuke, MANABE Atsushi, TSURUTA Toshihisa, OHTSUKA Yoshitoshi, EBIHARA Yasuhiro, KAWASAKI Hirohide, ARITAKI Kentaro, MATSUURA Keiko, HOSHIKA Akinori, TSUJI Kohichiro  日本小児血液学会雑誌  18-  (3)  155  -159  2004/06/30
• 小児骨髄異形成症候群(MDS)の中央診断 小児血液学会MDS委員会活動

  真部 淳, 土田 昌宏, 生田 孝一郎, 小島 勢二, 原 純一, 生嶋 聡, 秋山 祐一, 小田 慈, 加藤 剛二, 菊池 陽, 鶴沢 正仁, 増永 敦子, 中畑 龍俊  日本小児科学会雑誌  108-  (2)  155  -155  2004/02  [Not refereed][Not invited]
  
• 代謝拮抗薬 (小児の臨床薬理学) -- (抗腫瘍薬)

  鶴田 敏久, 真部 淳  小児科診療  67-  545  -555  2004
• The scientific research on idiopathic hematopoietic injury. The refractory anemia. Center diagnosis of the infant myelodysplastic syndrome.

  中畑龍俊, 真部淳  特発性造血障害に関する調査研究班 平成15年度総括・分担研究報告書  104  -106  2004  [Not refereed][Not invited]
  
• Autoimmune Lymphoproliferative Syndrome Presenting Hemolytic Anemia and Thrombocytopenia in Early Infancy

  INAI Ikuko, KANEGANE Hirokazu, MORIMOTO Tsuyoshi, MANABE Atsushi, MIYAWAKI Toshio, HOSOYA Ryota  日本小児血液学会雑誌  17-  (6)  492  -496  2003/12/31
• Therapy-related myelodysplastic syndrome in childhood: A retrospective study of 36 patients in Japan.

  M Tsurusawa, A Manabe, Y Akiyama, S Kojima, M Tsuchida, K Ikuta, J Hara, M Oda, A Ikushima, K Kato, A Masunaga, T Nakahata  BLOOD  102-  (11)  424A  -425A  2003/11  [Not refereed][Not invited]
  
• Pediatric RAEB-AMLM6a syndrome: A proposal of a unique entity.

  A Manabe, Y Zaike, S Sugahara, M Tsuchida, A Masunaga, A Kikuchi, S Kojima, M Oda, K Ikuta, K Kato, M Tsurusawa, Y Akiyama, J Hara, S Ikushima, T Nakahata  BLOOD  102-  (11)  329B  -329B  2003/11  [Not refereed][Not invited]
  
• No advantage of dexamethasone over prednisolone for the outcome of standard and intermediate risk childhood acute lymphoblastic leukemia in the Tokyo children's cancer study group L95-14 protocol.

  S Igarashi, M Tsuchida, A Manabe, A Ohara, M Kumagai, T Saito, Y Okimoto, A Kikuchi, Y Toyoda, T Kamijo, K Isoyama, M Kajiwara, M Sotomatsu, K Sugita, K Sugita, M Maeda, T Morimoto, M Saito, T Yanagisawa, H Yabe, T Mori, T Kaneko, Y Hayashi, R Hanada, K Ikuta  BLOOD  102-  (11)  879A  -879A  2003/11  [Not refereed][Not invited]
  
• Diminished erythroid colony formation in juvenile myelomonocytic leukemia.

  D Hasegawa, A Manabe, K Ishikawa, M Wada, H Yagasaki, T Yoshimasu, Y Ohtsuka, T Tsuruta, H Kawasaki, Y Ebihara, T Nakahata, K Tsuji  BLOOD  102-  (11)  328B  -328B  2003/11  [Not refereed][Not invited]
  
• Unrelated cord blood transplantation in adult patients with hematological malignancy is a safe and useful therapeutic modality.

  T Iseki, S Takahashi, J Ooi, A Tomonari, K Uchimaru, F Nagamura, N Ohno, Y Soda, H Kawasaki, T Tsuruta, A Manabe, T Nagamura-Inoue, T Takahashi, A Tojo, S Asano  BLOOD  102-  (11)  479A  -480A  2003/11  [Not refereed][Not invited]
  
• 骨髄異形成症候群

  真部 淳, SUGAWARA Sachiko, MANABE Atsushi, ZAIKE Yuuji, MASUNAGA Atsuko, IKUTA Koichiro, NAKAHATA Tatsutoshi  日本小児血液学会雑誌  17-  (5)  2003/10/30  [Not refereed][Not invited]
  
• MDSセントラルレビューのまとめ

  田 昌宏, 菅原 幸子, 真部 淳, 在家 祐司, 増永 敦子, 生田 孝一郎, 中畑 龍俊  日本小児血液学会雑誌  17-  (5)  433  -437  2003/10/30  [Not refereed][Not invited]
  
• 紫斑・出血斑 (小児救急看護に必要な基礎知識と処置技術) -- (症候・症状別対応)

  長谷川 大輔, 真部 淳  小児看護  26-  (9)  1196  -1200  2003/08
• CMV感染により若年性骨髄単球性白血病と先天性赤芽球癆類似病態を呈した2症例

  盛武 浩, 池田 俊郎, 日高 文郎, 満木 ひとみ, 上村 幸代, 布井 博幸, 峰松 俊夫, 吉益 哲, 真部 淳  日本小児血液学会雑誌  17-  (4)  318  -318  2003/08  [Not refereed][Not invited]
  
• 骨髄異形成症候群(MDS)委員会報告

  中畑 龍俊, 小島 勢二, 土田 昌宏, 生田 孝一郎, 鶴沢 正仁, 小田 慈, 菊地 陽, 秋山 祐一, 真部 淳, 生嶋 聡, 加藤 剛二, 原 純一, 骨髄異形成症候群, MDS)委員会  日本小児血液学会雑誌  17-  (4)  231  -231  2003/08  [Not refereed][Not invited]
  
• Monosomy7に伴う小児MDSにおける微少巨核球の増加とdysplasia所見の特徴

  菅原 幸子, 土田 昌宏, 在家 裕司, 真部 淳, 増永 敦子, 生田 孝一郎, 中畑 龍俊, 小児血液学会MDS委員会  日本小児血液学会雑誌  17-  (4)  231  -231  2003/08  [Not refereed][Not invited]
  
• JMMLにおける赤芽球系コロニー形成能

  長谷川 大輔, 真部 淳, 石川 久美子, 和田 美夏, 谷ヶ崎 博, 吉益 哲, 大塚 欣敏, 鶴田 敏久, 河崎 裕英, 海老原 康博, 中畑 龍俊, 辻 浩一郎  日本小児血液学会雑誌  17-  (4)  232  -232  2003/08  [Not refereed][Not invited]
  
• 小児のRAEB-AML-M6症候群についての検討

  在家 裕司, 真部 淳, 菅原 幸子, 土田 昌宏, 増永 敦子, 小島 勢二, 小田 慈, 生田 孝一郎, 加藤 剛二, 菊地 陽, 鶴澤 正仁, 秋山 祐一, 原 純一, 生嶋 聡, 中畑 龍俊  臨床血液  44-  (8)  695  -695  2003/08  [Not refereed][Not invited]
  
• 小児MDSにおけるAML型緩解導入化学療法の効果 小児MDS治療研究会MDS99

  大塚 欣敏, 岡村 純, 真部 淳, 小島 勢二, 小原 明, 土田 昌宏, 生田 孝一郎, 日比 成美, 河 敬世, 矢部 みはる, 渡辺 新, 上田 一博, 中澤 眞平, 宮崎 澄雄, 中畑 龍俊  臨床血液  44-  (8)  695  -695  2003/08  [Not refereed][Not invited]
  
• 若年性骨髄単球性白血病(JMML)におけるウイルス感染症の関与

  真部 淳, 吉益 哲, 谷ヶ崎 博, 和田 美夏, 石川 久美子, 海老原 康博, 原 純一, 小池 健一, 盛武 浩, 野口 靖, 朴 永東, 辻 浩一郎, 中畑 龍俊  臨床血液  44-  (8)  712  -712  2003/08  [Not refereed][Not invited]
  
• MxA expression in patients with viral infection after allogeneic stem cell transplantation

  T Yoshimasu, A Manabe, Y Ebihara, R Tanaka, J Ooi, T Iseki, N Shirafuji, T Maekawa, S Asano, N Yoshikawa, K Tsuji  BONE MARROW TRANSPLANTATION  32-  (3)  313  -316  2003/08  [Not refereed][Not invited]
   

  Many patients suffer febrile diseases soon after allogeneic stem cell transplantation (SCT). Some of the symptoms of viral infections and acute GVHD are often difficult to distinguish. However, an accurate diagnosis is important since the treatments for these conditions are different. It is known that MxA protein is specifically induced in patients with several viral infections. We investigated the cytoplasmic expression of MxA in the peripheral blood mononuclear cells (PBMCs) of patients with fever after allogeneic SCT using a newly generated monoclonal antibody (KM1135) and flow cytometry. The level of MxA expression was significantly higher in patients diagnosed with viral infections ( n = 6, cytomegalovirus in three, Epstein - Barr virus in one, human herpesvirus-6 in one, adenovirus in one) than control individuals ( n = 9) (P<0.05, Mann - Whitney test). The level of MxA in patients with aGVHD ( n = 7) was identical to that in controls. The level of MxA correlated well with the amount of the cytomegalovirus antigen-positive cells in the presence of acute GVHD in two patients. The measurement of MxA is simple and useful in distinguishing viral disease from acute GVHD after allogeneic SCT.
• MxA expression in patients with viral infection after allogeneic stem cell transplantation

  T Yoshimasu, A Manabe, Y Ebihara, R Tanaka, J Ooi, T Iseki, N Shirafuji, T Maekawa, S Asano, N Yoshikawa, K Tsuji  BONE MARROW TRANSPLANTATION  32-  (3)  313  -316  2003/08  [Not refereed][Not invited]
   

  Many patients suffer febrile diseases soon after allogeneic stem cell transplantation (SCT). Some of the symptoms of viral infections and acute GVHD are often difficult to distinguish. However, an accurate diagnosis is important since the treatments for these conditions are different. It is known that MxA protein is specifically induced in patients with several viral infections. We investigated the cytoplasmic expression of MxA in the peripheral blood mononuclear cells (PBMCs) of patients with fever after allogeneic SCT using a newly generated monoclonal antibody (KM1135) and flow cytometry. The level of MxA expression was significantly higher in patients diagnosed with viral infections ( n = 6, cytomegalovirus in three, Epstein - Barr virus in one, human herpesvirus-6 in one, adenovirus in one) than control individuals ( n = 9) (P<0.05, Mann - Whitney test). The level of MxA in patients with aGVHD ( n = 7) was identical to that in controls. The level of MxA correlated well with the amount of the cytomegalovirus antigen-positive cells in the presence of acute GVHD in two patients. The measurement of MxA is simple and useful in distinguishing viral disease from acute GVHD after allogeneic SCT.
• Outcome and the early phase of immunological recovery after cord blood transplantation in adult patients.

  ISEKI TOHRU, TAKAHASHI SATOSHI, OOI JUN, TOMONARI AKIRA, SEKINE RIEKO, OHNO NOBUHIRO, NAGAMURA HUMITAKA, UCHIMARU KAORU, TSURUTA TOSHIHISA, EBIHARA YASUHIRO, MANABE ATSUSHI, TSUJI KOUICHIRO, NAGAMURA TOKIKO, TOJO ARINOBU, TAKAHASHI TSUNEO, ASANO SHIGETAKA  無菌生物 = Japanese journal of germfree life and gnotobiology  33-  (1)  48  -49  2003/06/01
• 神経芽腫に対する遺伝子治療 (第1土曜特集 遺伝子治療--現状とその近未来) -- (遺伝子治療臨床研究の現状--悪性腫瘍)

  真部 淳, 辻 浩一郎, 山下 直秀  医学のあゆみ  203-  (5)  335  -339  2002/11/02
• Expression of MxA protein, a specific marker for viral infections, in children with juvenile myelomonocytic leukemia (JMML).

  A Manabe, T Yoshimasu, H Yagasaki, M Wada, K Ishikawa, Y Ebihara, H Moritake, Y Noguchi, E Boku, K Koike, K Tsuji, T Nakahata  BLOOD  100-  (11)  336B  -336B  2002/11  [Not refereed][Not invited]
  
• MxA expression as a specific marker for viral infections after allogeneic stem cell transplantation.

  T Yoshimasu, A Manabe, Y Ebihara, R Tanaka, J Ooi, T Iseki, N Shirafuji, T Maekawa, S Asano, N Yoshikawa, K Tsuji  BLOOD  100-  (11)  439B  -439B  2002/11  [Not refereed][Not invited]
  
• Allogeneic stem cell transplantation for patients with myelodysplastic syndrome/acute myeloid leukemia developing from congenital bone marrow failure syndrome.

  Y Ebihara, A Manabe, T Tsuruta, K Ishikawa, D Hasegawa, T Yoshimasu, R Tanaka, K Ogami, T Iseki, M Maeda, T Kanda, K Ishimoto, S Asano, K Tsuji  BLOOD  100-  (11)  428B  -428B  2002/11  [Not refereed][Not invited]
  
• Reconstitution of human haematopoiesis in non-obese diabetic/severe combined immunodeficient mice by clonal cells expanded from single CD34(+) CD38(-) cells expressing Flk2/Flt3

  Y Ebihara, M Wada, T Ueda, MJ Xu, A Manabe, R Tanaka, M Ito, H Mugishima, S Asano, T Nakahata, K Tsuji  BRITISH JOURNAL OF HAEMATOLOGY  119-  (2)  525  -534  2002/11  [Not refereed][Not invited]
   

  In the present study, we examined the expression of Flk2/Flt3, a tyrosine kinase receptor, on human cord blood CD34(+) haematopoietic progenitor/stem cells. In flow cytometric analysis, Flk2/Flt3 was expressed on 80% of CD34(+) cells and their immature subpopulations, CD34(+) CD33(-) and CD34(+) CD38(-) cells. Methycellulose clonal culture of sorted CD34(+) Flk2/ Flt3(+) and CD34(+) Flk2/Flt3(-) cells showed that most of myelocytic progenitors expressed Flk2/Flt3, but erythroid and haematopoietic multipotential progenitors were shared by both fractions. When 1 x 10(4) lineage marker-negative (Lin(-))CD34(+)Flk2/Flt3(-) cells were transplanted into non-obese diabetic/severe combined immunodeficient (NOD/SCID) mice, none of the recipients possessed human CD45(+) cells in bone marrow 11-12 weeks after the transplantation. In contrast, all recipients transplanted with 1 x 10(4) Lin(-) CD34(+) Flk2/Flt3(+) cells showed successful engraftment. Furthermore, clonal cells expanded from single Lin(-) CD34(+) CD38(-) Flk2/Flt3(+) cells in the culture with Flk2/Flt3 ligand, stem cell factor, thrombopoietin, and a complex of interleukin 6/soluble interleukin 6 receptor were individually transplanted into NOD/SCID mice. At 20 to 21 weeks after the transplantation, three out of 10 clones harvested at d 7 of culture, and three out of six clones at d 14 could reconstitute human haematopoiesis in recipient marrow. These results demonstrated that Flk2/Flt3 was expressed on a wide variety of human haematopoietic cells including long-term-repopulating haematopoietic stem cells.
• Reconstitution of human haematopoiesis in non-obese diabetic/severe combined immunodeficient mice by clonal cells expanded from single CD34(+) CD38(-) cells expressing Flk2/Flt3

  Y Ebihara, M Wada, T Ueda, MJ Xu, A Manabe, R Tanaka, M Ito, H Mugishima, S Asano, T Nakahata, K Tsuji  BRITISH JOURNAL OF HAEMATOLOGY  119-  (2)  525  -534  2002/11  [Not refereed][Not invited]
   

  In the present study, we examined the expression of Flk2/Flt3, a tyrosine kinase receptor, on human cord blood CD34(+) haematopoietic progenitor/stem cells. In flow cytometric analysis, Flk2/Flt3 was expressed on 80% of CD34(+) cells and their immature subpopulations, CD34(+) CD33(-) and CD34(+) CD38(-) cells. Methycellulose clonal culture of sorted CD34(+) Flk2/ Flt3(+) and CD34(+) Flk2/Flt3(-) cells showed that most of myelocytic progenitors expressed Flk2/Flt3, but erythroid and haematopoietic multipotential progenitors were shared by both fractions. When 1 x 10(4) lineage marker-negative (Lin(-))CD34(+)Flk2/Flt3(-) cells were transplanted into non-obese diabetic/severe combined immunodeficient (NOD/SCID) mice, none of the recipients possessed human CD45(+) cells in bone marrow 11-12 weeks after the transplantation. In contrast, all recipients transplanted with 1 x 10(4) Lin(-) CD34(+) Flk2/Flt3(+) cells showed successful engraftment. Furthermore, clonal cells expanded from single Lin(-) CD34(+) CD38(-) Flk2/Flt3(+) cells in the culture with Flk2/Flt3 ligand, stem cell factor, thrombopoietin, and a complex of interleukin 6/soluble interleukin 6 receptor were individually transplanted into NOD/SCID mice. At 20 to 21 weeks after the transplantation, three out of 10 clones harvested at d 7 of culture, and three out of six clones at d 14 could reconstitute human haematopoiesis in recipient marrow. These results demonstrated that Flk2/Flt3 was expressed on a wide variety of human haematopoietic cells including long-term-repopulating haematopoietic stem cells.
• 小児二次性MDS70例の後方視的解析

  鶴澤 正仁, 真部 淳, 秋山 祐一, 小島 勢二, 土田 昌宏, 生田 孝一郎, 原 純一, 小田 慈, 生嶋 聡, 加藤 剛二, 菊地 陽, 中畑 龍俊  臨床血液  43-  (8)  339  -339  2002/08  [Not refereed][Not invited]
  
• 小児骨髄異形成症候群(MDS)の病理セントラルレビュー

  真部 淳, 土田 昌宏, 生田 孝一郎, 小島 勢二, 原 純一, 生嶋 聡, 秋山 祐一, 鶴澤 正仁, 小田 慈, 菊地 陽, 加藤 剛二, 増永 敦子, 中畑 龍俊  臨床血液  43-  (8)  339  -339  2002/08  [Not refereed][Not invited]
  
• Growth of human T cell acute lymphoblastic leukemia lymphoblasts in NOD/SCID mouse fetal thymus organ culture

  F Ma, A Manabe, D Wang, M Ito, A Kikuchi, M Wada, M Ito, A Ohara, R Hosoya, S Asano, K Tsuji  LEUKEMIA  16-  (8)  1541  -1548  2002/08  [Not refereed][Not invited]
   

  The in vitro proliferation of T cell acute lymphoblastic leukemia (T-ALL) cells in its entirety has not been well delineated because of a lack of an appropriate culture system that mimics the growth pattern in a living body. We applied a NOD/SCID mouse fetal thymus organ culture (FTOC) for leukemic cells from fresh (one case) and frozen (seven cases) bone marrow (BM) samples of children with T-ALL. Cell growth was observed in all seven samples in the culture, reaching a proliferational peak at 4 weeks, and it was calculated that the proliferation potential was 212-to 319-fold. The FTOC-derived T-ALL cells showed similarity to the original cells morphologically and immunophenotypically, still possessed clonalities and were able to regenerate overt leukemia in NOD/SCID mice. These FTOC-derived T-ALL cells differed from ordinary cell lines because they always need FTOC support. Thus, we established a new in vitro culture for T-ALL cells. A comparison of the original and FTOC-derived T-ALL cells revealed that the proportion of cells expressing IL-7R increased in all seven cases. Sorting and re-seeding of FTOC-derived IL-7R+ and IL-7R- cells into secondary FTOC resulted in a predominant generation of IL-7R+ cells from both fractions, while IL-7R- cells proliferated more potently than did IL-7R+ cells, suggesting that a pathway for the conversion of IL-7R- to IL-7R+ exists during the proliferation of T-ALL lymphoblasts. Addition of exogenous IL-7 or neutralization with anti-IL-7 antibody did not influence the growth pattern of T-ALL cells in FTOC. The current study provides a unique assay system for the exploration of the hierarchy within human T-lymphoid leukemic cells, and should facilitate the establishment of novel therapeutic modalities.
• Growth of human T cell acute lymphoblastic leukemia lymphoblasts in NOD/SCID mouse fetal thymus organ culture

  F Ma, A Manabe, D Wang, M Ito, A Kikuchi, M Wada, M Ito, A Ohara, R Hosoya, S Asano, K Tsuji  LEUKEMIA  16-  (8)  1541  -1548  2002/08  [Not refereed][Not invited]
   

  The in vitro proliferation of T cell acute lymphoblastic leukemia (T-ALL) cells in its entirety has not been well delineated because of a lack of an appropriate culture system that mimics the growth pattern in a living body. We applied a NOD/SCID mouse fetal thymus organ culture (FTOC) for leukemic cells from fresh (one case) and frozen (seven cases) bone marrow (BM) samples of children with T-ALL. Cell growth was observed in all seven samples in the culture, reaching a proliferational peak at 4 weeks, and it was calculated that the proliferation potential was 212-to 319-fold. The FTOC-derived T-ALL cells showed similarity to the original cells morphologically and immunophenotypically, still possessed clonalities and were able to regenerate overt leukemia in NOD/SCID mice. These FTOC-derived T-ALL cells differed from ordinary cell lines because they always need FTOC support. Thus, we established a new in vitro culture for T-ALL cells. A comparison of the original and FTOC-derived T-ALL cells revealed that the proportion of cells expressing IL-7R increased in all seven cases. Sorting and re-seeding of FTOC-derived IL-7R+ and IL-7R- cells into secondary FTOC resulted in a predominant generation of IL-7R+ cells from both fractions, while IL-7R- cells proliferated more potently than did IL-7R+ cells, suggesting that a pathway for the conversion of IL-7R- to IL-7R+ exists during the proliferation of T-ALL lymphoblasts. Addition of exogenous IL-7 or neutralization with anti-IL-7 antibody did not influence the growth pattern of T-ALL cells in FTOC. The current study provides a unique assay system for the exploration of the hierarchy within human T-lymphoid leukemic cells, and should facilitate the establishment of novel therapeutic modalities.
• Allogeneic hematopoietic stem cell transplantation for 27 children with juvenile myelomonocytic leukemia diagnosed based on the criteria of the International JMML Working Group

  A Manabe, J Okamura, K Yumura-Yagi, Y Akiyama, M Sako, H Uchiyama, S Kojima, K Koike, T Saito, T Nakahata  LEUKEMIA  16-  (4)  645  -649  2002/04  [Not refereed][Not invited]
   

  Prognostic factors of juvenile myelomonocytic leukemia (JMML) have not been clarified because of its very low incidence and inaccuracy in the diagnosis. The purpose of this study was to evaluate children with JMML given an allogeneic hematopoletic stem cell transplantation (SCT) and the role of different variables potentially influencing outcome in a nationwide survey in Japan based on the newly proposed criteria by the International JMML Working Group. The study patients were 27 children who underwent SCT among 55 JMML patients retrospectively collected in the survey. The source of grafts was HLA-identical siblings in 12 cases, HLA-matched unrelated individuals in 10 and others in five. Total body irradiation was used in 18 cases. Event-free and overall survival (OS) at 4 years after SCT were 54.2 +/- 11.2% (s.e.) and 57.9 +/- 11.0% (s.e.), respectively. Six patients died of relapse and three of complications. Patients with abnormal karyotypes showed a significantly lower OS than those with normal karyotypes (P < 0.001). Patients below 1 year of age showed a significantly higher OS than those of 1 year of age or more (P = 0.02). Patients with grade 0-1 acute graft-versus-host disease (GVHD) or chronic GVHD had a more favorable OS than those without them, although they were not statistically significant (P > 0.05). Other variables studied were not associated with OS. A multivariate analysis of these factors yielded the abnormal karyotype as the only significant risk factor for lower OS (risk ratio: 11.0; 95% Cl: 2.7-45.1).
• Allogeneic hematopoietic stem cell transplantation for 27 children with juvenile myelomonocytic leukemia diagnosed based on the criteria of the International JMML Working Group

  A Manabe, J Okamura, K Yumura-Yagi, Y Akiyama, M Sako, H Uchiyama, S Kojima, K Koike, T Saito, T Nakahata  LEUKEMIA  16-  (4)  645  -649  2002/04  [Not refereed][Not invited]
   

  Prognostic factors of juvenile myelomonocytic leukemia (JMML) have not been clarified because of its very low incidence and inaccuracy in the diagnosis. The purpose of this study was to evaluate children with JMML given an allogeneic hematopoletic stem cell transplantation (SCT) and the role of different variables potentially influencing outcome in a nationwide survey in Japan based on the newly proposed criteria by the International JMML Working Group. The study patients were 27 children who underwent SCT among 55 JMML patients retrospectively collected in the survey. The source of grafts was HLA-identical siblings in 12 cases, HLA-matched unrelated individuals in 10 and others in five. Total body irradiation was used in 18 cases. Event-free and overall survival (OS) at 4 years after SCT were 54.2 +/- 11.2% (s.e.) and 57.9 +/- 11.0% (s.e.), respectively. Six patients died of relapse and three of complications. Patients with abnormal karyotypes showed a significantly lower OS than those with normal karyotypes (P < 0.001). Patients below 1 year of age showed a significantly higher OS than those of 1 year of age or more (P = 0.02). Patients with grade 0-1 acute graft-versus-host disease (GVHD) or chronic GVHD had a more favorable OS than those without them, although they were not statistically significant (P > 0.05). Other variables studied were not associated with OS. A multivariate analysis of these factors yielded the abnormal karyotype as the only significant risk factor for lower OS (risk ratio: 11.0; 95% Cl: 2.7-45.1).
• 神経芽腫細胞の初代培養：腫瘍ワクチンを用いた免疫遺伝子治療の予備的研究

  麦島 秀雄, 広瀬偉美子, 真部淳, 麦島秀雄, 三井哲夫, 細谷亮太, 菊地陽, 百名伸之, 設楽利二, 前田美穂, 中川原章, 辻浩一郎, 山下直秀  小児がん  39-  (1)  37  -39  2002  [Not refereed][Not invited]
  
• Problem in clinical statistics and diagnosis of the infant MDS (Ministry of Health,Labour and Welfare S ).

  中畑龍俊, 真部淳  特発性造血障害に関する研究班 平成13年度研究業績報告書  101  -102  2002  [Not refereed][Not invited]
  
• 委員会セッション:3.骨髄異形成症候群

  中畑 龍俊, 真部 淳  日本小児血液学会雑誌  16-  (4)  172  -175  2002  [Not refereed][Not invited]
  
• AMLを発症したKostmann症候群の一例

  早川 潤, 植田 高弘, 右田 真, 浅野 健, 前田 美穂, 福永 慶隆, 石川 久美子, 田中 竜平, 真部 淳, 辻 浩一郎  小児がん  38-  (4)  587  -587  2001/12  [Not refereed][Not invited]
  
• Unrelated cord blood transplantation in adult patients with hematological malignancy: A single institution experience.

  T Iseki, J Ooi, A Tomonari, T Takahashi, K Ishii, K Uchimaru, R Sekine, K Ishikawa, Y Ebihara, T Tsuruta, A Manabe, A Tojo, K Tsuji, K Tani, S Asano  BLOOD  98-  (11)  665A  -665A  2001/11  [Not refereed][Not invited]
  
• The sex difference in prognosis disappeared in children with acute lymphoblastic leukemia; A Tokyo children's cancer study group (TCCSG) study.

  M Tsuchida, K Ikuta, R Hanada, A Manabe, T Saito, K Koike, Y Toyoda, A Kinoshita, T Kaneko, Y Okimoto, M Kajiwara, Y Hayashi, M Kumagai, M Maeda, K Isoyama, H Fujita, M Sotomatsu, K Sugita, K Sugita, H Yabe, J Takayama, A Kikuchi, A Ohara, Y Hoshi, R Hosoya, F Bessho, S Nakazawa  BLOOD  98-  (11)  115A  -116A  2001/11  [Not refereed][Not invited]
  
• Role of stem cell transplantation (SCT) for children with acute lymphoblastic leukemia with very high risk features in first remission: A Tokyo children's cancer study group (TCCSG) study L95-14.

  K Ikuta, M Tsuchida, A Manabe, T Sato, A Kikuchi, T Kaneko, T Kamijo, A Kinoshita, Y Toyoda, Y Hayashi, H Yabe, T Morimoto, M Sotomatsu, K Sugita, M Kajiwara, A Ohara, Y Okimoto, K Sugita, H Fujita, M Maeda, K Isoyama, M Kumagai, R Hanada, T Saito, S Nakazawa  BLOOD  98-  (11)  116A  -117A  2001/11  [Not refereed][Not invited]
  
• Myelodysplastic syndrome in childhood: a retrospective study of 189 patients in Japan

  H Sasaki, A Manabe, S Kojima, M Tsuchida, Y Hayashi, K Ikuta, J Okamura, K Koike, A Ohara, E Ishii, Y Komada, S Hibi, T Nakahata  LEUKEMIA  15-  (11)  1713  -1720  2001/11  [Not refereed][Not invited]
   

  We report a retrospective analysis of children with myelodysplastic syndrome (MDS) diagnosed between 1990 and 1997 in Japan. In total, 189 patients were enrolled: 122 cases of primary MDS (26 RA, 18 RAEB, 25 RAEBt, 53 CMML/JMML), 24 cases with constitutional predisposition to MDS, and 43 cases of therapy-related MDS (t-MDS). The frequency of pediatric MDS was estimated to be 7.7% of all leukemias. Cytogenetic abnormalities were observed in 41% of primary MDS and 90% of t-MDS cases. The 4-year survival rate, estimated by Kaplan-Meier analysis, for primary RA was 78.9%, while other types of MDS and JMML had rates lower than 40%, and t-MDS showed an even more unfavorable prognosis. In primary MDS, the survival rate of patients with cytogenetic abnormalities was significantly lower. Among prognostic variables by IPSS, only the cytogenetic pattern was useful for predicting outcome in childhood MDS. There was no apparent advantage to chemotherapy for RA, and the survival rate In patients with primary RA, JMML, or t-MDS receiving stem cell transplantation was significantly higher. More precise designs of our diagnostic and classification systems, as well as therapeutic trials In large-scale prospective studies, are necessary for further Improvements in MDS outcome.
• Allogeneic bone marrow transplantation in first remission rescues children with Philadelphia chromosome-positive acute lymphoblastic leukemia: Tokyo Children's Cancer Study Group (TCCSG) studies L89-12 and L92-13

  T Mori, A Manabe, M Tsuchida, R Hanada, H Yabe, A Ohara, T Saito, S Nakazawa  MEDICAL AND PEDIATRIC ONCOLOGY  37-  (5)  426  -431  2001/11  [Not refereed][Not invited]
   

  Background. The prognosis of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) is generally poor and reports from large studies are scarce. We evaluated the efficacy of allogeneic bone marrow transplantation (allo-BMT) for children with this type of leukemia. Procedure. The chemotherapy regimens consisted of an induction phase and very intensive consolidation followed by a reinduction phase and late intensification treatment. The selection of treatment modalities such as chemotherapy, allo-BMT, or autologous transplantation was made by each institute. The principal endpoint was the outcome of children with Ph+ ALL according to the treatment options. Results. Thirty-two patients (4.3%) were diagnosed as Ph+ ALL out of the 741 cases of ALL consecutively enrolled in two protocols of the Tokyo Children's Cancer Study Group (TCCSG) from 1989 to 1994. Thirty patients (93.8%) were Induced into complete remission (CR). Of these 30 patients, eight children electively received allo-BMT in the first CR. Six of these patients are in continuous remission at a median follow-up of 58 (range 48-105) months after the diagnosis. One patient died following recurrence and another patient died of graft vs. host disease. Three patients treated with autologous BMT or peripheral blood stem cell transplantation in the first CR experienced a subsequent relapse, In the remaining 19 patients, 13 patients were treated with very high-risk chemotherapy alone and all relapsed within 28 months. One patient was excluded from the analysis because lie was treated with standard-risk chemotherapy until relapse. The other five patients were also excluded from the analysis because Philadelphia chromosome was not detected until they relapsed. None of the relapsed patients survived in spite of treatment including allo-BMT. In multivariate analysis, only allo-BMT remained as an independent factor for good prognosis. Conclusions. The only way to cure children with Ph+ ALL was allo-BMT in this study and its outcome seemed promising. (C) 2001 Wiley-Liss, Inc.
• Delay of the diagnostic lumbar puncture and intrathecal chemotherapy in children with acute lymphoblastic leukemia who undergo routine corticosteroid testing: Tokyo Children's Cancer Study Group study L89-12

  A Manabe, M Tsuchida, R Hanada, K Ikuta, Y Toyoda, Y Okimoto, K Ishimoto, H Okawa, A Ohara, T Kaneko, K Koike, T Sato, K Sugita, F Bessho, Y Hoshi, M Maeda, A Kinoshita, T Saito, Y Tsunematsu, S Nakazawa  JOURNAL OF CLINICAL ONCOLOGY  19-  (13)  3182  -3187  2001/07  [Not refereed][Not invited]
   

  Purpose: To determine the effects of eliminating initial lumbar punctures in 418 consecutively treated children with acute lymphoblastic leukemia (ALL). Patients and Methods: Patients were enrolled onto a trial conducted in central Japan between 1989 and 1992. Treatment consisted of standard four-drug induction therapy followed by a risk-based intensification phase, reinduction therapy, late intensification, and remission maintenance therapy (total of 104 weeks). The initial lumbar puncture, with an intrathecal injection of chemotherapy, was performed after 1 week of prednisolone sensitivity testing (day 8). End points included response to prednisolone, CNS status at the time of the day 8 lumbar puncture, subsequent adverse events in CNS and bone marrow, and event-free survival (EFS). Results: The remission induction rate was 93.1% with a 6-year EFS rate (+/- SE) of 68.7% +/- 2.4%, which is similar to historical results for patients who received their-diagnostic lumbar puncture and first instillation of intrathecal chemotherapy on day 0. Overall, 84.5% of the patients had good responses to prednisolone, whereas 15.5% had poor responses. Clinical outcome was strikingly better for the good responders (6-year EFS, 74.1% +/- 2.5% compared with 40.1% +/- 6.4% for patients with poor responses), suggesting that omission of intrathecal chemotherapy did not alter the predictive value of drug sensitivity testing. Eighteen patients experienced CNS relapse as their first adverse event (cumulative risk, 5.1%; 95% confidence interval, 2.7% to 7.4%), coincident with reports from groups using conventional strategies of CNS clinical management. Bleeding into the CSF at the time of the day 8 lumbar puncture was apparent in 29 cases (8.1%), but leukemic blasts were identified in only two. Conclusion: Delay of the initial lumbar puncture and intrathecal injection of chemotherapy seems to be feasible in children with ALL. Further controlled evaluations are needed to establish the validity of this conclusion. (C) 2001 by American Society of Clinical Oncology.
• Development of human lymphohematopoietic stem and progenitor cells defined by expression of CD34 and CD81

  F Ma, M Wada, H Yoshino, Y Ebihara, T Ishii, A Manabe, R Tanaka, T Maekawa, M Ito, H Mugishima, S Asano, T Nakahata, K Tsuji  BLOOD  97-  (12)  3755  -3762  2001/06  [Not refereed][Not invited]
   

  In this study, cord blood CD34(+) cells expressed CD81, a member of the transmembrane 4 superfamily, and were classified into 3 subpopulations on the basis of their expression levels: CD34(+)CD81(+) CD34(low)CD81(+), and CD34(+)CD81(high). The lymphohematopoietic activity of each subpopulation was then examined by using suspension and clonogenic cultures for hematopoietic potential, coculture with MS-5 cells for B-cell potential, organ cultures of thymus robes from nonobese diabetic/severe combined immunodeficiency disease (NOD/SCID) fetal mice, coculture with stromal cells derived from NOD/SCID fetal-mouse liver tissue for natural killer (NK) cell and mast cell potentials, and xenotransplantation into NODI SCID mice for long-term repopulating (LTR) ability. CD34(+)CD81(+) cells represented a heterogeneous population that had ail the lymphohematopoietic activities, including NOD/SCID mouse-repopulating ability. CD34(low)CD81(+) cells were enriched in erythroid, megakaryocytic, and NK lineage potentials but had lost T-cell and B-cell potentials and LTR ability. The CD34(+)CD81(high) fraction was depleted of most lymphohematopoietic potentials except NK cell and mast cell potentials. Thus, along the differentiation cascade from CD34(+)CD81(+) lymphohematopoietic stem cells, an up-regulation of CD81 or a down-regulation of CD34 results in a change in lymphohematopoietic properties. CD81 may serve as a marker for defining developmental stages of lymphohematopoietic stem cells. (C) 2001 by The American Society of Hematology.
• Prompt and durable hematopoietic reconstitution by unrelated cord blood transplantation in a child with Fanconi anemia

  T Yoshimasu, R Tanaka, S Suenobu, H Yagasaki, H Yoshino, T Ueda, H Hisakawa, T Ishii, T Mitsui, Y Ebihara, A Manabe, T Iseki, T Maekawa, T Nakahata, S Asano, K Tsuji  BONE MARROW TRANSPLANTATION  27-  (7)  767  -769  2001/04  [Not refereed][Not invited]
   

  We describe here the case of an 8-year-old girl with Fanconi anemia (FA) whose hematopoiesis was successfully restored by unrelated umbilical cord blood (UCB) transplantation. The patient became resistant to androgen therapy, and developed intracranial hemorrhage and dyserythropoiesis. Her hematopoietic recovery after the transplantation was excellent and a complete chimerism has been durably maintained. UCB should be considered as a stem cell source for transplantation when a patient with FA does not have an HLA-identical unaffected sibling donor.
• Evidence for the presence of murine primitive megakarycytopoiesis in the early yolk sac

  MJ Xu, S Matsuoka, FC Yang, Y Ebihara, A Manabe, R Tanaka, M Eguchi, S Asano, T Nakahata, K Tsuji  BLOOD  97-  (7)  2016  -2022  2001/04  [Not refereed][Not invited]
   

  During mouse embryogenesis, primitive erythropoiesis occurs in blood islands of the yolk sac (YS) on the seventh day of gestation. This study demonstrated for the first time the presence of unique primitive megakaryocytic (Mk) progenitors in the early YS, which disappeared by 13.5 days postcoitum (dpc). When 7.5 dpc YS cells were incubated in the presence of stem cell factor (SCF), interleukin (IL)-3, IL-6, erythropoietin (EPO), thrombopoietin (TPO), and granulocyte colony-stimulating factor in methylcellulose clonal culture, not only erythroid bursts but also megakaryocyte colonies were observed. The megakaryocytes in the colonies matured to proplatelet stages and produced platelets as early as day 3 of culture, much earlier than those from adult bone marrow, although their ploidy class was lower. These megakaryocytes were stained with acetylcholine esterase, and expressed platelet glycoprotein (GP)lb beta, GPllla, and platelet factor 4 by reverse transcription-polymerase chain reaction analysis, The analysis of hemoglobin types in erythrocytes obtained from hematopoietic multilineage colonies containing the megakaryocytes indicated that the Mk progenitors originated from primitive hematopoiesis. The primitive Mk progenitors formed colonies in the absence of any cytokines in fetal bovine serum (FBS)-containing culture, and SCF, IL-3, EPO, and TPO significantly enhanced the Mk colony formation. In FBS-free culture, however, no colony formation was induced without these cytokines. Because megakaryocytes were detected in 8.5-dpc YS, these unique primitive Mk progenitors may rapidly mature and give rise to platelets to prevent hemorrhage in the simultaneously developing blood vessels until definitive hematopoiesis begins to produce platelets. (Blood. 2001;97:2016-2022) (C) 2001 by The American Society of Hematology.
• The First Report from the MDS Committee

  中畑 龍俊, 小島 勢二, 田 昌宏, 生田 孝一郎, 岡村 純, 小池 健一, 小原 明, 原 純一, 真部 淳, 林 泰秀, 生嶋 聡, 秋山 祐一, 林 英蔚, 増永 敦子  日本小児血液学会雑誌  15-  (1)  54  -56  2001/02/28  [Not refereed][Not invited]
  
• Myelodysplastic syndrome in childhood : a retrospective study of 189 patients in Japan

  Leukemia  15(4), 1713-1720-  2001  [Not refereed][Not invited]
  
• Allogeneic bone warrow transpcantation in first remission rescues children withe Philadelphia chromosome-positive acute lymphoblastic leukemia : Tokyo children Concerstudy Group L89-12 and L92-13

  Medical and Pediatric Oncology  37(11), 426-431-  2001  [Not refereed][Not invited]
  
• CD34 expression on long-term repopulating hematopoietic stem cells changes during developmental stages

  S Matsuoka, Y Ebihara, MJ Xu, T Ishii, D Sugiyama, H Yoshino, T Ueda, A Manabe, R Tanaka, Y Ikeda, T Nakahata, K Tsuji  BLOOD  97-  (2)  419  -425  2001/01  [Not refereed][Not invited]
   

  The CD34 antigen serves as an important marker for primitive hematopoietic cells in therapeutic transplantation of hematopoietic stem cells (HSC) and gene therapy, but it has remained an open question as to whether or not most HSC express CD34, Using a competitive long-term reconstitution assay, the results of this study confirm developmental changes in CD34 expression on murine HSC, In fetuses and neonates, CD34 was expressed on Lin(-)c-Kit(+) long-term repopulating HSC of bone marrow (BM), liver, and spleen. However, CD34 expression on HSC decreased with aging, and in mice older than 10 weeks, HSC were most enriched in the Lin(-)c-Kit(+)CD34(-) marrow cell fraction. A second transplantation was performed from primary recipients who were transplanted with neonatal Lin(-)c-Kit(+) CD34(high) HSC marrow. Although donor-type HSC resided in CD34-expressing cell fraction in BM cells of the first recipients 4 weeks after the first transplantation, the stem cell activity had shifted to Lin(-)c-Kit(+)CD34(-) cells after 16 weeks, indicating that adult Lin-c-Kit(+)CD34- HSC are the progeny of neonatal CD34-expresssing HSC, Assays for colony-forming cells showed that hematopoietic progenitor cells, unlike HSC, continue to express CD34 throughout murine development. The present findings are important because the clinical application of HSC can be extended, in particular as related to CD34-enriched HSC and umbilical cord blood HSC, (C) 2001 by The American Society of Hematology.
• Cytokine requirement for the development of T-lymphoid lineage potential in clonal lymphohaematopoietic progenitors in vitro

  F Ma, FC Yang, A Kaneko, A Manabe, R Tanaka, S Asano, T Nakahata, K Tsuji  BRITISH JOURNAL OF HAEMATOLOGY  111-  (4)  1170  -1179  2000/12  [Not refereed][Not invited]
   

  The early process of T-cell development prior to thymic colonization has been poorly investigated because of the lack of a sensitive assay, We have developed a two-step in vitro culture system by combining a clonal culture with a fetal thymus organ culture (FTOC) and analysed the early development of T cells from lymphohaematopoietic progenitors. Cells of immature colonies derived from bone marrow cells of 5-fluorouracil (5FU)-treated mice using various combinations of early acting cytokines were transferred into a FTOC. All the combinations of stem cell factor (SCF), interleukin (IL)-3 and IL-6 capable of inducing colony formation supported T-cell generation. IL-11 and the Flt3 ligand possessed T-lineage promotional effects similar to IL-6 and SCF respectively However, there were some quantitative differences in the final T-cell yield among cytokine combinations. Thus, the commitment towards T lineage in lymphohaematopoietic progenitors may be an event determined intrinsically rather than induced by specific stimuli, but there map be a hierarchy between the activity of cytokines in further development. Furthermore. we examined the T-lineage potential of individual colonies derived from Lin(-)c-Kit(+)Sca-1(+) cells clone-sorted from post-5FU marrow cells. No colonies that contained only myelocytic progenitors showed T-lineage potential, but 23.3% of colonies with a haematopoietic multipotentiality did. Therefore, the divergence of the T lineage from other lineages such as myeloid potential may occur at an early stage of the hierarchy of haematopoiesis. The proposed method should prove valuable for exploring the molecular and cellular changes that occur during early T-cell development before thymic colonization.
• Long-term follow-up of childhood acute lymphoblastic leukemia in Tokyo Children's Cancer Study Group 1981-1995

  M Tsuchida, K Ikuta, R Hanada, T Saito, K Isoyama, K Sugita, Y Toyoda, A Manabe, K Koike, A Kinoshita, M Maeda, K Ishimoto, T Sato, Y Okimoto, T Kaneko, M Kajiwara, M Sotomatsu, Y Hayashi, H Yabe, R Hosoya, Y Hoshi, M Ohira, F Bessho, Y Tsunematsu, Tsukimoto, I, S Nakazawa  LEUKEMIA  14-  (12)  2295  -2306  2000/12  [Not refereed][Not invited]
   

  The objectives were as follows: Firstly, to estimate the overall probability of event-free survival (EFS) and isolated CNS relapse in the studies for children with acute lymphoblastic leukemia (ALL) during the 1980s and 1990s. Secondly, to report the EFS according to presenting features and lineage. Thirdly, to evaluate the treatment results re-classified by the risks of NCI criteria. Four consecutive protocol studies were performed in the Tokyo Children's Cancer Study Group: L81-10 protocol (1981-1984, 189 patients), L84-11 (1984-1989, 484 patents), L89-12 (1989-1992 418 patients) and L92-13 (1992-1995, 347 patients). Overall EFS at 5 years in each protocol was 56.5 +/- 3.8(1 s.e.)%, 71.0 +/- 2.1%, 67.8 +/- 2.3%, and 63.4 +/- 2.7%, respectively. The cumulative isolated CNS relapse rate at 5 years was 8.1 +/- 2.1%, 3.5 +/- 0.9%, 3.6 +/- 1.0%, 1.0 +/- 0.6. The EFS in SR/HR (standard risk/high risk) according to the NCI criteria in B-precursor ALL at 5 years was 61.9 +/- 4.3%/41.4 +/- 7.4% (lineage was not confirmed.), 72.5 +/- 2.6%/63.4 +/- 5.0%, 77.4 +/- 2.7%/56.3 +/- 4.7%, and 67.8 +/- 3.4%/56.7 +/- 5.4% in each protocol. Also EFSs according to NCI SR/HR at 5 years of T-ALL in protocols L84-11, L89-12 and L92-13 were 55.6 +/- 16.6%/60.9 +/- 10.1%, 72.7 +/- 13.4%/51.6 +/- 9.1%, and 77.1 +/- 14.4%/53.6/10.1%, respectively. The truncation of maintenance therapy to 6 months resulted in a decreased EFS in L92-13, particularly due to an increase of bone marrow relapse after cessation of therapy in SR and HR. The NCI risk criteria work properly even in the patients treated by different intensities, so that it makes the comparison possible among the patients in various groups. The overall EFSs in childhood ALL improved in 1980s, but it seemed stable or decreased in 1990s. The short maintenance therapy resulted in poor outcome in SR on the L92-13 protocol. Many of these late relapsers were effectively rescued and over-all survival remained at a high level. The proportion of patients who received cranial irradiation reduced without any increase of the CNS events.
• Natural killer cell depletion by anti-asialo GM1 antiserum treatment enhances human hematopoietic stem cell engraftment in NOD/Shi-scid mice

  H Yoshino, T Ueda, M Kawahata, K Kobayashi, Y Ebihara, A Manabe, R Tanaka, M Ito, S Asano, T Nakahata, K Tsuji  BONE MARROW TRANSPLANTATION  26-  (11)  1211  -1216  2000/12  [Not refereed][Not invited]
   

  The scid mutation was backcrossed on to the NOD/Shi mouse background, resulting in the development of NOD/Shi-scid mice, which showed lack of mature lymphocytes, macrophage dysfunction and absence of circulating complement, but were not as impaired in natural killer (NK) cell activity as NOD/LtSz-scid mice. We then examined the effect of recipient NK cell depletion by anti-asialo GM1 antiserum on the repopulation of human cord blood (CB) hematopoietic stem cells (HSC) in NOD/Shi-scid mice to clarify the role of recipient NK cells in human HSC engraftment. The anti-asialo GM1 antiserum treatment significantly enhanced the engraftment of CB CD34(+) cells, but did not affect the differentiation of the engrafted HSC into each hematopoietic lineage. The NK cell depletion was effective at early stages of the engraftment, but not 3 weeks after the transplantation. The anti-asialo GM1 antiserum treatment did not improve the engraftment by human HSC in scid mice which lack mature lymphocytes, but show neither macrophage dysfunction nor a reduction in circulating complement, indicating that macrophages and/or complement also have roles in HSC graft rejection. The present study indicates that the preconditioning targeting of recipient NK cells in addition to T cell suppression and myeloablation might prevent HSC graft failure, and that NOD/Shi-scid mice treated with anti-asialo GM1 antiserum could provide a useful tool for evaluating the repopulating ability of transplantable human HSC.
• Allogeneic stem cell transplantation (SCT) for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in children: A Tokyo Childrens Cancer Study Group (TCCSG) study L95-14.

  A Manabe, Y Toyoda, K Ikuta, R Hanada, H Yabe, A Kinoshita, K Koike, Y Okimoto, Y Noguchi, Kajiwara, V, H Uchiyama, M Kumagai, KJ Sugita, K Isoyama, Y Hayashi, K Ishimoto, A Kikuchi, T Saito, M Tsuchida, S Nakazawa  BLOOD  96-  (11)  464A  -464A  2000/11  [Not refereed][Not invited]
  
• Growth of human T-cell acute lymphoblastic leukemia (T-ALL) lymphoblasts in NOD/SCID fetal thymus organ culture (FTOC): A possible role for the expression of IL-7 receptor (IL-7R) in the proliferation of T-lymphoid leukemic cells.

  F Ma, A Manabe, R Tanaka, S Asano, K Tsuji  BLOOD  96-  (11)  116A  -116A  2000/11  [Not refereed][Not invited]
  
• L-Asparaginase-Induced Necrotizing Acute Pancreatitis in the Late Phase of Treatment for Acute Lymphoblastic Leukemia : A Case Report

  ISHII Takefumi, MANABE Atsushi, EBIHARA Yasuhiro, UEDA Takahiro, YOSHINO Hiroshi, MITSUI Tetsuo, HISAKAWA Hiroaki, YAGASAKI Hiroshi, KIKUCHI Akira, TANAKA Ryuhei, NAKAHATA Tatsutoshi, TSUJI Kohichiro  日本小児血液学会雑誌  14-  (5)  328  -332  2000/10  [Not refereed][Not invited]
   

  急性リンパ性白血病(ALL)の治療開始10ヵ月後にL-アスパラギナーゼ(L-ASP)による急性膵炎を発症した9歳女児.発症時,壊死巣を有する膵炎と左胸部全体に及ぶ胸水を認めた.初期治療として循環動態の安定化,疼痛対策,膵外分泌の抑制,感染症予防を行った.次に,膵仮性嚢胞を形成したが,外科的手技を要せずに軽快した.膵炎発症60日後より化学療法を再開し,ALL発症後2年間完全緩解を維持している
• ヒト臍帯血CD34陽性細胞におけるFlk2/Flt3の発現 単一細胞レベルでの解析

  海老原 康博, 和田 美夏, 植田 高弘, 田中 竜平, 真部 淳, 中畑 龍俊, 浅野 茂隆, 辻 浩一郎  臨床血液  41-  (10)  990  -990  2000/10  [Not refereed][Not invited]
  
• Improvement in bronchiolitis obliterans organizing pneumonia in a child after allogeneic bone marrow transplantation by a combination of oral prednisolone and low dose erythromycin

  T Ishii, A Manabe, Y Ebihara, T Ueda, H Yoshina, T Mitsui, H Hisakawa, H Yagasaki, A Kikuchi, T Yoshimasu, T Tanaka, T Takahashi, A Masunaga, K Sugita, T Nakahata, S Asano, K Tsuji  BONE MARROW TRANSPLANTATION  26-  (8)  907  -910  2000/10  [Not refereed][Not invited]
   

  We report a 13-year-old boy who developed dyspnea at rest 1 year after the occurrence of cGVHD following an allogeneic bone marrow transplant (BMT), Pulmonary function data, imaging studies, lung biopsy, and bronchoalveolar lavage were consistent with the diagnosis of bronchiolitis obliterans organizing pneumonia (BOOP), Although reports suggest that oral methylprednisolone or methylprednisolone pulse therapies improve BOOP after BMT, we treated our patient with a combination of oral prednisolone (1 mg/kg) and low dose erythromycin (10 mg/kg) to avoid the side-effects of high-dose steroids. With this therapy, our patient showed clinical and radiological improvements within 1 week, The steroids were tapered off 12 months later and erythromycin was given for 14 months, We conclude that therapy consisting of a combination of oral prednisolone and low-dose erythromycin for BOOP after BMT may minimize the dose and duration of steroid use.
• 晩期再発に対しHLA1座不一致の父親から同種移植を行ったmyeloid/NK cell precursor acute leukemiaの一男児例

  吉野浩, 田中竜平, 吉益哲, 海老原康博, 真部淳, 辻浩一郎, 村上綾子, 石黒精  日本小児血液学会雑誌  14-  (4)  243  2000/08/31  [Not refereed][Not invited]
  
• Massive pericardial and pleural effusion with anasarca following allogeneic bone marrow transplantation

  T Ueda, A Manabe, A Kikuchi, H Yoshino, Y Ebihara, T Ishii, H Yagasaki, T Mitsui, H Hisakawa, A Masunaga, K Tsuji, T Nakahata  INTERNATIONAL JOURNAL OF HEMATOLOGY  71-  (4)  394  -397  2000/06  [Not refereed][Not invited]
   

  A 10-year-old girl presented with massive pericardial/pleural effusion with anasarca 216 days after an allogeneic bone marrow transplantation from her HLA-matched sibling for relapsed acute lymphoblastic leukemia. She did not show any other symptoms of chronic graft-versus-host disease (GVHD). The antinucleolar antibody was elevated in the blood and the pleural fluid. The lymphocytes in the fluid were mostly CD8(+)/HLA-DR+, and a majority of CD8(+) cells in the blood expressed CD57. These data suggested that she had chronic GVHD. Immunosuppressive therapy including prednisolone, cyclosporin A, high-dose methylprednisolone, tacrolimus (FK506), and methotrexate had no effect, and the patient died of Aspergillus pneumonia 183 days after the presentation of the disease. Although it has not been described before, isolated serositis with edema should be recognized as a clinical feature of chronic GVHD. Int J Hematol. 2000;71:394-397. (C) 2000 The Japanese Society of Hematology.
• The blastic transformation of juvenile myelomonocytic leukemia (JMML)

  J Okamura, A Ohara, H Kigasawa, K Asami, O Mabuchi, M Yabe, A Manabe, S Kojima, M Tsuchida, Y Hayashi, K Ikuta, K Koike, Y Akiyama, J Hara, S Ikushima, T Nakahata  LEUKEMIA  14-  (5)  967  -967  2000/05  [Not refereed][Not invited]
  
• Allogeneic stem cell transplantation (SCT) for juvenile myelomonocytic leukema (JMML). A retrospective analysis of 27 children in Japan

  A Manabe, S Kojima, M Tsuchida, Y Hayashi, K Ikuta, J Okamura, K Koike, A Ohara, Y Akiyama, J Hara, S Ikushima, T Nakahata  LEUKEMIA  14-  (5)  970  -970  2000/05  [Not refereed][Not invited]
  
• Myelodysplastic syndromes (MDS) in childhood: A retrospective study in Japan

  H Sasaki, A Manabe, S Kojima, M Tsuchida, Y Hayashi, K Ikuta, J Okamura, K Koike, A Ohara, E Ishii, Y Komada, S Hibi, T Nakahata  LEUKEMIA  14-  (5)  968  -968  2000/05  [Not refereed][Not invited]
  
• Expression of MxA protein in children with juvenile myelomonocytic leukemia (JMML)

  A Manabe, H Yagasaki, R Hosoya, K Koike, M Oda, T Sigimoto, H Mugishima, H Ayukawa, M Sako, T Nakahata, K Tsuji  LEUKEMIA  14-  (5)  963  -963  2000/05  [Not refereed][Not invited]
  
• サイトメガロウイルス(CMV)感染症合併胆道閉鎖症の1例(若年性骨髄単球性白血病(JMML)との鑑別)

  高橋 和浩, 谷ヶ崎 博, 真部 淳, 中畑 龍俊, 浅野 貴子, 秋岡 祐子, 中島 一朗, 渕之上 昌平, 阿岸 鉄三, 白髪 宏司  肝臓  41-  (5)  385  -386  2000/05  [Not refereed][Not invited]
  
• サイトメガロウイルス(CMV)感染症合併胆道閉鎖症の1例 若年性骨髄単球性白血病(JMML)との鑑別

  高橋和浩, 浅野貴子, 白髪宏司, 伊藤克己, 中島一朗, 阿岸鉄三, 谷ケ崎博, 真部淳, 中畑龍俊  移植  35-  (2)  114  -115  2000/04/10  [Not refereed][Not invited]
  
• Immunological aspects in cluster of Salmonella OranienburgSepsis cases

  K Takahashi, S Miykawa, A Manabe, M Hattori, H Shiraga, K Ito  PEDIATRIC RESEARCH  47-  (4)  278A  -278A  2000/04  [Not refereed][Not invited]
  
• Exclusive expression of G-CSF receptor on myeloid progenitors in bone marrow CD34(+) cells

  Y Ebihara, MJ Xu, A Manabe, A Kikuchi, R Tanaka, S Kato, T Nakahata, K Tsuji  BRITISH JOURNAL OF HAEMATOLOGY  109-  (1)  153  -161  2000/04  [Not refereed][Not invited]
   

  Although granulocyte colony-stimulating factor (G-CSF) has been reported to act on cells of neutrophilic lineage, the administration of G-CSF to induce the mobilization of various haematopoietic progenitors into the circulation. We analysed the expression of receptors for G-CSF (G-CSFR) on human bone marrow and G-CSF-mobilized peripheral blood CD34(+) cells, and examined the proliferation and differentiation capabilities of sorted CD34(+)G-CSFR+ and CD34(+)G-CSFR- cells using methylcellulose clonal culture. Flow cytometric analysis showed that G-CSFR was expressed on 14.9 +/- 4.9% of bone marrow CD34(+) cells, most of which were included in CD34(+)CD33(+) and CD34(+)CD38(+) cell fractions. In clonal cultures, CD34(+)G-CSFR+ cells produced only myeloid colonies, whereas CD34(+)G-CSFR- cells produced erythroid bursts, megakaryocyte and multilineage colonies. When incubated with the cytokine cocktail for 5 d, CD34(+)G-CSFR- cells generated CD34(+)G-CSFR+ myeloid progenitors. In G-CSF-mobilized peripheral blood, CD34(+) cells contained 10.8 +/- 5.8% of G-CSFR+ cells, most of which were also myeloid progenitors, although CD34(+)G-CSFR- cells contained a substantial number of myeloid progenitors. These results indicated that the expression of G-CSFR on CD34(+) cells is restricted to myeloid progenitors, suggesting that the specific activity of G-CSF on myelopoiesis depends on the exclusive expression of its receptor on myeloid progenitors, and that the mobilization of various haematopoietic progenitors is not a direct effect of G-CSF in humans.
• Expansion of human NOD/SCID-repopulating cells by stem cell factor, Flk2/Flt3 ligand, thrombopoietin, IL-6, and soluble IL-6 receptor

  T Ueda, K Tsuji, H Yoshino, Y Ebihara, H Yagasaki, H Hisakawa, T Mitsui, A Manabe, R Tanaka, K Kobayashi, M Ito, K Yasukawa, T Nakahata  JOURNAL OF CLINICAL INVESTIGATION  105-  (7)  1013  -1021  2000/04  [Not refereed][Not invited]
   

  Here, we demonstrate a significant ex vivo expansion of human hematopoietic stem cells capable of repopulating in NOD/SCID mice. Using a combination of stem cell factor (SCF), Flk2/Flt3 ligand (FL), thrombopoietin (TPO), and a complex of IL-6 and soluble IL-6 receptor (IL-6/sIL-6R), we cultured cord blood CD34(+) cells for 7 days and transplanted these cells into NOD/SCID mice. Bone marrow engraftment was judged successful when recipient animals contained measurable numbers of human CD45(+) cells 10-12 weeks after transplantation When cells were cultured with SCF+FL+TPO+IL-6/sIL-6R, 13 of 16 recipients were successfully engrafted, and CD45(+) cells represented 11.5% of bone marrow cells in engrafted recipients. Cells cultured with a subset of these factors were less efficiently engrafted, both as measured by frequency of successful transplantations and prevalence of CD45(+) cells. In animals receiving cells cultured with all 4 factors, human CD45(+) cells represented various lineages, including a large number of CD34(+) cells. The proportion of CD45(+) cells in recipient marrow was 10 times higher in animals receiving these cultured cells than in those receiving comparable numbers of fresh CD34(+) cells, and the expansion rate was estimated at 4.2-fold by a limiting dilution method. Addition of IL-3 to the cytokine combination abrogated the repopulating ability of the expanded cells. The present study may provide a novel culture method for the expansion of human transplantable hematopoietic stem cells suitable for clinical applications.
• Six months of maintenance chemotherapy after intensified treatment for acute lymphoblastic leukemia of childhood

  Y Toyoda, A Manabe, M Tsuchida, R Hanada, K Ikuta, Y Okimoto, A Ohara, Y Ohkawa, T Mori, K Ishimoto, T Sato, T Kaneko, M Maeda, K Koike, T Shitara, Y Hoshi, R Hosoya, Y Tsunematsu, F Bessho, S Nakazawa, T Saito  JOURNAL OF CLINICAL ONCOLOGY  18-  (7)  1508  -1516  2000/04  [Not refereed][Not invited]
   

  Purpose: We postulated that intensification of chemotherapy immediately after remission induction might reduce the leukemic cell burden sufficiently to allow an abbreviated period of antimetabolite therapy. Patients and Methods: Three hundred forty-seven children (ages 1 to 15 years) with previously untreated acute lymphoblastic leukemia (ALL) were enrolled onto the Tokyo L92-13 study, which excluded patients with mature B-cell ALL and patients less than 1 year old. One hundred twenty-four patients were classified as standard risk, 122 as high risk, and 101 as extremely high risk, according to age, peripheral-blood leukocyte count selected genetic abnormalities, and immunophenotype. All subjects received four drugs for remission induction, followed by a risk-directed multidrug intensification phase and therapy for presymptomatic leukemia in the CNS. Maintenance chemotherapy with oral mercaptopurine and methotrexate was administered for 6 months, with all treatment stopped by 1 year after diagnosis. Results: The mean (+/- SD) event-free survival (EFS) and overall survival rates far all patients were 59.5% +/- 3.4% and 81.5% +/- 2.2%, respectively, at 5.5 years after diagnosis. EFS rates by risk category were similar (60.2% +/- 6.0% for standard risk, 57.7% +/- 5.6% for high risk, and 62.5% +/- 5.7% for extremely high risk), whereas overall survival rates differed significantly (91.2% +/- 2.7%, 80.0% +/- 4.1%, and 72.1% +/- 4.5%, respectively, P < .0001 by the lag-rank test). There were 107 relapses. Eighty-five (79.4%) of these 107 patients achieved second complete remissions, with subsequent EFS rates of 61.5% +/- 7.9% (standard risk), 42.6% +/- 8.1% (high risk), and 9.6% +/- 6.4% (extremely high risk). Of the five risk factors analyzed, only the response to prednisolone monotherapy among extremely high-risk patients proved important. Conclusion: Early treatment intensification did nat compensate for a truncated phase of maintenance chemotherapy in children with standard or high-risk ALL, However, 6 months of antimetabolite treatment seemed adequate for extremely high-risk patients who were good responders to prednisolone and received intensified chemotherapy that included high-dose cytarabine early in the clinical course. (C) 2000 by American Society of Clinical Oncology.
• 非血縁者間臍帯血移植後,良好に経過しているFanconi貧血の1女児例

  吉益 哲, 田中 竜平, 末延 聡一, 谷ヶ崎 博, 吉野 浩, 久川 浩章, 海老原 康博, 真部 淳, 中畑 龍俊, 辻 浩一郎  臨床血液  41-  (3)  235  -235  2000/03  [Not refereed][Not invited]
  
• Long-term remission induced by corticosteroids, cyclophosphamide, and methotrexate in a patient with natural killer cell leukemia

  A Manabe, K Takahashi, R Shibata, M Takeuchi, M Morita, R Hosoya  MEDICAL AND PEDIATRIC ONCOLOGY  34-  (3)  224  -225  2000/03  [Not refereed][Not invited]
  
• NOD/SCIDマウスを用いたヒト臍帯血造血幹細胞のex vivo増幅法の検討

  植田 高弘, 吉野 浩, 海老原 康博, 石井 武文, 真部 淳, 田中 竜平, 福永 慶隆, 中畑 龍俊, 辻 浩一郎  日本小児科学会雑誌  104-  (2)  175  -175  2000/02  [Not refereed][Not invited]
  
• 非血縁者間臍帯血移植後,経過良好なFanconi貧血(A群)の8歳女児例

  吉益 哲, 田中 竜平, 末延 聡一, 谷ヶ崎 博, 吉野 浩, 久川 浩章, 海老原 康博, 真部 淳, 中畑 龍俊, 辻 浩一郎  日本小児科学会雑誌  104-  (2)  326  -326  2000/02  [Not refereed][Not invited]
  
• Hematopoietic capabilities of Flk2/Flt3-expressing cord blood stem/progenitor cells.

  Y Ebihara, T Ueda, H Yoshino, H Yagasaki, H Hisakawa, T Mistui, T Ishii, A Manabe, R Tanaka, S Asano, K Tsuji, T Nakahata  BLOOD  94-  (10)  253A  -253A  1999/11  [Not refereed][Not invited]
  
• Efficient ex vivo expansion of human NOD/SCID-repopulating cells by a combination of stem cell factor, FLK2/FLT3 ligand, thrombopoietin and a complex of interleukin-6 and soluble interleukin-6 receptor.

  T Ueda, H Yoshino, Y Ebihara, H Yagasaki, H Hisakawa, T Mitsui, A Manabe, R Tanaka, K Kobayashi, M Ito, K Yasukawa, S Asano, T Nakahata, K Tsuji  BLOOD  94-  (10)  130A  -130A  1999/11  [Not refereed][Not invited]
  
• Early response to 1-week oral prednisolone (PSL) without intrathecal therapy in childhood acute lymphoblastic leukemia (ALL): A Tokyo children's cancer study group (TCCSG) study

  A Manabe, M Tsuchida, R Hanada, K Ikuta, Y Toyoda, Y Okimoto, K Ishimoto, H Okawa, A Ohara, T Kaneko, K Koike, T Sato, K Sugita, F Bessho, Y Hoshi, M Maeda, A Kinoshita, T Saito, Y Tsunematsu, S Nakazawa  BLOOD  94-  (10)  297A  -297A  1999/11  [Not refereed][Not invited]
  
• Allogeneic apoptotic tumor cells with TNFa efficiently leads the dendritic cell maturation and increases antigen presentation capacity.

  S Nakahara, A Manabe, S Asano, K Tsuji, T Nakahata  BLOOD  94-  (10)  215A  -215A  1999/11  [Not refereed][Not invited]
  
• A Guide to Diagnosis of Childhood Myelodysplastic Syndromes The MDS Committee of The Japanese Society of Pediatric Hematology

  中畑 龍俊, 小島 勢二, 田 昌宏, 林 泰秀, 生田 孝一郎, 岡村 純, 小池 健一, 小原 明, 石井 栄一, 駒田 美弘, 日比 成美, 佐々木 秀樹, 真部 淳  The Japanese Journal of Pediatric Hematology  13-  (5)  381  -393  1999/10/31  [Not refereed][Not invited]
  
• NOD/SCIDマウスを用いたヒト造血幹細胞の増幅法の検討

  植田 高弘, 吉野 浩, 海老原 康博, 石井 武文, 久川 浩章, 三井 哲夫, 真部 淳, 田中 竜平, 中畑 龍俊, 辻 浩一郎  臨床血液  40-  (9)  923  -923  1999/09  [Not refereed][Not invited]
  
• JMMLとまぎらわしかったウイルス感染症の乳児例

  川上 緑, 森本 克, 細谷 亮太, 谷ヶ崎 博, 真部 淳, 中畑 龍俊  臨床血液  40-  (9)  936  -936  1999/09  [Not refereed][Not invited]
  
• Differential effects of human granulocyte colony-stimulating factor (hG-CSF) and thrombopoietin on megakaryopoiesis and platelet function in hG-CSF receptor-transgenic mice

  FC Yang, K Tsuji, A Oda, Y Ebihara, MJ Xu, A Kaneko, S Hanada, T Mitsui, A Kikuchi, A Manabe, S Watanabe, Y Ikeda, T Nakahata  BLOOD  94-  (3)  950  -958  1999/08  [Not refereed][Not invited]
   

  Granulocyte-colony stimulating factor (G-CSF) has been found to act on the neutrophilic lineage. We recently showed that human G-CSF (hG-CSF) has effects similar to early-acting cytokines such as interleukin-3 (IL-3) in the development of multipotential hematopoietic progenitors in transgenic (Tg) mice expressing receptors (R) for hG-CSF. In the present study, we examined the effects of hG-CSF on more mature hematopoietic cells committed to megakaryocytic lineage in these Tg mice. The administration of hG-CSF to the Tg mice increased the numbers of both platelets in peripheral blood and megakaryocytes in the spleen, indicating that hG-CSF stimulates megakaryopoiesis in the Tg mice in vivo. The stimulatory effect of hG-CSF was also supported by the results of studies in vitro, hG-CSF supported megakaryocyte colony formation in a dose-dependent fashion in clonal cultures of bone marrow cells derived from the Tg mice. Direct effects of hG-CSF on megakaryocytic progenitors in the Tg mice were confirmed by culture of single-cell sorted from bone marrow cells. hG-CSF showed a stronger effect on maturation of megakaryocytes in the Tg mice than that of IL-3 alone, but weaker than that of TPO alone. In addition, hG-CSF induced phosphorylation of STATE but not Jak2 or STAT5 while TPO induced phosphorylation of both. In contrast to TPO, hG-CSF did not enhance ADP induced aggregation. Thus, hG-CSF has a wide variety of functions in megakaryopoiesis of hG-CSFR-Tg mice, as compared with other megakaryopoietic cytokines, but the activity of hG-CSF in megakaryocytes and platelets does not stand up to a comparison with that of TPO. Specific signals may be required for the full maturation and activation of platelets. (C) 1999 by The American Society of Hematology.
• NOD-SCIDマウスを用いたヒト造血幹細胞の増幅法の検討

  植田 高弘, 吉野 浩, 海老原 康博, 真部 淳, 菊地 陽, 辻 浩一郎, 中畑 龍俊  International Journal of Hematology  69-  (Suppl.1)  169  -169  1999/04  [Not refereed][Not invited]
  
• ヒト造血幹細胞のNOD/SCIDマウスへの生着に及ぼす抗asialo GM1抗体投与の効果

  吉野 浩, 植田 高弘, 海老原 康博, 真部 淳, 菊地 陽, 辻 浩一郎, 中畑 龍俊  International Journal of Hematology  69-  (Suppl.1)  169  -169  1999/04  [Not refereed][Not invited]
  
• マウス造血幹細胞におけるCD34抗原の発現の発達に伴う推移

  松岡 佐保子, 辻 浩一郎, 海老原 康博, 真部 淳, 菊地 陽, 中畑 龍俊  International Journal of Hematology  69-  (Suppl.1)  171  -171  1999/04  [Not refereed][Not invited]
  
• AGM領域由来ストローマ細胞による二次造血幹細胞の発生の誘導

  辻 浩一郎, 松岡 佐保子, 海老原 康博, 真部 淳, 菊地 陽, 中畑 龍俊  International Journal of Hematology  69-  (Suppl.1)  47  -47  1999/04  [Not refereed][Not invited]
  
• 臍帯血造血幹細胞の長期造血再構築能の検討

  植田 高弘, 吉野 浩, 海老原 康博, 真部 淳, 菊地 陽, 辻 浩一郎, 中畑 龍俊  日本小児科学会雑誌  103-  (2)  132  -132  1999/02  [Not refereed][Not invited]
  
• 若年性骨髄単球性白血病(JMML)と鑑別を要したサイトメガロウイルス(CMV)感染症合併胆道閉鎖症(BA)の1例

  高橋 和浩, 谷ヶ崎 博, 真部 淳, 中畑 龍俊, 浅野 貴子, 秋岡 祐子, 白髪 宏司, 伊藤 克己  日本小児科学会雑誌  103-  (2)  176  -176  1999/02  [Not refereed][Not invited]
  
• 日本におけるFanconi貧血の遺伝子解析

  谷ヶ崎 博, 二木 真琴, 山田 薫, 真部 淳, 菊地 陽, 辻 浩一郎, 中畑 龍俊  日本小児科学会雑誌  103-  (2)  134  -134  1999/02  [Not refereed][Not invited]
  
• Hyperdiploid acute lymphoblastic leukemia with 51 to 65 chromosomes: A distinct biological entity with a marked propensity to undergo apoptosis

  C Ito, M Kumagai, A Manabe, E Coustan-Smith, SC Raimondi, FG Behm, KG Murti, JE Rubnitz, CH Pui, D Campana  BLOOD  93-  (1)  315  -320  1999/01  [Not refereed][Not invited]
   

  To determine the cellular basis for the excellent clinical outcome of hyperdiploid acute lymphoblastic leukemia (ALL), defined by a modal chromosome number of 51 to 65, we assessed the growth potential of leukemic cells from 129 children with newly diagnosed ALL. Flow cytometric analysis was used to compare leukemic cell recoveries at the beginning and at the end of 7-day cultures on allogeneic bone marrow-derived stromal layers. The median percentage of cell recovery after culture was 91% (range, <1% to 550%). Among the 25 hyperdiploid cases, only two had cell recoveries above the median value, compared with 63 of 104 cases with different ploidies (P < .001); 21 had recoveries within the first quartile, in contrast to only 12 of the 104 other cases. Cell recoveries in the 16 cases with duplications of chromosomes 4 and 10, a feature previously associated with a superior outcome, were all within the first quartile. Flow cytometric studies indicated that rapid induction of apoptosis was the underlying cause of low cell recoveries in cases with hyperdiploidy. The demise of hyperdiploid cells on stroma was not due to failure to adhere with stromal elements (as shown by electron microscopy) or to deficiencies of interleukin-1 (IL-1), IL-2, IL-3, IL-4, IL-6, IL-7, IL-11, stem-cell factor, interferon-alpha (IFN-alpha), tumor necrosis factor-alpha (TNF-a), or to combinations of these cytokines. Inactivation of IL-4, IFN-alpha and TNF-alpha, which if secreted by stromal layers could he toxic to ALL cells, failed to improve the survival of hyperdiploid blasts. We conclude that leukemic cells bearing 51 to 65 chromosomes have a marked propensity to undergo apoptosis. The stringent survival requirements of these cells, together with their potentially higher sensitivity to antileukemic drugs, may well account for the high cure rates achieved in patients with this form of ALL. (C) 1999 by The American Society of Hematology.
• Hyperfractionated High-dose Total Body Irradiation in Bone Marrow Transplantation for Ph^1-positive Acute Lymphoblastic Leukemia

  KIKUCHI Akira, EBIHARA Yasuhiro, MITSUI Tetsuo, UMEMOTO Yumi, UEDA Takahiro, YOSINO Hiroshi, ISHII Takefumi, EGUCHI Naohiro, HISAKAWA Hiroaki, YAGASAKI Hiroshi, MANABE Atsushi, TSUJI Kohichiro, NAKAHATA Tatsutoshi  日本小児血液学会雑誌  12-  (6)  452  -456  1998/12  [Not refereed][Not invited]
   

  2症例(14歳男児,9歳男児)において,多分割高線量の全身放射線照射(13.5Gy,9分割)を含む前処置を用いた同種骨髄移植を施行した.移植病期は症例1が血液学的再発期,症例2がPCRレベルでの再発期であり,ドナーは症例1が非血縁者,症例2がHLA部分不一致の母親であった.症例1ではday 14,症例2ではday 12に生着を確認し,骨髄のBCR/ABLのメッセージは症例1ではday 89,症例2ではday 19に消失し以後,再出現することはなかった.症例1ではIV度,症例2ではIII度のGVHDがみられ,又,2例ともアデノウイルス11型による出血性膀胱炎を発症した.症例1は間質性肺炎の為day442で死亡したが,症例2はday 231現在無病生存中である
• Exclusive expression of G-CSF receptor on myeloid progenitors in bone marrow CD34+ cells.

  Y Ebihara, K Tsuji, M Xu, A Manabe, A Kikuchi, S Kato, T Nakahata  BLOOD  92-  (10)  364A  -364A  1998/11  [Not refereed][Not invited]
  
• 単球由来樹状細胞(DC)の生成に対する可溶性CD 40Ligand(sCD40L)の作用の検討

  江口 直宏, 真部 淳, 谷ヶ崎 博, 海老原 康博, 菊地 陽, 辻 浩一郎, 中畑 龍俊, 布井 博幸  臨床血液  39-  (10)  943  -943  1998/10  [Not refereed][Not invited]
  
• Stem-KitTM CD34+HPC Enumeration Kitを用いたCD34陽性細胞絶対数の検討

  海老原 康博, 真部 淳, 菊地 陽, 辻 浩一郎, 中畑 龍俊  臨床血液  39-  (10)  1017  -1017  1998/10  [Not refereed][Not invited]
  
• マウス胎生期一次造血における巨核球造血の解析

  辻 浩一郎, 許 明江, 松岡 佐保子, 楊 逢春, 海老原 康博, 真部 淳, 菊地 陽, 中畑 龍俊  臨床血液  39-  (10)  946  -946  1998/10  [Not refereed][Not invited]
  
• Engraftment of human umbilical cord blood stem cells in NOD-SCID mice

  植田 高弘, 吉野 浩, 海老原 康博, 真部 淳, 菊地 陽, 辻 浩一郎, 中畑 龍俊  日本産婦人科・新生児血液学会誌 = The Japanese journal of obstetrical, gynecological & neonatal hematology  8-  (2)  "S  -57"-"S-58"  1998/09/01  [Not refereed][Not invited]
  
• Stimulation of mouse and human primitive hematopoiesis by murine embryonic aorta-gonad-mesonephros-derived stromal cell lines

  MJ Xu, K Tsuji, T Ueda, Y Mukouyama, T Hara, FC Yang, Y Ebihara, S Matsuoka, A Manabe, A Kikuchi, M Ito, A Miyajima, T Nakahata  BLOOD  92-  (6)  2032  -2040  1998/09  [Not refereed][Not invited]
   

  We report here on a novel stromal cell line, AGM-S3, derived from the aorta-gonad-mesonephros (AGM) region of a 10.5 days postcoitum (dpc) mouse embryo. The AGM-SB cells promoted production of hematopoietic progenitors and day-12 spleen colony-forming cells from Lin(-)c-Kit(+)Sca-1(+) murine primitive hematopoietic cells. They also supported for 6 weeks generation of human multipotential progenitors from cord blood CD34(+)CD38(-) primitive hematopoietic cells. Human long-term repopulating hematopoietic stem cells (LTR-HSC) with the potential to reconstitute hematopoiesis in NOD/SCID mice were maintained on AGM-SB cells for at least 4 weeks. Flow cytometric analysis showed that CD13, vascular cellular adhesion molecule-1, and Sca-1 were expressed on AGM-S3 cells. Because stem cell factor, interleukin-6 (IL-6), and oncostatin M, but not IL-3, IL-11, leukemia-inhibitory factor, granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, thrombopoietin, and Flk2 ligand were detected in reverse transcription-polymerase chain reaction analysis of AGM-SB cells, the cells seem to express species-cross reactive molecule(s) other than the cytokines examined and which act on primitive hematopoietic progenitor/stem cells. This cell line is expected to elucidate molecular mechanisms regulating early hematopoiesis and pave the way for developing strategies for expansion of human transplantable HSC. (C) 1998 by The American Society of Hematology.
• Phagocytosis of Fungi in the Peripheral Blood Neutrophils of Two Children with Cancer During Treatment with Fluconazole

  MANABE Atushi, EBIHARA Yasuhiro, SAITO Akiko, TAKAHASHI Kazuhiro, HOSOYA Ryota  臨床血液  38-  (8)  669  -673  1998/08/30  [Not refereed][Not invited]
  
• Juvenile Chronic Myelogenous Leukemia in Japan : A Report from Childhood Chronic Myelogenous Leukemia Study Croup

  INAMITSU Takeshi, OHGA Shouichi, MANABE Atsushi, SAKO Masahiro, IKUTA Koichiro, YABE Miharu, HORIBE Keizou, OKAMURA Jun, MATSUYAMA Takaharu, TSUKIMOTO Ichiro, UEDA Kazuhiro  J.J.P.H.  12-  (5)  351  -358  1998  [Not refereed][Not invited]
   

  We retrospectively surveyed for juvenile chronic myelogenous leukemia in Japan. Fifty patients diagnosed from 1986 to 1995 were registered from 47 institutions. The median age of diagnosis was 2 yr 1 mo and the range was from 2 mo to 5 yr 6 mo. The male female ratio was 2 : 1. The overall survival of the evaluable 49 patients was 23.3%. The survival of 14 patients with allogeneic stem cell transplantation (SCT) and 35 patients without it was 49.0% and 13.7%, respectively. Total body irradiation was performed as the condition-ing regimen before SCT in 13 of 14 patients. Poor prognostic factors of the patients who did not receive allogeneic SCT were high age at diagnosis (≥ 2 yr), low platelet count (< 33, 000/μl), and mild splenomegaly (< 5 cm). Four of five patients who survived in good condition without intensive chemotherapy had been diagnosed before one year of age.
• Characterization of leukemic cells in CD2/CD19 double positive acute lymphoblastic leukemia

  A Manabe, T Mori, Y Ebihara, T Koyama, Okuyama, I, R Hosoya, M Kaneko, K Ishimoto, T Nakahata, S Nakazawa  INTERNATIONAL JOURNAL OF HEMATOLOGY  67-  (1)  45  -52  1998/01  [Not refereed][Not invited]
   

  In the diagnosis of leukemia, CD2 which is a T-cell associated marker and CD19 which is a B-cell associated marker are widely used to determine the lineage of leukemic cells. It is known that the cells of acute lymphoblastic leukemia (ALL) express both CD2 and CD19 in some cases. The origins of these cells are generally thought to be a common precursor for T- and B-lymphocytes. However, cytoplasmic staining of CD3 which is a more specific marker for T-lineage and cytoplasmic staining of mb-1 (CD79a) which is more specific for B-lineage were not performed in previous reports and the determination of the cell lineages of these cells was unclear. We had two cases of ALL whose blasts were CD2/CD19 double positive. The first case was assessed as B-lineage because the cells expressed cytoplasmic CD79a and lacked cytoplasmic CD3. The immunoglobulin (Ig) heavy chain gene was rearranged. The other cell surface markers including CD22 and HLA-DR also suggested that these cells were B-lineage. The CD? expression may be a coincidence and should not be taken as a T-cell marker in this case. It was difficult to determine the lineage in the second case because both cytoplasmic CD79a and cytoplasmic CD3 were expressed and neither TCR beta chain nor Ig heavy chain genes were rearranged. The other surface markers were not useful to determine the lineage. We concluded that this case was really an unclassified ALL. Accordingly, cytoplasmic staining of CD3 and CD79a should be carried out in the diagnosis of leukemia when it is difficult to determine the cell lineage. (C) 1998 Elsevier Science Ireland Ltd. All rights reserved.
• Prevalence and growth characteristics of malignant stem cells in B-lineage acute lymphoblastic leukemia

  H Nishigaki, C Ito, A Manabe, M Kumagai, E CoustanSmith, Y Yanishevski, FG Behm, SC Raimondi, CH Pui, D Campana  BLOOD  89-  (10)  3735  -3744  1997/05  [Not refereed][Not invited]
   

  We used a stroma-supported culture method to study the prevalence and growth characteristics of malignant stem cells in acute lymphoblastic leukemia (ALL). In 51 of 108 B-lineage ALL samples, bone marrow-derived stroma oat only inhibited apoptosis of ALL cells but also supported their proliferation in serum-free medium. When single leukemic cells were placed in the stroma-coated wells of microtiter plates, the percentage of wells with leukemic cell growth after 2 to 5 months of culture ranged from 6% to 20% (median, 15%; 5 experiments). The immunophenotypes and genetic features of cells recovered from these cultures were identical to those noted before culture. All cells maintained their stroma dependency and self-renewal capacity. Leukemic clones derived from single cells contained approximately 10(3) to 10(6) cells after 1 month of culture; other clones became detectable only after prolonged culture. Cell growth in stroma-coated wells correlated with the number of initially seeded cells (1 or 10: r = .87). However, the observed percentages of positive wells seeded with 10 cells always exceeded values predicted from results with single-cell-initiated cultures (P < .003 by paired t-test), suggesting stimulation of leukemic cell growth by paracrine factors. In conclusion, the proportion of ALL cells with clonogenic potential may be considerably higher than previously thought. (C) 1997 by The American Society of Hematology.
• Prevalence and growth characteristics of malignant stem cells in acute lymphoblastic leukemia.

  H Nishigaki, C Ito, A Manabe, M Kumagai, E CoustanSmith, Y Yanishevski, FG Behm, SC Raimondi, CH Pui, D Campana  BLOOD  88-  (10)  276  -276  1996/11  [Not refereed][Not invited]
  
• Stroma-supported culture of childhood B-lineage acute lymphoblastic leukemia cells predicts treatment outcome

  MA Kumagai, A Manabe, CH Pui, FG Behm, SC Raimondi, ML Hancock, H Mahmoud, WM Crist, D Campana  JOURNAL OF CLINICAL INVESTIGATION  97-  (3)  755  -760  1996/02  [Not refereed][Not invited]
   

  We developed a stroma cell culture system that suppresses apoptosis of malignant cells from cases of B-lineage acute lymphoblastic leukemia. By multiparameter flow cytometric measurements of cell recovery after culture on stromal layers, we assessed the growth potential of 70 cases of newly diagnosed B-lineage acute lymphoblastic leukemia and related the findings to treatment outcome in a single program of chemotherapy. The numbers of leukemic cells recovered after 7 d of culture ranged from < 1 to 292% (median, 91%). The basis of poor cell recoveries from stromal layers appeared to be a propensity of the lymphoblasts to undergo apoptosis. The probability of event-free survival at 4 yr of follow-up was 50+/-9% (SE) among patients with higher cell recoveries (> 91%), and 94+/-6% among those with reduced cell recoveries (less than or equal to 91%; P = 0.0003). The prognostic value of leukemic cell recovery after culture exceeded estimates for all other recognized high-risk features and remained the most significant after adjustment with all competing covariates. Thus, the survival ability of leukemic cells on bone marrow-derived stromal layers reflects aggressiveness of the disease and is a powerful, independent predictor of treatment outcome in children with B-lineage acute lymphoblastic leukemia.
• Demonstration of bone involvement associated with t(17;19)(+) acute lymphoblastic leukemia (ALL) in severe combined immunodeficiency (SCID) mice

  A Manabe, H Kaneko, J Fujimoto, T Inaba, M Takeuchi, M Ohira, T Mori, R Hosoya  BLOOD  86-  (10)  3061  -3061  1995/11  [Not refereed][Not invited]
  
• A NOVEL MONOCLONAL-ANTIBODY, KOR-SA3544 WHICH REACTS TO PHILADELPHIA-CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC-LEUKEMIA CELLS WITH HIGH-SENSITIVITY

  T MORI, K SUGITA, T SUZUKI, T OKAZAKI, A MANABE, R HOSOYA, S MIZUTANI, A KINOSHITA, S NAKAZAWA  LEUKEMIA  9-  (7)  1233  -1239  1995/07  [Not refereed][Not invited]
   

  A monoclonal antibody which primarily reacted with Philadelphia chromosome (Ph(1))-positive ALL cells was produced. The reactivity of a monoclonal antibody, KOR-SA3544 (IgG2a) was evaluated on normal hemopoietic cells, 68 leukemic cell lines and freshly obtained cells from 190 patients with leukemia and lymphoma. in cultured cells, KOR-SA3544 reacted with Ph(1)-positive ALL cell lines (5/5) and leukemic cell lines with 11q23 translocation (3/11). In lymphoid cells, KOR-SA3544 was reactive with all of Ph(1)-positive ALL (26/26), a part of common ALL (5/38) and one case of early B precursor leukemia with 11q23 translocation, but not with peripheral lymphocytes. Normal mature granulocytes were also strongly stained. In myeloid leukemias, KOR-SA3544 was positive (16/56) only in patients with acute myeloid leukemia with FAB-MS and overt leukemia following myelodysplastic syndrome, but neither with other types of myeloid leukemias nor with blast crisis in chronic myelogenous leukemia. KOR-SA3544 recognized a 90 KDa protein on the membrane of a leukemic cell line, KOPN-57bi. In normal bone marrow, CD19(+)/KOR-SA3544(+) cells were not identified, while Ph(1)-positive ALL cells were strongly positive for both antibodies. KOR-SA3544 is useful not only for making the diagnosis of Ph(1)-positive ALL but for detection of the minimal residual disease during remission.
• IN-VITRO LEUKEMIC-CELL GROWTH ON STROMA PREDICTS OUTCOME IN CHILDHOOD B-LINEAGE ACUTE LYMPHOBLASTIC-LEUKEMIA (ALL)

  M KUMAGAI, A MANABE, FG BEHM, SC RAIMONDI, M HANCOCK, WM CRIST, H MAHMOUD, CH PUI, D CAMPANA  BLOOD  84-  (10)  A516  -A516  1994/11  [Not refereed][Not invited]
  
• USE OF STROMA-SUPPORTED CULTURES OF LEUKEMIC-CELLS TO ASSESS ANTILEUKEMIC DRUGS .2. POTENT CYTOTOXICITY OF 2-CHLORO-DEOXYADENOSINE IN ACUTE LYMPHOBLASTIC-LEUKEMIA

  M KUMAGAI, A MANABE, E COUSTANSMITH, RL BLAKLEY, WT BECK, VM SANTANA, FG BEHM, SC RAIMONDI, D CAMPANA  LEUKEMIA  8-  (7)  1116  -1123  1994/07  [Not refereed][Not invited]
   

  We used a recently established stroma-supported tissue culture technique that allows long-term culture of acute lymphoblastic leukemia (ALL) cells to study 2-chloro-2'-deoxyadenosine (2CdA) cytotoxicity to leukemic lymphoblasts. In the 20 cases of ALL studied, the number of cells recovered after 7 days of culture on allogeneic stromal layers were 58-192% (median, 95.5%) of those originally seeded. In parallel cultures with 2CdA (100 nM), 74->99% (median, 97.5%) of leukemic lymphoblasts were killed. The cytotoxicity of 2CdA extended to all ten samples with either the t(9;22) (q34;q11) or 11q23 chromosomal abnormalities, karyotypes associated with an extremely poor outcome, as well as to two samples collected at the time of relapse. The effects of 2CdA were dose-dependent, and were due to triggering of apoptosis as shown by typical morphologic changes and occurrence of DNA fragmentation. Stromal layers were apparently not affected by 2CdA treatment, even when used at 1000 nM. We also tested 2CdA cytotoxicity to multidrug resistant subclones of the CCRF-CEM ALL cell line. CEM/VLB(100) expresses P-glycoprotein, whereas CEM/VM-1 and CEM/VM-1-5 have topoisomerase II mutations that are associated with resistance to topoisomerase II inhibitors. Overexpression of P-glycoprotein or alterations in topoisomerase II did not protect cells from 2CdA cytotoxicity. We conclude that 2CdA is cytotoxic in most cases of ALL. The method used in this study may be applied to evaluate leukemic blast cell sensitivity to compounds with potential anti-leukemic activity, and to select patients for entry into clinical trials.
• GROWTH REQUIREMENTS OF NORMAL AND LEUKEMIC HUMAN B-CELL PROGENITORS

  D CAMPANA, E COUSTANSMITH, MA KUMAGAI, A MANABE  LEUKEMIA & LYMPHOMA  13-  (5-6)  359  -371  1994/05  [Not refereed][Not invited]
   

  Leukemic lymphoblasts in B-lineage acute lymphoblastic leukemia (ALL) express morphologic, phenotypic and genotypic features which resemble those of B lymphocyte progenitors in normal bone marrow. Normal immature B cells and cells from most cases of B-lineage ALL rapidly die in vitro unless they are supported by bone marrow-derived stromal feeder layers. Techniques suitable for maintaining normal and leukemic immature B cells in culture have been developed. Thus, the stromal cell types and growth factors that generate a milieu suitable for immature B-cell development can now be elucidated. In addition, the similarities and discrepancies in survival requirements of normal and leukemic B cell precursors can be studied. We postulate that leukemic B cell precursors can survive and expand in microenvironments incapable of supporting their normal counterparts, and that the study of the survival requirements of ALL cells will provide indications about the aggressivity of the disease in vivo. In this review, we discuss the culture conditions that support in vitro survival of human immature B cells, some of the factors that influence their expansion, and the putative molecular basis for the prolonged life-span of leukemic lymphoblasts.
• INTERLEUKIN-4 INDUCES PROGRAMMED CELL-DEATH (APOPTOSIS) IN CASES OF HIGH-RISK ACUTE LYMPHOBLASTIC-LEUKEMIA

  A MANABE, E COUSTANSMITH, MA KUMAGAI, FG BEHM, SC RAIMONDI, CH PUI, D CAMPANA  BLOOD  83-  (7)  1731  -1737  1994/04  [Not refereed][Not invited]
  
• ADHESION-DEPENDENT SURVIVAL OF NORMAL AND LEUKEMIC HUMAN-B LYMPHOBLASTS ON BONE-MARROW STROMAL CELLS

  A MANABE, KG MURTI, E COUSTANSMITH, M KUMAGAI, FG BEHM, SC RAIMONDI, D CAMPANA  BLOOD  83-  (3)  758  -766  1994/02  [Not refereed][Not invited]
  
• USE OF STROMA-SUPPORTED CULTURES OF LEUKEMIC-CELLS TO ASSESS ANTILEUKEMIC DRUGS .1. CYTOTOXICITY OF INTERFERON-ALPHA IN ACUTE LYMPHOBLASTIC-LEUKEMIA

  A MANABE, TL YI, M KUMAGAI, D CAMPANA  LEUKEMIA  7-  (12)  1990  -1995  1993/12  [Not refereed][Not invited]
   

  Leukemic cells from most cases of acute lymphoblastic leukemia (ALL) rapidly die by apoptosis in vitro, unless they are cultured onto bone marrow-derived stromal layers. We have recently established a stroma-supported tissue culture technique that allows long-term culture of leukemic lymphoblasts. In this study, we used this technique to examine interferon alpha (IFN alpha) cytotoxicity to ALL blasts. In 16 ALL cases tested (14 B-lineage ALL, 2 T-ALL), the number of calls recovered after 7 days of culture on stromal feeder layers was 60-178% (median, 108%) of those originally seeded. The percentage of lymphoblasts killed by 2000 U/ml IFN alpha(2b) after 7 days of culture, ranged from < 1 % to 91 % (median, 56%). Cytotoxicity was (i) dose-dependent, (ii) eliminated by a neutralizing antibody to IFN alpha, and (iii) accompanied by tyrosine phosphorylation of a 135 kDa protein, which was detectable after 5 minutes of treatment. Numbers of residual normal lymphoid cells in the cultures remained low and conditioned medium prepared from IFN alpha-stimulated T, NK, and stromal calls was not cytotoxic to ALL blast calls. In contrast to results in freshly isolated ALL cells, six ALL cell lines tested were completely resistant to IFN alpha cytotoxicity. We conclude that IFN alpha is directly cytotoxic in most ALL cases but that the intensity of its effects varies widely among cases. The method used in this study may be applied to evaluate leukemic blast cell sensitivity to compounds with potential antileukemic activity, and to select patients to be entered in to clinical trials.
• INTERLEUKIN-4 (IL-4) INDUCES PROGRAMMED CELL-DEATH (APOPTOSIS) IN HUMAN B-CELL PROGENITORS

  A MANABE, E COUSTANSMITH, M KUMAQAI, FG BEHM, SC RAIMONDI, CH PUI, D CAMPANA  BLOOD  82-  (10)  A49  -A49  1993/11  [Not refereed][Not invited]
  
• KOR-SA3544 - A NOVEL MONOCLONAL-ANTIBODY WHICH SPECIFICALLY BINDS TO THE CELL-MEMBRANE OF PHILADELPHIA-CHROMOSOME (PH(1)) POSITIVE ACUTE LYMPHOBLASTIC-LEUKEMIA (ALL)

  T MORI, A MANABE, T OKAZAKI, T SUZUKI, K SUGITA, R HOSOYA, K NISHIMURA, S MIZUTANI, S NAKAZAWA  BLOOD  82-  (10)  A52  -A52  1993/11  [Not refereed][Not invited]
  
• HYPERDIPLOID ACUTE LYMPHOBLASTIC-LEUKEMIA (ALL) - A DISTINCT BIOLOGICAL ENTITY WITH MARKED PROPENSITY TO PROGRAMMED CELL-DEATH

  D CAMPANA, M KUMAGAI, A MANABE, KG MURTI, FG BEHM, H MAHMOUD, SC RAIMONDI  BLOOD  82-  (10)  A49  -A49  1993/11  [Not refereed][Not invited]
  
• ADHESION-DEPENDENT SURVIVAL OF NORMAL AND LEUKEMIC HUMAN B-LYMPHOBLASTS ON BONE-MARROW STROMAL CELLS

  A MANABE, GK MURTI, E COUSTANSMITH, M KUMAQAI, FG BEHM, SC RAIMONDI, D CAMPANA  BLOOD  82-  (10)  A48  -A48  1993/11  [Not refereed][Not invited]
  
• STROMA-SUPPORTED IMMUNOCYTOMETRIC ASSAY (SIA) - A NOVEL METHOD FOR TESTING THE SENSITIVITY OF ACUTE LYMPHOBLASTIC-LEUKEMIA CELLS TO CYTOTOXIC DRUGS

  D CAMPANA, A MANABE, WE EVANS  LEUKEMIA  7-  (3)  482  -488  1993/03  [Not refereed][Not invited]
   

  The accuracy of drug-sensitivity assays for neoplastic cells depends on the ability to sustain cell survival in vitro, but cells in most cases of acute lymphoblastic leukemia (ALL) rapidly die by apoptosis in culture. We recently reported that allogeneic bone marrow stromal layers support long-term culture of ALL cells. We now describe the standardization of a novel drug-sensitivity assay for ALL lymphoblasts maintained on stromal layers, in which the viability of treated and untreated cells is compared using flow cytometry. Cultures were performed in U-bottomed 96-well plates: 2 x 10(4) stromal cells per well produced rapidly confluent layers which supported the survival of ALL blasts. In four ALL cases studied, 68.8-106% (median 94.8%) of the lymphoblasts originally seeded were recovered after 7 days of culture, in contrast to <5% recovered in the absence of stroma. Sensitivity to five antileukemic drugs was tested at the indicated concentrations: vincristine (0.001-1 mug/ml); dexamethasone (0.001-100 muM); 6-thioguanine (0.078-20 mug/ml); teniposide (0.001-10 muM); cytosine arabinoside (0.039-10 muM). After 4 days of culture, cells were labeled with CD19 monoclonal antibody and analyzed by flow cytometry. The concentration of each antileukemic agent producing 50% cytotoxicity (LC50) was determined for each patient by fitting a sigmoid model to the drug concentrations versus percentage viability data. Clinically relevant drug concentrations produced cytotoxic effects, and ALL blast sensitivity varied considerably among patients. We conclude that this is an informative method of systematically evaluating drug sensitivity in ALL patients.
• PROLONGED SURVIVAL OF B-LINEAGE ACUTE LYMPHOBLASTIC-LEUKEMIA CELLS IS ACCOMPANIED BY OVEREXPRESSION OF BCL-2 PROTEIN

  D CAMPANA, E COUSTANSMITH, A MANABE, M BUSCHLE, SC RAIMONDI, FG BEHM, R ASHMUN, M ARICO, A BIONDI, CH PUI  BLOOD  81-  (4)  1025  -1031  1993/02  [Not refereed][Not invited]
  
• BONE MARROW-DERIVED STROMAL CELLS PREVENT APOPTOTIC CELL-DEATH IN B-LINEAGE ACUTE LYMPHOBLASTIC-LEUKEMIA

  A MANABE, E COUSTANSMITH, FG BEHM, SC RAIMONDI, D CAMPANA  BLOOD  79-  (9)  2370  -2377  1992/05  [Not refereed][Not invited]
  
• EFFECTIVENESS OF HIGH-DOSE MCNU THERAPY AND HEMATOPOIETIC STEM-CELL AUTOGRAFTS TREATMENT OF CHILDHOOD ACUTE-LEUKEMIA LYMPHOMA WITH HIGH-RISK FEATURES

  Y TAKAUE, T WATANABE, Y HOSHI, T ABE, K MATSUNAGA, S SAITO, A HIRAO, Y KAWANO, T NINOMIYA, Y KURODA, T KOYAMA, T SUZUE, T SHIMOKAWA, H UCHIYAMA, A WATANABE, T MATSUSHITA, A KIKUTA, A YOKOBAYASHI, R MURAKAMI, A MANABE, R HOSOYA, M OHIRA, T FUJIMOTO  CANCER  67-  (7)  1830  -1837  1991/04  [Not refereed][Not invited]
   

  Clinical and pharmacokinetic studies were performed regarding the toxicity of methyl 6-[3-(2-chloroethyl)-3-nitrosoureido]-6-deoxy-alpha-D-glucopyranoside (MCNU) with other drugs, in conjunction with a peripheral blood stem cell autograft (PBSCT), for treating 26 children with acute leukemia or lymphoma associated with high-risk features. In the early phase of the study, MCNU (300 to 500 mg/m2) was administered with cytosine arabinoside (Ara-C) (1.6 to 16 g/m2), etoposide (VP-16) (0.8 to 1.6 g/m2), cyclophosphamide (CY) (100 to 200 mg/kg), or busulfan (16 mg/kg). No acute toxicity was noticed after this high-dose therapy. The dose-limiting factor of the regimens was significant but reversible interstitial pneumonitis (IP). In a subsequent trial with an MCNU/VP-16/Ara-C/CY (MCVAC) regimen in which the dose of MCNU was reduced, the risk of IP diminished. This study is still in progress, but the clinical response has so far been encouraging. Fifteen of 26 children are alive and well in unmaintained complete remission (CR) with a median follow-up period of 11 months (range, 3 to 34 months) after transplantation.
• CLINICAL EVALUATION OF AZTREONAM FOR INFECTIONS ACCOMPANYING FEBRILE NEUTROPENIC CHILDREN WITH HEMATOLOGIC DISORDERS AND SOLID TUMORS: A COOPERATIVE STUDY

  HIROTSU TAKUO, AKATSUKA JUN-ICHI, HOSHI YASUTAKA, UCHIYAMA HIROSHI, FUJISAWA KOJI, KOBAYASHI NAOAKI, ISHIDOYA NAOKO, OHIRA MUTSURO, TAKAYAMA JUN, ISHIDA YASUSHI, TANAKA RYUHEI, MATSUSHITA TAKEJI, TSUCHIYA NOBUKO, KOIDE RYO, TAGUCHI NOBUYUKI, KUMAGAYA MASAAKI, SUGITA KIYOKO, SEKINE YURIKO, NAKAZAWA SINPEI, KINOSHITA AKITOSHI, KANEKO MASAFUMI, YOSHIDA HISAKUNI, TSUJI ATSUKO, NISHIMURA KOZO, HOSOYA RYOTA, MANABE ATSUSI, FUKUSHIMA NAOKI, IWAHORI AKIRA, AIKO HIROSHI, MORIMOTO TSUYOSHI, OHKAWA HIROJI, TAKAGI SHUJI, KAJIWARA MICHIKO, TAKEKUMA KOJI, TSUYUKI KAZUMITSU, KINOUE KEIKO, BESSHO FUMIO, WADA EMIKO, TAMURA MARIKO, GOTO KEIKO, KIM NYONFA, KAMIHARA MISUZU, OHBA MINAKO, KANEKO TAKASHI, OHTSUKI HIROSHI, TSUKIMOTO ICHIRO, SAWA FUMIHIRO, OKAMOTO NORIHIKO, ITO TADAATSU, HATTORI TAKUYA, OKANO SHUKO, MUGISHIMA HIDEO, CHIN MOTOAKI, TAKAHASHI HIDEO, INANA ICHIRO, SHIMIZU HISASHI, YAMAMOTO MASAO, KANEKO KIYOSHI, UEDA YUTAKA  The Japanese Journal of Antibiotics  43-  (12)  2069  -2077  1990  

  One hundred four children with infection accompanying hematologic disorders and solid tumors were treated with aztreonam (AZT)(120-150mg/kg), either alone or in combination with one of the fbllowing drugs;cefmetazole (CMZ)(120-150mg/kg), piperacillin (PIPC)(120-150mg/kg), or amikacin (AMK)(5-10mg/kg).The overall emcacy rate was69.2%.Efficacy rates by regimen were as follows: AZT alone was 63.2%, AZT plus CMZ was 73.6%, AZT plus PIPC was 74.1% and AZT plus AMK was 20.0%. Efficacy rates in different types of infections were 53.2 % for sepsis and suspected sepsis, 78.9% for pneumonia and respiratory tract infection, 93.1% for fever of undetermined origin and 55.6% for other infections. The efficacy rate was 71.3% in 94 patients in whom causative organisms were not identified and 50.0% in 10 patients in whom causative organisms were identified.
  Most of infections in which causative organisms were identified were caused by Gram-negative pathogens. The response rate among infections caused by Gram-negative bacilli was 50.0%. A combination of AZT and CMZ or PIPC was effective in 3 (100.0 %) out of 3 patients in whom Escherichia coli was the causative organism. Efficacies classified according to different neutrophil counts were59.3%for<100/μl, 78.6%for101-500/μland82.4%fbr>501/μl.No significant adverse reactions were observed.
  These results indicated that combination of AZT and 2nd generation cephalosporins or penicillins were well tolerated and effective for infections complicated with accompanying hematologic disorders and solid tumors.

Books etc

• 小児白血病の世界 : 病態の解明から治療まで

  真部, 淳 
  中外医学社 2021/04 (ISBN: 9784498225329) 149p
• 小児疾患

  真部, 淳, 松藤, 凡, 小林, 京子(看護学) 
  南江堂 2019/04 (ISBN: 9784524237555) xii, 368p
• よくわかる臨床研究 : 小児がん

  足立, 壯一, 堀部, 敬三, 福澤, 正洋, 真部, 淳, 小川, 千登世, 瀧本, 哲也, 齋藤, 明子, 水谷, 修紀 
  医薬ジャーナル社 2016/08 (ISBN: 9784753228102) 315p
• はじめての血友病診療実践マニュアル

  石黒, 精, 嶋, 緑倫, 瀧, 正志, 中舘, 尚也, 真部, 淳 
  診断と治療社 2012/04 (ISBN: 9784787819543) xv, 118p
• 厚生労働科学研究費補助金がん臨床研究事業働き盛りや子育て世代のがん患者やがん経験者、小児がんの患者を持つ家族の支援の在り方についての研究研究報告書

  真部, 淳 
  [真部淳] 2009/03 冊
• 小児がん : チーム医療とトータル・ケア

  細谷, 亮太, 真部, 淳 
  中央公論新社 2008/11 (ISBN: 9784121019738) vi, 208p
• 小児科研修の素朴な疑問に答えます

  真部, 淳, 上村, 克徳 
  メディカル・サイエンス・インターナショナル 2008/05 (ISBN: 9784895925594) xiv, 301p
• 神経芽腫に対する分子標的療法の基礎的研究と臨床展開

  真部, 淳 
  真部淳 2004/03 1冊
• 小児の急性リンパ性白血病と正常骨髄B前駆細胞の比較研究 : 新たな治療法の開発と白血化のメカニズムの解明

  真部, 淳 
  真部淳 2002/03 1冊

Association Memberships

• 日本臨床血液学会   国際血液学会(International Society of Hematology)   国際小児がん学会(International Society of Pediatric Oncology)   日本小児がん学会   日本小児血液学会   アメリカ血液学会(American Society of Hematology)   日本血液学会   日本小児科学会   

Research Projects

• がん特異的糖鎖抗原を用いた小児がんに対する近赤外光線免疫療法の確立：前臨床モデル

  日本学術振興会：科学研究費助成事業

  Date (from‐to) : 2022/04 -2025/03 

  Author : 長 祐子, 真部 淳, 小川 美香子, 樋田 泰浩, 植木 将弘, 中島 孝平
• 小児・AYA世代におけるMDSの発生機序と治療戦略の解明

  日本学術振興会：科学研究費助成事業

  Date (from‐to) : 2021/04 -2024/03 

  Author : 平林 真介, 真部 淳, 鳴海 覚志, 三谷 絹子, 小野澤 真弘

   

  本研究は本邦の小児からAYA世代のMDSの先天性素因の同定と臨床データを合わせて統合解析を行い、発生機序の解明と治療戦略へ繋げる。成人MDSは加齢性変化の影響が大きいが、小児・AYAのMDSは遺伝的要因による造血幹細胞の脆弱性から、感染、炎症による造血ストレス環境、内因性アルデヒド代謝の違いなどにより、骨髄不全の進行と早期のクローン性造血に至ると考えられる。遺伝、環境とも多様な因子があり、未解明な部分が多い。小児科・血液内科・基礎研究を一元的に行い、先天性素因を把握する。令和3年度は症例集積と解析を進めていった。その中で、染色体異常der(1;7)(q10;p10)が、小児、AYA世代の主要な先天性素因であるGATA2異常症においてmonosomy 7に次ぐ特徴であることがわかった。これはドイツ、米国との国際共同研究に加わり、多数例の検討を行った結果であり、そのまま論文発表に至ることができた(Blood.2021;138(23):2441-2445.）。今後とも検討すべき課題はあり、国際共同研究を発展させるべく協力を継続していく。今年度も小児領域、成人領域をまたがる形で、小児科、血液内科との共同研究を開始し、遺伝子解析系とデータベースの構築に努める。また引き続き先天性素因を疑わせる核型異常に注目して、小児、AYA世代のMDS、AML症例を中心に造血転写因子の生殖細胞系列バリアントの解析を開始する。先行解析として20例の当該症例において解析系の構築を進めている。
• Epidemiological investigation of risk factors for childhood leukemia onset and adverse effects among survivors

  Japan Society for the Promotion of Science：Grants-in-Aid for Scientific Research

  Date (from‐to) : 2018/04 -2022/03 

  Author : Urayama Kevin

   

  We established the first epidemiological study of childhood hematological cancers (Epi-HCC) focusing on the examination of risk factors during pregnancy of the mother, birth characteristics, and early childhood exposures. We collected data from the Maternal and Child Health Handbook and saliva samples as a source of DNA, and several analyses have been completed and are also ongoing. Case and control comparisons show an association with maternal age, delivery methods, birthweight, and having older siblings. Through international collaboration (16 studies across 8 countries), we found that infection during pregnancy is associated with an increased risk of childhood leukemia. In genetic analyses, we identified 8 genetic loci associated childhood leukemia risk which have also been reported in non-Asian populations. We found two additional risk-associated genes which may be specific to the Japanese population.
• Elucidation of gene polymorphisms related with adverse events in the treatment of childhood acute lymphoblastic leukemia

  Japan Society for the Promotion of Science：Grants-in-Aid for Scientific Research

  Date (from‐to) : 2017/04 -2020/03 

  Author : Manabe Atsushi

   

  Acute lymphoblastic leukemia (ALL) is the most common childhood cancer and long-term survival is expected in roughly 80% of patients. However, treatment-related toxicity is still a problem. We conducted a pharmacogenomic study in children with ALL. As a result, MTHFR gene polymorphism was related with clearance of methotrexate (MTX) in high-dose MTX treatment (n=79) among 5 genes (SLCO1B1, SLC19A1, ABCB1, ABCC2, ABCG2, and MTHFR). The most relevant gene polymorphism related with hematotoxicity of 6-mercaptopurine was NUDT15 (n=239), but not TPMT, which was strongly correlated in Caucasians. The result was validated using another cohort of patients (n=55). The difference in ethnicity should be considered to interpret the pharmacogenomic data.
• Research for mechanism of hematological malignancies in rare syndrome in children

  Japan Society for the Promotion of Science：Grants-in-Aid for Scientific Research

  Date (from‐to) : 2016/04 -2019/03 

  Author : HIRABAYASHI Shinsuke, MANABE Atsushi

   

  Pathogenesis of hematological malignancies in rare syndromes is not clarified yet. In this study, we performed comprehensive genetic analysis of hematological malignancies associated with rare syndromes such as Maffucci syndrome and Pearson syndrome. In addition to the genetic abnormalities responsible for the syndrome, hematologic malignancy-specific genetic abnormalities have been elucidated. These syndromes were predisposed to cancer. The phenotype of the leukemia was different based on the acquired genetic abnormality.
• 小児造血器腫瘍（リンパ系腫瘍）に対する標準治療確立のための研究

  厚生労働省科学研究委託費：革新的がん医療実用化研究事業

  Date (from‐to) : 2014/04 -2017/03 

  Author : 真部 淳
• Congenital dyserythropoietic anemia (CDA) およびサラセミア貧血の効果的診断法の確立に関する研究

  厚生労働科学研究費補助金：難治性疾患克服 研究事業

  Date (from‐to) : 2010/04 -2011/03 

  Author : 真部 淳
• 働き盛りや子育て世代のがん患者やがん経験者、小児がんの患者を持つ家族の支援の在り方についての研究

  厚生労働科学研究費補助金：がん臨床 研究事業

  Date (from‐to) : 2008/04 -2010/03 

  Author : 真部 淳
• 小児の骨髄異形成症候群に対する分子標的療法の基礎的研究と臨床展開

  日本学術振興会：科学研究費助成事業

  Date (from‐to) : 2004 -2004 

  Author : 眞部 淳
• A Study of Immunotherapy for Pediatric Malignancy : Molecular Identification of Tumor Specific Antigen

  Japan Society for the Promotion of Science：Grants-in-Aid for Scientific Research

  Date (from‐to) : 2003 -2004 

  Author : HYAKUNA Nobuyuki, AWATA Hisataka

   

  Purpose : It is needed to obtain a significant number of live tumor cells to identify the tumor antigens. Thus we started the study to establish primary cell culture from freshly excised tumor samples. Additionally, we try to expand tumor infiltrating lymphocytes from the same samples. Method : Tumor samples were obtained from the patients for diagnosis or treatment. Sample specimens were cut into 1 mm cubic, and digested with collagenase, then they were cultured in humidified incubator with 5% Co_2 at 37℃ After 1 to 2 weeks culture when cells were proliferating, cells were passaged with trypsine treatment. Cultured cells were identified as follows ; for neroblastoma, : positivity for anti-GD2 antibody by flowcytometry, for Ewing sarcoma, : positivity for anti-MIC2 antibody by immunohistochemistry and expression of EWS-F1i1 chmeric gene by RT-PCR. Results : Six neuroblastoma, 2 Ewing sarcoma, 1 Wilms tumor samples were subjected for the study. In all specimens primary culture was successful and cells were passaged 3 to 4 times for the period of 1 to 4 months. Cells were negative for GD2 in 2 out of 5 neuroblastoma samples tested, and cells were positive for MIC2 in Ewing sarcoma sample. Expression of EWS-Flit chimeric gene was not detected in in one Ewing sarcoma cells which expressed EWS-F1i1 in the primary tissue. For lymphocytes culture, cells proliferated from only one specimen. The recovered lymphocytes (tumor infiltrating lymphocytes) were co-cultured with autologous tumor cells and IFN-γ secretion in the supernatant was measured by ELISA The IFN-γ secretion by tumor infiltrating lymphocytes was not higher than control. Discussion : This study showed that primary cell culture from clinically obtained tumor samples is successful. However, contamination of normal stroma cells was inevitable and in some cases tumor related antigen might be lost while on passage. We could not induce any tumor specific lymphocytes from tumor specimens, indicating tumor infiltrating lymphocytes might not be sensitized by tumor antigens. Further experiments : On the basis of the above study, we dealt with established tumor cell lines (NB16). In brief, lymphocytes from healthy donor peripheral blood are expanded with IL-2 on the NB16 cell layer. After 3 times stimulation by NB16 cells, IFN-γ secretion in the supernatant was measured by ELISA. Again, the IFN-γ secretion was not higher than control. This results might be induced by HLA incompatibility between donor cells and NB16, low or no expression of tumor antigens, or some unknown mechanism that suppress the immune responses of donor against NB16.
• The induction cf the differentiation of human embryonic stem cells into hematopoietic stem and progenitor cells.

  Japan Society for the Promotion of Science：Grants-in-Aid for Scientific Research

  Date (from‐to) : 2003 -2004 

  Author : TSUJI Kohichiro, KAWASAKI Hirohide

   

  Human embryonic stem cells (ESC) recently established from the inner cell mass of human preimplantation embryos have the abilities to be maintained as undifferentiated cells in culture without apparent limit and to differentiate into all types of tissue cells. This property of human ESC indicates the potential application for blood medicine including cellular therapies, such as blood transfusion and hematopoietic stem cell transplantation, and the evaluation of drug effect on various blood cells in vitro. Because hematopoietic tissues play crucial roles in survival, differentiation and proliferation of hematopoietic cells, it is important to reproduce the circumstance surrounding hematopoietic cells in vitro for their development. In embryo, the development of hemotopoietic system is a complex process which sequentially occurs in several tissues, but fetal liver (FL) is the predominant source of blood cells until just before time when the hematopoiesis resides in bone marrow. We then established stromal cells from mouse FL cells and cocultured human embryonic stem cells (ESC) with them. Human ESC began to differentiate at day 6 of coculture, and generated immature hematopoietic cells at day 12. At day 16, we performed clonal cultures of these cocultured cells for 2 weeks. The human ESC-derived cells produced a number of myeloid, erythroid and multi-lineage colonies, which consist of myeloid cells including neutrophils and macrophages, erythroid cells which contain mature erythrocytes, and both, respectively. This result indicates that human ESC have the capability to generate a variety of hematopoietic progenitors which can produce mature blood cells in coculture with mouse FL-derived stromal cells. The human ESC-derived hematopoietic progenitors can be a novel source for the cells applicable to various cellular therapies.
• 小児がんに対する新しい治療法の確立

  Date (from‐to) : 1997 -2004
• 白血病細胞生物学

  Date (from‐to) : 1997 -2004
• Establishment of novel treatments for cancer in childhood

  Date (from‐to) : 1997 -2004
• Leukemia cell biology

  Date (from‐to) : 1997 -2004
• Exploration of molecular targeted therapy for neuroblastoma.

  Japan Society for the Promotion of Science：Grants-in-Aid for Scientific Research

  Date (from‐to) : 2002 -2003 

  Author : ATSUSHI Manabe

   

  This study aimed at the establishment of molecular targeted therapy for HER-2/neu expressed on the neuroblastoma cells. Recently, the mouse-human chimeric monoclonal antibody (trastuzumab) against HER-2/neu overexpressed on breast cancer cells has been used successfully in adult clinical oncology. I-IER-2/neu was first identified on neumblastoma cells of rats. There were very few reports describing the expression of HER-2/neu in human neumblastoma and there was no report demonstrating the effect of trastuzumab on neuroblastoma. Therefore, we investigated the expression of HER-2/neu on neuroblastoma cells from patients with neuroblastoma. Bone marrow cells were obtained from 11 children diagnosed as having stage 4 neuroblastoma with consents from guardians. Mononuclear cells were separated using a density gradient and cultured in the flasks coated with Engelbreth-Hoim-Swarm Natrix. GD2 (specifically expressed on neuroblastoma cells) disialoganglioside of adherent cells was analyzed using flow cytometry. Then, cytospin preparation of the GD2+ cells were immunostained to detect L-IER-2/neu protein. HER-2/neu was positive only in one case. The cytotoxicity of trastuzumab was investigated using ADCC (antibody-dependent cell-mediated cytotoxicity) assay in this case and the drug had no effect. It was reported that HER-2/neu was expressed in a majority of samples obtained from patients with neuroblastoma at advanced stages using pathological specimens by the other investigator. However, HER-2/neu was negative in most cases using cultured cells in this study. The method described here using cultured cells has advantages when testing cytotoxicity in vitro. The result suggests that a clinical trial of trastrizumab forneuroblastoma would not be warranted.
• 神経芽腫に対する免疫遺伝子治療

  Date (from‐to) : 1999 -2003
• Immune gene therapy for neuroblastoma

  Date (from‐to) : 1999 -2003
• 神経芽細胞腫を標的とする遺伝子治療の臨床展開とその有用性の検討

  日本学術振興会：科学研究費助成事業

  Date (from‐to) : 2002 -2002 

  Author : 辻 浩一郎, 真部 淳, 山下 直秀

   

  我々は再発あるいは進行性の第IV期神経芽腫と診断された4歳以上16歳未満の患者に対するIL-2とLymphotactinを組み込んだ神経芽腫細胞(腫瘍ワクチン細胞)を用いた免疫遺伝子治療の臨床試験(Phase I)を計画した。前臨床試験にて、神経芽腫細胞の培養・遺伝子の導入についての方法と安全性は確立された。その後、この計画は02年3月厚労省と文科省において承認された。 02年5月から適応候補患児が紹介されている。 第1症例:治療抵抗性神経芽腫の8歳男児。98年4月発症。腹部原発腫瘍は標準的な化学療法に抵抗性で、02年9月全身の骨に転移した。骨髄では光顕上腫瘍を認めなかったが、1週間の培養によりGD2陽性細胞が多数出現した。 第2症例:治療抵抗性神経芽腫の7歳女児。97年12月発症。化学療法後自家骨髄移植を施行したがその後も腫瘍は残存した。その後化学療法・MIBGによる核医学治療を受けるも抵抗性。骨髄転移あり。 第3症例:治療抵抗性神経芽腫の13歳女児。95年8月頚部に発症。化学療法後自家骨髄移植を施行したが、骨髄・骨盤・頭部に再発した。化学療法と放射線治療を行うもコントロール不能。 これら3例について症例検討会議ならびに施設内審査会において遺伝子治療の適否が討議されたが、いずれも適応なしと判断された。
• 神経芽細胞腫を標的とする遺伝子治療の基礎的研究と臨床展開

  日本学術振興会：科学研究費助成事業

  Date (from‐to) : 2001 -2001 

  Author : 辻 浩一郎, 真部 淳, 山下 直秀

   

  1)再発性・治療不応性神経芽細胞腫に対する遺伝子治療のための基礎的検討 再発性・治療不応性神経芽細胞腫に対する遺伝子治療実施の可能性の検討のために、進行性神経芽細胞腫患者の骨髄細胞からの神経芽細胞腫細胞の初代培養法の確立を試みた。stageIVの神経芽細胞腫患児の親権者より同意を得た後、10例の患児から採取された骨髄細胞を用いて培養を開始した。骨髄単核細胞をEHS-Natrixを塗布されたプラスチックフラスコに入れ、10%ウシ胎仔血清添加RPMI-1640液中で培養した。継代にはトリプシン+EDTAを用いた。神経芽細胞腫細胞の同定は、光顕的観察、フローサイトメトリーによる細胞表面GD2発現解析、組織免疫染色によるNeurofilament、NSE等の発現解析、RT-PCRによるTyrosine hydroxylaseの検出等により行った。その結果、4例において、7-14日後に神経芽細胞腫細胞の増殖が見られた。3例が初発時の凍結骨髄、1例が再発時の新鮮骨髄であった。増殖した神経芽細胞腫細胞には、比較的容易にinterleukin(IL)-2およびlymphotactin遺伝子の導入が可能であった。 2)再発性・治療不応性神経芽細胞腫に対する遺伝子治療プロトコールの提案 上記の基礎的検討結果に基づき、遺伝子治療プロトコールを作成し、東京大学医科学研究所倫理審査委員会に提出した。その審査を経た後、文部科学省科学技術・学術審議会および厚生科学審議会科学技術部会に「再発性・治療不応性神経芽腫に対するサイトカインとケモカインを用いた免疫遺伝子治療(第I相臨床研究)」として申請を行った。現在その審議の結果を待っている段階である。
• Comparative study of normal and leukemic B-precursor cells.

  Japan Society for the Promotion of Science：Grants-in-Aid for Scientific Research

  Date (from‐to) : 2000 -2001 

  Author : MANABE Atsushi

   

  The objective of this study was to establish a precise diagnostic method and a novel treatment modality for children with acute lymphoblastic leukemia (ALL) by analyzing leukemia cell biology. We first investigated CD58 expression in ALL and normal precursor cells. In all the 16 Samples from patients with B-lineage ALL, CD58 was positive in CD19-positive and CD45-weakly-positive cells. We are now testing CD58 expression in normal B-precursor cells. Next, we measured the telomere length using flow cytometry. We used an oligonucleotide probe against unique DNA repeats of telomere, conjugated with FITC. With this method, the membrane antigens and telomere length can be simultaneously analyzed. We are now compare the telomere length in ALL cells and normal B-precursor cells. Finally, we tried to culture T-ALL cells using a recently established fetal thymus organ culture (FTOC). The fetal thymus was derived from NOD-SCID mouse. With this method, in all the 7 cases, T-ALL cells expanded vigorously after 4-week FTOC. This was the first method to reproducibly cultivate T-ALL cells in vitro. We now plan to investigate cytokines and drugs which influence the proliferation of T-ALL cells.